<SEC-DOCUMENT>0001104659-26-065876.txt : 20260526
<SEC-HEADER>0001104659-26-065876.hdr.sgml : 20260526
<ACCEPTANCE-DATETIME>20260526060054
ACCESSION NUMBER:		0001104659-26-065876
CONFORMED SUBMISSION TYPE:	DEFM14A
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20260526
DATE AS OF CHANGE:		20260526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				621765329
		STATE OF INCORPORATION:			TN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFM14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		261015778

	BUSINESS ADDRESS:	
		STREET 1:		1600 WEST END AVENUE
		STREET 2:		SUITE 1300
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		1600 WEST END AVENUE
		STREET 2:		SUITE 1300
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFM14A
<SEQUENCE>1
<FILENAME>tm2612585-2_defm14a.htm
<DESCRIPTION>DEFM14A
<TEXT>
<html>
  <head>
    <title>tm2612585-2_defm14a - none - 25.1872742s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">UNITED STATES </font>
          <br >
          <font style="letter-spacing:-0.24pt;">SECURITIES AND EXCHANGE COMMISSION </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Washington, D.C. 20549</font><font style="font-weight:normal;font-size:12pt;">&#8203;<font style="letter-spacing:0.24pt;"> </font></font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">Schedule&#160;14A</font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Proxy Statement Pursuant to Section&#160;14(a) of </font>
          <br >
          <font style="letter-spacing:0.2pt;">the Securities Exchange Act of 1934 </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Filed by the Registrant &#9746; </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Filed by a party other than the Registrant &#9744; </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Check the appropriate box:</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Preliminary Proxy Statement </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Confidential, for Use of the Commission Only (as permitted by Rule&#160;14a-6(e)(2)) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9746;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Definitive Proxy Statement </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Definitive Additional Materials </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Soliciting Material under &#167;&#160;240.14a-12 </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Cumberland Pharmaceuticals Inc. </font>
        </div>
        <div style="margin-top:1.167pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:10pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Name of Registrant as Specified In Its Charter) </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8199;</font>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2pt; text-align:center; width:456pt; line-height:10pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</font><font style="font-size:10pt;">&#8203;<font style="letter-spacing:0.2pt;"> </font></font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Payment of Filing Fee (Check all boxes that apply):</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">No fee required </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9746;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Fee paid previously with preliminary materials. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Fee computed on table in exhibit required by Item&#160;25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CUMBERLAND PHARMACEUTICALS INC.</font>
          <br >
          <font style="letter-spacing:-0.2pt;">1600 West End Avenue, Suite 1300</font>
          <br >
          <font style="letter-spacing:-0.2pt;">Nashville, TN 37203</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(615) 255-0068</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:right; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">May&#160;26, 2026</font>&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dear Shareholder: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You are cordially invited to attend a special meeting of shareholders of Cumberland Pharmaceuticals Inc. (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221; or &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Cumberland</font><font style="letter-spacing:0.2pt;">&#8221;) to be held on June&#160;24, 2026, at 10:00 a.m., Central Time, at the Company&#8217;s corporate offices located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee&#160;37203. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the special meeting, you will be asked to consider and vote on a proposal to approve a strategic transaction in which Cumberland will integrate its commercial products with the U.S. branded business of an affiliate of Apotex Inc. (such affiliate, &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Apotex</font><font style="letter-spacing:0.2pt;">&#8221;), the largest Canadian-based pharmaceutical company. The transaction will be effected through an asset purchase agreement whereby Apotex and certain affiliates of Apotex will acquire Cumberland&#8217;s assets relating to the Company&#8217;s FDA-approved products, which consist of Acetadote</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Caldolor</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Sancuso</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vaprisol</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vibativ</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, as well as certain of the Company&#8217;s product-related equity interests. Under the terms of the agreement, Apotex will acquire these assets in exchange for cash consideration of $100&#160;million payable to Cumberland at the closing of the transaction and will create a platform to deliver specialty medicines that improve the quality of patient care. The Company will retain the assets associated with its ifetroban product candidates and Cumberland Emerging Technologies, our majority-owned subsidiary focused on earlier-stage product development, which the Company intends to continue to develop following the closing of the transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Information regarding each of the matters to be voted on at the special meeting, including approval of the transaction described above, is contained in the accompanying Notice of Special Meeting of Shareholders and Proxy Statement. We encourage you to read the enclosed Proxy Statement carefully and in its entirety before voting. Cumberland&#8217;s board of directors unanimously recommends that you vote &#8220;for&#8221; each of the proposals to be presented at the special meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">It is important that you be represented at the special meeting regardless of the number of shares you own. Whether or not you plan to attend the special meeting, we urge you to vote as soon as possible. The matters to be considered by shareholders at the special meeting are described in the accompanying materials. You may vote by marking, signing and dating your proxy card and returning it in the envelope provided. Alternatively, you may vote over the Internet or by mobile device. Voting over the Internet, by mobile device or by written proxy will not prevent you from attending the special meeting and voting, but will ensure that your vote is counted if you are unable to attend. Please review the instructions on the proxy card regarding each of these voting options. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you have any questions or need assistance in voting your shares, please contact our proxy solicitor, Sodali &amp; Co, by telephone at (203) 658-9400, or by email at CPIX@info.sodali.com. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Your continued support of and interest in Cumberland Pharmaceuticals Inc. are sincerely appreciated. </font>
        </div>
        <div style="margin-left:240pt; margin-top:8pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sincerely, </font>
        </div>
        <div style="margin-left:240pt; margin-top:18pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">/s/ A.J. Kazimi</font>
        </div>
        <div style="margin-left:240pt; margin-top:2.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A.J. Kazimi </font>
          <br >
          <font style="font-style:italic;letter-spacing:0.2pt;">Chairman and Chief Executive Officer</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:3pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;text-align:center; width:456pt;">
          <img src="lg_cumberland-4clr.jpg" alt="[MISSING IMAGE: lg_cumberland-4clr.jpg]" height="75" width="333" >
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CUMBERLAND PHARMACEUTICALS INC.</font>
          <br >
          <font style="letter-spacing:-0.2pt;">1600 West End Avenue, Suite 1300</font>
          <br >
          <font style="letter-spacing:-0.2pt;">Nashville, TN 37203</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(615) 255-0068</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTICE OF SPECIAL MEETING OF SHAREHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;min-height:13pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 3pt 0pt; width:96pt;">
              <font style="letter-spacing:0.2pt;">DATE &amp; TIME: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 3pt 0pt; width:348pt;">
              <font style="letter-spacing:0.2pt;">June&#160;24, 2026, at 10:00 a.m., Central Time. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:55pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:96pt;">
              <font style="letter-spacing:0.2pt;">PLACE: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:348pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">The special meeting of shareholders of Cumberland Pharmaceuticals Inc., a Tennessee corporation (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">,&#8221; &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Cumberland</font><font style="letter-spacing:0.2pt;">,&#8221; &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">we</font><font style="letter-spacing:0.2pt;">,&#8221; &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">us</font><font style="letter-spacing:0.2pt;">,&#8221; or &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">our</font><font style="letter-spacing:0.2pt;">&#8221;), will be at Cumberland&#8217;s corporate offices located at 1600 West End Avenue, Suite&#160;1300, Nashville, Tennessee 37203. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:96pt;">
              <font style="letter-spacing:0.2pt;">ITEMS OF</font>
              <br >
              <font style="letter-spacing:0.2pt;">BUSINESS: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:348pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">The purposes of the meeting are to consider and vote upon the following proposals, which are described in more detail in the accompanying proxy statement:</font>
              </div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">(1)</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">A proposal to authorize and approve the sale of the Company&#8217;s FDA-approved commercial products and related assets (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Transaction</font><font style="letter-spacing:0.2pt;">&#8221;) as contemplated by the Asset Purchase Agreement, dated as of April&#160;22, 2026 (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Agreement</font><font style="letter-spacing:0.2pt;">&#8221;), by and among Nuvo Pharmaceuticals (Ireland) DAC (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Apotex</font><font style="letter-spacing:0.2pt;">&#8221;), Apotex Inc. (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Guarantor</font><font style="letter-spacing:0.2pt;">&#8221;), and the Company, which may under Tennessee law be deemed a sale of substantially all of our property and assets otherwise than in the usual and regular course of business.</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">(2)</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">To authorize the Company&#8217;s board of directors to adjourn and postpone the special meeting to a later date or dates, if necessary, to allow time for further solicitation of proxies if there are not sufficient votes present in person or represented by proxy at the special meeting to approve Proposal No. 1; and</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">(3)</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">To transact any other business that properly may be brought before the special meeting or any adjournment or postponement thereof, including matters incidental to its conduct. </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:43pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:96pt;">
              <font style="letter-spacing:0.2pt;">RECORD DATE: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:348pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">You are entitled to vote at the special meeting or any adjournment of that meeting only if you were a shareholder at the close of business on May&#160;12, 2026 (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Record Date</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:96pt;">
              <font style="letter-spacing:0.2pt;">VOTING BY</font>
              <br >
              <font style="letter-spacing:0.2pt;">PROXY: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:348pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Please submit a proxy as soon as possible so that your shares can be voted at the meeting in accordance with your instructions. You may submit your proxy (1)&#160;over the Internet, (2)&#160;by mobile device, or (3)&#160;by mail. For specific instructions, please refer to the information in the proxy statement and the instructions on the proxy card. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:57pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:96pt;">
              <font style="letter-spacing:0.2pt;">SHAREHOLDER LIST: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:348pt;">
              <font style="letter-spacing:0.2pt;">In accordance with Tennessee law, a list of record shareholders as of the Record Date will be available for inspection by any shareholder during the period from May 28, 2026 through the special meeting at the Company&#8217;s corporate offices located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:96pt;">
              <font style="letter-spacing:0.2pt;">APPRAISAL RIGHTS: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:348pt;">
              <font style="letter-spacing:0.2pt;">Holders of shares of our common stock, $0.00 par value per share (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Common Stock</font><font style="letter-spacing:0.2pt;">&#8221;), do not have appraisal rights under Tennessee law or under the governing documents of the Company in connection with this solicitation of proxies.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:16pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This proxy statement, including the form of proxy, is first being mailed to shareholders on or about May&#160;26, 2026. </font>
        </div>
        <div style="margin-left:240pt; margin-top:8pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">BY ORDER OF THE BOARD OF DIRECTORS, </font>
        </div>
        <div style="margin-left:240pt; margin-top:8pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sincerely, </font>
        </div>
        <div style="margin-left:240pt; margin-top:8pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">/s/ A.J. Kazimi</font>
        </div>
        <div style="margin-left:240pt; margin-top:2.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:5pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A.J. Kazimi </font>
          <br >
          <font style="font-style:italic;letter-spacing:0.2pt;">Chairman and Chief Executive Officer</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Nashville, TN </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">May 26, 2026 </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">YOU ARE CORDIALLY INVITED TO ATTEND THE SPECIAL MEETING. IT IS IMPORTANT THAT YOUR SHARES BE REPRESENTED REGARDLESS OF THE NUMBER OF SHARES YOU OWN. THE BOARD OF DIRECTORS URGES YOU TO COMPLETE, SIGN AND DATE THE ENCLOSED PROXY CARD AND RETURN IT PROMPTLY IN THE ENCLOSED ENVELOPE. RETURNING THE PROXY CARD WILL NOT PREVENT YOU FROM ATTENDING THE SPECIAL MEETING AND VOTING IN PERSON. IF YOU ATTEND THE SPECIAL MEETING AND VOTE YOUR SHARES, YOUR PROXY WILL NOT BE USED. PLEASE REVIEW THE INSTRUCTIONS ON EACH OF YOUR VOTING OPTIONS DESCRIBED IN THE ACCOMPANYING PROXY STATEMENT AS WELL AS ON THE PROXY CARD.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CUMBERLAND PHARMACEUTICALS INC.</font>
          <br >
          <font style="letter-spacing:-0.2pt;">1600 West End Avenue, Suite 1300 Nashville, TN 37203</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(615) 255-0068</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROXY STATEMENT FOR THE SPECIAL MEETING OF SHAREHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TO BE HELD ON JUNE 24, 2026</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">GENERAL INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Why did you furnish me this proxy statement?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This proxy statement and the enclosed proxy card are furnished in connection with the solicitation of proxies by the board of directors (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Board of Directors</font><font style="letter-spacing:0.2pt;">&#8221; or &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Board</font><font style="letter-spacing:0.2pt;">&#8221;) of Cumberland Pharmaceuticals Inc., a Tennessee corporation (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">,&#8221; &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Cumberland</font><font style="letter-spacing:0.2pt;">,&#8221; &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">we</font><font style="letter-spacing:0.2pt;">,&#8221; &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">us</font><font style="letter-spacing:0.2pt;">,&#8221; or &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">our</font><font style="letter-spacing:0.2pt;">&#8221;), for use at the special meeting of the Company&#8217;s shareholders to be held on June 24, 2026, at 10:00 a.m., Central Time, at Cumberland&#8217;s corporate offices located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203, and at any adjournments or postponements of the special meeting. This proxy statement summarizes the information that you need to make an informed vote on the proposals to be considered at the special meeting. However, you do not need to attend the special meeting to vote your shares. Instead, you may simply complete, sign, and return the enclosed proxy card using the postage-prepaid envelope provided, or you may grant a proxy to vote your shares by means of the Internet or mobile device. The approximate date on which this proxy statement and the enclosed proxy card were sent to the Company&#8217;s shareholders is May 26, 2026. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What proposals will be addressed at the special meeting?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Shareholders will be asked to consider the following proposals at the special meeting: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To authorize and approve the sale of the Company&#8217;s FDA-approved commercial products and related assets (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Transaction</font><font style="letter-spacing:0.2pt;">&#8221;) as contemplated by the Asset Purchase Agreement, dated as of April&#160;22, 2026 (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Agreement</font><font style="letter-spacing:0.2pt;">&#8221;), by and among Nuvo Pharmaceuticals (Ireland) DAC (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Apotex</font><font style="letter-spacing:0.2pt;">&#8221;), Apotex Inc. (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Guarantor</font><font style="letter-spacing:0.2pt;">&#8221;), and the Company, which may be deemed under Tennessee law to be a sale of substantially all of the Company&#8217;s property and assets otherwise than in the usual and regular course of business (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Transaction Proposal</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To authorize the Board of Directors to adjourn and postpone the special meeting to a later date or dates, if necessary, to allow time for further solicitation of proxies if there are not sufficient votes present in person or represented by proxy at the special meeting to approve the Transaction Proposal (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Adjournment Proposal</font><font style="letter-spacing:0.2pt;">&#8221;); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To transact any other business that properly may be brought before the special meeting or any adjournment or postponement thereof, including matters incidental to its conduct. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Board of Directors has taken unanimous affirmative action with respect to each of the foregoing proposals and recommends that the shareholders vote as set forth in the following pages of this proxy statement with respect to each proposal.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:627pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.25pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#SUM"><font style="letter-spacing:0.2pt;">SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#SUM">1</a></font><a href="#SUM"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#QAAA"><font style="letter-spacing:0.2pt;">QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#QAAA">8</a></font><a href="#QAAA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#CSRF"><font style="letter-spacing:0.2pt;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#CSRF">12</a></font><a href="#CSRF"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#UPFF"><font style="letter-spacing:0.2pt;">UNAUDITED PRO FORMA FINANCIAL INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#UPFF">13</a></font><a href="#UPFF"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#UPFF1"><font style="letter-spacing:0.2pt;">Unaudited Pro Forma Financial Information </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#UPFF1">13</a></font><a href="#UPFF1"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#PN1T"><font style="letter-spacing:0.2pt;">PROPOSAL NO. 1 THE TRANSACTION PROPOSAL </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#PN1T">21</a></font><a href="#PN1T"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#IATP"><font style="letter-spacing:0.2pt;">Information about the Parties </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#IATP">21</a></font><a href="#IATP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#GDOT"><font style="letter-spacing:0.2pt;">General Description of the Transaction </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#GDOT">28</a></font><a href="#GDOT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#BOTT"><font style="letter-spacing:0.2pt;">Background of the Transaction </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#BOTT">28</a></font><a href="#BOTT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#OOTC"><font style="letter-spacing:0.2pt;">Opinion of the Company&#8217;s Financial Advisor </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#OOTC">39</a></font><a href="#OOTC"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#CPFI"><font style="letter-spacing:0.2pt;">Certain Prospective Financial Information </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#CPFI">42</a></font><a href="#CPFI"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#RFTT"><font style="letter-spacing:0.2pt;">Reasons for the Transaction </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#RFTT">44</a></font><a href="#RFTT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#UOPA"><font style="letter-spacing:0.2pt;">Use of Proceeds and Future Operations </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#UOPA">47</a></font><a href="#UOPA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#APRI"><font style="letter-spacing:0.2pt;">Appraisal Rights </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#APRI">47</a></font><a href="#APRI"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#CMUF"><font style="letter-spacing:0.2pt;">Certain Material U.S. Federal Income Tax Consequences </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#CMUF">47</a></font><a href="#CMUF"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#AAT"><font style="letter-spacing:0.2pt;">Anticipated Accounting Treatment </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#AAT">48</a></font><a href="#AAT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#LICP"><font style="letter-spacing:0.2pt;">2007 Long-Term Incentive Compensation Plan and the 2007 Directors&#8217; Incentive Plan </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#LICP">48</a></font><a href="#LICP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:427.33pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#EOOC"><font style="letter-spacing:0.2pt;">Effects on our Company if the Transaction is Completed and the Nature of our Business following the Transaction </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#EOOC">48</a></font><a href="#EOOC"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#TAPA"><font style="letter-spacing:0.2pt;">The Asset Purchase Agreement </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#TAPA">49</a></font><a href="#TAPA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <a href="#PASO"><font style="letter-spacing:0.2pt;">Purchase and Sale of the Assets</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#PASO">49</a></font><a href="#PASO"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <a href="#AOL"><font style="letter-spacing:0.2pt;">Assumption of Liabilities</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#AOL">49</a></font><a href="#AOL"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <a href="#CFTT"><font style="letter-spacing:0.2pt;">Consideration for the Transaction</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#CFTT">50</a></font><a href="#CFTT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <a href="#RAW"><font style="letter-spacing:0.2pt;">Representations and Warranties</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#RAW">50</a></font><a href="#RAW"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="font-style:italic;">
                <a href="#COV"><font style="letter-spacing:0.2pt;">Covenants</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#COV">52</a></font><a href="#COV"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <a href="#CLCO"><font style="letter-spacing:0.2pt;">Closing Conditions</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#CLCO">53</a></font><a href="#CLCO"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="font-style:italic;">
                <a href="#EXC"><font style="letter-spacing:0.2pt;">Exclusivity</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#EXC">53</a></font><a href="#EXC"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="font-style:italic;">
                <a href="#TER"><font style="letter-spacing:0.2pt;">Termination</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#TER">54</a></font><a href="#TER"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <a href="#EOTA"><font style="letter-spacing:0.2pt;">Effect of Termination and the Parties&#8217; Obligations Upon Termination</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#EOTA">54</a></font><a href="#EOTA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <a href="#POAR"><font style="letter-spacing:0.2pt;">Post-Closing Arrangements</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#POAR">55</a></font><a href="#POAR"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#TOTA"><font style="letter-spacing:0.2pt;">The Other Transaction Agreements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#TOTA">57</a></font><a href="#TOTA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <a href="#VASA"><font style="letter-spacing:0.2pt;">Voting and Support Agreements</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#VASA">57</a></font><a href="#VASA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <a href="#TSA"><font style="letter-spacing:0.2pt;">Transition Services Agreement</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#TSA">57</a></font><a href="#TSA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#PN2"><font style="letter-spacing:0.2pt;">PROPOSAL NO. 2 THE ADJOURNMENT PROPOSAL </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#PN2">59</a></font><a href="#PN2"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:427.33pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#SOOC"><font style="letter-spacing:0.2pt;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#SOOC">60</a></font><a href="#SOOC"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#IOCD"><font style="letter-spacing:0.2pt;">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#IOCD">62</a></font><a href="#IOCD"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#OTIN"><font style="letter-spacing:0.2pt;">OTHER INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#OTIN">63</a></font><a href="#OTIN"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#WYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#WYCF">64</a></font><a href="#WYCF"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#MAOM"><font style="letter-spacing:0.2pt;">MISCELLANEOUS AND OTHER MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#MAOM">65</a></font><a href="#MAOM"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#ANA"><font style="letter-spacing:0.2pt;">ANNEX A ASSET PURCHASE AGREEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#ANA">A-1</a></font><a href="#ANA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#ANB"><font style="letter-spacing:0.2pt;">ANNEX B FORM OF VOTING AND SUPPORT AGREEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#ANB">B-1</a></font><a href="#ANB"> </a>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#ANC"><font style="letter-spacing:0.2pt;">ANNEX C OPINION OF VELOCITYHEALTH SECURITIES, INC. </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#ANC">C-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0.315000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="SUM">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights information contained elsewhere in this proxy statement and may not contain all the information that is important to you with respect to the Transaction, the Agreement and the other matters being considered at the special meeting of the Company&#8217;s shareholders to which this proxy statement relates. We urge you to read carefully the remainder of this proxy statement, including the attached annexes, and the other documents to which we have referred you. For additional information on the Company included in documents incorporated by reference into this proxy statement, see the section entitled &#8220;Where You Can Find More Information&#8221; beginning on page <a href="#WYCF">64</a>. We have included page references in this summary to direct you to a more complete description of the topics presented below.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Any reference in this proxy statement to:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;font-style:italic;">
            <font style="font-style:normal;letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;font-style:italic;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Agreement</font><font style="letter-spacing:0.2pt;">&#8221; refers to the Asset Purchase Agreement, dated as of April&#160;22, 2026, by and among Apotex, Guarantor and the Company, a copy of which is attached as Annex A;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="font-style:italic;letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Apotex</font><font style="font-style:italic;letter-spacing:0.2pt;">&#8221; refers to Nuvo Pharmaceuticals (Ireland) DAC an Ireland designated activity company;</font><font style="letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;font-style:italic;">
            <font style="font-style:normal;letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;font-style:italic;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Guarantor</font><font style="letter-spacing:0.2pt;">&#8221; refers to Apotex Inc., a corporation incorporated under the laws of the Province of Ontario and an Affiliate of Apotex; and</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;font-style:italic;">
            <font style="font-style:normal;letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;font-style:italic;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Cumberland</font><font style="letter-spacing:0.2pt;">,&#8221; the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">,&#8221; &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">we</font><font style="letter-spacing:0.2pt;">,&#8221; &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">us</font><font style="letter-spacing:0.2pt;">,&#8221; or &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">our</font><font style="letter-spacing:0.2pt;">&#8221; refers to Cumberland Pharmaceuticals Inc., a Tennessee corporation.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Capitalized terms used but not otherwise defined in this proxy statement have the definitions as stated in the Agreement.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Information about the Parties to the Asset Purchase Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Company</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Cumberland is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. We are dedicated to our mission of working together to provide unique products that improve the quality of patient care. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by relatively small, targeted sales forces. We promote our approved products through our hospital, field and oncology sales divisions in the United States. We have also established a network of international partners with the needed regulatory and commercial capabilities to register and provide our medicines to patients in their countries. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our portfolio of brands approved for marketing by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) includes: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Acetadote</font><font style=" position:relative; bottom:4.25pt;font-weight:bold;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">acetylcysteine</font><font style="letter-spacing:0.2pt;">) injection, for the treatment of acetaminophen poisoning; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Caldolor</font><font style=" position:relative; bottom:4.25pt;font-weight:bold;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">ibuprofen</font><font style="letter-spacing:0.2pt;">) injection, for the treatment of pain and fever; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Kristalose</font><font style=" position:relative; bottom:4.25pt;font-weight:bold;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">lactulose</font><font style="letter-spacing:0.2pt;">) oral solution, a prescription laxative for the treatment of constipation; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Sancuso</font><font style=" position:relative; bottom:4.25pt;font-weight:bold;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">granisetron</font><font style="letter-spacing:0.2pt;">) transdermal patch, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Vaprisol</font><font style=" position:relative; bottom:4.25pt;font-weight:bold;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">conivaptan</font><font style="letter-spacing:0.2pt;">) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Vibativ</font><font style=" position:relative; bottom:4.25pt;font-weight:bold;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">telavancin</font><font style="letter-spacing:0.2pt;">) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Talicia</font><font style=" position:relative; bottom:4.25pt;font-weight:bold;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">omeprazole, amoxicillin and rifabutin</font><font style="letter-spacing:0.2pt;">) oral capsule, for the treatment of </font><font style="font-style:italic;letter-spacing:0.2pt;">H. pylori</font><font style="letter-spacing:0.2pt;"> infection. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In addition to these commercial brands, we have announced breakthrough results in a clinical study of our ifetroban product candidate in patients with cardiomyopathy associated with </font><font style="font-style:italic;letter-spacing:0.2pt;">Duchenne muscular dystrophy</font><font style="letter-spacing:0.2pt;"> (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">DMD</font><font style="letter-spacing:0.2pt;">&#8221;). This rare, fatal genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles. We then completed and submitted a clinical study report to the FDA and began interactions to determine their remaining development requirements. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We also have Phase&#160;II clinical programs underway evaluating our ifetroban product candidate in patients with 1) Systemic Sclerosis (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">SSc</font><font style="letter-spacing:0.2pt;">&#8221;) or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs and 2) Idiopathic Pulmonary Fibrosis (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">IPF</font><font style="letter-spacing:0.2pt;">&#8221;), the most common form of progressive fibrosing interstitial lung disease. Investigational new drug applications have been cleared by the FDA enabling us to launch clinical studies in each of these areas. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Cumberland has built core competencies for the acquisition, development, registration and commercialization of pharmaceutical products in the U.S. We believe we can leverage this existing infrastructure to support our continued growth. Our management team consists of pharmaceutical industry veterans with experience in business development, product development, regulatory affairs, manufacturing, sales, marketing and finance. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion arrangements. Our product development team creates proprietary formulations, manages our clinical studies, prepares our FDA submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacturing, release and shipment of our brands. Our marketing and sales organization is responsible for our commercial activities, and we work closely with our distribution partners to ensure the availability and delivery of our products, both domestically and internationally. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Apotex and Guarantor</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Apotex is a wholly owned subsidiary of Guarantor. Guarantor is a Canadian-based global health company with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, Guarantor is the largest Canadian-based pharmaceutical company. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Asset Purchase Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The Company has entered into the Agreement with Apotex and Guarantor pursuant to which the Company has agreed, subject to certain conditions, including the authorization and approval of the Agreement by its shareholders, to sell to Apotex its assets relating to the Company&#8217;s FDA-approved products, which consist of Acetadote</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Caldolor</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Sancuso</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vaprisol</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vibativ</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, as well as the Company&#8217;s equity interests in Talicia Holdings, Inc. (which holds the rights and assets associated with Talicia</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">) (collectively, the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Assets</font><font style="letter-spacing:0.2pt;">&#8221;), and Apotex has agreed to assume certain liabilities relating to the Assets arising after the closing of the transaction, in each case, subject to the terms and conditions of the Agreement. The Company will retain the assets associated with the Company&#8217;s ifetroban product candidates and CET (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Retained Programs</font><font style="letter-spacing:0.2pt;">&#8221;), our majority-owned subsidiary focused on earlier-stage product development, which the Company intends to continue to develop following the closing of the Transaction. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">For additional information on the Agreement, see the section entitled &#8220;Proposal No. 1: The Transaction Proposal&#8221; beginning on page <a href="#PN1T">21</a>. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Voting and Support Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Simultaneously with the execution of the Agreement, Apotex and the Company entered into voting and support agreements (each, a &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Voting and Support Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) with certain of the Company&#8217;s directors and executive officers who, collectively, hold approximately 41% of the total outstanding shares of the Company&#8217;s common stock, $0.00 par value per share (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Common Stock</font><font style="letter-spacing:0.2pt;">&#8221;), as of the Record Date. Pursuant to the Voting and Support Agreements, each shareholder signatory thereto has agreed, with respect to all of the shares of Common Stock that such shareholder beneficially owns as of the date thereof or thereafter (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Covered Stock</font><font style="letter-spacing:0.2pt;">&#8221;), to, among other things, (a)&#160;vote in favor of the Transaction; and (b)&#160;not transfer any such Covered Stock during the term of such Voting and Support Agreement. The Voting and Support </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Agreements will terminate upon the earlier of the termination of the Agreement in accordance with its terms or the consummation of the closing of the Transaction, with certain provisions surviving, including, in the case of the Company&#8217;s Chief Executive Officer, restrictive covenants that mirror those to which the Company will be subject. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The foregoing description of the Voting and Support Agreements is only a summary, does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the form of Voting and Support Agreement, a copy of which is attached as </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex B</font><font style="letter-spacing:0.2pt;"> hereto and is incorporated herein by reference. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Consideration for the Transaction</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">As consideration for the Transaction, Apotex agreed to pay the Company $100&#160;million at the closing (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Consideration</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Use of Proceeds and Future Operations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We currently intend to utilize the cash proceeds from the sale of the Assets to maximize the value of our Retained Programs and for other working capital purposes. Our Board of Directors will also continue to evaluate other activities aimed at enhancing shareholder value, which may potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. No such activities are currently pending. The Company does not currently intend to distribute any of the proceeds from the Transaction as a dividend to the Company&#8217;s shareholders. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Expected Timing of the Transaction</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We expect to complete the Transaction in the second or third quarter of 2026, promptly following the special meeting of shareholders, if the Transaction Proposal is approved by our shareholders and all other conditions to closing are satisfied or waived. However, there can be no assurance that the Transaction will be completed within the anticipated timeframe, or at all. Certain factors, including factors outside of our control and the control of Apotex, could result in the Transaction being delayed or not consummated. Please refer to the section entitled &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; beginning on page <a href="#CSRF">12</a>. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Conditions to Closing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The completion of the Transaction is subject to the satisfaction or waiver of certain closing conditions, including, among other things, the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the Company obtaining the Requisite Stockholder Approval; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the required third-party consents or notices to assign to Apotex each Material Contract or other Acquired Asset; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the delivery of certificates in connection with the Transaction; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the absence of a law or any Action pending governmental action that would prohibit the consummation of the Transaction; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the absence of a Material Adverse Effect; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the accuracy of the representations and warranties of Apotex and the Company set forth in the Agreement as of the date of the closing, subject, in certain circumstances, to certain materiality thresholds; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the performance and material compliance by Apotex and the Company of their agreements, covenants and conditions required by the Agreement prior to or on the date of closing. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">For additional information on the parties&#8217; conditions to closing, see &#8220;Proposal No. 1: The Transaction Proposal&#8201;&#8212;&#8201;The Asset Purchase Agreement&#8201;&#8212;&#8201;Closing Conditions&#8221; beginning on page <a href="#CLCO">53</a>. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-bottom:20pt; margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Exclusivity</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The Agreement requires that the Company, from execution of the Agreement until the earlier of the termination of the Agreement or closing of the Transaction, not initiate contact with or solicit any inquiry or proposal or engage in any discussions with third parties in connection with possible proposals regarding a sale or licensing of the Assets and certain other strategic transactions involving the Company, subject to a customary &#8220;fiduciary out&#8221; provision that allows the Company to participate in discussions and engage in negotiations with third parties under certain specified circumstances. The Company has agreed to promptly provide notice to Apotex of any solicitation or offer made by any third party in connection with such alternative transaction. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Termination of the Asset Purchase Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The Agreement may be terminated prior to closing, subject to limitations relating to a party&#8217;s breach or failure to perform, as follows: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">by the mutual written agreement of the Company and Apotex; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">by either Apotex or the Company if a Law or final, non-appealable governmental Order prohibits the consummation of the Transaction; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">by either Apotex or the Company if the Transaction has not been consummated by the Outside Date; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">by either Apotex or the Company if the Requisite Stockholder Approval is not obtained; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">by Apotex if prior to obtaining the Requisite Stockholder Approval, the Company&#8217;s Board of Directors effects a Board Recommendation Change; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">by the Company, prior to obtaining the Requisite Stockholder Approval, to enter into an Alternative Transaction Agreement with respect to a Superior Proposal; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">by Apotex for a material breach of the Agreement by the Company or if the Company&#8217;s representations and warranties fail to be true and correct; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">by the Company for a material breach of the Agreement by Apotex or if Apotex&#8217;s representations and warranties fail to be true and correct. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Parties&#8217; Obligations Upon Termination</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The Agreement may be terminated by either party if the transaction is not completed by August&#160;20, 2026 (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Outside Date</font><font style="letter-spacing:0.2pt;">&#8221;) or otherwise under certain specified conditions. If the Agreement is validly terminated pursuant to the Outside Date provision, and prior to such termination an Acquisition Proposal has been received and, within twelve (12) months following such termination, the Company consummates an Acquisition Transaction or enters into a definitive agreement with respect to an Acquisition Transaction (which is subsequently consummated), then the Company must pay a termination fee of $4,000,000 (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Cumberland Termination Fee</font><font style="letter-spacing:0.2pt;">&#8221;) to Apotex. The Company must also pay the Cumberland Termination Fee to Apotex if Apotex terminates the Agreement due to a breach of the Agreement by the Company, the Company fails to obtain the Requisite Stockholder Approval, the Board effects a Board Recommendation Change, or the Company terminates the Agreement in order to enter into a definitive agreement with respect to a Superior Proposal. If the Agreement is validly terminated pursuant to the Outside Date provision at a time when all closing conditions of Apotex have been satisfied or are capable of being satisfied and the Company stood (and stands) ready, willing and able to consummate the closing, and Apotex fails to consummate the closing within three (3)&#160;Business Days after when it is required to do so, then Apotex must pay a termination fee of $4,000,000 to the Company. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">For additional information on the parties&#8217; obligations upon termination, see &#8220;Proposal No. 1: The Transaction Proposal&#8201;&#8212;&#8201;The Asset Purchase Agreement&#8201;&#8212;&#8201;Effect of Termination and the Parties&#8217; Obligations Upon Termination&#8221; beginning on page <a href="#EOTA">54</a>. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Post-Closing Arrangements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The Agreement contains certain covenants that will survive the closing of the transaction, including: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Subject to the limitations in the Agreement, the Company has agreed to indemnify Apotex and its Affiliates and their respective successors, permitted assigns, directors, officers, agents and employees for any losses incurred by any of them in connection with (i)&#160;any breach of any representation or warranty of the Company (subject to the applicable survival periods, deductible and cap limitations described below), (ii)&#160;any breach of the Cumberland Fundamental Representations, (iii)&#160;any breach of the Cumberland Sufficiency Representations, (iv)&#160;a breach of, default in, or failure to perform any of the covenants given or made by the Company in the Agreement, the IP Assignment Agreement or the Bill of Sale and Assignment and Assumption Agreement, (v)&#160;the Company&#8217;s ownership and operation of the Assets, and the research, development, obtaining and maintaining of regulatory approvals for, manufacture, sale, licensure, marketing, promotion, commercialization, distribution, exportation, importation or offering of the Products and INDs by the Company through the Closing Date, (vi)&#160;any and all Excluded Assets and Excluded Liabilities, and (vii)&#160;any businesses of the Company other than the Business. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Subject to the limitations in the Agreement, Apotex has agreed to indemnify the Company and its Affiliates and their respective successors, permitted assigns, directors, officers, agents and employees for any losses incurred by any of them in connection with (i)&#160;any breach of any representation or warranty of Apotex (other than the Apotex Fundamental Representations), (ii)&#160;any breach of any Apotex Fundamental Representation, (iii)&#160;a breach of, default in, or failure to perform any of the covenants given or made by Apotex in the Agreement, the IP Assignment Agreement or the Bill of Sale and Assignment and Assumption Agreement, (iv)&#160;Apotex&#8217;s ownership and operation of the Assets, and the research, development, obtaining and maintaining of Regulatory Registrations and Regulatory Approvals for, manufacture, sale, licensure, marketing, promotion, commercialization, distribution, exportation, importation or offering of the Products and INDs by Apotex after the Closing Date, and (v)&#160;any and all Assumed Liabilities. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">The indemnification obligations under the Agreement are subject to certain limitations. With respect to the Company&#8217;s general representations and warranties, the aggregate amount recoverable by the Apotex Indemnified Parties is limited to ten&#160;percent (10%) of the Purchase Price (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">General Cap</font><font style="letter-spacing:0.2pt;">&#8221;). Claims for breaches of the Cumberland Fundamental Representations, Cumberland Sufficiency Representations, and certain representations related to tax matters are excluded from the General Cap. The aggregate amount recoverable by the Apotex Indemnified Parties for breaches of the Company&#8217;s representations and warranties (including the Cumberland Fundamental Representations, the Cumberland Sufficiency Representations and the tax representations) and breaches of the Company&#8217;s covenants (other than for Fraud) is limited to the Purchase Price. The aggregate amount recoverable by the Cumberland Indemnified Parties for breaches of Apotex&#8217;s general representations and warranties is limited to the General Cap, and the aggregate amount recoverable for breaches of Apotex&#8217;s representations and warranties (including the Apotex Fundamental Representations) and breaches of Apotex&#8217;s covenants (other than for Fraud) is limited to the Purchase Price. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">No indemnification is payable for claims under the Company&#8217;s or Apotex&#8217;s representations and warranties until the aggregate losses exceed $1,000,000 (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Deductible</font><font style="letter-spacing:0.2pt;">&#8221;), and then only to the extent such aggregate amount exceeds the Deductible. In addition, no individual claim is recoverable unless it exceeds $50,000 (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">De Minimis Threshold</font><font style="letter-spacing:0.2pt;">&#8221;), but any Losses below the De Minimis Threshold will be taken into account for purposes of determining whether the Deductible has been exceeded. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">The parties&#8217; indemnification rights under Article&#160;IX of the Agreement constitute the sole and exclusive monetary remedy with respect to matters covered by the Agreement, subject to exceptions for Fraud and claims under the Transition Services Agreement. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Each party has agreed to keep confidential, and to use commercially reasonable efforts to cause its Representatives and Affiliates who actually receive such information to keep confidential, all Confidential Information relating to the Agreement, the Business, the Products, the Assets (including trade secrets in perpetuity and any confidential information transferred to Apotex pursuant to the </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">terms of the Agreement), the Assumed Liabilities, the financial information and operations of the Company which have not been publicly disclosed, and any liabilities or obligations excluded from the Assumed Liabilities, until the later of three&#160;years after Closing and the date the Products are no longer marketed by Apotex (with trade secrets protected for so long as they remain trade secrets). Exceptions include disclosures required by applicable Laws or securities exchange rules, disclosures necessary to defend or prosecute indemnification claims or litigation, disclosures required by transition and license obligations, and information that is lawfully available to the public as of the Closing Date or that thereafter becomes public other than through a breach. </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">From the Effective Date until thirty (30) days after the Closing Date, the Company has agreed to make the Business Employees available to Apotex for purposes of interviews and to cooperate with Apotex in the employment of such Business Employees. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">For a period of up to three (3)&#160;years after the Closing Date, the Company has agreed to deliver to Apotex certain government price reporting information for the Assets and Assumed Liabilities. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">The Company and its Affiliates have agreed to certain restrictive covenants that will survive the closing, including (i)&#160;an eighteen (18)-month non-solicitation and non-hire restriction with respect to Transferred Business Employees, (ii)&#160;a four (4)-year non-interference restriction with respect to business relations of Apotex relating to the Products, (iii)&#160;a four (4)-year non-compete restriction prohibiting the Company and its Affiliates from engaging in any business in the Territory that competes with the Products (subject to customary carve-outs), and (iv)&#160;a three (3)-year non-disparagement restriction. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Apotex has agreed to an eighteen (18)-month non-solicitation and non-hire restriction with respect to employees of the Company (other than Transferred Business Employees) with whom Apotex and its Subsidiaries had material interactions in connection with the Transactions, subject to customary carve-outs. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Apotex has agreed to pay the Company up to $10&#160;million, subject to the terms and conditions set forth in the Agreement, upon the achievement of two milestones: (i)&#160;prior to the two (2)&#160;year anniversary of the closing of the Transaction, Apotex or its Affiliates is awarded a contract by the United States Department of Health and Human Services (or any division thereof) for the supply of Vibativ for certain specified uses (the &#8220;Vibativ Contract&#8221;), and (ii)&#160;prior to the ten (10) year anniversary of the closing of the Transaction, Apotex and its Affiliates realize certain net sales pursuant to the Vibativ Contract. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">For a period of up to three (3)&#160;years after the Closing Date, the parties will cooperate to ensure that any Assets or other assets primarily related to the Products or the Business that were not properly transferred at the closing, or any Excluded Assets that were transferred to Apotex, are promptly transferred to the correct party. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">In connection with the guarantee of Apotex&#8217;s obligations, Guarantor has absolutely, irrevocably and unconditionally guaranteed to the Company the due and punctual payment in full of any payments (including the Purchase Price), indemnification obligations, and the payment of any other obligations of Apotex required under the Agreement or under any other Transaction Document. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Opinion of the Company&#8217;s Financial Advisor on the Transaction</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In connection with the Transaction, the Company&#8217;s financial advisor, VelocityHealth Securities, Inc. (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">VelocityHealth</font><font style="letter-spacing:0.2pt;">&#8221;) delivered to Cumberland&#8217;s Board of Directors its written opinion, dated April&#160;15, 2026 (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">VelocityHealth Opinion</font><font style="letter-spacing:0.2pt;">&#8221;), that, as of that date and based upon market multiples typical for acquisitions of branded pharmaceutical products and its valuation analysis, the Consideration to be paid to the Company from Apotex in the Transaction pursuant to the Agreement was fair and reasonable to the Company, from a financial point of view. The full text of the opinion, which describes, among other things, the assumptions made, procedures followed, factors considered and limitations on the review undertaken, is attached as </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex C</font><font style="letter-spacing:0.2pt;"> to this proxy statement and is incorporated herein by reference in its entirety. The VelocityHealth Opinion was for the information of, and directed to, the Board for its information and assistance in connection with its consideration of the financial terms of the Transaction and only addresses the fairness to the Company, from a financial point of view and as of the date of the VelocityHealth </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Opinion, of the Consideration to be received by the Company from Apotex pursuant to the Agreement. The VelocityHealth Opinion did not constitute a recommendation to the Board or any other person as to how the Board or any other person should vote or otherwise act with respect to the Transaction or any other matter, or to any shareholder of the Company as to how any such shareholder should vote or act with respect to the Transaction or any other matter, including, without limitation, whether or not any shareholder of the Company should enter into a voting agreement with respect to the Transaction. Shareholders are encouraged to read the opinion carefully and in its entirety. See &#8220;Proposal No. 1: The Transaction Proposal&#8201;&#8212;&#8201;Opinion of the Company&#8217;s Financial Advisor&#8221; beginning on page <a href="#OOTC">39</a>.</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="QAAA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How do I attend the special meeting?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will host the special meeting at the Company&#8217;s corporate offices located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203. There will be no virtual attendance option for the special meeting, whether by teleconference, electronic meeting or otherwise. You do not need to attend the special meeting in order to vote. Instructions on how to vote shares are described herein. </font>
        </div>
        <div style="margin-top:11.02pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Who may vote at the special meeting?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Shareholders who owned shares of Common Stock as of the close of business on May&#160;12, 2026 (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Record Date</font><font style="letter-spacing:0.2pt;">&#8221;) are entitled to vote at the special meeting on all matters properly brought before the special meeting. </font>
        </div>
        <div style="margin-top:11.02pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Shareholder of Record: Shares Registered in Your Name</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If on May&#160;12, 2026, your shares were registered directly in your name with Cumberland&#8217;s transfer agent, Continental Stock Transfer &amp; Trust Company, then you are a shareholder of record. As a shareholder of record, you may vote by proxy or by attending the special meeting and voting online. Whether or not you plan to attend the meeting, we urge you to fill out and return the enclosed proxy card or vote by proxy on the Internet or by mobile device as instructed below to ensure your vote is counted. </font>
        </div>
        <div style="margin-top:11.02pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Beneficial Owner: Shares Registered in the Name of a Broker or Bank</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If on May&#160;12, 2026, your shares were held, not in your name, but rather in an account at a brokerage firm, bank or other similar organization, then you are the beneficial owner of shares held in &#8220;street name&#8221; and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered to be the shareholder of record for purposes of voting at the special meeting. As a beneficial owner, you have the right to direct your broker, bank or other agent regarding how to vote the shares in your account. You are also invited to attend the special meeting. However, since you are not the shareholder of record, you may not vote your shares at the meeting unless you request and obtain a valid proxy from your broker, bank or other agent. </font>
        </div>
        <div style="margin-top:11.01pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How many votes do I have?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each share of Common Stock is entitled to one vote on each matter that comes before the special meeting. </font>
        </div>
        <div style="margin-top:11.01pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Why might the special meeting be adjourned or postponed?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board intends to adjourn and postpone the special meeting if the number of shares of Common Stock anticipated to be present at the special meeting, in person or represented by proxy, is insufficient to constitute a quorum. The special meeting may also be adjourned in the circumstances contemplated by the Adjournment Proposal, described below. </font>
        </div>
        <div style="margin-top:10.92pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What constitutes a quorum?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In accordance with Tennessee law (the law under which we are incorporated) and our bylaws, the presence at the special meeting, by proxy or by attending in person, of the holders of a majority of the shares entitled to vote at the special meeting constitutes a quorum, thereby permitting the shareholders to conduct business at the special meeting. As of the Record Date, there were 14,983,107 shares of Common Stock outstanding and entitled to vote at the special meeting; thus a quorum for the special meeting will be 7,491,554 shares of Common Stock. Abstentions will be counted for the purpose of establishing a quorum at the special meeting, but broker non-votes will not be counted for this purpose. </font>
        </div>
        <div style="margin-top:10.91pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How do I vote?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">You are entitled to attend and participate in the special meeting only if you were a shareholder as of the Record Date or if you hold a valid proxy for the special meeting. We encourage shareholders to vote well before the special meeting, even if you plan to attend the special meeting in person. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you are a shareholder of record and your shares are registered directly in your name, you may vote: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">By Internet</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;You may vote by proxy via the Internet at www.cstproxyvote.com by following the instructions provided on the proxy card. You must have the proxy card available when voting. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">By Mobile Device</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;On your Smartphone/Tablet, open the QR Reader and scan the image on the proxy card. Once the voting site is displayed, enter your Control Number from the proxy card and vote your shares. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">By Mail</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided. Your proxy will be voted in accordance with your instructions. If you sign and return the enclosed proxy but do not specify how you want your shares voted, they will be voted in accordance with the recommendations of the Board and will be voted according to the discretion of the named proxy holders on the proxy card upon any other business that may properly be brought before the special meeting and at all adjournments and postponements thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">At the Special Meeting</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;You may vote by attending the special meeting in person. The special meeting will be held at the Company&#8217;s corporate offices located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Will my shares be voted if I do not return my proxy?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If your shares are registered directly in your name, your shares will not be voted if you do not vote over the Internet or by mobile device, by returning your proxy or by attending the special meeting and voting in person. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Stock exchange rules allow brokers to vote on behalf of their customers for certain routine matters if customers do not provide voting instructions with respect to their shares, but brokers are not permitted to vote on non-routine matters. Broker non-votes are shares represented at the special meeting held by banks, brokers or other nominees for which instructions have not been received from the beneficial owners or persons entitled to vote such shares and such banks, brokers or other nominees do not have the discretion to vote such shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because each proposal being considered at the special meeting is a non-routine matter, shares of our Common Stock as to which brokers have not received any voting instructions will not be deemed present for any purpose at the special meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The inspector of elections will treat broker non-votes as shares that are not present and entitled to vote for the purpose of determining the presence of a quorum. Because the vote required to approve the Transaction Proposal is based on a&#160;percentage of the total number of shares entitled to vote on the proposal, broker non-votes will have the effect of a vote &#8220;AGAINST&#8221; the Transaction Proposal. However, broker non-votes, if any, will have no effect on the outcome of any vote on the Adjournment Proposal. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We encourage you to vote using one of the methods described above or to provide voting instructions to your bank, broker or other nominee in accordance with their directions. This ensures that your shares will be voted at the special meeting according to your instructions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Board does not currently know of any other matter that may come before the special meeting. However, your proxies are authorized to vote on your behalf, using their discretion, on any other business that properly comes before the special meeting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How does our Board of Directors recommend that I vote?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Board of Directors recommends that you vote: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:7.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">FOR</font><font style="letter-spacing:0.2pt;"> the authorization and approval of the Transaction as contemplated by the Agreement regarding the sale to Apotex of substantially all of the assets comprising the Company&#8217;s FDA-approved products and related assets, which may be deemed under Tennessee law to be a sale of substantially all of our property and assets otherwise than in the usual and regular course of business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:7.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">FOR</font><font style="letter-spacing:0.2pt;"> the Board authorization to adjourn and postpone the special meeting to a later date or dates if there are insufficient votes to approve the Transaction Proposal; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">3.</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">In the proxy&#8217;s discretion with respect to any other business which is properly brought before the special meeting or any adjournment or postponement thereof, including matters incidental to its conduct. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of the date of this proxy statement, we are not aware of any matters other than those set forth in proposals 1 and 2 that will be brought before the special meeting. </font>
        </div>
        <div style="margin-top:11.81pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">May I revoke my proxy?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you submit a proxy, then you may revoke it at any time before it is exercised, as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:6.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">You may send in another proxy bearing a later date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:6.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">You may send written notice (if the shareholder is an entity, by an officer or other authorized person of the entity) addressed to the Corporate Secretary at the Company&#8217;s principal executive office before the special meeting that you are revoking your proxy; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:6.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">You may attend the special meeting and vote in person. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:11.82pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What vote is required to approve each proposal?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">The Transaction Proposal</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;The authorization and approval of the Transaction Proposal require the affirmative vote of the holders of a majority of all shares entitled to vote on the Transaction Proposal. You may vote &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN.&#8221; Failures to vote, abstentions and broker non-votes, if any, will have the same effect as a vote &#8220;AGAINST&#8221; the Transaction Proposal. As of the Record Date, there were 14,983,107 shares of Common Stock outstanding and entitled to vote at the special meeting; thus approval of the Transaction Proposal will require the affirmative vote of at least 7,491,554 shares of Common Stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">The Adjournment Proposal</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;The approval of the Adjournment Proposal requires that the number of votes cast for the Adjournment Proposal at the special meeting exceed the number of votes cast against the Adjournment Proposal. You may vote &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN.&#8221; Failures to vote, abstentions and broker non-votes, if any, will have no effect on the outcome of the vote on the Adjournment Proposal. </font>
        </div>
        <div style="margin-top:11.71pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Are there any dissenters&#8217; rights of appraisal?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">No, holders of shares of Common Stock do not have appraisal rights under Tennessee law or under the governing documents of the Company in connection with the Transaction and this solicitation. </font>
        </div>
        <div style="margin-top:11.71pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Who bears the cost of soliciting proxies?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company will bear the cost of soliciting proxies in the accompanying form and will reimburse brokerage firms and others for expenses involved in forwarding proxy materials to beneficial owners or soliciting their execution. To assist in the solicitation of proxies, the Company has retained Sodali &amp; Co, as proxy solicitor, for a fee of $15,000 plus (i)&#160;$2,500 for administration, technology, and research and data services, (ii)&#160;a telephone solicitation charge, and (iii)&#160;reimbursement of out-of-pocket expenses for its services. The Company and its proxy solicitor may also request banks, brokers, trustees and other intermediaries holding shares of Common Stock beneficially owned by others to send this document to, and obtain proxies from, the beneficial owners and may reimburse such record holders for their reasonable out-of-pocket expenses in so doing. Solicitation of proxies by mail may be supplemented by telephone and other electronic means, advertisements and personal solicitation. No additional compensation will be paid to the Company&#8217;s directors, officers or employees for solicitation of proxies. </font>
        </div>
        <div style="margin-top:11.71pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Where is the Company&#8217;s principal executive office?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The principal executive office of the Company is located at 1600 West End Ave., Suite 1300, Nashville, TN 37203-7003, and the telephone number is (615) 255-0068. </font>
        </div>
        <div style="margin-top:11.72pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How can I obtain additional information about the Company?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Exchange Act</font><font style="letter-spacing:0.2pt;">&#8221;), which requires that it file reports, proxy statements and other information </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:364pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with the United States Securities and Exchange Commission (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">SEC</font><font style="letter-spacing:0.2pt;">&#8221;). The SEC maintains a website on the Internet that contains reports, proxy and information statements and other information regarding registrants, including the Company, that file electronically with the SEC. The SEC&#8217;s website address is http://www.sec.gov. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Whom can I call with questions about the special meeting or the Transaction?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you have questions about the special meeting or the Transaction, need additional copies of this document, have questions about the process for voting or need a replacement proxy card, you should contact: </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sodali &amp; Co</font> <br ><font style="letter-spacing:0.2pt;">430 Park Ave, 14th Floor</font> <br ><font style="letter-spacing:0.2pt;">New York, NY 10022</font> <br ><font style="letter-spacing:0.2pt;">Phone: (203) 658-9400</font> <br ><font style="letter-spacing:0.2pt;">Email: CPIZ@info.sodali.com </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Will the Transaction be a taxable transaction to me?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Transaction is entirely a corporate action, taxable to the Company. Holders of our shares will not realize any gain or loss for U.S. federal income tax purposes as a result of the Transaction. See the section below entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Certain Material U.S. Federal Income Tax Consequences</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#CMUF">47</a> for more information. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="CSRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:204pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This proxy statement and the attached annexes contain &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws. These forward-looking statements include statements concerning our outlook for the future, as well as other statements of beliefs, future plans and strategies or anticipated events, and similar expressions concerning matters that are not historical facts. These statements can be identified by the use of forward-looking terminology such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;anticipates,&#8221; &#8220;projects,&#8221; &#8220;targets&#8221;, &#8220;optimistic,&#8221; &#8220;intends,&#8221; or &#8220;aims,&#8221; or the negative thereof or other variations thereon or other comparable terminology. The forward-looking statements included in this proxy statement or the attached annexes are based on management&#8217;s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statement. These risks and uncertainties include, but are not limited to, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our shareholders failing to approve the Transaction Proposal; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the failure of one or more conditions to the closing of the Transaction to be satisfied or waived by the applicable party; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an increase in the amount of costs, fees, expenses and other charges related to the Agreement or Transaction, including in connection with any litigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the occurrence of any event, change or other circumstances that could give rise to the termination of the Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">risks arising from the diversion of management&#8217;s attention from our ongoing business operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">risks associated with our ability to monetize the Retained Programs and/or to identify and realize business opportunities following the Transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">risks of losing key personnel or suppliers; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the matters discussed under &#8220;Item&#160;1A. Risk Factors&#8221; of the Company&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2025 filed with the SEC on March&#160;9, 2026, as amended and updated from time to time in the Company&#8217;s subsequent filings with the SEC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Readers are cautioned not to place undue reliance on forward-looking statements. Any forward-looking statement speaks only as of the date that it was made and we undertake no obligation to update any forward-looking statement, whether as a result of new information or otherwise. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="UPFF">&#8203;</a><a name="UPFF1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UNAUDITED PRO FORMA FINANCIAL INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are providing the following information to aid you in your financial analysis of the proposed Transaction. The following unaudited pro&#160;forma condensed consolidated financial data gives effect to the Transaction. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unaudited Pro Forma Financial Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following unaudited pro&#160;forma condensed consolidated balance sheet data as of March&#160;31, 2026 is presented to show how the Transaction might have affected the historical financial statements of the Company if the Transaction had occurred on March&#160;31, 2026. The following unaudited pro&#160;forma condensed consolidated statements of operations data for the year ended December&#160;31, 2024, December&#160;31, 2025 and the three&#160;months ended March&#160;31, 2026 are presented as if the Transaction occurred on January&#160;1, 2024. The Transaction is expected to meet the criteria in ASC 205-20 to begin being presented as a discontinued operation in the second quarter of 2026 due to disposal of most of the Company&#8217;s revenue-generating operations and the resulting strategic shift toward development-stage activities. As a disposal that meets the criteria for discontinued operations, we are required to present an unaudited pro&#160;forma condensed consolidated statement for each historical period presented in the Company&#8217;s Annual Report on Form&#160;10-K. The unaudited pro&#160;forma condensed consolidated financial statements are derived from, and should be read in conjunction with our historical financial statements and notes thereto, as presented in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2025 and in the Company&#8217;s Quarterly Report on Form 10-Q for the three&#160;months ended March&#160;31, 2026, as previously filed with the SEC. The unaudited pro&#160;forma condensed consolidated financial information has been prepared in accordance with Article&#160;11 of Regulation&#160;S-X. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Article&#160;11 of Regulation&#160;S-X requires that pro&#160;forma financial information include pro&#160;forma adjustments to the historical financial statements of the registrant that reflect only the application of required accounting to the Transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Transaction accounting adjustments to reflect the Transaction in the unaudited pro&#160;forma condensed consolidated financial statements include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the sale of the operations, assets and liabilities of the Company&#8217;s Assets involved in the Transaction pursuant to the Agreement, and; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">adjustments required to record the estimated impact of the proceeds received in connection with the Transaction, net of transaction costs. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, Regulation&#160;S-X permits registrants to reflect adjustments that depict synergies and dis-synergies of the disposition for which pro&#160;forma effect is being given. The unaudited pro&#160;forma condensed consolidated financial statements do not reflect any such adjustments. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company expects to execute a transition services agreement at closing of the Transaction, which will include services to be provided to Apotex for up to 12&#160;months following the Closing Date. The unaudited pro&#160;forma condensed consolidated statements of operations are not required to present the impact of the transition services agreement, as these amounts are not expected to be material. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The unaudited pro&#160;forma condensed consolidated financial statement information is presented for informational purposes only and is based upon estimates by the Company&#8217;s management, which are based upon available information and certain assumptions that Company&#8217;s management believes are reasonable as of the date of this proxy statement. The unaudited pro&#160;forma condensed consolidated financial statements are not intended to be indicative of the actual financial position or results of operations that would have been achieved had the Transaction been consummated as of the dates and for the periods indicated above, nor does it purport to indicate results which may be attained in the future. Actual amounts could differ materially from these estimates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The unaudited pro&#160;forma condensed consolidated balance sheet as of March&#160;31, 2026 and the unaudited pro&#160;forma condensed consolidated statements of operations for the three&#160;months ended March&#160;31, 2026 and&#160;years ended December&#160;31, 2025 and December&#160;31, 2024 should be read in conjunction with the notes thereto. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cumberland Pharmaceuticals, Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET</font>
          <br >
          <font style="letter-spacing:-0.2pt;">AS OF MARCH 31, 2026</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:601pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:228.02pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="19">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">March&#160;31, 2026 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Historical CPIX, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transaction</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Accounting</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:36.3pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">ProForma </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Cumberland</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Pharmaceuticals, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">ASSETS </font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current assets: </font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,007,245</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">99,241,674</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.3pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(iii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">110,248,919</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivable, net of allowances </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">14,261,978</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">14,261,978</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Inventories </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,453,836</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(5,423,901<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.3pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) &amp; (iv) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">29,935</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Prepaid assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,066,198</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(1,144,950<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.3pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">921,248</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Deferred tax assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">32,789,257</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">92,672,823</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">125,462,080</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Intercompany accounts </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Investment in subsidiary </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Property and Equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">237,375</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">237,375</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Intangible assets, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12,793,249</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(12,743,179<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.3pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">50,070</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Goodwill </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">914,000</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(914,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.3pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Deferred tax assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Noncurrent Inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,875,505</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(9,834,626<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.3pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) &amp; (iv) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">40,879</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating lease right-of-use assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,618,720</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(1,770,712<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.3pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">5,848,008</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other Investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,840,700</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(3,840,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.3pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,926,214</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">2,926,214</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">70,995,020</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">63,569,605</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">134,564,625</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current liabilities: </font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Current portion of long-term debt </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Revolving line of credit </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Current portion of other long-term obligations </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">16,537,072</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">16,537,072</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating lease current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">485,162</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">485,162</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other accrued liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">17,465,817</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">2,567,863</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.3pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(ii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">20,033,680</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">34,488,051</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">2,567,863</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">37,055,914</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Revolving line of credit </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,240,733</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">5,240,733</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Long-term debt, excluding current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Deferred Tax Liability&#8201;&#8211;&#8201;Long-term </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income Taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">3,294,607</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.3pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(iii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">3,294,607</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating lease non-current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,343,892</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">4,343,892</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:228.02pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Other long-term obligations, excluding current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,619,332</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(2,028,809<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:36.3pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">3,590,523</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">49,692,008</td>
            <td style="padding:0pt;padding-left:6.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">3,833,661</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">53,525,669</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:433pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:178pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:228.02pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="19">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">March&#160;31, 2026 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:228.02pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Historical CPIX, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transaction</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Accounting</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:36.3pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">ProForma </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Cumberland</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Pharmaceuticals, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:228.02pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Shareholders&#8217; equity: </font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:228.02pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Cumberland Pharmaceuticals Inc. shareholders&#8217; equity: </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.375pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">51,730,222</td>
            <td style="padding:0pt;padding-left:4.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">51,730,222</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Retained earnings </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.375pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(30,093,698<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">59,735,944</td>
            <td style="padding:0pt;padding-left:1.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.3pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(iii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">29,642,246</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:228.02pt;white-space:normal;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Total Cumberland Pharmaceuticals Inc. shareholders&#8217; equity </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.375pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">21,636,524</td>
            <td style="padding:0pt;padding-left:4.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.665pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">59,735,944</td>
            <td style="padding:0pt;padding-left:1.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">81,372,468</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Noncontrolling interest </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.375pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(333,512<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">(333,512<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:228.02pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total liabilities and shareholders&#8217; equity </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.375pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">70,995,020</td>
            <td style="padding:0pt;padding-left:4.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">63,569,605</td>
            <td style="padding:0pt;padding-left:1.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.3pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">134,564,625</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:133pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cumberland Pharmaceuticals, Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UNAUDITED PROFORMA CONSOLIDATED STATEMENTS OF OPERATIONS </font>
          <br >
          <font style="letter-spacing:-0.2pt;">FOR THE TWELVE MONTHS ENDED March&#160;31, 2026</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:426pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:242.87pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="19">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">March&#160;31, 2026 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:242.87pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Historical CPIX, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transaction </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Accounting</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:19.78pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">ProForma </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Cumberland</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Pharmaceuticals, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Revenues: </font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net product revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8,962,467</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(8,962,467<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">168,850</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(v) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">168,850</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Net revenues </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,131,317</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(8,962,467<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">168,850</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Costs and expenses: </font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of products sold </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,933,889</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(1,933,889<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Selling and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,064,875</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(5,064,875<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,458,436</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(698,216<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(ii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">760,220</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,445,944</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(248,512<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(iii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,197,432</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Amortization of product license right </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,248,934</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(1,248,934<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">108,531</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(v) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">108,531</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total costs and expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">12,260,609</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(9,194,426<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">3,066,183</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Operating income </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(3,129,292<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">231,959</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(2,897,333<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">78,031</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,090,719</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(iv) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,168,750</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other Income (Loss) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(146,080<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">146,080</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(vi) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(85,839<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">85,839</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(vii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Income (loss) before income taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(3,283,180<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,554,597</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(1,728,583<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax benefit (expense) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(3,871<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">3,871</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(viii) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Net income (loss) from continuing Operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(3,287,051<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,558,468</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(1,728,583<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:242.87pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Net (income) loss at subsidiary attributable to non-controlling interests </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(2,588<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(2,588<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:242.87pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss attributable to commonshareholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(3,289,639<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">1,558,468</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(1,731,171<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:242.87pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Basic and Diluted Net Loss per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(0.22<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">0.10</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(0.12<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:242.87pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted Average Shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,963,724</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,963,724</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,963,724</td>
            <td style="padding:0pt;padding-left:3.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:134.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cumberland Pharmaceuticals, Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UNAUDITED PROFORMA CONSOLIDATED STATEMENT OF OPERATIONS </font>
          <br >
          <font style="letter-spacing:-0.2pt;">FOR THE 12 MONTHS ENDED 12/31/2025</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:424.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:227.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="19">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">31-Dec-25 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:227.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Historical CPIX, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transaction </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Accounting</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:33.73pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">ProForma </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Cumberland</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Pharmaceuticals, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Revenues: </font>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.73pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net product revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">40,396,278</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(40,396,278<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:33.73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">4,125,153</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(3,000,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:33.73pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) &amp; (v) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">1,125,153</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Net revenues </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">44,521,431</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(43,396,278<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.73pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">1,125,153</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Costs and expenses: </font>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.73pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of products sold </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">6,667,207</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(6,667,207<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:33.73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Selling and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">19,098,153</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(19,098,153<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:33.73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,566,498</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(2,637,979<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:33.73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(ii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">2,928,519</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,489,783</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(1,175,102<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:33.73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(iii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">10,314,681</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Amortization of product license right </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,034,657</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(4,034,657<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:33.73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">457,126</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:33.73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(v) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">457,126</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total costs and expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">47,313,424</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(33,613,098<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:33.73pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">13,700,326</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Operating income </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(2,791,993<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(9,783,180<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.73pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(12,575,173<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">476,748</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">4,198,252</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:33.73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(iv) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">4,675,000</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other Income </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(13,220<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.73pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(13,220<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(495,990<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">495,990</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:33.73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(vii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:33.73pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Income (loss) before income taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(2,824,455<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(5,088,938<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.73pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(7,913,393<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax benefit (expense) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(40,256<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">40,256</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:33.73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(viii) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Net income (loss) from continuing Operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(2,864,711<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(5,048,682<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.73pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(7,913,393<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:227.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Net (income) loss at subsidiary attributable to non-controlling interests </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">28,583</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:33.73pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">28,583</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:227.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss attributable to commonshareholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(2,836,128<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(5,048,682<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:33.73pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(7,884,810<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Basic and Diluted Net Loss per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(0.19<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(0.34<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.73pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(0.53<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:227.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted Average Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,854,619</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">14,854,619</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:33.73pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">14,854,619</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:122.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cumberland Pharmaceuticals, Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UNAUDITED PROFORMA CONSOLIDATED STATEMENT OF OPERATIONS </font>
          <br >
          <font style="letter-spacing:-0.2pt;">FOR THE 12 MONTHS ENDED 12/31/2024</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:436.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:241.54pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="19">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">31-Dec-24 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:241.54pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Historical CPIX, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transaction </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Accounting</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:19.78pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">ProForma </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Cumberland</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Pharmaceuticals, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Revenues: </font>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net product revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">36,537,704</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(36,537,704<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">1,330,241</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(v) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">1,330,241</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Net revenues </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">37,867,945</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(36,537,704<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">1,330,241</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Costs and expenses: </font>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of products sold </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">6,585,972</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(6,585,972<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Selling and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">17,023,023</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(17,023,023<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,816,206</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(2,277,847<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(ii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">2,538,359</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10,722,963</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(1,197,527<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(iii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">9,525,436</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Amortization of product license right </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,748,252</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(4,748,252<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">403,938</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(v) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">403,938</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total costs and expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">44,300,354</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(31,832,621<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">12,467,733</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Operating income </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(6,432,409<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(4,705,083<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(11,137,492<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">334,444</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">4,340,556</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(iv) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">4,675,000</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other Income </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">237,089</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">237,089</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(605,508<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">605,508</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(vii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Net income before income taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(6,466,384<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">240,981</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(6,225,403<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax benefit (expense) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">22,669</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(22,669<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:19.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(viii) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Net income (loss) from continuing Operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(6,443,715<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">218,312</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(6,225,403<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:241.54pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Net loss at subsidiary attributable to noncontrolling interest </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(36,055<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(36,055<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.583pt 0pt; width:241.54pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Net income attributable to Cumberland Pharmaceuticals </font>
                <br >
                <font style="letter-spacing:0.2pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(6,479,770<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">218,312</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(6,261,458<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Basic and Diluted Net Loss per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(0.46<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">0.02</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(0.45<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:241.54pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted Average Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,060,272</td>
            <td style="padding:0pt;padding-left:3.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">14,060,272</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:19.78pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">14,060,272</td>
            <td style="padding:0pt;padding-left:1.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cumberland Pharmaceuticals, Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO THE UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL DATA</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:10.5pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;22, 2026, Cumberland Pharmaceuticals Inc. (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221; or &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Cumberland</font><font style="letter-spacing:0.2pt;">&#8221;) entered into an Asset Purchase Agreement (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) with an affiliate of Apotex Inc. (such affiliate,&#8221;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Apotex</font><font style="letter-spacing:0.2pt;">&#8221;), pursuant to which Apotex will acquire the Company&#8217;s right, title and interest in, to and under the assets relating to the Company&#8217;s FDA-approved products, which consist of Acetadote</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Caldolor</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Sancuso</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vaprisol</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vibativ</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, as well as certain of the Company&#8217;s product related equity interests (collectively, the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Acquired Assets</font><font style="letter-spacing:0.2pt;">&#8221;) in exchange for $100,000,000 payable at the closing of the transaction (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Transaction</font><font style="letter-spacing:0.2pt;">&#8221;). The Company will retain the assets associated with Emerging Technologies, Inc., its majority-owned subsidiary focused on earlier-stage product development, and the Company&#8217;s ifetroban product candidates (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Retained Programs</font><font style="letter-spacing:0.2pt;">&#8221;), which the Company intends to continue to develop following the closing of the Transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:10.5pt;">
          <font style="letter-spacing:0.2pt;">The unaudited pro&#160;forma combined financial statements reflect the following transaction accounting adjustments to the condensed consolidated balance sheet as of March&#160;31, 2026 and consolidated statements of operations for the three&#160;months ended March&#160;31, 2026 and the&#160;years ended December&#160;31, 2025 and 2024 to show how the Transaction might have affected the Company&#8217;s historical financial statements if the Transaction had been completed at an earlier time.</font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Adjustments to the Proforma Balance Sheet: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Eliminate the assets and liabilities disposed of in the asset sale transaction, which includes </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:416pt;height:88pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:358.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,423,901</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:358.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Prepaid Assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,144,950</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:358.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Goodwill &amp; Intangible Assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">13,657,179</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:358.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Non-current inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,834,626</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:358.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Investment in Manufacturing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,770,712</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:358.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Investment in THI </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,840,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:358.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Milestones &amp; Long Term Contingent Royalty Liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,028,809</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Eliminate the current accrued liabilites disposed of in the asset sale transaction, and recognize additional transaction related and other reserves </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:416pt;height:49.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:360.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Current Contingent Royalty Liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">1,945,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:360.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">THI Liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">4,487,137</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:360.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additional Transaction Related &amp; Other Reserves </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">-9,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt; width:360.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net Change </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(2,567,863<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Record the expected net consideration received, the expected gain on sale of the acquired assets, and the impact on retained earnings </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:416pt;height:102.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash received from Buyer upon closing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">100,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less: Estimated Transaction Costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">(758,326<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net proceeds from sale of assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">99,241,674</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less Assets and Liabilities Transferred </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">(27,211,123<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less Additional Transaction &amp; Other Reserves</font><font style=" position:relative; bottom:4.25pt;line-height:6.5pt;font-size:6.5pt;letter-spacing:0.15pt;">(a)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">(9,000,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Estimated Gain on Sale </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">63,030,551</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Estimated Income Tax (After consideration of tax loss carry forwards)</font><font style=" position:relative; bottom:4.25pt;line-height:6.5pt;font-size:6.5pt;letter-spacing:0.15pt;">(b)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">(3,294,607<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Estimated Gain after tax impact to retained earnings </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">59,735,944</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iv)</font>
          <br >
        </div>
        <div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The buyer has agreed to reimburse seller for up to $9M of existing inventory. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:10.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(a)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">anticipated liabilities for employee retention bonuses, termination severance costs, agreement termination penalties and additional legal or consulting fees. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the tax liability as stated is an estimate based on current assumptions. . </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:147pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cumberland Pharmaceuticals, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO THE UNAUDITED PROFORMA CONSOLIDATED STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Adjustments to the Proforma Consolidated Statement of Operations: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To eliminate operating activity directly attributable to the Program Assets which includes </font>
        </div>
        <table style="width:456pt;height:126pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:229.91pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Historical CPIX, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transaction </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Accounting</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:19.41pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">ProForma</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Cumberland</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Pharmaceuticals, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:229.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of Goods</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(a)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,933,889</td>
            <td style="padding:0pt;padding-left:8.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(1,933,889<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:19.41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:229.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Selling and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,064,875</td>
            <td style="padding:0pt;padding-left:8.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(5,064,875<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:229.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,458,436</td>
            <td style="padding:0pt;padding-left:8.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(698,216<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(ii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">760,220</td>
            <td style="padding:0pt;padding-left:8.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:229.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and Administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,445,944</td>
            <td style="padding:0pt;padding-left:8.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(248,512<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(iii) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,197,432</td>
            <td style="padding:0pt;padding-left:8.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:229.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Amortization of product license right </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:30.75pt; text-align:right; white-space:nowrap;">1,248,934</td>
            <td style="padding:0pt;padding-left:8.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">(1,248,934<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:19.41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">(i) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:229.91pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(9,194,426<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Net Product revenue, product related milestone revenue, cost of goods, sales and marketing and amortization of product license rights pertain to the products acquired by Apotex. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The adjustment to research and development includes FDA fees to be paid by Apotex, the Medical Sciensce Liaison department expenses and the compensation cost associated with select employees transferred to Apotex. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The adjustment to general and administrative includes product related insurance, legal fees, audit and tax preparation services. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iv)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">average expected return on a cash and debt instrument balance of approximately $85M at 5.5%. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(v)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Other revenue and expense consists of CET sub-lease income and expense. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(vi)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The Other Loss amount pertains to the investment in Talicia Holdings, Inc. to be acquired by Apotex. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(vii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">With the significant increase in cash, Cumberland will pay down the line of credit with Pinnacle Bank. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(viii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">With the divestiture, the Company&#8217;s nexus is limited to the state of Tennessee only. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:10.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(a)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Apotex has agreed to reimburse seller for up to $9M of existing inventory. We believe these transactions will be recognized on a post closing basis.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="PN1T">&#8203;</a><a name="IATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROPOSALS RECOMMENDED FOR CONSIDERATION BY SHAREHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROPOSAL NO. 1</font>
          <br >
          <font style="letter-spacing:-0.2pt;">THE TRANSACTION PROPOSAL</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Information about the Parties</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Company</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cumberland is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. We are dedicated to our mission of working together to provide unique products that improve the quality of patient care. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by relatively small, targeted sales forces. We promote our approved products through our hospital, field and oncology sales divisions in the United States. We have also established a network of international partners with the needed regulatory and commercial capabilities to register and provide our medicines to patients in their countries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our portfolio of brands approved for marketing by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) includes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Acetadote</font><font style=" position:relative; bottom:4.25pt;font-weight:bold;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">acetylcysteine</font><font style="letter-spacing:0.2pt;">) injection, for the treatment of acetaminophen poisoning; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Caldolor</font><font style=" position:relative; bottom:4.25pt;font-weight:bold;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">ibuprofen</font><font style="letter-spacing:0.2pt;">) injection, for the treatment of pain and fever; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Kristalose</font><font style=" position:relative; bottom:4.25pt;font-weight:bold;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">lactulose</font><font style="letter-spacing:0.2pt;">) oral solution, a prescription laxative for the treatment of constipation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Sancuso</font><font style=" position:relative; bottom:4.25pt;font-weight:bold;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">granisetron</font><font style="letter-spacing:0.2pt;">) transdermal patch, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Vaprisol</font><font style=" position:relative; bottom:4.25pt;font-weight:bold;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">conivaptan</font><font style="letter-spacing:0.2pt;">) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Vibativ</font><font style=" position:relative; bottom:4.25pt;font-weight:bold;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">telavancin</font><font style="letter-spacing:0.2pt;">) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Talicia</font><font style=" position:relative; bottom:4.25pt;font-weight:bold;font-size:7.5pt;letter-spacing:-0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">omeprazole, amoxicillin and rifabutin</font><font style="letter-spacing:0.2pt;">) oral capsule, for the treatment of </font><font style="font-style:italic;letter-spacing:0.2pt;">H. pylori</font><font style="letter-spacing:0.2pt;"> infection. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to these commercial brands, we have announced breakthrough results in a clinical study of our ifetroban product candidate in patients with cardiomyopathy associated with </font><font style="font-style:italic;letter-spacing:0.2pt;">Duchenne muscular dystrophy</font><font style="letter-spacing:0.2pt;"> (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">DMD</font><font style="letter-spacing:0.2pt;">&#8221;). This rare, fatal genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles. We then completed and submitted a clinical study report to the FDA and began interactions to determine their remaining development requirements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We also have Phase&#160;II clinical programs underway evaluating our ifetroban product candidate in patients with 1) Systemic Sclerosis (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">SSc</font><font style="letter-spacing:0.2pt;">&#8221;) or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs and 2) Idiopathic Pulmonary Fibrosis (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">IPF</font><font style="letter-spacing:0.2pt;">&#8221;), the most common form of progressive fibrosing interstitial lung disease. Investigational new study applications have been cleared by the FDA enabling us to launch clinical studies in each of these areas. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cumberland has built core competencies for the acquisition, development, registration and commercialization of pharmaceutical products in the U.S. We believe we can leverage this existing infrastructure to support our continued growth. Our management team consists of pharmaceutical industry veterans with experience in business development, product development, regulatory affairs, manufacturing, sales, marketing and finance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion arrangements. Our product development team creates proprietary formulations, manages our clinical studies, prepares our FDA submissions and staffs our medical call center. Our quality and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">manufacturing professionals oversee the manufacturing, release and shipment of our brands. Our marketing and sales organization is responsible for our commercial activities, and we work closely with our distribution partners to ensure the availability and delivery of our products, both domestically and internationally. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Products</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Agreement provides that the Company will sell its FDA-approved products to Apotex upon the closing of the Transaction. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Acetadote</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Acetadote is an intravenous formulation of N-acetylcysteine, indicated for the treatment of liver toxicity associated with acetaminophen poisoning. Cumberland developed and obtained U.S. FDA approval for Acetadote and then introduced the product through our hospital sales division. Acetadote is typically used in hospital emergency departments to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many over-the-counter and prescription pain-relieving and fever-reducing products. Acetaminophen overdose continues to be a leading cause of poisonings reported by hospital emergency departments in the U.S., and Acetadote became a standard of care for treating this potentially life-threatening condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Acetadote received U.S. FDA approval as an Orphan Drug, which provided seven&#160;years of marketing exclusivity from the date of approval. That exclusivity has since expired. In connection with the FDA&#8217;s approval of Acetadote, we committed to certain post-marketing activities for the product. Completion of our first Phase&#160;IV commitment resulted in the FDA&#8217;s approval of expanded labeling for Acetadote&#8217;s use in pediatric patients. Completion of our second Phase&#160;IV commitment resulted in further revised labeling for the product with FDA approval of additional safety data. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Completion of our third and final Phase&#160;IV commitment culminated in the FDA&#8217;s approval of a new formulation for the product. The next generation formulation contains no ethylene diamine tetracetic acid (&#8220;EDTA&#8221;) or other stabilization agent, chelating agent or preservative. Cumberland introduced this new Acetadote formulation replacing the original form of the product which we no longer manufacture. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA subsequently approved updated labeling for Acetadote revising the product&#8217;s indication and providing new dosing guidance for specific patient populations. As a result, dosing guidance was included for patients weighing over 100 kg, and new language was added to alert health care providers that, in certain clinical situations, therapy should be extended for some patients. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2024, the FDA also approved a supplemental New Drug Application for Acetadote, adding a simplified dosing regimen for the product prescribing information. This newly approved dosing regimen simplifies the administration of Acetadote by combining the first two bags of the standard three-bag regimen into a single, slower infusion for patients 41 kg or greater. This streamlined approach has been implemented in hospitals across multiple countries and has been shown to reduce the frequency of medication errors and potentially serious non-allergic anaphylactoid reactions without compromising the effectiveness of Acetadote. The FDA subsequently provided three&#160;years exclusivity for this new dosing regimen based on the supporting clinical data that the Company submitted, extending the exclusivity period for Acetadote to November&#160;26, 2027. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The United States Patent and Trademark Office (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">USPTO</font><font style="letter-spacing:0.2pt;">&#8221;) has issued Cumberland a series of patents associated with our Acetadote product. The FDA has approved several abbreviated new drug applications (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">ANDA</font><font style="letter-spacing:0.2pt;">&#8221;) filed by various generics companies referencing Acetadote. Those products all possess the old formulation containing EDTA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We entered into an agreement with Perrigo Company resulting in the distribution of our Authorized Generic acetylcysteine injection (our &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Authorized Generic</font><font style="letter-spacing:0.2pt;">&#8221;) product. Both Acetadote and our Authorized Generic utilize the new, EDTA-free formulation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">An Illinois judge issued a final ruling in favor of Cumberland Pharmaceuticals Inc. in a patent case associated with Acetadote. By ruling in Cumberland&#8217;s favor, the court upheld the validity of the patent that encompasses our EDTA-free formulation. The court also granted a permanent injunction preventing </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">challengers from marketing a generic version of our proprietary Acetadote product formulation before the expiration of one of Cumberland&#8217;s patents in August&#160;2025. An Appeals Court affirmed the District Court ruling in the Company&#8217;s favor upholding Cumberland&#8217;s Acetadote patent and expressly rejected the validity challenge. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Caldolor</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Caldolor, our intravenous formulation of ibuprofen, was the first injectable product approved in the U.S. for the treatment of both pain and fever. We conducted a series of clinical studies in over 900 adult patients to develop the data to support our FDA submission for the product&#8217;s registration. Following a priority review, the FDA approved Caldolor for marketing in the U.S. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A non-steroidal anti-inflammatory drug (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">NSAID</font><font style="letter-spacing:0.2pt;">&#8221;), the product was indicated for use in adults as a sole treatment for the management of mild to moderate pain and for the management of moderate to severe pain as an adjunct to opioid analgesics. It was also the first FDA-approved intravenous therapy for treating fever. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We then launched Caldolor and continue to promote the product in the U.S. through our hospital sales division. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We completed a series of Phase&#160;IV studies to gather additional data to support our Caldolor product. Those clinical trials involved an additional 1,000 adult and pediatric patients. The studies included data on a shortened infusion time and pre-surgical administration of the product. To address our Phase&#160;IV commitment to the FDA, these studies also included evaluation of the product for the reduction of fever in hospitalized children and the treatment of pain in children undergoing tonsillectomy surgeries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In early 2018, we completed and filed the application for FDA approval of a next generation Caldolor product featuring an improved presentation and formulation which was approved in January&#160;2019. The new, premixed presentation provides health care professionals with a formulation that is easy to administer, helping manage the treatment of patient pain and fever, while reducing opioid consumption. It is provided in a pre-mixed bag containing 800 mg of ibuprofen in a 200 mL patented low sodium formulation for injection that is ready to use. It is the first and only FDA-approved pre-mixed bag of ibuprofen. Caldolor is still available as an 800 mg/8mL single-dose vial for dilution in addition to the ready-to-use bag. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2021, the FDA approved our submission to expand the labeling for Caldolor to include administration of the product prior to surgery. During our clinical studies we found that the product delivered its best results when dosed prior to surgery, reducing both patients&#8217; pain as well as their need for opiates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In 2023, the FDA approved expanded labeling for Caldolor to include use in infants. The safety and efficacy of Caldolor has now been established for the treatment of pain and fever in pediatric patients aged 3&#160;months and older. With this newly approved labeling, Caldolor is the only non-opioid product approved to treat pain in infants that is delivered through injection. The FDA subsequently provided three&#160;years of exclusivity for the drug for this new patient population, extending the exclusivity period for Caldolor to May&#160;11, 2026. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In 2024, we announced the release of a Special Report evaluating the growing amount of current data supporting the use of Caldolor as a standard of care for the treatment of pain and fever in adults, children and infants. The results demonstrated that the product is a safe and effective treatment for pain and fever in adults, children and infants as young as 3&#160;months of age. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally in 2024, we announced the publication of new real-world outcomes research comparing Caldolor to its key competitor&#8201;&#8212;&#8201;ketorolac&#8201;&#8212;&#8201;in 150,000 patients. Published in Frontiers of Pain Research, the results provided compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions and improved health care utilization. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In 2025, we announced publication of our study investigating Caldolor in older patients. The analysis evaluated the safety and efficacy of Caldolor for the management of pain and fever in patients 60&#160;years of age and older. It marks an important advancement in pain management for older individuals, as it is one of the first studies specifically evaluating our product in this vulnerable population. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In late 2025, the Centers for Medicare &amp; Medicaid Services (CMS) issued a permanent J-Code for Caldolor. This important reimbursement milestone enhances access, simplifies hospital billing and further supports Caldolor&#8217;s role as a standard of care for pain and fever management. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During 2025, we distributed both the vial and the ready-to-use premixed bag presentations of Caldolor. We supported the brand through our hospital sales division and group of medical science liaisons. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Kristalose is a prescription laxative administered orally for the treatment of acute and chronic constipation. An innovative, dry powder crystalline formulation of lactulose, Kristalose is designed to enhance patient acceptance and compliance. It is the only branded prescription laxative available in pre-measured powder packets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Kristalose dissolves easily in 4 ounces of water, offering patients a virtually taste-free, grit-free and essentially calorie-free alternative to lactulose syrups. We conducted a preference study which indicated that 77% of patients surveyed prefer the taste, consistency and portability of Kristalose over similar products in syrup forms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We acquired the assets and exclusive rights to Kristalose through a series of transactions, then assembled a dedicated field sales division which re-launched the product as a Cumberland brand. We directed our sales efforts to physicians who are the most prolific writers of prescription laxatives, including gastroenterologists and internists. We supplemented this personal promotion with telemarketing campaigns to expand our reach and support of the product. Using preference data as a cornerstone of our marketing efforts, we then repositioned the brand, enhancing patient affordability through a coupon program and expanded managed care coverage for the product. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We added a co-promotion partner, Poly Pharmaceuticals, who is promoting Kristalose to physician targets not covered by our field sales forces. We then added another partner, Foxland Pharmaceuticals, Inc., who is repackaging Kristalose and featuring it with additional new physician targets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Kristalose award-winning marketing campaign was designed to support increased engagement with our customers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Substitution by pharmacists dispensing generic alternatives in place of Kristalose prescriptions has historically impacted the brand. During 2025, substitution rates increased with the entry of new generic competitors. As a result, we are implementing targeted initiatives to protect the product&#8217;s market position and support its growth. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During 2025, we continued to support Kristalose through our field sales division, as well as our partnerships with Poly Pharmaceuticals and Foxland Pharmaceuticals, Inc. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Sancuso</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment for their cancer. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2022, we entered into an agreement with Kyowa Kirin to acquire the U.S. assets and rights to Sancuso. We then assumed full commercial responsibility for the product in the U.S.&#8201;&#8212;&#8201;including its marketing, promotion, distribution, manufacturing and medical support activities. Kyowa Kirin retained international rights, continuing to deliver the product to address oncology patients&#8217; needs throughout the rest of the world. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As we began shipments of the product, we also formed a new sales division, Cumberland Oncology, to feature the brand with medical professionals treating cancer patients. Following our acquisition of Sancuso, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">we completed the transition of the product from Kyowa Kirin to Cumberland, including the NDA transfer in August&#160;2023, and expanded our oncology sales division to further support the brand. We also successfully transferred manufacture of the product to a new facility. Kyowa Kirin retained international rights. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We continued to support Sancuso in 2025 through our oncology sales division. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Vaprisol</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We acquired the assets and rights to Vaprisol, a prescription brand indicated to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. It is one of two branded prescription products indicated for the treatment of hyponatremia, and the only intravenously administered branded treatment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Hyponatremia, an imbalance of serum sodium to body water, is the most common electrolyte disorder among hospitalized patients. These electrolyte disturbances occur when the sodium ion concentration in the plasma is lower than normal and are often associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. Vaprisol raises serum sodium to appropriate levels and promotes free water secretion. Our Vaprisol product has a proven day-one response rate to normalize serum sodium levels in hyponatremic patients and move them out of the Intensive Care Unit as efficiently as possible. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Vaprisol is supported by our hospital sales division. Demand for the product increased during the pandemic, and we worked to support the expanded use of the product in hospitals and clinics during the health care crisis. We shipped all remaining inventory of the product and notified the FDA that supplies of the product are not currently available. The product has been on FDA&#8217;s drug shortage list since March&#160;2022. We have since transferred the product&#8217;s manufacturing to a new facility. Our new manufacturing partner is working with the FDA to address several Form 483 and warning letter issues in a timely manner. We next expect to file for the approval to manufacture branded Vaprisol at the new manufacturing site once all FDA issues at the new site are resolved. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Vibativ</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Vibativ is an FDA-approved antibacterial drug administered via injection for intravenous use. It is designed to treat serious infections due to </font><font style="font-style:italic;letter-spacing:0.2pt;">Staphylococcus aureus (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">S. Aureus</font><font style="font-style:italic;letter-spacing:0.2pt;">&#8221;)</font><font style="letter-spacing:0.2pt;"> and other Gram-positive bacteria, including </font><font style="font-style:italic;letter-spacing:0.2pt;">Methicillin-resistant Staphylococcus aureus (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">MRSA</font><font style="font-style:italic;letter-spacing:0.2pt;">&#8221;)</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">Methicillin-sensitive Staphylococcus aureus (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">MSSA</font><font style="font-style:italic;letter-spacing:0.2pt;">&#8221;</font><font style="letter-spacing:0.2pt;">) when alternative treatments are not suitable. Vibativ addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Vibativ can serve as a potentially life-saving treatment in patients with hospital-acquired and ventilator-associated pneumonia resulting from infections including the flu, RSV and COVID-19. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pneumonia caused by secondary bacterial infections is common among patients with viral respiratory infections. Research shows that hospital-acquired pneumonia (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">HAP</font><font style="letter-spacing:0.2pt;">&#8221;) and ventilator-associated pneumonia (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">VAP</font><font style="letter-spacing:0.2pt;">&#8221;) have historically accounted for 22% of common hospital-acquired infections. MSSA and MRSA are important disease-causing pathogens in these cases. While many recently introduced antibiotics are quickly losing the ability to fight the bacteria they were designed to kill because those bacteria have become drug-resistant, Vibativ was specifically designed to kill drug-resistant bacteria. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The molecule of an existing antibiotic to which bacteria had developed a resistance, vancomycin, was altered by adding a lipophilic (fat-loving) component and a hydrophilic (water-loving) component. The lipophilic addition increases Vibativ&#8217;s ability to penetrate the cell wall and inhibits the formation of new cell walls (the development of new and/or additional cell walls is the most common way that bacteria become resistant to drugs). The hydrophilic addition increases Vibativ&#8217;s penetration into tissue&#8201;&#8212;&#8201;so it is able to attack infections that are not reachable by other antibiotics. In comparison to vancomycin, Vibativ is 32 times more potent against MRSA strains when tested under in vitro conditions. Further, in clinical trials, Vibativ demonstrated superior cure rates of patients with hospital-acquired bacterial pneumonia. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The Company reached an agreement to acquire the Vibativ assets and assume global responsibility for the brand including the related marketing, distribution, manufacturing and regulatory activities. We then introduced the Cumberland-packaged product, which is supported by our hospital sales force. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">A new publication in </font><font style="font-style:italic;letter-spacing:0.2pt;">Antimicrobial Agents and Chemotherapy</font><font style="letter-spacing:0.2pt;"> detailed the results of the first clinical study investigating the safety and pharmacokinetics of our Vibativ product in children 2 to 17&#160;years of age. The results of the study suggest that a single dose of Vibativ is safe in children, and they experience reduced exposure to Vibativ, compared with the same body weight-based dosing in adults. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">In 2025, we announced the availability of the Vibativ 4-Vial Starter Pak through a new supply arrangement with Vizient Inc., making it accessible to their health care providers nationwide. As the country&#8217;s largest provider-driven health care performance improvement company, Vizient serves more than 65% of the nation&#8217;s acute care providers, including 97% of academic medical centers and 35% of the non-acute market. Through this agreement, Vizient members now have access to Vibativ&#8217;s new 4-vial configuration, which supports flexible treatment initiation in both inpatient and outpatient settings for this potentially life-saving therapy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Additionally, we announced that Vibativ was added to a national group purchasing agreement with Premier, Inc., in 2025. The product addition allows Premier members to purchase Vibativ, in the 12-vial carton and 4-vial Starter Pak. Premier is a leading health care improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 325,000 other providers and organizations to transform health care. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost. With expanded access, Premier member health care providers now have greater flexibility in ordering Vibativ for both inpatient and outpatient settings. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">While we remain focused on promoting Vibativ in the U.S. market, we are building a network of other established companies to bring Vibativ to patients in their countries and territories. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">During 2025, Vibativ was supported by our hospital sales division, national accounts group and team of medical science liaison. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Talicia</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Talicia was approved by the FDA for marketing in the U.S. for the treatment of </font><font style="font-style:italic;letter-spacing:0.2pt;">Helicobacter pylori</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">H.&#160;pylori)</font><font style="letter-spacing:0.2pt;"> infection in adults. Talicia is a combination of three approved drug products&#8201;&#8212;&#8201;omeprazole, a proton pump inhibitor, which prevents the secretion of hydrogen ions increasing the pH of the stomach, plus amoxicillin and rifabutin, antibiotics. It is administered to patients orally in the form of a fixed-dose, all-in-one, delayed release capsule. Talicia is the only all-in-one treatment for </font><font style="font-style:italic;letter-spacing:0.2pt;">H. pylori</font><font style="letter-spacing:0.2pt;"> and is now listed as a first-line therapy option in the 2024 </font><font style="font-style:italic;letter-spacing:0.2pt;">American College of Gastroenterology</font><font style="letter-spacing:0.2pt;"> (ACG) clinical guidelines. The product is patent protected through 2042 and received eight&#160;years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation. Additionally, Talicia obtained a 5-year Generating Antibiotic Incentives Now (GAIN) extension of exclusivity, which expires November&#160;1, 2027. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2025, we announced arrangements with RedHill Biopharma Ltd. (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">RedHill</font><font style="letter-spacing:0.2pt;">&#8221;) to jointly commercialize Talicia, therefore adding the brand as the newest addition to our commercial product portfolio. We also formed a new company with RedHill named Talicia Holdings, Inc. (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">THI</font><font style="letter-spacing:0.2pt;">&#8221;), which holds the worldwide rights and assets associated with the brand. The new company provides operational support with responsibility for the product&#8217;s marketing, manufacturing, regulatory, medical and supply chain functions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Through a co-commercialization agreement, we assumed responsibility for the distribution and sale of Talicia in the U.S. Cumberland records Talicia product sales and equally shares Talicia&#8217;s net revenues. We also provide an annual investment to cover certain distribution, marketing and sales costs. Cumberland is responsible for the sales promotion for Talicia through our established field sales division to increase the number of patients benefiting from Talicia. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Retained Programs</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following the closing of the Transaction, Cumberland will retain the assets associated with the Company&#8217;s ifetroban product candidates and CET, our majority-owned subsidiary focused on earlier-stage product development, which the Company intends to continue to develop following the closing of the Transaction. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Ifetroban Clinical Studies</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Ifetroban is a selective thromboxane-prostanoid receptor (&#8220;TPr&#8221;) antagonist that has been dosed in over 1,400 subjects, demonstrating safety and well-tolerated profiles in both healthy volunteers and various patient populations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We have been evaluating our ifetroban product candidate in a series of clinical studies. We have three Phase&#160;II clinical programs evaluating our ifetroban product candidate in 1) Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs, 2)&#160;patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease, and 3) treatment of the cardiomyopathy associated with Duchenne muscular dystrophy, a rare, fatal, genetic neuromuscular disease that results in deterioration of the skeletal, heart and lung muscles. Investigational new drug applications have been cleared by the FDA enabling us to launch clinical studies in each of these areas. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2025, we announced positive top-line results from our completed Phase&#160;II study (CPI-IFE-007, the FIGHT DMD trial) in patients with cardiomyopathy associated with Duchenne muscular dystrophy. The study enrolled 41 DMD patients who received either low-dose ifetroban (100 mg per day), high-dose ifetroban (300 mg per day), or placebo. High-dose ifetroban treatment resulted in a 3.3% improvement in left ventricular ejection fraction (LVEF) compared to placebo. When compared to propensity-matched natural history controls, the difference was even more pronounced, with high-dose treatment providing a statistically significant 5.4% overall improvement in LVEF (p=0.002), as control patients experienced a 3.6% decline in LVEF. Both doses of ifetroban were well tolerated with no serious drug-related adverse events. All subjects who completed the 12-month treatment period opted into the open-label extension, with long-term follow-up continuing through Month 24 and Month 36 assessments. Ifetroban received Orphan Drug Designation and Rare Pediatric Drug Designation for DMD in November&#160;2024. Fast Track Designation was granted in February&#160;2026. An End-of-Phase&#160;2 meeting was held with FDA in September&#160;2025, and a subsequent Type C meeting was held in January&#160;2026 to continue regulatory pathway discussions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Systemic Sclerosis study (CPI-IFE-004) closed to enrollment in February&#160;2025. The diffuse cutaneous SSc cohort met its target enrollment goal of 20 patients who completed the 12-month treatment period. The SSc-associated Pulmonary Arterial Hypertension cohort enrolled 9 of the targeted 14 subjects before study closure. Cardiac imaging analysis is complete, and topline results for the diffuse cutaneous arm are expected by the end of the first quarter of 2026. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Idiopathic Pulmonary Fibrosis study (CPI-IFE-008, the FIGHTING FIBROSIS trial) is actively enrolling, with over 70 subjects enrolled across 17 activated sites. A safety interim analysis was completed in November&#160;2025 evaluating the first 25% of patients completing 12 weeks of treatment; the independent committee concluded no new safety signals were identified and no changes in study conduct were needed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We have also completed a pilot Phase&#160;II study involving 1) patients suffering from Hepatorenal Syndrome, a life-threatening condition involving liver and kidney failure, 2) patients with Portal Hypertension associated with chronic liver disease and 3) patients with Aspirin-Exacerbated Respiratory Disease, a severe form of asthma. There were no significant safety issues identified with the use of ifetroban in these patients. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Based on the results from our completed and ongoing studies, we are pursuing ifetroban registration for DMD-associated cardiomyopathy as our lead indication, with the IPF and SSc programs providing additional potential indications for our first new chemical entity. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cumberland Emerging Technologies</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We are supplementing these activities with the earlier-stage product development at CET, our majority-owned subsidiary. CET partners with academic research institutions to identify and support the progress of promising new product candidates, which Cumberland can further develop and commercialize. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="GDOT">&#8203;</a><a name="BOTT">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Apotex and Guarantor</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Apotex is a wholly owned subsidiary of Guarantor. Guarantor is a Canadian-based global health company with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, Guarantor is the largest Canadian-based pharmaceutical company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General Description of the Transaction</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has entered into the Agreement with Apotex pursuant to which the Company has agreed, subject to certain conditions, including the authorization and approval of the Agreement by its shareholders, to sell to Apotex the Assets, and Apotex has agreed to assume certain liabilities relating to the Assets arising after the closing of the transaction, in each case, subject to the terms and conditions of the Agreement. The Company will retain the assets associated with the Retained Programs, which the Company intends to continue to develop following the closing of the Transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Simultaneously with the execution of the Agreement, Apotex and the Company entered into Voting and Support Agreements with certain of the Company&#8217;s directors and executive officers who, collectively, hold approximately 41% of the total outstanding shares of Common Stock as of the Record Date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The discussion set forth below in the sections entitled &#8220;The Asset Purchase Agreement&#8221; and &#8220;The Other Transaction Agreements&#8221; starting on pages <a href="#TAPA">49</a> and <a href="#TOTA">57</a>, respectively, of the principal terms of the Agreement and the form of Voting and Support Agreement is not complete and is qualified in its entirety by reference to the complete text of the agreements, copies of which are attached as </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annexes A</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">B</font><font style="letter-spacing:0.2pt;">, respectively, to this proxy statement and are incorporated herein by reference. The rights and obligations of the parties are governed by the express terms and conditions of these agreements and not by this discussion, which is summary in nature. You are encouraged to read the Agreement and the form of Voting and Support Agreement carefully and in their entirety, as well as this proxy statement and any documents incorporated by reference herein, before making any decisions regarding the proposals being brought before the special meeting.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Background of the Transaction</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following chronology summarizes the material events that led to the execution of the Asset Purchase Agreement by and among Cumberland Pharmaceuticals Inc., a Tennessee corporation (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Cumberland</font><font style="letter-spacing:0.2pt;">&#8221;), Nuvo Pharmaceuticals (Ireland) DAC, an Ireland designated activity company, and Apotex Inc., as Buyer Guarantor (collectively with Nuvo Pharmaceuticals (Ireland) DAC, &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Apotex</font><font style="letter-spacing:0.2pt;">&#8221;). It does not purport to catalog every conversation or action among the members of the Board or Board Special Committee of Cumberland, members of Cumberland&#8217;s management or their respective representatives or advisors, and other parties. In particular, the following background and any summary of the Asset Purchase Agreement is incomplete and is qualified in its entirety by reference to the copy of the Asset Purchase Agreement attached as Annex A to this Proxy Statement and incorporated by reference herein. You should carefully read this Proxy Statement and the other documents to which we refer, including the Asset Purchase Agreement, for a complete understanding of the terms of the Transaction.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cumberland is a specialty pharmaceutical company headquartered in Nashville, Tennessee, focused on the acquisition, development, and commercialization of branded prescription products for the hospital acute care, gastroenterology, and oncology market segments. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Cumberland&#8217;s portfolio of FDA-approved brands includes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Acetadote</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (acetylcysteine) injection for the treatment of acetaminophen poisoning, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Caldolor</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (ibuprofen) injection for the treatment of pain and fever, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (lactulose) oral solution, a prescription laxative for the treatment of constipation, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Sancuso</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (granisetron) transdermal extended release film for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Vaprisol</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (conivaptan) injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Vibativ</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (telavancin) injection, for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections, and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Talicia</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (omeprazole, amoxicillin, and rifabutin) oral capsule for the treatment of Helicobacter pylori infection, a bacterial infection in the stomach lining. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cumberland also has a series of Phase&#160;II clinical programs underway evaluating its ifetroban product candidate in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, and Idiopathic Pulmonary Fibrosis. As of June&#160;30, 2025, Cumberland had approximately $16&#160;million in cash, approximately $67.9&#160;million in total assets, $40.2&#160;million in liabilities and $27.7&#160;million of shareholders&#8217; equity, and approximately 14.96&#160;million shares of its common stock outstanding, with insiders (Board members, employees and consultants) holding approximately 50.9% of those shares. Cumberland&#8217;s market capitalization was approximately $51.46&#160;million as of September&#160;15, 2025, and its stock had traded between a 52-week high of $7.25 and a 52-week low of $1.04 per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During 2025, Cumberland&#8217;s business demonstrated positive operating trends. Cumberland&#8217;s product portfolio delivered combined net revenues of $11.7&#160;million during the first quarter of 2025, a 38% increase over the prior year period, and Cumberland generated a net profit of $1.3&#160;million and cash flow from operations of $3.9&#160;million for the quarter. Year-to-date revenues for the first six&#160;months of 2025 totaled $22.6&#160;million, representing a 23% increase over the first half of 2024. Cumberland also achieved significant milestones during this period, including the approval of Vibativ in China in February&#160;2025, with its commercial partner SciClone Pharmaceuticals Inc., and the approval of Caldolor in Mexico in September&#160;2025. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board of Directors of Cumberland (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Cumberland Board</font><font style="letter-spacing:0.2pt;">&#8221; or the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Board</font><font style="letter-spacing:0.2pt;">&#8221;) consists of seven members: A.J. Kazimi (Chairman and Chief Executive Officer), Dr.&#160;Gordon R. Bernard, James R. Jones, Caroline R. Young, Kenneth J. Krogulski, Joseph C. Galante, and Martin&#160;S. Brown. Together with members of Cumberland&#8217;s management team, the Board regularly reviews and assesses the performance, future growth prospects, business plans, and overall strategic direction of Cumberland, and considers a variety of strategic alternatives that may be available to Cumberland, including continuing to pursue Cumberland&#8217;s strategy as a standalone public company or pursuing potential strategic or financing transactions with third parties, in each case with the goal of maximizing shareholder value. In connection with these ongoing evaluations, the Cumberland Board previously formed, on June&#160;24, 2022, a special committee of the Board (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Board Special Committee</font><font style="letter-spacing:0.2pt;">&#8221;) for efficiency purposes rather than potential conflicts of interests in order to evaluate potential significant transactions involving Cumberland. The Board Special Committee was composed of Mr.&#160;Kazimi, Mr.&#160;Krogulski, Mr.&#160;Jones and Mr.&#160;Brown. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;12, 2024, Cumberland entered into a confidentiality agreement with an international pharmaceutical company (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Investor A</font><font style="letter-spacing:0.2pt;">&#8221;), which was focused on the development and commercialization of innovative medicines, with a product portfolio spanning multiple therapeutic areas, including but not limited to cardiometabolic, central nervous system, analgesic, antidotes, and nutraceuticals. The confidentiality agreement was entered into in connection with preliminary discussions initiated by Investor A, regarding a potential strategic transaction between the parties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;23, 2024, Cumberland delivered a corporate presentation to representatives of Investor A, providing an overview of Cumberland&#8217;s business, product portfolio, financial performance, development pipeline, and strategic outlook. The presentation was designed to provide Investor A with an understanding of Cumberland&#8217;s operations and the potential value of its commercial and development-stage assets. The presentation also addressed Cumberland&#8217;s growth strategy and the potential opportunities that a strategic partnership could provide to enhance shareholder value. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;5, 2025, representatives of Cumberland and Investor A met to discuss the potential for a strategic transaction between the two companies. During this meeting, the parties discussed their respective businesses, strategic objectives, and the potential synergies that could result from a combination or other strategic relationship. They explored the complementary nature of their respective product portfolios and the potential benefits a transaction could provide to Cumberland&#8217;s shareholders, including Investor A&#8217;s established commercial presence in international markets. Following the meeting, discussions concerning a potential transaction continued between the parties. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At a meeting of the Board held on April&#160;22, 2025 at Cumberland&#8217;s corporate headquarters, the Chairman reported on the Board Special Committee&#8217;s preliminary discussions regarding a potential product-related transaction with Investor A. He noted that if there was mutual interest in moving forward with any transaction, the Board would be presented with the relevant information for consideration. The Board asked questions and discussed the matter. The Board also received updates regarding Cumberland&#8217;s first quarter financial results, regulatory progress across the product portfolio, and the status of its clinical programs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On May&#160;12, 2025, Cumberland and Investor A negotiated and executed a non-binding letter of intent (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Initial Investor A LOI</font><font style="letter-spacing:0.2pt;">&#8221;) outlining the general terms of a potential strategic transaction between the parties. The letter of intent reflected the preliminary understanding of the parties with respect to a potential transaction structure and key terms, while leaving definitive agreement terms subject to further negotiation and due diligence. Under the Initial Investor A LOI, Investor A proposed to combine its U.S. operations with Cumberland&#8217;s commercial operations&#8201;&#8212;&#8201;including its portfolio of FDA-approved products, related assets, intellectual property, the &#8220;Cumberland Pharmaceuticals&#8221; registered name, and business organization&#8201;&#8212;&#8201; through a U.S. affiliate of Investor A, in a transaction structured as an asset purchase on a cash-free, debt-free basis. The Initial Investor A LOI contemplated that the ifetroban asset would be excluded from the transaction and that CET, as an entity, may be excluded from the transaction based on the parties&#8217; mutual agreement following an assessment during the diligence process. The Initial Investor A LOI further contemplated that Investor A would be granted a right of first offer with respect to any future transaction involving CET&#8217;s pipeline or related assets if the parties mutually agreed to exclude CET from the transaction, and that Investor A would nominate a member to CET&#8217;s board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2025, Cumberland hosted a management meeting with Investor A executives and advisors at which members of Cumberland&#8217;s management team provided presentations regarding Cumberland&#8217;s products, operations, financial condition, and strategic plans. Cumberland and Investor A representatives engaged in discussions regarding Cumberland&#8217;s business, including its commercialized products, development pipeline, international partnerships, and growth strategy. Mr.&#160;Kazimi held an additional meeting with representatives of Investor A on August&#160;27, 2025 to further discuss the potential transaction, including updated financial information regarding Cumberland, the anticipated benefits and risks associated with a combination, and the timeline and process for completing a transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;26, 2025, Cumberland was approached by representatives of Apotex Inc. (&#8220;Apotex&#8221;) regarding exploring a strategic transaction between the two companies. Apotex, the largest Canadian-based pharmaceutical company and a portfolio company of SK Capital Partners, LP, develops, manufactures, and globally distributes pharmaceutical products, including generic drugs, biosimilars and active pharmaceutical ingredients. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;12, 2025, Cumberland entered into a confidentiality agreement with Apotex to facilitate the exchange of non-public information in connection with discussions regarding a potential strategic transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Representatives of Cumberland met by video conference with representatives of Apotex on September&#160;16, 2025 and delivered a corporate presentation providing an overview of Cumberland&#8217;s business, product portfolio, commercial operations, financial performance, pipeline programs, and strategic outlook. The presentation was intended to familiarize Apotex with Cumberland&#8217;s operations and the potential strategic value of its platform of FDA-approved brands. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Within a few weeks of the presentation to Apotex, Cumberland received both a non- binding offer from Apotex and an updated, non-binding offer from Investor A, each setting forth proposed terms for a potential strategic transaction involving Cumberland. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;26, 2025, a representative of Apotex contacted a representative of Cumberland by phone, expressed Apotex&#8217;s continued interest in a strategic transaction with Cumberland and verbally communicated a non-binding offer to acquire Cumberland&#8217;s U.S. and global rights (where applicable) to Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Sancuso</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vibativ</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Caldolor</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Acetadote</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vaprisol</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, and Omeclamox-Pak</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> through an asset purchase (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Initial Apotex Offer</font><font style="letter-spacing:0.2pt;">&#8221;). The Initial Apotex Offer valued the total transaction at up to $95&#160;million, consisting of a $60&#160;million upfront cash payment at closing and gross profit earnout payments of up to $35&#160;million. The earnout structure provided for a $15&#160;million payment upon achievement of annual </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> gross profit of $12.5&#160;million by December&#160;31, 2027, and a $20&#160;million payment upon achievement of annual Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> gross profit of $14&#160;million by December&#160;31, 2030, with earnout payments payable only once (not stacked), and with the earnout obligation terminated if the thresholds were not achieved by the specified dates. Gross profit was defined as net sales (gross invoice price less standard and customary industry deductions) less the cost of goods to manufacture and third-party royalties. The transaction was to be structured on a cash-free, debt-free basis and was not subject to any financing contingency, as Apotex represented it would finance the transaction entirely through existing liquidity. Apotex confirmed in writing the terms of the Initial Apotex Offer in a letter, dated October&#160;2, 2025, which was delivered to representatives of Cumberland on October&#160;3, 2025. Based on Cumberland&#8217;s approximately 14.96&#160;million shares of common stock then outstanding, the $95&#160;million total transaction value implied a per-share value of approximately $6.35, representing a premium of approximately 96% to Cumberland&#8217;s closing price of $3.24 a share and market capitalization of approximately $48.47&#160;million as of October&#160;2, 2025. The Initial Apotex Offer assumed the transaction would include all product approvals, intellectual property and regulatory files, related contracts, and select commercial infrastructure, and contemplated a transition services agreement for a limited time period to support continuity of operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;30, 2025, Cumberland received an updated offer from Investor A (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Revised Investor A Offer</font><font style="letter-spacing:0.2pt;">&#8221;), which proposed a combination of Investor A&#8217;s U.S. business with Cumberland&#8217;s commercial operations&#8201;&#8212;&#8201;including its portfolio of FDA-approved products, related assets, intellectual property, the &#8220;Cumberland Pharmaceuticals&#8221; registered name, and business organization&#8201;&#8212;&#8201;through a newly formed U.S. subsidiary of Investor A (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">NewCo</font><font style="letter-spacing:0.2pt;">&#8221;), in a transaction structured as an asset purchase, on a cash-free, debt-free basis. The Revised Investor A Offer valued the total transaction at $100&#160;million, consisting of a $90&#160;million upfront cash payment at closing, plus the potential to receive a one-time earnout payment of up to $10&#160;million. The full $10&#160;million earnout would have been payable if a third-party audit firm determined that cumulative 24-month post-closing net revenue equaled or exceeded $93&#160;million; if a third-party audit firm determined that cumulative 24-month post-closing net revenue equaled or exceeded $91&#160;million but was below $93&#160;million, the earnout payment would have been $6&#160;million; and no earnout would have been paid if cumulative 24-month post-closing revenue was below $91&#160;million. The net revenue target would have included only sales generated from the Cumberland assets acquired in the transaction and any sales from assets that NewCo acquired or developed after the closing date. Based on Cumberland&#8217;s approximately 14.96&#160;million shares of common stock then outstanding, the $100&#160;million total transaction value implied a per-share value of approximately $6.68, representing a premium of approximately 94% to Cumberland&#8217;s market capitalization of approximately $51.46&#160;million as of September&#160;15, 2025 (implying a stock price of approximately $3.44 per share). Investor A represented that its proposal was not subject to any financing contingency, as Investor A stated it had sufficient cash on hand to fund the transaction without requiring outside financing. The Revised Investor A Offer included a 30-day exclusivity period, with an automatic extension to 90&#160;days if an asset purchase agreement was executed within the initial period; it also contained a limited fiduciary out permitting Cumberland to discuss and enter into a competing transaction that the Board believed in good faith would be &#8220;much more favorable&#8221; to the company&#8217;s shareholders. The Revised Investor A Offer contemplated that Mr.&#160;Kazimi would continue as the senior executive of NewCo, with an employment agreement to be mutually agreed prior to closing, and that all key Cumberland executives and commercial staff would be offered continuation of employment with NewCo. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Cumberland Board held a meeting on September&#160;30, 2025, to consider the status of Cumberland&#8217;s strategic review process. The meeting covered, among other agenda items, reviews of the Company&#8217;s mission, strategy, and portfolio; regulatory updates across the product portfolio (including the status of the Sancuso gastroparesis indication, the Caldolor labeling initiative under the NOPAIN Act, the ifetroban DMD program&#8217;s End-of-Phase&#160;2 meeting with the FDA, and the Vaprisol manufacturing requalification); clinical development updates; and marketing and sales performance. Additionally, at this meeting, management updated the Board on the ongoing discussions with Investor A and with Apotex. The Board discussed the potential benefits, risks, and relative merits of each potential transaction, including consideration of the financial terms that each party might offer, the strategic fit of each counterparty with Cumberland&#8217;s business, and the likelihood that each transaction could be completed on terms favorable to Cumberland&#8217;s shareholders. Although the aggregate valuations in the two initial offers were similar, the Apotex transaction involved a larger deferred payment component, which the Board viewed as introducing additional uncertainty regarding the ultimate consideration to be received by Cumberland. After weighing the relative certainty of the consideration structure, the absence of a financing contingency in the Investor A proposal, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and the strategic alignment between the two companies, the Board ultimately decided to pursue the Revised Investor A Offer as the preferred path forward. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following further discussions, Cumberland received an updated letter of intent from Investor A (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Updated Investor A Offer</font><font style="letter-spacing:0.2pt;">&#8221;) in early October&#160;2025, which reflected revised terms from the Initial Investor A LOI. The Updated Investor A Offer incorporated changes that Investor A proposed following its continued evaluation of Cumberland&#8217;s business and its analysis of the potential transaction. The Updated Investor A Offer maintained the same aggregate transaction value of $100&#160;million, consisting of a $90&#160;million upfront cash payment at closing and the same earnout structure as the Initial Investor A Offer (up to $10&#160;million based on cumulative 24-month post-closing net revenue thresholds). The transaction remained a combination of Cumberland&#8217;s commercial products and operations with Investor A&#8217;s U.S. business, structured as an asset purchase on a cash-free, debt-free basis, with no financing contingency. However, the Updated Investor A Offer contained several material modifications to the non-financial terms. Notably, the exclusivity period was extended from 30&#160;days to 52&#160;days, with the same automatic extension to 90&#160;days if an asset purchase agreement was executed within the exclusivity period. The Updated Investor A Offer removed the fiduciary out provision that had been included in the Initial Investor A Offer&#8201;&#8212;&#8201;which had permitted Cumberland to discuss and enter into a competing transaction that the Board believed in good faith would be &#8220;more favorable&#8221; to the company&#8217;s shareholders&#8201;&#8212;&#8201;and instead required Cumberland, upon execution, to immediately terminate all discussions regarding any competing transaction. The Updated Investor A Offer also added an expiration provision, requiring acceptance by 5:00&#160;p.m. MDT on November&#160;7, 2025. Investor A also proposed additional terms regarding a dual role for Cumberland&#8217;s CEO, specifying he would devote a majority of his time (estimated at approximately two-thirds) to NewCo and would enter into an employment agreement with arrangements to address potential conflicts of interest arising from his concurrent service as CEO of both NewCo and Cumberland&#8217;s development activities, including CET. The Updated Investor A Offer also expressly added Cumberland shareholder approval as a closing condition in the definitive agreements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On November&#160;5, 2025, representatives of Cumberland received an updated non-binding offer on behalf of Apotex (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Updated Apotex Offer</font><font style="letter-spacing:0.2pt;">&#8221;). The Updated Apotex Offer conveyed Apotex&#8217;s continued interest in pursuing a strategic transaction with Cumberland and included modifications to certain key terms based on information Apotex had obtained through its preliminary review of Cumberland&#8217;s business. Like the Investor A proposals, the Updated Apotex Offer was structured as an integration of Apotex&#8217;s branded U.S. pharmaceutical business with Cumberland&#8217;s commercial operations, in a transaction structured as an asset purchase that would include the U.S. and global rights (where applicable) to Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Sancuso</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vibativ</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Caldolor</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Acetadote</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vaprisol</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Omeclamox-Pak</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, and Talicia</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">. The Updated Apotex Offer increased the total transaction consideration to up to $100&#160;million (compared to $95&#160;million in the Initial Apotex Offer), on a cash-free, debt-free basis, consisting of a $75&#160;million upfront cash payment at closing (compared to $60&#160;million in the Initial Apotex Offer) and gross profit earnout payments of up to $25&#160;million (compared to $35&#160;million in the Initial Apotex Offer). The revised earnout structure provided for a $10&#160;million payment upon achievement of annual Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> and Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> authorized generic total gross profit of $11.0&#160;million by December&#160;31, 2027, and a $15&#160;million payment upon achievement of annual Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> and Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> authorized generic total gross profit of $13&#160;million by December&#160;31, 2030, with earnout payments payable only once (not stacked), and with the earnout obligation terminated if the thresholds were not achieved by the specified dates. The Updated Apotex Offer thus maintained the same aggregate transaction value of $100&#160;million as the Updated Investor A Offer but provided for $75&#160;million in upfront cash (compared to Investor A&#8217;s $90&#160;million) with $25&#160;million in earnout payments tied to the achievement of specific gross profit thresholds for Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> over a five-year period (compared to Investor A&#8217;s $10&#160;million earnout tied to cumulative 24-month post-closing net revenue for all acquired products). Based on Cumberland&#8217;s approximately 14.96&#160;million shares of common stock then outstanding, the $100&#160;million total transaction value implied a per-share value of approximately $6.68, representing a premium of approximately 187% to Cumberland&#8217;s closing stock price of $2.33 per share and market capitalization of approximately $34.86&#160;million as of November&#160;5, 2025. Like the Initial Apotex Offer, the Updated Apotex Offer was not subject to any financing contingency, as Apotex represented it would finance the transaction entirely through existing liquidity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board Special Committee met on November&#160;6, 2025 by videoconference to consider the two proposals. The Board Special Committee reviewed and discussed the specific proposals that had been </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">presented, noting that one letter of intent had been received from Investor A which could potentially involve the combination of a substantial portion of Cumberland, and that a second letter of intent had been received from Apotex which would be similarly structured. The Board Special Committee discussed the terms and relative strengths of each offer, including the aggregate consideration proposed by each party, the relative proportion of upfront cash versus deferred or contingent consideration, the absence of a financing contingency in both proposals, the ability of each prospective buyer to close the proposed transaction, and other economics of the respective proposals. The Board Special Committee also consulted with Cumberland&#8217;s legal and financial advisors regarding the terms of each proposal and the fiduciary duties of the Board in evaluating the available alternatives. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Following its deliberations, the Board Special Committee unanimously determined that it was in the best interests of Cumberland and its shareholders to move forward with the Investor A proposal, which the Board Special Committee concluded offered the most favorable combination of financial terms and strategic alignment at that time. The Board Special Committee noted that the Updated Investor A Offer included an expiration provision requiring acceptance by November&#160;7, 2025, and that the proposed 52-day exclusivity period would expire in late December&#160;2025 if a definitive agreement was not reached. Accordingly, on November&#160;6, 2025, Cumberland and Investor A negotiated and executed an amended letter of intent that included a new exclusivity period running through December&#160;28, 2025 (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Investor A LOI with Exclusivity</font><font style="letter-spacing:0.2pt;">&#8221;), during which Cumberland agreed to negotiate exclusively with Investor A regarding a potential transaction and to refrain from engaging in discussions with other parties regarding alternative strategic transactions. Unlike the Initial Investor A Offer, the Investor A LOI with Exclusivity did not include a fiduciary out provision, meaning Cumberland was contractually obligated to refrain from soliciting, entertaining, or pursuing any competing transaction during the exclusivity period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Following the Board Special Committee&#8217;s decision, Cumberland sent a letter to Apotex on November&#160;12, 2025, informing Apotex that Cumberland had decided to pursue an alternative strategic direction and would not be moving forward with Apotex&#8217;s proposal at that time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Beginning on November&#160;7, 2025, and continuing through December&#160;28, 2025, Cumberland supported Investor A&#8217;s due diligence review by providing access to Cumberland data and information to Investor A&#8217;s executives and advisors. During this period, Cumberland made available extensive materials regarding Cumberland&#8217;s business, operations, financial condition, intellectual property, regulatory matters, commercial agreements, and other aspects of Cumberland relevant to the proposed transaction. Investor A and its advisors conducted a thorough review of the information provided and engaged in discussions with Cumberland&#8217;s management regarding Cumberland&#8217;s operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The exclusivity period under the Investor A LOI with Exclusivity expired on December&#160;28, 2025, in accordance with its terms. Despite the due diligence that had been conducted, Cumberland and Investor A had not reached agreement on the definitive terms of a transaction during the exclusivity period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">With exclusivity having expired, and the Investor A due diligence process having concluded without a definitive agreement, representatives of Cumberland met with representatives of Apotex on January&#160;7, 2026 by videoconference, and during that meeting, a representative of Cumberland informed the Apotex representatives that the exclusivity period for the alternative transaction with Investor A had expired and that Cumberland was now in a position to reengage with Apotex regarding a potential strategic transaction. During this meeting, Cumberland&#8217;s and Apotex&#8217;s representatives discussed the status of Cumberland&#8217;s strategic review process and the potential for Apotex to submit a revised proposal. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;14, 2026, a representative of Cumberland met in-person with representatives of Apotex in San Francisco. During that meeting, a representative of Cumberland informed them that Apotex&#8217;s bid would need to include no less than $100&#160;million in upfront cash consideration for it to be strongly considered by the Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Following such discussions, Apotex responded with an updated non-binding offer on January&#160;26, 2026 (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">January&#160;2026 Apotex Offer</font><font style="letter-spacing:0.2pt;">&#8221;), which included revised financial and other terms reflecting Apotex&#8217;s continued interest in pursuing a strategic transaction with Cumberland and incorporating modifications based on additional information Apotex had obtained regarding Cumberland&#8217;s business. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The January&#160;2026 Apotex Offer was also structured as an asset purchase that would include the U.S. and global rights (where applicable) to Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Sancuso</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vibativ</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Caldolor</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Acetadote</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vaprisol</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Omeclamox-Pak</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, and Talicia</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">. The January&#160;2026 Apotex Offer improved the financial terms compared to the prior Apotex proposals, offering a total upfront cash payment of $100&#160;million on a cash-free, debt-free basis, with no earnout or contingent consideration. In the Board&#8217;s view, this represented a substantial increase from the Updated Apotex Offer&#8217;s $75&#160;million upfront cash payment (plus up to $25&#160;million in earnout payments) and from the Initial Apotex Offer&#8217;s $60&#160;million upfront cash payment (plus up to $35&#160;million in earnout payments). The January&#160;2026 Apotex Offer also compared favorably to the Investor A proposals, which had included $90&#160;million upfront cash plus up to $10&#160;million in earnout payments (for a total potential value of $100&#160;million), because the January&#160;2026 Apotex Offer provided the full $100&#160;million in upfront cash consideration with no contingent or deferred component. Based on Cumberland&#8217;s approximately 14.96&#160;million shares of common stock then outstanding, the $100&#160;million transaction value implied a per-share value of approximately $6.68, representing a premium of approximately 78% to Cumberland&#8217;s closing stock price of $3.75 a share and market capitalization of approximately $56.10&#160;million as of January&#160;26, 2026. The January&#160;2026 Apotex Offer was not subject to any financing contingency, as Apotex represented it would finance the transaction entirely through existing liquidity. The January&#160;2026 Apotex Offer assumed the transaction would include all product approvals, intellectual property and regulatory files, related contracts, and select commercial infrastructure that support the business, and contemplated that Apotex would seek to re-hire the majority of Cumberland&#8217;s commercial personnel that support the products where there was no overlap, subject to due diligence. The proposal also assumed a transition services agreement would be executed for services including transitional support around intake and processing of reportable safety information, pharmacovigilance activities, distribution logistics, commercial and government contract related financial services, and quality assurance activities for a limited defined time period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The next day, on January&#160;27, 2026, the Cumberland Board held a meeting at which it considered the proposals received to date, including the January&#160;2026 Apotex Offer and the status of discussions with Investor A. The Board reviewed and discussed the financial terms, strategic rationale, deal certainty, and potential risks associated with each proposal. The Board also considered Cumberland&#8217;s strategic position, financial condition, and the range of alternatives available to Cumberland, including continuing as a standalone public company. Management and Cumberland&#8217;s advisors presented their analyses of the respective proposals and discussed the potential benefits and risks of each alternative. The Board weighed the fact that the Investor A exclusivity period had expired without a definitive agreement, the continued interest demonstrated by Apotex, and the relative certainty of execution offered by each path forward. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After deliberation and consultation with Cumberland&#8217;s legal and financial advisors, the Cumberland Board passed resolutions to pursue the January&#160;2026 Apotex Offer and to authorize management to enter into an exclusivity agreement with Apotex. The Board unanimously determined that the Apotex proposal presented the best opportunity to maximize value for Cumberland&#8217;s shareholders, taking into account the totality of the terms offered, the strategic fit of Apotex with Cumberland&#8217;s business, the resources and capabilities Apotex would bring to the transaction, and the likelihood of completing a transaction on the proposed terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cumberland and Apotex negotiated and executed an agreement on February&#160;2, 2026, providing for an exclusivity period (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Apotex Exclusivity Agreement</font><font style="letter-spacing:0.2pt;">&#8221;). The Apotex Exclusivity Agreement provided for an initial exclusivity period of 60&#160;days from the date of execution (i.e., through approximately April&#160;3, 2026), during which Cumberland agreed that Apotex would have the exclusive right to negotiate the transaction and complete due diligence on the products and related matters, and that Cumberland would immediately terminate all discussions, negotiations, arrangements, or agreements with any other person relating to a competing transaction. Cumberland further agreed not to solicit, entertain, initiate, pursue, encourage, or actively respond to any approach from, or supply any information or due diligence materials to, any other party in relation to a competing transaction during the exclusivity period. The Apotex Exclusivity Agreement provided that the exclusivity period would automatically be extended by an additional two weeks if Apotex had not provided notice of its intention to terminate prior to the expiration of the initial 60-day period. In addition, if Apotex notified Cumberland during the exclusivity period that it was reducing the proposed purchase price or proposing other terms materially inconsistent with the terms set forth in Apotex&#8217;s non-binding transaction proposal, the exclusivity period would have expired five days after Cumberland&#8217;s receipt of such notice. The Apotex Exclusivity Agreement did not include a break fee or expense </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">reimbursement provision, and each party agreed to bear its own costs and expenses in connection with the negotiation of the transaction. The Apotex Exclusivity Agreement did not contain a fiduciary out or superior proposal provision, and was governed by the laws of the State of Delaware, with the parties consenting to the exclusive jurisdiction of the courts of the State of Delaware. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Later that same day, Cumberland sent a letter to Investor A informing it of Cumberland&#8217;s decision to pursue an alternative transaction with exclusivity and that Cumberland would not continue discussions with Investor A at that time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Representatives of Cumberland and Apotex held a formal kick-off meeting by videoconference on February&#160;10, 2026, to commence the due diligence process. During this meeting, the parties discussed the scope and timeline of the due diligence review, identified key workstreams&#8201;&#8212;&#8201;including commercial operations, product portfolio, intellectual property, regulatory and quality matters, manufacturing and supply chain, financial statements and projections, employee and benefit matters, litigation, and insurance&#8201;&#8212;&#8201;and established a framework for the efficient exchange of information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Starting the following day and continuing through March&#160;2026, Cumberland supported Apotex&#8217;s due diligence review by providing data and access to information to Apotex&#8217;s executives and advisors, including via a virtual data room. During this period, Cumberland made available materials regarding Cumberland&#8217;s business, operations, financial condition, product portfolio, intellectual property, regulatory matters, manufacturing and supply chain arrangements, commercial agreements, international licensing and distribution partnerships, employee matters, and other aspects of Cumberland relevant to the proposed transaction. Apotex and its advisors conducted a review of the information provided and engaged in ongoing discussions with Cumberland&#8217;s management regarding Cumberland&#8217;s operations, products, pipeline, and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Concurrently with the due diligence process, representatives of Cumberland and Apotex, together with their respective legal and financial advisors, negotiated the terms of the definitive transaction agreement (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Asset Purchase Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) and related transaction documents. From February&#160;11, 2026 through April&#160;22, 2026, the parties exchanged multiple drafts of the Asset Purchase Agreement and annexes and disclosure schedules thereto and engaged in discussions regarding the terms and conditions of the proposed transaction, including representations and warranties, covenants, closing conditions, termination rights, and indemnification provisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cumberland delivered an initial draft of the Asset Purchase Agreement to Apotex on February&#160;11, 2026, including a preliminary draft of key annexes thereto. Cumberland&#8217;s initial draft contemplated, among other things, a fixed price consideration in exchange for the Acquired Assets and Assumed Liabilities, a closing condition requiring that Cumberland obtain the approval of a majority of Cumberland&#8217;s shareholders entitled to vote upon the proposed transactions, and reciprocal indemnification obligations by Cumberland and Apotex for any losses arising out of the ownership and operation of the Acquired Assets and the development, manufacture, distribution, market or sale of the products during the period of each party&#8217;s respective ownership thereof. On February&#160;23, 2026, Representatives of Cumberland&#8217;s management team and internal legal counsel, Apotex&#8217;s management team and internal legal counsel, and Apotex&#8217;s outside legal counsel met via videoconference to discuss the proposed terms of the Asset Purchase Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following these initial discussions, Apotex delivered to Cumberland a revised draft of the Asset Purchase Agreement on March&#160;3, 2026. Apotex&#8217;s draft contemplated, among other things, that Cumberland&#8217;s Chief Executive Officer and Board members holding Cumberland stock would each execute and deliver a Voting and Support Agreements committing to vote all of their shares of Cumberland stock in support of the proposed transaction at any Cumberland shareholder meeting, Cumberland would not solicit or encourage any other inquiries or proposals or engage in any negotiations or communications with any other third parties regarding the Acquired Assets (subject to customary fiduciary exceptions), Cumberland would retain and indemnify Apotex from all liabilities of Cumberland other than those expressly assumed by Apotex and, from and after the closing, Cumberland would be subject to five-year noncompete and business non-interference covenants, a two-year employee non-solicit and no-hire covenant, and a three-year non- disparagement covenant (and that Cumberland&#8217;s Chief Executive Officer would ultimately be subject to the same covenants as Cumberland in his personal capacity in his Voting and Support Agreement). The Apotex draft of the Asset Purchase Agreement also provided that, in the event that the agreement was </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">terminated because Cumberland failed to obtain the Requisite Stockholder Approval or the Board changed its recommendation to shareholders or withdrew its support of the proposed transactions, then Cumberland would reimburse Apotex for its third party out-of-pocket transaction expenses up to $5&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After further internal deliberations with management and legal counsel, Cumberland provided to Apotex a further revised draft of the Asset Purchase Agreement on March&#160;12, 2026. Cumberland&#8217;s draft of the agreement contemplated, among other things, that Cumberland would be subject to two-year noncompete and business non-interference covenants and a one-year employee non-solicitation and no-hire covenant, neither party would have any indemnification obligations other than for breaches of representations, warranties and covenants and for assumed or excluded liabilities, Cumberland&#8217;s indemnification obligations for breaches of representations, warranties, and covenants would be subject to certain liability limits, a $2&#160;million deductible and a </font><font style="font-style:italic;letter-spacing:0.2pt;">de minimis</font><font style="letter-spacing:0.2pt;"> threshold of $100,000 for any such claims, Apotex would pay to Cumberland a $2&#160;million termination fee in the event that the agreement was terminated for a range of reasons including a law or order prohibiting the proposed transactions or failure to close by the Outside Date and Cumberland would reimburse Apotex for its third party out-of-pocket transaction expenses up to $2&#160;million in the event that the agreement was terminated because the Board changed its recommendation to shareholders or withdrew its support of the proposed transactions. The Cumberland draft also contemplated that Apotex Inc. would guarantee the obligations of Nuvo Pharmaceuticals (Ireland) DAC under the agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;18, 2026, representatives from Cumberland and Apotex, as well as their respective outside legal counsel met by videoconference to engage in further negotiations regarding the Asset Purchase Agreement. Following these negotiations, Cumberland delivered to Apotex a further revised draft on March&#160;20, 2026 that modified certain of Cumberland&#8217;s representations, warranties and covenants in the agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;19, 2026, Apotex&#8217;s outside legal counsel delivered to Cumberland&#8217;s outside legal counsel a draft of the form Voting and Support Agreement. The agreement contemplated, among other things, that Cumberland&#8217;s Chief Executive Officer and Board members holding Cumberland stock commit to vote all of their shares of Cumberland stock in support of the proposed transaction at any Cumberland shareholder meeting and against any other acquisition proposal and that Cumberland&#8217;s Chief Executive Officer would be subject to the same restrictive covenants to which Cumberland was subject under the Asset Purchase Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;20, 2026, Cumberland&#8217;s outside legal counsel sent a revised draft of the form Voting and Support Agreement to Apotex&#8217;s outside legal counsel, which contemplated, among other things, that any Cumberland shareholders that were party to such agreement would not be required to vote against any Acquisition Proposal that the Board determined would be more favorable from a financial point of view to Cumberland or its shareholders than the transactions contemplated by the Asset Purchase Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;25, 2026, representatives of Cumberland met by videoconference with representatives of Apotex to discuss, among other things, the status of the due diligence process, the proxy solicitation process, the allocation of certain costs and expenses in connection with the transaction and the treatment of employees in connection with the proposed transaction. During that meeting, representatives of Cumberland informed Apotex of their efforts to secure a contract with the U.S. Department of Health and Human Services (together with any division thereof, &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">HHS</font><font style="letter-spacing:0.2pt;">&#8221;) for the supply of Vibativ for certain specified uses and formally requested that Apotex compensate Cumberland in the event that such contract were secured. The representatives of Apotex agreed to consider the request. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;25, 2026 and March&#160;27, 2026, Cumberland&#8217;s outside legal counsel delivered to Apotex&#8217;s outside legal counsel drafts of the annexes and disclosure schedules to the Asset Purchase Agreement, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;26, 2026, Apotex&#8217;s outside legal counsel delivered to Cumberland&#8217;s outside legal counsel a revised draft of the Asset Purchase Agreement on behalf of Apotex. Apotex&#8217;s revised draft of the agreement contemplated, among other things, that Cumberland would be subject to five-year noncompete and business non-interference covenants and an eighteen month employee non-solicitation and no-hire covenant, Cumberland and Apotex would indemnify each other for any losses arising out of the ownership and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">operation of the Acquired Assets and the development, manufacture, distribution, market or sale of the products during the period of each party&#8217;s respective ownership thereof, Cumberland&#8217;s indemnification obligations for breaches of representations, warranties, and covenants would be subject to certain liability limits, a $500,000 deductible and a </font><font style="font-style:italic;letter-spacing:0.2pt;">de minimis</font><font style="letter-spacing:0.2pt;"> threshold of $25,000 for any such claims, and Apotex would pay to Cumberland a termination fee equal to $4&#160;million in the event that the agreement was terminated for a failure to close by the Outside Date if all the closing conditions were otherwise satisfied and Cumberland stood ready, willing and able to close at such time. The revised agreement also contemplated that Cumberland would pay to Apotex a termination fee equal to 4.0% of the purchase price in the event that the agreement was terminated upon specified termination events, including a material breach by Cumberland, a failure to obtain the Requisite Stockholder Approval, a Board Recommendation Change, Cumberland&#8217;s termination of the Asset Purchase Agreement and entry into an alternative acquisition agreement with respect to a superior proposal, and a termination at the Outside Date followed by Cumberland&#8217;s consummation of, or entry into a definitive agreement for and subsequent consummation of, an alternative Acquisition Transaction within twelve&#160;months in connection with an Acquisition Proposal received prior to such termination. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;29, 2026, representatives of Cumberland and Apotex discussed the treatment of Cumberland employees in connection with the proposed transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;1, 2026, Cumberland&#8217;s outside legal counsel delivered to Apotex&#8217;s outside legal counsel a further revised draft of the Asset Purchase Agreement on behalf of Cumberland. The revised draft of the agreement contemplated, among other things, that Apotex would be subject to an eighteen month non-solicitation and no-hire covenant with respect to any Cumberland employees other than certain employees, Cumberland would be subject to three-year noncompete and business non-interference covenants and each of Apotex&#8217;s and Cumberland&#8217;s indemnification obligations for breaches of representations and warranties would be subject to a $1,000,000 deductible and a </font><font style="font-style:italic;letter-spacing:0.2pt;">de minimis</font><font style="letter-spacing:0.2pt;"> threshold of $75,000 for any such claims. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;4, 2026 and April&#160;7, 2026, Apotex&#8217;s outside legal counsel delivered to Cumberland&#8217;s outside legal counsel further revised drafts of the form Voting and Support Agreement, and the parties agreed upon the final form of the Voting and Support Agreement on April&#160;7, 2026. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;5, 2026, Apotex&#8217;s outside legal counsel delivered to Cumberland&#8217;s outside legal counsel a further revised draft of the Asset Purchase Agreement on behalf of Apotex. The revised draft of the Asset Purchase Agreement contemplated, among other things, that Cumberland would be subject to four-year noncompete and business non-interference covenants, Cumberland&#8217;s indemnification obligations for breaches of representations and warranties would be subject to a </font><font style="font-style:italic;letter-spacing:0.2pt;">de minimis</font><font style="letter-spacing:0.2pt;"> threshold of $50,000 for any such claims and Apotex would pay to Cumberland a milestone payment if Cumberland or Apotex were awarded a contract with HHS for the supply of Vibativ for certain specified uses within one year of closing and if net sales under such agreement exceeded certain targets within seven&#160;years of closing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;7, 2026, Cumberland&#8217;s outside legal counsel delivered to Apotex&#8217;s outside legal counsel a further revised draft of the Asset Purchase Agreement, which contemplated, among other things, that Apotex would be required to extend formal job offers to certain specified employees of Cumberland within thirty days following closing, Apotex would pay to Cumberland a milestone award if Apotex were awarded a contract with HHS for the supply of Vibativ for certain specified uses within two&#160;years of closing and if net sales under such agreement exceeded certain targets within ten&#160;years of closing, and, by the one year anniversary of closing, Apotex would pay to Cumberland an aggregate amount equal to no less than $9&#160;million for inventory sold by Apotex during the twelve month period following the closing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;11, 2026, representatives of Cumberland met by videoconference with representatives of Apotex to continue discussing, among other things, the treatment of Cumberland employees in connection with the proposed transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Between April&#160;8, 2026, and April&#160;19, 2026, the parties and their respective legal counsel exchanged additional drafts of the Asset Purchase Agreement and held several negotiation sessions. During the course of these negotiations, the parties discussed and resolved several terms in the Asset Purchase Agreement. Among the terms negotiated during this period were the milestone award that would be payable to Cumberland in respect of any contract with HHS for the supply of Vibativ and Apotex&#8217;s covenant to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">extend formal offers of employment to certain Cumberland employees. On April&#160;17, 2026, the Apotex Exclusivity Agreement and the automatic two-week extension thereunder expired, and although the parties did not renew or extend such agreement, they continued to negotiate the terms of the Asset Purchase Agreement and the proposed transactions. The parties reached agreement on the final form of the Asset Purchase Agreement on April&#160;19, 2026. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Between April&#160;19, 2026 and April&#160;22, 2026, Cumberland, Apotex and their respective legal counsel continued to negotiate and exchange multiple drafts of the annexes and disclosure schedules to the Asset Purchase Agreement and other ancillary agreements to close out all remaining open issues and finalize such annexes, disclosures schedules and ancillary agreements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;27, 2026, Cumberland also engaged VelocityHealth Securities, Inc. (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">VelocityHealth</font><font style="letter-spacing:0.2pt;">&#8221;), an investment banking firm specializing in healthcare transactions, to provide an independent valuation of Cumberland and to deliver a fairness opinion in connection with the proposed transaction with Apotex. The Board&#8217;s decision to engage VelocityHealth was based on VelocityHealth&#8217;s experience and expertise as a financial advisor in a wide variety of transactions involving companies in the pharmaceutical and broader healthcare industries, including its experience with mergers and acquisitions advisory services, fairness opinions, and valuations for specialty pharmaceutical companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">VelocityHealth then conducted its independent financial analysis of Cumberland in connection with the preparation of its fairness opinion. VelocityHealth reviewed, among other considerations, Cumberland&#8217;s historical and projected financial results, overviews for each of Cumberland&#8217;s commercial brands, the financial terms of the proposed transaction, publicly available financial data for comparable companies and comparable transactions, and other such information, financial metrics and factors that VelocityHealth deemed relevant in rendering its opinion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;17, 2026, the Cumberland Board held a meeting at which VelocityHealth presented its financial analysis of Cumberland&#8217;s commercial brands and the proposed transaction, delivering to the Board its written fairness opinion, dated April&#160;15, 2026, which stated that, as of the date thereof and based upon and subject to the assumptions, factors, qualifications and procedures set forth in the written opinion the consideration to be received by Cumberland pursuant to the Asset Purchase Agreement was fair to Cumberland from a financial point of view. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;21, 2026, the Cumberland Board held a meeting at which it considered and voted on the approval of the Asset Purchase Agreement and holding a special meeting of Cumberland&#8217;s shareholders to approve the Transaction. At this meeting, Cumberland&#8217;s legal counsel reviewed with the Board the proposed final terms of the Asset Purchase Agreement, including the material provisions thereof and any changes since the Board&#8217;s prior meetings. Cumberland&#8217;s legal counsel also reviewed with the Board the Board&#8217;s fiduciary duties in connection with its evaluation of the proposed transaction. The Board discussed the anticipated timeline for the shareholder approval process, including the preparation and filing of the proxy statement with the Securities and Exchange Commission, the distribution of the proxy statement to Cumberland&#8217;s shareholders, and the scheduling of a special meeting of shareholders to vote on the proposed transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After deliberation, including a review of the terms of the Asset Purchase Agreement, the fairness opinion delivered by VelocityHealth, the presentations of management and Cumberland&#8217;s legal and financial advisors, and the factors discussed in the section of this Proxy Statement entitled &#8220;Reasons for the Transaction&#8221;, the Cumberland Board unanimously determined that the Asset Purchase Agreement and the transactions contemplated thereby were advisable and in the best interests of Cumberland and its shareholders, approved and declared advisable the Asset Purchase Agreement and the transactions contemplated thereby, and resolved to recommend that Cumberland&#8217;s shareholders vote to approve the transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;22, 2026, Cumberland and Apotex executed the Asset Purchase Agreement. Prior to the opening of equity trading markets in the United States on April&#160;23, 2026, Cumberland and Apotex issued press releases announcing the signing of the Asset Purchase Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For additional information regarding the final terms of the Asset Purchase Agreement, see the section titled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Asset Purchase Agreement</font><font style="letter-spacing:0.2pt;">&#8221; and the copy of the Asset Purchase Agreement attached as Annex A </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="OOTC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">to this Proxy Statement. For additional information regarding the final terms of the Voting and Support agreement, see the section titled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Other Transaction Agreements</font><font style="letter-spacing:0.2pt;">&#8221; and the copy of the form Voting and Support Agreement attached as Annex B to this Proxy Statement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Opinion of the Company&#8217;s Financial Advisor</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the Transaction, the Company engaged VelocityHealth to act as its financial advisor. As part of that engagement, on April&#160;15, 2026, VelocityHealth delivered to the Board, its written opinion that, as of that date and based upon market multiples typical for acquisitions of branded pharmaceutical products and its valuation analysis, the Consideration to be received by the Company from Apotex in the Transaction pursuant to the Agreement was fair and reasonable to the Company, from a financial point of view. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company did not impose any limitations on VelocityHealth with respect to the investigations made or procedures followed in rendering the VelocityHealth Opinion. In selecting VelocityHealth, the Board considered, among other things, the fact that VelocityHealth is a reputable investment banking firm with substantial experience advising companies in the biotechnology and pharmaceutical sectors and in providing strategic advisory services in general. VelocityHealth, as part of its investment banking business, is regularly engaged in the valuation of businesses and product related assets in connection with mergers and acquisitions, private placements, product licenses, and other financial transactions. VelocityHealth has completed over 125 relevant transactions with over 100 in the specialty pharmaceutical sector, including M&amp;A, financings, valuations, and licensing transactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The full text of the written VelocityHealth Opinion that VelocityHealth delivered to the Board is attached to this proxy statement as </font><font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Annex C</font><font style="letter-spacing:-0.2pt;"> and is incorporated into this document by reference. The summary of the VelocityHealth Opinion set forth in this proxy statement is qualified in its entirety by reference to the full text of the VelocityHealth Opinion. Company shareholders are urged to read the VelocityHealth Opinion carefully and in its entirety for a discussion of the assumptions made, procedures followed, matters considered and limits of the review undertaken by VelocityHealth in connection with the VelocityHealth Opinion.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The VelocityHealth Opinion was for the information of, and directed to, the Board for its information and assistance in connection with its consideration of the financial terms of the Transaction and only addresses the fairness to the Company, from a financial point of view and as of the date of the VelocityHealth Opinion, of the Consideration to be received by the Company from Apotex pursuant to the Agreement. The VelocityHealth Opinion did not constitute a recommendation to the Board or any other person as to how the Board or any other person should vote or otherwise act with respect to the Transaction or any other matter, or to any shareholder of the Company as to how any such shareholder should vote or act with respect to the Transaction or any other matter, including, without limitation, whether or not any shareholder of the Company should enter into a voting agreement with respect to the Transaction. In addition, the VelocityHealth Opinion did not compare the relative merits of the Transaction with any other alternative transactions or business strategies which may have been available to the Company and did not address the underlying business decision of the Board to proceed with or effect the Transaction. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In rendering the VelocityHealth Opinion, VelocityHealth, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">i.</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reviewed the draft Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">ii.</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reviewed data furnished to VelocityHealth by the Company&#8217;s management, including certain internal financial analyses, budgets, forecasts, reports and other information; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">iii.</font>
          <br >
        </div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">held discussions with senior management of the Company concerning the Products and their prospects, including recent financial performance; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">iv.</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reviewed the valuations of publicly available patented pharmaceutical product transactions that we deemed comparable in certain respects to the Products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">v.</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">prepared a discounted cash flow analysis of each Product on a stand-alone basis and as a basket of Products; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">vi.</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">conducted such other quantitative reviews, analyses and inquiries relating to the Products as we considered appropriate in preparing the valuation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In rendering the VelocityHealth Opinion, VelocityHealth assumed, without independent verification or any responsibility, the accuracy and completeness of the financial, legal, regulatory, tax, accounting, and data furnished to, discussed with, or reviewed by VelocityHealth for purposes of its valuation and have relied upon such data as being complete and accurate. In that regard, VelocityHealth assumed that the data, including the forecasts, have been reasonably prepared on the basis reflecting the best currently available estimates and judgments of the management of the Company. VelocityHealth relied on the data for purposes of its analysis and valuation. VelocityHealth expressed no view or opinion as to the data or the assumptions on which it is based. VelocityHealth is not a legal, regulatory, tax or accounting advisor, and VelocityHealth expressed no opinion as to any legal, regulatory, tax or accounting matters. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The VelocityHealth Opinion was necessarily based on economic, market, financial and other conditions as they existed on, and on the information made available to VelocityHealth by or on behalf of the Company or its advisors, or information otherwise reviewed by VelocityHealth, as of the date of the VelocityHealth Opinion. It is understood that subsequent developments may affect the conclusion reached in the VelocityHealth Opinion and that VelocityHealth does not have any obligation to update, revise or reaffirm the VelocityHealth Opinion. Further, as the Board was aware, the credit, financial and stock markets had been experiencing unusual volatility and VelocityHealth expressed no opinion or view as to any potential effects of such volatility on the Assets, the Company, Apotex, Guarantor or the Transaction. The VelocityHealth Opinion is not a solvency opinion and does not in any way address the solvency or financial condition of the Company or any other party. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Neither the VelocityHealth Opinion nor VelocityHealth&#8217;s analyses were determinative of the Consideration or of the views of the Board or our management with respect to the Transaction. The type and amount of consideration payable in the Transaction were determined through negotiation between the Company and Apotex and the decision to enter into the Transaction was solely that of the Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In accordance with customary investment banking practice, VelocityHealth employed generally accepted valuation methods and financial analyses in reaching the VelocityHealth Opinion. The following is a brief summary of the material financial analyses performed by VelocityHealth in arriving at the VelocityHealth Opinion. These summaries of financial analyses alone do not constitute a complete description of the financial analyses VelocityHealth employed in reaching its conclusions. None of the analyses performed by VelocityHealth were assigned a greater significance by VelocityHealth than any other, nor does the order of analyses described represent relative importance or weight given to those analyses by VelocityHealth. The summary text describing each financial analysis does not constitute a complete description of VelocityHealth&#8217;s financial analyses, including the methodologies and assumptions underlying the analyses, and if viewed in isolation could create a misleading or incomplete view of the financial analyses performed by VelocityHealth. The summary text set forth below does not represent and should not be viewed by anyone as constituting conclusions reached by VelocityHealth with respect to any of the analyses performed by it in connection with the VelocityHealth Opinion. Rather, VelocityHealth made its determination as to the fairness to the Company, from a financial point of view, of the Consideration to be received by the Company from Apotex in the Transaction pursuant to the Agreement on the basis of its experience and professional judgment after considering the results of all of the analyses performed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise noted, the information utilized by VelocityHealth in its analyses, to the extent based on market data, was based on market data as it existed on or before April&#160;15, 2026 and is not necessarily indicative of current market conditions. The analyses described below do not purport to be indicative of actual future results, or to reflect the prices at which any securities may trade in the public markets, which may vary depending upon various factors, including changes in interest rates, dividend rates, market conditions, economic conditions and other factors that influence the price of securities. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Financial Analysis of the Consideration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">VelocityHealth evaluated the Consideration of $100.0&#160;million plus reimbursement for inventory transferred, and for transition services to be provided in relation to the implied valuation of the Marketed Product Portfolio. The analysis assessed whether the total purchase price consideration reflected fair value </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">relative to VelocityHealth&#8217;s concluded valuation of the seven standalone marketed products (Talicia</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vibativ</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Acetadote</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Sancuso</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Caldolor</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vaprisol</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, and Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">) on a going-concern basis. Based on the application of both the Income Approach (Discounted Cash Flow Method) and the Market Approach (Guideline Transaction Method), with equal weighting applied to each methodology at the individual product level, the aggregate implied value of the Marketed Product Portfolio was determined to be approximately $102.1&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">This analysis resulted in an implied present value to revenue multiple of 2.06x for the combined Marketed Product Portfolio, which was utilized as part of the valuation benchmarking framework. The total purchase price consideration of $100.0&#160;million plus reimbursement for inventory transferred, and for transition services to be provided, when compared to the concluded valuation of approximately $102.1&#160;million, indicates that the Consideration is within a reasonable range of the estimated standalone value of the Marketed Product Portfolio on a going-concern basis. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Financial Analysis of the Marketed Product Portfolio</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">VelocityHealth estimated the concluded product value (present value) of the Marketed Product Portfolio using a sum-of-the-parts valuation framework. Individual product valuations for Talicia</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vibativ</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Acetadote</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Sancuso</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Caldolor</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vaprisol</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, and Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> were estimated through the application of both the Income Approach (Discounted Cash Flow Method) and the Market Approach (Guideline Transaction Method), with equal weighting assigned to each methodology at the product level. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The aggregation of these individual product valuations resulted in an implied total portfolio value of approximately $102.1&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Under the Income Approach, VelocityHealth conducted a Discounted Cash Flow (&#8220;DCF&#8221;) analysis to estimate the present value of the stand-alone, unlevered, after-tax free cash flows attributable to the Marketed Product Portfolio. This analysis was based on financial projections comprising combined income statement forecasts for CY2026&#8201;&#8211;&#8201;CY2030, as provided by Company management. In the absence of discrete product-level projections, cost of goods sold and operating expenses were allocated proportionately based on each product&#8217;s contribution to net revenue. Product-specific assumptions were developed to reflect long-term growth expectations (a long-term growth rate of 1.5%), profitability profiles (free cash flow margins ranging from 11% to 19% of the combined results), and the respective risk characteristics of each product. These cash flows and terminal value were discounted to present value using an estimated weighted average cost of capital of 11.2%, which reflected market participant expectations, the maturity of the products, and VelocityHealth&#8217;s professional judgment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Market Approach, VelocityHealth considered valuation multiples implied by observed transactions involving comparable pharmaceutical products, with adjustments made to account for differences in profitability, growth prospects, and development status. Implied valuation multiples, expressed as product value-to-revenue, ranged from 1.19x to 2.98x across the selected guideline transactions. A weighted average multiple of 2.06x was applied to the Marketed Product Portfolio. Appropriate adjustments were made to these multiples to reflect execution risk and product-specific commercial considerations. A downward adjustment of 15% was applied to account for potential deviations between historical performance and management projections based on the combined results of Cumberland Pharmaceuticals. Additional downward adjustments, ranging from 12.0% to 16.3%, were applied to reflect product-level commercial risks, as assessed through a weighted SWOT framework incorporating factors such as competitive positioning, patent and licensing status, market dynamics, and lifecycle considerations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">VelocityHealth applied equal weighting to the Income and Market Approaches, reflecting the complementary nature of forward-looking cash flow analysis and observed market evidence, as well as the inherent limitations of relying exclusively on any single valuation methodology. Based on this analysis, VelocityHealth estimated the implied product-level values. The concluded valuation reflects a comprehensive consideration of product-specific growth prospects, profitability characteristics, and associated risks, including execution and commercial risks. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Key Analytical Procedures</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the course of its valuation analysis, VelocityHealth reviewed and relied upon the long-term financial projections of Cumberland and engaged with Company management to gain an understanding of the key </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="CPFI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">assumptions and underlying drivers supporting such forecasts. VelocityHealth performed a detailed product-level assessment, including analysis of revenue growth trajectories, profitability profiles, and lifecycle considerations. This review encompassed evaluation of patent and licensing expirations, classification of products as newly launched versus mature offerings, and examination of historical and projected trends in volume and pricing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, VelocityHealth conducted benchmarking analyses of implied valuation multiples against observed market transaction data through the application of the Guideline Transaction Method. This process involved the selection and evaluation of comparable transactions, ensuring alignment in terms of product characteristics, therapeutic areas, and prevailing market conditions with those of the subject Marketed Product Portfolio. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Miscellaneous</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The preparation of a fairness opinion is a complex process that is not necessarily susceptible to partial analysis or summary description. In arriving at its opinion, VelocityHealth considered the results of its analyses in their entirety, with the Income Approach (Discounted Cash Flow Method) and the Market Approach (Guideline Transaction Method) applied with equal weighting at the individual product level. No additional weighting was assigned to any other individual factor or consideration. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">VelocityHealth believes that the analyses described herein should be evaluated as a whole, as each component contributes to the overall valuation conclusion. Selective reliance on any individual analysis or methodology, without consideration of the full range of procedures performed, could result in an incomplete or potentially misleading understanding of the valuation process and the underlying assumptions. Accordingly, valuation indications derived from any single analytical component should not be viewed in isolation as representing VelocityHealth&#8217;s definitive conclusion regarding the value of the Marketed Product Portfolio, which is based on the combined application of the Income and Market Approaches, with equal weighting at the product level. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Based on the procedures performed and analyses considered, VelocityHealth concluded that the Consideration of $100.0&#160;million plus reimbursement for inventory transferred, and for transition services to be provided is within a reasonable range relative to the estimated standalone value of the Marketed Product Portfolio as of the valuation date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">VelocityHealth is acting as financial advisor to the Company in connection with the Transaction and will receive a fee for its services of $250,000, which is contingent upon the closing of the Transaction. VelocityHealth will not receive any other significant payment or compensation contingent upon the successful consummation of the Transaction. In addition, the Company has agreed to reimburse VelocityHealth for its expenses incurred in connection with VelocityHealth&#8217;s engagement and to indemnify VelocityHealth and its affiliates and their respective officers, directors, employees and agents, and any person controlling VelocityHealth or any of its affiliates, against certain liabilities arising out of its engagement. VelocityHealth may seek to provide investment banking services to the Company or other parties in the future, for which VelocityHealth would seek customary compensation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the two&#160;years preceding the date of the VelocityHealth Opinion, VelocityHealth was not engaged by the Company in any engagement in which VelocityHealth received any compensation or is intended to receive any compensation, other than the engagements and any amounts that were paid under the engagements described in this proxy statement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Certain Prospective Financial Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company does not as a matter of course publicly disclose long-term forecasts or internal projections as to future performance, revenues, earnings, financial condition or other results due to, among other reasons, the uncertainty of the underlying assumptions and estimates. However, in connection with VelocityHealth&#8217;s preparation of the VelocityHealth Opinion, Company management prepared unaudited prospective financial information for the Assets on a stand-alone, pre-Transaction basis. The Company is electing to provide the unaudited prospective financial information in this proxy statement to give the Company&#8217;s shareholders access to certain non-public unaudited prospective financial information that was provided to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:36pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">the Company&#8217;s financial advisor. The unaudited prospective financial information was not prepared with a view toward public disclosure and the inclusion of this information should not be regarded as an indication that the Company or any other recipient of this information considered, or now considers, it to be necessarily predictive of actual future results for the Assets. Neither the Company nor any of its affiliates, nor any of their respective advisors or representatives, assumes any responsibility for the accuracy of this information. Readers of this proxy statement are cautioned not to place undue reliance on the unaudited prospective financial information. No representation has been made to any Company shareholder regarding the information included in the unaudited prospective financial information or the ultimate performance of the Company compared to the information included in the unaudited prospective financial information. The unaudited prospective financial information is not being included in this proxy statement to influence the decision of the Company&#8217;s shareholders whether to vote in favor of adoption of the Transaction, but rather because such information was provided to VelocityHealth. The unaudited prospective financial information should be evaluated, if at all, in conjunction with the historical financial statements and other information regarding the Company contained in the Company&#8217;s public filings with the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All prospective financial information consists of forward-looking statements. These and other forward-looking statements are expressly qualified in their entirety by the risks and uncertainties identified above and the cautionary statements contained in the Company&#8217;s most recent Annual Report on Form 10-K, as amended and updated from time to time in the Company&#8217;s subsequent filings with the SEC. Please refer to the section entitled &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; beginning on page <a href="#CSRF">12</a>. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unaudited prospective financial information was not prepared with a view toward complying with U.S. generally accepted accounting principles (&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">GAAP</font><font style="letter-spacing:0.2pt;">&#8221;), the published guidelines of the SEC regarding projections or the guidelines established by the American Institute of Certified Public Accountants with respect to the preparation or presentation of prospective financial information. Certain of the financial metrics presented in the unaudited prospective financial information were not prepared in accordance with GAAP. These non-GAAP financial measures may be different from non-GAAP financial measures used by other companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There can be no assurance that the assumptions made in preparing such information will prove accurate or that the projected results reflected therein will be realized. Neither the Company&#8217;s independent registered public accounting firm, nor any other independent accountants, have compiled, examined or performed any procedures with respect to the unaudited prospective financial information contained herein, nor have they expressed any opinion or any other form of assurance on such information or its achievability, and they assume no responsibility for the unaudited prospective financial information. Furthermore, the unaudited prospective financial information does not take into account any circumstance or event occurring after the date it was prepared or which may occur in the future, and, in particular, does not take into account any revised prospects of the Company or the Assets, changes in general business, regulatory or economic conditions, competition or any other transaction or event that has occurred since the date on which such information was prepared or which may occur in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While presented with numeric specificity, the unaudited prospective financial information reflects numerous estimates and assumptions made by Company management with respect to industry performance and competition, general business, economic, market and financial conditions and matters specific to the Company and the Assets, all of which are difficult to predict and many of which are beyond the Company&#8217;s control. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a result, the unaudited prospective financial information reflects numerous assumptions and estimates as to future events and there can be no assurance that these assumptions will accurately reflect future conditions, that the projected results will be realized or that actual results will not be significantly higher or lower than estimated. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="RFTT">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table presents a summary of the material unaudited prospective financial information of the Assets contained in the forecast provided to VelocityHealth (in thousands): </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Cumberland Pharmaceuticals Inc.</font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Annual Projections </font>
        </div>
        <table style="width:456pt;height:418pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:167.76pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Forecast </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Projections </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Draft Projections </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:167.76pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2026 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2027 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2028 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2029 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2030 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Product Sales</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Domestic </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">64,502</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">91,760</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">97,985</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">102,127</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">106,893</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">111,709</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">International </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,749</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">5,055</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">7,603</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">8,422</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">9,217</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">9,952</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Gross Product Sales </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">66,251</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">96,815</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">105,589</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">110,548</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">116,110</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">121,661</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Revenue</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Domestic </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">42,439</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">52,157</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">53,759</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">55,914</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">58,522</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">61,193</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">International </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,749</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">5,055</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">7,603</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">8,422</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">9,217</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">9,952</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net Revenues </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">44,188</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">57,212</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">61,363</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">64,336</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">67,739</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">71,145</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Expenses</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of Products Sold </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,574</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11,159</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">12,129</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">12,590</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">13,093</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">13,748</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Selling and Marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">15,988</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">17,963</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">17,981</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">18,251</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">18,707</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">19,062</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Royalty Expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,086</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,526</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,734</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,843</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,996</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">6,577</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and Development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,535</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,306</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,626</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">6,076</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">6,301</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">6,490</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and Administration </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11,467</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11,786</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">11,798</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">12,270</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">12,466</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">12,616</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Amortization of Intangibles </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">4,035</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">4,039</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">4,051</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">4,092</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">4,071</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">4,035</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating Expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">46,685</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">55,779</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">57,319</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">59,121</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">60,635</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">62,528</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <font style="letter-spacing:0.2pt;">Operating Income (loss)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(2,497<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,433</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,043</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,215</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">7,105</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">8,617</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest Income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">477</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">540</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other Income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;-</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest and Other Expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(496<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(439<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(439<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(439<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(439<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(439<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <font style="letter-spacing:0.2pt;">Net Income (loss) before Taxes</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(2,516<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,534</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,104</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,276</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">7,168</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">8,682</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:167.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net Income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">(2,532<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,518</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">4,088</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">5,260</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">7,152</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">8,666</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Amortization </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,518</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,518</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,518</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,518</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,518</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,518</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Income Taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">19</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(101<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(61<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(61<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(61<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(61<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:167.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Stock Based Comp. Expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">360</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">350</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">350</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">350</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">350</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">350</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:167.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Adjusted Earnings </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">2,381</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">6,301</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">8,911</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">10,083</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">11,975</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">13,489</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Reasons for the Transaction</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In reaching its decision to approve the Transaction, and to recommend that our shareholders vote to approve the Transaction Proposal, the Board and Board Special Committee consulted with outside advisors and considered, among other things, Cumberland&#8217;s strategic priorities, its current portfolio of commercial products, its clinical-stage ifetroban programs, and Cumberland&#8217;s longer-term innovation and incubation activities conducted through CET. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board&#8217;s decision was based on its judgment as to Cumberland&#8217;s prospects, opportunities, and risks, and the Board&#8217;s belief that the Transaction is advisable and in the best interests of Cumberland and its shareholders. The Board and Board Special Committee considered numerous factors relating to the Agreement and the proposed Transaction, including, without limitation, the following (many of which were discussed at prior meetings) but without assigning specific numerical weight, emphasis, or relative priority among those factors: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">that the consideration to be received by Cumberland pursuant to the Agreement represents a fair valuation of the Assets and that Cumberland will have a better chance of increasing shareholder value by selling the Assets in this Transaction than it would if it retained the Assets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">that the purchase price of $100&#160;million represented a premium of approximately 114% to Cumberland&#8217;s market capitalization of approximately $46.7&#160;million as of April&#160;13, 2026 (based on a closing price of $3.12 per share); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">that the purchase price consists solely of cash at closing, which provides certainty of value to Cumberland; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the VelocityHealth Opinion received by the Board, dated April&#160;15, 2026, that, as of the date thereof, the consideration to be received by Cumberland from Apotex in the Transaction pursuant to the Agreement was fair and reasonable to Cumberland, from a financial point of view; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the view of the Board that, following the proposed Transaction, Cumberland will have a viable business to pursue, albeit with fewer employees; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">that the cash proceeds from the Transaction will provide Cumberland with financial liquidity and flexibility, which is important to Cumberland and its shareholders in order to provide Cumberland with the opportunity to maximize value of its Retained Programs, while pursuing other initiatives intended to increase shareholder value; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">that Cumberland&#8217;s ability to advance and potentially realize value from the Retained Programs could be enhanced by separating the FDA-approved commercial portfolio from the retained development-stage assets and by reallocating financial and managerial resources toward those Retained Programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">that, on February&#160;4, 2025, Cumberland announced breakthrough results from the Phase&#160;2 FIGHT DMD trial evaluating ifetroban, and that in the weeks following the announcement the trading price of Cumberland&#8217;s Common Stock increased 190% from a closing price of $2.13 per share on February&#160;3, 2025 to a closing price of $6.19 per share on February&#160;19, 2025 (representing an increase in market capitalization of approximately $56.7&#160;million), demonstrating the value that investors place in the Retained Programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the Board&#8217;s belief that a narrower operating scope could allow Cumberland to redeploy management attention and internal infrastructure toward advancing the Retained Programs and evaluating strategic opportunities, and could also reduce execution risk associated with supporting a diversified commercial portfolio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">other historical information regarding (i)&#160;Cumberland&#8217;s business, financial performance and results of operations, (ii)&#160;market prices, volatility and trading activity with respect to Cumberland&#8217;s Common Stock, and (iii)&#160;market prices with respect to other industry participants and general market indices; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">current information regarding (i)&#160;Cumberland&#8217;s business, prospects, financial condition, operations, technology, products, services, management, competitive position and strategic business goals and objectives, (ii)&#160;general economic, industry and financial market conditions, (iii)&#160;opportunities and competitive factors within Cumberland&#8217;s industry and (iv)&#160;Cumberland&#8217;s current financial and cash positions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">that a portfolio of FDA-approved commercial products is subject to risks that can adversely affect revenue and profitability, including pricing and reimbursement pressures, competition (including from generics and therapeutic alternatives), tariffs, product supply and manufacturing risks, and the potential for fluctuations in demand; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the value of obtaining a substantial monetization event at this time in light of Cumberland&#8217;s historical operating results, the evolving market environment for specialty pharmaceutical products, and the inherent uncertainties associated with Cumberland&#8217;s future commercial performance and development programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the potential for other third parties to enter into strategic relationships with or to seek to acquire Cumberland or a significant portion of the assets of Cumberland, including a review of management&#8217;s </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">dealings in the past, an assessment of what prospective buyers would be willing to pay for the Assets, and an assessment of the likelihood that a third party would offer a higher price than the purchase price; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the proposals and negotiations with Investor A and the Board&#8217;s belief that the current transaction represented the best opportunity to maximize value for Cumberland&#8217;s shareholders, taking into account the totality of the terms offered, the strategic fit of Apotex with Cumberland&#8217;s business, the resources and capabilities Apotex would bring to the transaction, and the likelihood of completing a transaction on the proposed terms; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">that the Transaction is the result of a thorough evaluation of strategic alternatives reasonably available to Cumberland; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the Board&#8217;s belief that the Transaction was more favorable to Cumberland&#8217;s shareholders than any other alternative reasonably available to Cumberland and its shareholders, including the alternative of retaining Assets based upon: (i)&#160;the Board&#8217;s knowledge of the current and prospective environment in which Cumberland operates, the competitive environment, and Cumberland&#8217;s overall strategic position; (ii)&#160;the Board&#8217;s understanding of Cumberland&#8217;s business, operations, management, financial condition, earnings and prospects; and (iii)&#160;Cumberland&#8217;s current financial and cash positions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the fact that, pursuant to the Agreement, Apotex will assume the Assumed Liabilities and will pay, perform and discharge the Assumed Liabilities listed in the Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the fact that the Transaction will be taxable and Cumberland has significant net operating losses available; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the belief of the Board that continuing with negotiations with other parties would not result in a transaction at a more attractive price than the purchase price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the belief of the Board that the Transaction has a reasonable likelihood of closing without material potential issues under applicable antitrust laws or material potential issues from any governmental authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">that the Transaction will not be subject to a financing contingency and that Guarantor has guaranteed the payment in full of all payment and indemnification obligations of Apotex under the Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">that the Transaction is subject to approval by Cumberland&#8217;s shareholders, and that if such shareholders do not approve the Transaction, then it will not close; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the possible effects of the Transaction and public announcement of the Transaction on Cumberland&#8217;s financial performance, operating results and stock price and Cumberland&#8217;s relationships with other business partners, management and employees; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the fact that the Agreement precludes Cumberland from actively soliciting competing acquisition proposals, subject to a customary &#8220;fiduciary out&#8221; provision; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the fact that the Agreement imposes restrictions on the conduct of Cumberland&#8217;s business in the pre-closing period, which may adversely affect Cumberland&#8217;s business in the event the Transaction is not completed (including by delaying or preventing Cumberland from pursuing business opportunities that may arise or precluding actions that would be otherwise advisable), and which may significantly restrict the operation of Cumberland&#8217;s business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the risks involved with the Transaction and the likelihood that Cumberland and Apotex will be able to complete it, the possibility that the Transaction might not be consummated and Cumberland&#8217;s prospects going forward; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the potential risk of diverting management focus and resources from operational matters and other strategic opportunities while working to implement the Transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the absence of appraisal rights or rights of an objecting shareholder for Cumberland shareholders under Tennessee law and the Company&#8217;s fourth amended and restated charter; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the fact that there are third-party contract consents that must be obtained as a condition to closing the Transaction and the uncertainties with obtaining those consents, which could result in the failure of the Transaction to be consummated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="UOPA">&#8203;</a><a name="APRI">&#8203;</a><a name="CMUF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the fact that the Transaction must be completed within 120&#160;days of the execution of Agreement and that the shareholder meeting to approve the Transaction must occur by such date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the fact that, under the terms of the Agreement, Cumberland may have to pay Apotex a termination fee of $4&#160;million in certain circumstances; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the risks associated with Cumberland being required to satisfy indemnification obligations under the Agreement; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">other potentially adverse factors and uncertainties relating to the Transaction, including, among other things: (i)&#160;the loss of revenue and cash flows historically associated with the Assets and the resulting increased dependence on Cumberland&#8217;s retained development-stage assets and strategies; (ii)&#160;the risks inherent in clinical development, regulatory review, and the commercialization of ifetroban and other pipeline or CET-supported assets, including the possibility that such programs may not achieve favorable clinical results or regulatory outcomes; (iii)&#160;the costs associated with the Transaction, including transaction expenses and potential dis-synergies and the negative impact of such expenses on Cumberland&#8217;s cash reserves and operating results should the Transaction not be completed; and (iv)&#160;the impact of the Transaction on employees and other stakeholders, as well as Cumberland&#8217;s ability to retain and attract personnel critical to the retained strategy. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The foregoing discussion of the factors considered by our Board is not intended to be exhaustive. Our Board collectively reached the conclusion to approve the Agreement and the Transaction in light of the various factors described above, as well as other factors that our Board felt were appropriate. In view of the wide variety of factors considered by our Board in connection with its evaluation of the Transaction and the complexity of these matters, our Board did not consider it practical, and did not attempt, to quantify, rank or otherwise assign relative weights to the specific factors it considered in reaching its decision. Rather, our Board made its recommendation based on the totality of the information presented to, and the investigation conducted by, the Board. In considering the factors discussed above, individual members of the Board may have valued certain factors more or less than others. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">After evaluating these factors and consulting with its outside legal counsel and financial advisor, our Board unanimously approved and declared advisable the Agreement and the Transaction and determined that the transactions contemplated thereby are fair to and in the best interests of Cumberland&#8217;s shareholders.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Use of Proceeds and Future Operations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently intend to utilize the cash proceeds from the sale of the Assets to maximize the value of our Retained Programs and for other working capital purposes. Our Board of Directors will also continue to evaluate other activities aimed at enhancing shareholder value, which may potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. No such activities are currently pending. The Company does not currently intend to distribute any of the proceeds from the Transaction as a dividend to the Company&#8217;s shareholders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Appraisal Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Holders of shares of our Common Stock do not have appraisal rights under Tennessee law or under the governing documents of the Company in connection with the Transaction or this solicitation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Certain Material U.S. Federal Income Tax Consequences</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following discussion is a general summary of certain of the anticipated material U.S. federal income tax consequences of the Transaction. The following discussion is based upon the Internal Revenue Code of 1986, as amended (which we refer to as the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Code</font><font style="letter-spacing:0.2pt;">&#8221;), its legislative history, currently applicable and proposed Treasury Regulations under the Code and published rulings and decisions, all as currently in effect as of the date of this proxy statement, and all of which are subject to change, possibly with retroactive effect. Tax consequences under state, local and non-U.S. laws, or federal laws other than those pertaining to income tax, are not addressed in this proxy statement. No rulings have been requested or received from the IRS as to the tax consequences of the Transaction and there is no intent to seek any such ruling. Accordingly, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="AAT">&#8203;</a><a name="LICP">&#8203;</a><a name="EOOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">no assurance can be given that the IRS will not challenge the tax treatment of the Transaction discussed below or, if it does challenge the tax treatment, that it will not be successful. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Transaction will be treated for U.S. federal income tax purposes as a taxable transaction upon which we will recognize gain or loss. The amount of gain or loss we recognize with respect to the sale of a particular asset (including any deemed sale of a particular asset) will be measured by the difference between the amount realized by us on the sale of that asset and our tax basis in that asset. The amount realized by us on the Transaction will include the amount of cash received, the fair market value of any other property received, and total liabilities assumed or taken by Apotex. For purposes of determining the amount realized by us with respect to specific assets, the total amount realized by us will generally be allocated among the assets according to the rules set forth in Section&#160;1060(a) of the Code and the Treasury Regulations thereunder. Our basis in our assets is generally equal to the cost of such assets, as adjusted for certain items, such as depreciation. The determination of whether we will recognize gain or loss will be made with respect to each of the assets to be sold. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Accordingly, we may recognize gain on the sale of certain assets and loss on the sale of certain others, depending on the amount of consideration allocated to an asset as compared with the basis of that asset. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To the extent the Transaction results in us recognizing a net gain for U.S. federal income tax purposes, we expect that our current year losses or our available net operating loss carryforwards will offset a substantial part of such gain. The determination of our realized gain and/or loss and whether and to what extent our net operating losses will be available to offset any gain is highly complex and is based in part upon facts that will not be known until the completion of the Transaction and the finalization of any purchase price adjustments associated with the Transaction. Therefore, it is possible that we will incur U.S. federal income tax as a result of the proposed Transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Transaction is entirely a corporate action, taxable to the Company. Shareholders will not realize any gain or loss for U.S. federal income tax purposes as a result of the Transaction. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anticipated Accounting Treatment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under generally accepted accounting principles, upon completion of the Transaction, we will remove the net assets and liabilities related to the Assets from our consolidated balance sheet. We expect that the results of operations from the Assets will be treated as discontinued operations. The unaudited proforma financial information, included elsewhere in this proxy statement, provides the pro&#160;forma effect of the sale of the Assets. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2007 Long-Term Incentive Compensation Plan and the 2007 Directors&#8217; Incentive Plan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s 2007 Long-Term Incentive Compensation Plan and 2007 Directors&#8217; Incentive Plan provide for the accelerated vesting of options and restricted stock granted under such plans upon a &#8220;Change in Control Event,&#8221; which includes any sale of all or substantially all of the assets of the Company. The Company&#8217;s directors and named executive officers have agreed to waive any accelerated vesting of options or restricted stock resulting from the Transaction. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Effects on our Company if the Transaction is Completed and the Nature of our Business following the Transaction</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the Transaction is consummated, the cash purchase price we receive will be paid directly to the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently intend to utilize the cash proceeds from the sale of the Assets to maximize the value of our Retained Programs and for other working capital purposes. Our Board of Directors will also continue to evaluate other activities aimed at enhancing shareholder value, which may potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. No such activities are currently pending. The Company does not currently intend to distribute the proceeds from the Transaction as a dividend to the Company&#8217;s shareholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board currently anticipates that the Company will remain as a reporting company following the consummation of the Transaction. The Transaction will not alter the rights, privileges or nature of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TAPA">&#8203;</a><a name="PASO">&#8203;</a><a name="AOL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">issued and outstanding shares of our Common Stock. A shareholder who owns shares of our Common Stock immediately prior to the closing of the Transaction will continue to hold the same number of shares immediately following the closing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Asset Purchase Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Purchase and Sale of the Assets</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Assets</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the terms and conditions of the Agreement, at the Closing of the Transaction, the Company will sell, assign, transfer, convey and deliver, and Apotex will purchase, acquire and accept, all of the Company&#8217;s and its applicable Affiliates&#8217; right, title and interest in, to and under the Assets, including the following assets: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The Products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The Transferred Contracts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Inventory related to the Products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Intellectual Property primarily related to, developed for, used with, or held for use in connection with the Products and the Business and Intellectual Property in or to the formulations of the Products, together with all Ancillary IP rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Active, inactive, or withdrawn investigational new drug applications (INDs) associated with the Products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Product Records; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">FDA Product NDA and ANDA Approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Permits granted by Governmental Authorities exclusively in connection with the operation of the Business prior to the closing date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">All Prescription Drug User Fee Act (PDUFA) and Generic Drug User Fee Act (GDUFA) fees with respect to the Business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Brand marketing and promotional materials currently used by the Company and specifically related to the Products, and any corresponding marketing and regulatory authorizations to sell and distribute the Products, together with all related Intellectual Property and Ancillary IP Rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Cumberland Work Product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Regulatory Registrations and Regulatory Approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Transferred Equity Interests; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Personnel Records related solely to the Business Employees; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Any other properties, assets (including contracts), and goodwill exclusively related to the Products or the Business. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Excluded Assets</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Transaction excludes certain assets of the Company that are not identified or described in the Assets under the Agreement (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Excluded Assets</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Assumption of Liabilities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Assumed Liabilities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the terms and conditions of the Agreement, at the Closing of the Transaction, Apotex will assume and, following the Closing, will be responsible for paying, performing or otherwise satisfying and discharging when due, the Assumed Liabilities, including the following: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="CFTT">&#8203;</a><a name="RAW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Obligations under the Transferred Contracts and any purchase orders for the supply of Products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Obligations relating to Regulatory Registrations, Regulatory Approvals and investigational new drug applications (INDs), including post-marketing activities, pharmacovigilance, safety, clinical studies, quality assurance, compliance with good manufacturing practices, good distribution practices, deficiency letters, corrective action plan agreements, and other related obligations described in the Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Liabilities arising from any patent infringement claim or Proceeding brought by any Third Party, including any Governmental Authority, at or after the Closing to the extent arising out of the conduct of the Business after the Closing or any activities of Apotex or any of its Affiliates with respect to the Business, the Products or any Acquired Asset after the Closing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Liabilities arising from any action or notification by a Governmental Authority, at or after the Closing, to the extent arising out of the conduct of the Business after the Closing, or any activities of Apotex or any of its Affiliates with respect to the Business, the Products or any Acquired Asset after the Closing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Liabilities arising out of the Products made or sold at or after the Closing, including product warranty claims or Product Liabilities arising after the Closing relating to such Products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Liabilities for Taxes to the extent arising out of Apotex&#8217;s or any of its Affiliates&#8217; conduct of the Business for all taxable periods (or portions thereof) beginning on or after the Closing Date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Liabilities relating to the Transferred Regulatory Documentation solely to the extent arising out of the conduct of the Business after the Closing or any activities of Apotex or any of its Affiliates with respect to the Business, the Products or any Acquired Asset after the Closing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Liabilities of Apotex under the Transition Services Agreement; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Any other Liability occurring at or after the Closing solely to the extent arising out of the conduct of the Business after the Closing or any activities of Apotex or any of its Affiliates with respect to the Business, the Products or any Acquired Asset after the Closing. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Excluded Liabilities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except for the Assumed Liabilities, Apotex will not assume any other liabilities in connection with the Transaction. The following liabilities (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Excluded Liabilities</font><font style="letter-spacing:0.2pt;">&#8221;) will be retained by, and remain the responsibility of, the Company and its Affiliates: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Liabilities for Excluded Taxes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Liabilities to the extent related to any Excluded Asset; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Obligations of the Company under the Agreement and the Transaction Documents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Liabilities arising or occurring prior to the Closing solely to the extent relating to the Business, the Products or any Acquired Asset or any activities of the Company or any of its Affiliates with respect to the Business, the Products or any Acquired Asset; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Excise taxes, duties, other government taxes or charges on the sales and any other allowances or adjustments for Product sold by the Company or any of its Subsidiaries prior to Closing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Liabilities of the Company under the Transition Services Agreement; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Any cost or Liability arising or resulting from any breach or alleged breach of any Transferred Contract as a result of the Transactions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Consideration for the Transaction</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As consideration for the Transaction, Apotex agreed to pay the Company $100&#160;million at the closing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Representations and Warranties</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Agreement contains representations and warranties that the Company and Apotex have made to each other as of specific dates relating to themselves and their respective businesses. The assertions embodied </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">in these representations and warranties were made solely for purposes of the Agreement and may be subject to important qualifications and limitations agreed to by the parties in connection with negotiating the terms of the Agreement. Accordingly, the Company&#8217;s shareholders should not rely on the representations and warranties as characterizations of the actual state of facts or circumstances, and should bear in mind that the representations and warranties were made solely for the benefit of the parties to the Agreement, were negotiated for purposes of allocating contractual risk among the parties to the Agreement rather than to establish matters as facts, may be subject to contractual standards of materiality different from those generally applicable to shareholders, and may be qualified by publicly filed reports and documents filed with the SEC and matters contained in the disclosure schedules that the Company delivered to Apotex in connection with the Agreement, which are not reflected in the Agreement. Moreover, information concerning the subject matter of such representations and warranties may change after the date of the Agreement, which subsequent information may or may not be reflected in the Company&#8217;s public disclosures. This description of the representations and warranties is included solely to provide shareholders with information regarding the terms of the Agreement. The representations and warranties in the Agreement and their description in this proxy statement should be read in conjunction with the other information contained in the reports, statements and filings that we publicly file with the SEC. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">The Company&#8217;s Representations and Warranties</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s representations and warranties relate to, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Organization and Good Standing </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Board Approval </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Authority; Execution and Delivery </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">No Violation; Consents </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Title to Assets </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Litigation </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Regulatory Matters; Compliance with Law </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Contracts </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Intellectual Property </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Inventory </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Ordinary Course of Business </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">No Brokers </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Customers and Suppliers </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Transactions with Affiliates </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Sales Information; No Undisclosed Liabilities </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Taxes </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Labor and Employment </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Employee Benefit Plan </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Solvency </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Apotex&#8217;s Representations and Warranties</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Apotex&#8217;s representations and warranties relate to, among other things, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Organization and Good Standing </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Authority; Execution and Delivery </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">No Violations; Consents </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="COV">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Litigation </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">No Brokers </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consents </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Financial Capacity </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Solvency </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Investigation </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The representations and warranties of the Company will survive the closing on a limited basis, as follows: (a)&#160;the Company&#8217;s general representations and warranties (other than the Cumberland Fundamental Representations, the Cumberland Sufficiency Representations and the representation and warranty relating to Taxes) will survive for a period of twelve (12) months following the Closing Date; (b)&#160;the Cumberland Fundamental Representations (being the representations and warranties relating to Organization; Good Standing, Board Approval, Authority; Execution and Delivery, No Violation; Consents, Title to Assets, No Brokers, and Transactions with Affiliates) will survive for sixty (60) days following the expiration of the applicable statute of limitations; (c)&#160;the Cumberland Sufficiency Representations (being the representations and warranties set forth in Section&#160;5.5(b) of the Agreement relating to the Assets and Section&#160;5.9 of the Agreement relating to Intellectual Property) will survive for sixty (60) days following the expiration of the applicable statute of limitations; and (d)&#160;the representations set forth on Section&#160;5.16 of the Agreement (being the representation and warranty relating to Taxes) will survive for sixty (60) days following the expiration of the applicable statute of limitations. The representations and warranties of Apotex (other than the Apotex Fundamental Representations) will survive until twelve (12) months following the Closing Date, and the Apotex Fundamental Representations (being the representations and warranties relating to Organization; Good Standing, Authority; Execution and Delivery, and No Brokers) will survive for sixty (60) days following the expiration of the applicable statute of limitations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Covenants</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Agreement contains certain covenants that relate to, among other things, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Regulatory Commitments </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Intellectual Property Commitments </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Bulk Transfer Laws </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Marketing of Assets </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Conduct of Business Prior to the Closing </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Cooperation and Commercially Reasonable Efforts </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Employee Covenants </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Government Price Reporting </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Regulatory Matters </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Exclusivity </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Proxy Statement and Other Required SEC Filings </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Stockholder Meeting </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Wrong Pockets </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Payments from Third Parties </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Notice of Certain Events </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Tax Matters </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Restrictive Covenants </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="CLCO">&#8203;</a><a name="EXC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Access and Reports </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Vibativ Award Milestone </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Delivery of Certain Work Product </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Lien Releases </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Confidential Information </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Closing Conditions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Conditions to the Obligation of Apotex</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The obligations of Apotex to consummate the Transaction are subject to the satisfaction or waiver, at or prior to the Closing, of the following closing conditions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The Company obtaining the Requisite Stockholder Approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The receipt of required third-party consents or the evidence of required third-party notices, as applicable, necessary for the assignment to Apotex of certain Material Contracts and Assets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Delivery of a certificate of a duly authorized officer of the Company that each of the conditions set forth in the immediately following three bullets has been satisfied; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The accuracy of the Company&#8217;s representations and warranties at the Closing, subject to the applicable materiality, Material Adverse Effect, and de minimis standards set forth in the Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The Company&#8217;s performance and compliance, in all material respects, of its agreements, covenants and conditions under the Agreement required to be performed or complied with by it prior to or at the date of closing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The absence of a Material Adverse Effect with respect to the Company since the date of the Agreement; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">No law shall be in effect and no governmental action shall be pending that would prohibit the consummation of the Transaction. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Conditions to the Obligation of the Company</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The obligations of the Company to consummate the Transaction are subject to the satisfaction or waiver, at or prior to the Closing, of the following closing conditions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The Company obtaining the Requisite Stockholder Approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">No law shall be in effect and no governmental action shall be pending that would prohibit the consummation of the Transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Delivery of a certificate of a duly authorized officer of Apotex that each of the conditions set forth in the immediately following two bullets has been satisfied; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The accuracy of Apotex&#8217;s representations and warranties at the Closing, subject to specified materiality standards, including with respect to representations made as of the date of closing; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Apotex&#8217;s performance and compliance, in all material respects, with its agreements, covenants and conditions required to be performed or complied with by it prior to or at the Closing under the Agreement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exclusivity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Agreement requires that the Company, from the Effective Date until the earlier of the termination of the Agreement or closing of the Transaction, not initiate contact with or solicit any inquiry or proposal or engage in any discussions with third parties in connection with possible proposals regarding a sale or licensing of the Assets and certain other strategic transactions involving the Company, subject to a customary &#8220;fiduciary out&#8221; provision that allows the Company to participate in discussions and engage in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TER">&#8203;</a><a name="EOTA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">negotiations with third parties under certain specified circumstances. The Company has agreed to promptly provide notice to Apotex of any solicitation or offer made by any third party in connection with such alternative transaction. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Termination</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Agreement may be terminated prior to Closing as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">by the mutual written agreement of the Company and Apotex; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">by either Apotex or the Company if any Law or final, non-appealable Order permanently enjoins, prohibits or makes illegal the consummation of the Transaction, provided that the terminating party is not in material breach of the Agreement in a manner that caused such prohibition; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">by either the Company or Apotex if the Transaction has not closed by the Outside Date, as may be extended by mutual agreement, provided that the terminating party&#8217;s material breach did not cause the failure to close by such date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">by the Company if Apotex&#8217;s representations and warranties fail to be true and correct or Apotex has materially breached or failed to comply with its covenants under the Agreement, in each case such that the applicable closing conditions would not be satisfied and such failure or breach cannot be cured or is not cured within the applicable cure period; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">by Apotex if the Company&#8217;s representations and warranties fail to be true and correct or Cumberland has materially breached or failed to comply with its covenants under the Agreement, in each case such that the applicable closing conditions would not be satisfied and such failure or breach cannot be cured or is not cured within the applicable cure period; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">by the Company, prior to obtaining the Requisite Stockholder Approval, in order to enter into an Alternative Transaction Agreement with respect to a Superior Proposal, subject to compliance with the non-solicitation and fiduciary exceptions of the Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">by either the Company or Apotex if the Company fails to obtain the Requisite Stockholder Approval at the Stockholder Meeting (or any adjournment or postponement thereof), provided that the terminating party did not cause such failure; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">by Apotex, prior to obtaining the Requisite Stockholder Approval, if the Company&#8217;s Board effects a Board Recommendation Change regarding the Transaction. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Effect of Termination and the Parties&#8217; Obligations Upon Termination</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the Agreement is terminated prior to the Closing, the Agreement will become void and have no further force or effect, and neither party will have any further obligations thereunder, except for certain provisions that expressly survive termination, including provisions relating to confidential information and miscellaneous matters. Termination of the Agreement will not relieve any party of liability arising from fraud or a Willful Breach of the Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the Agreement is validly terminated because the Closing did not occur by the Outside Date and (A)&#160;all conditions to closing were satisfied, waived, or capable of being satisfied, (B)&#160;the Company confirmed in writing that it was ready, willing, and able to consummate Closing, (C)&#160;Apotex failed to consummate the Closing within three business days after the later of the Company&#8217;s delivery of such notice and the date on which Apotex was required to consummate the Closing and during these periods the Company was ready, willing, and able to consummate the Closing, then Apotex would be required to pay the Company a termination fee of $4,000,000. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the Agreement is validly terminated because the Closing did not occur by the Outside Date (and such termination was not the result of the terminating party&#8217;s material breach of the Agreement), and following execution of the Agreement and prior to such termination the Company received an Acquisition Proposal that was not irrevocably withdrawn prior to such termination, or an Acquisition Proposal was publicly made or disclosed and not publicly withdrawn or abandoned, and within twelve&#160;months following such termination an Acquisition Transaction is consummated or the Company enters into a definitive </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="POAR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">agreement for an Acquisition Transaction (which is subsequently consummated), then the Company would be required to pay Apotex a termination fee of $4,000,000, payable concurrently with the consummation of such Acquisition Transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the Company would be required to pay the $4,000,000 termination fee if the Agreement is terminated under specified provisions including (i)&#160;termination by the Company prior to receiving the Requisite Stockholder Approval in order to accept a Superior Proposal and enter into an Alternative Transaction; (ii)&#160;termination by Apotex as a result of the Company&#8217;s breach of its representations, warranties, or covenants under the Agreement that would cause closing conditions not to be satisfied; (iii)&#160;termination by either party because the Requisite Stockholder Approval was not obtained; or (iv)&#160;termination by Apotex following a change in the board of directors&#8217; recommendation. In no event would the Company be required to pay the termination fee more than once. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Agreement provides that the termination fees are an integral part of the Agreement and constitute liquidated damages rather than penalties. Following a valid termination of the Agreement under the applicable provisions, payment of the applicable termination fee, together with any related enforcement costs, generally constitutes the sole and exclusive remedy available to the non-terminating party for losses arising out of the termination of the Agreement and the transactions. In certain circumstances, a party may seek specific performance of the Agreement. However, no party may recover both specific performance and a termination fee. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Following termination of the Agreement, Apotex is generally required to return or destroy Confidential Information received from the Company relating to the Products or the Assets, subject to exemptions for information retained in accordance with applicable law, Apotex&#8217;s document retention policies, and standard archiving and back-up procedures. Any Confidential Information of the Business, the Products and the Assets will continue to be subject to the confidentiality obligations set forth in the parties&#8217; Confidentiality Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Post-Closing Arrangements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Agreement contains certain covenants that will survive the closing of the transaction, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Subject to the limitations in the Agreement, the Company has agreed to indemnify Apotex and its Affiliates and their respective successors, permitted assigns, directors, officers, agents and employees for any losses incurred by any of them in connection with (i)&#160;any breach of any representation or warranty of the Company (subject to the applicable survival periods, deductible and cap limitations described below), (ii)&#160;any breach of the Cumberland Fundamental Representations, (iii)&#160;any breach of the Cumberland Sufficiency Representations, (iv)&#160;a breach of, default in, or failure to perform any of the covenants given or made by the Company in the Agreement, the IP Assignment Agreement or the Bill of Sale and Assignment and Assumption Agreement, (v)&#160;the Company&#8217;s ownership and operation of the Assets, and the research, development, obtaining and maintaining of regulatory approvals for, manufacture, sale, licensure, marketing, promotion, commercialization, distribution, exportation, importation or offering of the Products and INDs by the Company through the Closing Date, (vi)&#160;any and all Excluded Assets and Excluded Liabilities, and (vii)&#160;any businesses of the Company other than the Business. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Subject to the limitations in the Agreement, Apotex has agreed to indemnify the Company and its Affiliates and their respective successors, permitted assigns, directors, officers, agents and employees for any losses incurred by any of them in connection with (i)&#160;any breach of any representation or warranty of Apotex (other than the Apotex Fundamental Representations), (ii)&#160;any breach of any Apotex Fundamental Representation, (iii)&#160;a breach of, default in, or failure to perform any of the covenants given or made by Apotex in the Agreement, the IP Assignment Agreement or the Bill of Sale and Assignment and Assumption Agreement, (iv)&#160;Apotex&#8217;s ownership and operation of the Assets, and the research, development, obtaining and maintaining of Regulatory Registrations and Regulatory Approvals for, manufacture, sale, licensure, marketing, promotion, commercialization, distribution, exportation, importation or offering of the Products and INDs by Apotex after the Closing Date, and (v)&#160;any and all Assumed Liabilities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The indemnification obligations under the Agreement are subject to certain limitations. With respect to the Company&#8217;s general representations and warranties, the aggregate amount recoverable by Apotex is limited to ten&#160;percent (10%) of the Purchase Price (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">General Cap</font><font style="letter-spacing:0.2pt;">&#8221;). Claims for breaches of the Cumberland Fundamental Representations, Cumberland Sufficiency Representations and certain representations related to tax matters are excluded from the General Cap. The aggregate amount recoverable by the Apotex Indemnified Parties for breaches of the Company&#8217;s representations and warranties (including the Cumberland Fundamental Representations, the Cumberland Sufficiency Representations and the tax representations) and breaches of the Company&#8217;s covenants (other than for Fraud) is limited to the Purchase Price. The aggregate amount recoverable by the Cumberland Indemnified Parties for breaches of Apotex&#8217;s general representations and warranties is limited to the General Cap, and the aggregate amount recoverable for breaches of Apotex&#8217;s representations and warranties (including the Apotex Fundamental Representations) and breaches of Apotex&#8217;s covenants (other than for Fraud) is limited to the Purchase Price. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">No indemnification is payable for claims under the Company&#8217;s or Apotex&#8217;s representations and warranties until the aggregate losses exceed $1,000,000 (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Deductible</font><font style="letter-spacing:0.2pt;">&#8221;), and then only to the extent such aggregate amount exceeds the Deductible. In addition, no individual claim is recoverable unless it exceeds $50,000 (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">De Minimis Threshold</font><font style="letter-spacing:0.2pt;">&#8221;), but any Losses below the De Minimis Threshold will be taken into account for purposes of determining whether the Deductible has been exceeded. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The parties&#8217; indemnification rights under Article&#160;IX of the Agreement constitute the sole and exclusive monetary remedy with respect to matters covered by the Agreement, subject to exceptions for Fraud and claims under the Transition Services Agreement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Each party has agreed to keep confidential, and to use commercially reasonable efforts to cause its Representatives and Affiliates who actually receive such information to keep confidential, all Confidential Information relating to the Agreement, the Business, the Products, the Assets (including trade secrets in perpetuity and any confidential information transferred to Apotex pursuant to the terms of the Agreement), the Assumed Liabilities, the financial information and operations of the Company which have not been publicly disclosed, and any liabilities or obligations excluded from the Assumed Liabilities, until the later of three&#160;years after Closing and the date the Products are no longer marketed by Apotex (with trade secrets protected for so long as they remain trade secrets). Exceptions include disclosures required by applicable Laws or securities exchange rules, disclosures necessary to defend or prosecute indemnification claims or litigation, disclosures required by transition and license obligations, and information that is lawfully available to the public as of the Closing Date or that thereafter becomes public other than through a breach. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">From the Effective Date until thirty (30) days after the Closing Date, the Company has agreed to make Business Employees available to Apotex for purposes of interviews and to cooperate with Apotex in the employment of such Business Employees. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">For a period of up to three (3)&#160;years after the Closing Date, the Company has agreed to deliver to Apotex certain government price reporting information for the Assets and Assumed Liabilities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The Company and its Affiliates have agreed to certain restrictive covenants that will survive the closing, including (i)&#160;an eighteen (18)-month non-solicitation and non-hire restriction with respect to Transferred Business Employees, (ii)&#160;a four (4)-year non-interference restriction with respect to business relations of Apotex relating to the Products, (iii)&#160;a four (4)-year non-compete restriction prohibiting the Company and its Affiliates from engaging in any business in the Territory that competes with the Products (subject to customary carve-outs), and (iv)&#160;a three (3)-year non-disparagement restriction. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Apotex has agreed to an eighteen (18)-month non-solicitation and non-hire restriction with respect to employees of the Company (other than Transferred Business Employees) with whom Apotex and its Subsidiaries had material interactions in connection with the Transactions, subject to customary carve-outs. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Apotex has agreed to pay the Company up to $10&#160;million, subject to the terms and conditions set forth in the Agreement, upon the achievement of two milestones: (i)&#160;prior to the two (2)&#160;year </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOTA">&#8203;</a><a name="VASA">&#8203;</a><a name="TSA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">anniversary of the closing of the Transaction, Apotex or its Affiliates is awarded a contract by the United States Department of Health and Human Services (or any division thereof) for the supply of Vibativ for certain specified uses (the &#8220;Vibativ Contract&#8221;), and (ii)&#160;prior to the ten (10) year anniversary of the closing of the Transaction, Apotex and its Affiliates realize certain net sales pursuant to the Vibativ Contract. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">For a period of up to three (3)&#160;years after the Closing Date, the parties will cooperate to ensure that any Assets or other assets primarily related to the Products or the Business that were not properly transferred at the closing, or any Excluded Assets that were transferred to Apotex, are promptly transferred to the correct party. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">In connection with the guarantee of Apotex&#8217;s obligations, Guarantor has absolutely, irrevocably and unconditionally guaranteed to the Company the due and punctual payment in full of any payments (including the Purchase Price), indemnification obligations, and the payment of any other obligations of Apotex required under the Agreement or under any other Transaction Document. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Other Transaction Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting and Support Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Simultaneously with the execution of the Agreement, Apotex and the Company entered into Voting and Support Agreements with certain of the Company&#8217;s directors and executive officers who, collectively, hold approximately 41% of the total outstanding shares of Common Stock as of the Record Date. Pursuant to the Voting and Support Agreements, each shareholder signatory thereto has agreed, with respect to all of the shares of Covered Stock that such shareholder beneficially owns as of the date thereof or thereafter, to, among other things, (a)&#160;vote in favor of the Transaction; and (b)&#160;not transfer any such Covered Stock during the term of such Voting and Support Agreement. The Voting and Support Agreements will terminate upon the earlier of the termination of the Agreement in accordance with its terms or the consummation of the closing of the Transaction, with certain provisions surviving, including, in the case of the Company&#8217;s Chief Executive Officer, restrictive covenants that mirror those to which the Company will be subject. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The foregoing description of the Voting and Support Agreements is only a summary, does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the form of Voting and Support Agreement, a copy of which is attached as </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex B</font><font style="letter-spacing:0.2pt;"> hereto and is incorporated herein by reference. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transition Services Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the closing of the Transaction, the Company intends to enter into a transition services agreement (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Transition Services Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) with Apotex and Guarantor, pursuant to which Cumberland will provide Apotex and its Affiliates certain transition services following the date of the closing of the Transaction in accordance with the terms and conditions set forth in the Transition Services Agreement. As consideration for the provision of the transition services, Apotex and its Affiliates will pay Cumberland $150,000 per month plus reimbursement of certain pre-approved pass-through costs. In addition, Apotex will also make a one-time payment to Cumberland on the one-year anniversary of the closing of the Transaction to reimburse Cumberland for finished goods inventory received by Apotex in the Transaction in an aggregate amount of $9&#160;million less finished goods inventory sold by Cumberland on behalf of Apotex under the Transition Services Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Vote Required</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Approval of this Proposal No. 1 requires the affirmative vote of the holders of a majority of all shares entitled to vote on the proposal, in person or by proxy. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Consequences of Failing to Approve this Proposal</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the Transaction Proposal is not approved, we will be unable to complete the Transaction. If the Transaction is not completed, the Company will continue to operate its business in the ordinary course. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:548pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">However, the Company would not receive the benefits anticipated from the Transaction, including the proceeds from the sale of the Assets. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Board Recommendation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">The Board of Directors unanimously recommends that the shareholders vote &#8220;FOR&#8221; the Transaction Proposal. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="PN2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:272pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROPOSAL NO. 2 </font>
          <br >
          <font style="letter-spacing:-0.2pt;">THE ADJOURNMENT PROPOSAL</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the number of shares of the Company&#8217;s Common Stock present at the special meeting, in person or represented by proxy, and voting in favor of the Transaction Proposal is insufficient to approve the Transaction Proposal, then the Board intends to move to adjourn and postpone the special meeting to a later date or dates, if necessary, to enable the Board to solicit additional proxies for the approval of the Transaction Proposal. In that event, we will ask the Company&#8217;s shareholders to vote only upon the adjournment and postponement of the special meeting, as described in this Proposal No. 2, and not any of the other proposals. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In this proposal, shareholders are being asked to grant authority to the holder of any proxy solicited by the Board of Directors so that such holder can vote in favor of the proposal to adjourn and postpone the special meeting to a later date or dates, if necessary, so that the Board can solicit additional proxies for the approval of the Transaction Proposal. If the shareholders approve this Adjournment Proposal, then we could adjourn the special meeting, and any adjourned session of the special meeting, and use the additional time to solicit additional proxies, including the solicitation of proxies from shareholders who have previously voted against the approval of the Transaction Proposal. Among other things, approval of the Adjournment Proposal could mean that, even if we had received proxies representing a sufficient number of votes against the Transaction Proposal to defeat the Transaction Proposal, we could adjourn the special meeting without a vote and seek to convince the holders of those shares to change their votes in favor of the Transaction Proposal. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Vote Required</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Assuming a quorum is present, approval of this Proposal No. 2 requires that the number of votes cast for the Adjournment Proposal at the special meeting exceed the number of votes cast against the Adjournment Proposal. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Board Recommendation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Board unanimously recommends that shareholders vote &#8220;FOR&#8221; the Adjournment Proposal.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="SOOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</font>
          <br >
          <font style="letter-spacing:-0.2pt;">AND RELATED SHAREHOLDER MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Based solely upon information made available to us, the following table sets forth information with respect to the beneficial ownership of our Common Stock as of May&#160;12, 2026 (except as otherwise indicated) by (1)&#160;each person who is known by us to beneficially own more than five&#160;percent of our Common Stock (based solely on our review of SEC filings); (2)&#160;each of our directors and nominees; (3)&#160;our Chief Executive Officer, Chief Financial Officer and our three most highly compensated executive officers (other than our CEO and CFO), or collectively, our Named Executive Officers; and (4)&#160;all executive officers and directors as a group. Unless otherwise indicated, each of the persons below has sole voting and investment power with respect to the shares beneficially owned by such person and the address of each beneficial owner listed on the table is c/o&#160;Cumberland Pharmaceuticals Inc., 1600 West End Avenue, Suite 1300, Nashville, Tennessee&#160;37203. To the knowledge of the Company, no other person or entity holds more than 5% of the outstanding shares of Common Stock, except as set forth in the following table. No Common Stock beneficially owned by any director or named executive officer has been pledged as security for a loan. </font>
        </div>
        <table style="width:416pt;height:206.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:269.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name of Beneficial Owner</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares of Common</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stock Beneficially </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common Stock</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:269.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">A. J. Kazimi</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,775,310</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">38.57<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Kenneth J. Krogulski</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">302,338</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.03<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Joseph C. Galante</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">63,656</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.43<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">James R. Jones</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">46,863</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.31<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">James L. Herman</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">47,255</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.32<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Caroline R. Young</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(8)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">35,109</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.24<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">John M. Hamm</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(9)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">25,073</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.17<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Todd M. Anthony</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(10)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">25,328</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.17<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Christopher T. Bitterman</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">11,683</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.08<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Martin S. Brown, Jr.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(12)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">10,300</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.07<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Gordon R. Bernard</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(13)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Directors and executive officers as a group (11 persons) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">6,342,915</td>
            <td style="padding:0pt;padding-left:11.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">42.38<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The SEC has defined &#8220;beneficial ownership&#8221; of a security to mean the possession, directly or indirectly, of voting power and/or investment power over such security. A stockholder is also deemed to be, as of any date, the beneficial owner of all securities that such stockholder has the right to acquire within 60&#160;days after that date through (1)&#160;the exercise of any option, warrant or right, (2)&#160;the conversion of a security, (3)&#160;the power to revoke a trust, discretionary account or similar arrangement or (4)&#160;the automatic termination of a trust, discretionary account or similar arrangement. In computing the number of shares beneficially owned by a person and the&#160;percentage ownership of that person, our Common Stock subject to options or other rights (as set forth above) held by that person that are currently exercisable or will become exercisable within 60&#160;days thereafter, are deemed outstanding, while such shares are not deemed outstanding for purposes of computing&#160;percentage ownership of any other person. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Based on 14,983,107 shares of Common Stock outstanding on May&#160;12, 2026. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Includes 80,000 shares that Mr.&#160;Kazimi has the right to acquire upon the exercise of incentive stock options. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Includes 5,800 shares Mr.&#160;Krogulski has the right to acquire upon the vesting of restricted stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Includes 1,800 shares Mr.&#160;Galante has the right to acquire upon the vesting of restricted stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Includes 1,800 shares Mr.&#160;Jones has the right to acquire upon the vesting of restricted stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Includes 9,000 shares Mr.&#160;Herman has the right to acquire upon the exercise of incentive stock options. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Includes 1,800 shares Ms.&#160;Young has the right to acquire upon the vesting of restricted stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:504pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(9)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Includes 5,000 shares Mr.&#160;Hamm has the right to acquire upon the exercise of incentive stock options. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(10)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Includes 9,000 shares Mr.&#160;Anthony has the right to acquire upon the exercise of incentive stock options. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Includes 7,000 shares Mr.&#160;Bitterman has the right to acquire upon the exercise of incentive stock options. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(12)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Includes 1,800 shares Mr.&#160;Brown has the right to acquire upon the vesting of restricted stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(13)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Dr.&#160;Bernard, as required by a policy change by his employer, is prohibited from owning shares in a pharmaceutical company. The policy change resulted in Dr.&#160;Bernard selling 118,729 shares during 2019, but it did not impact his ability to serve on the Company&#8217;s Board of Directors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="IOCD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:336pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to &#8220;incorporate by reference&#8221; into this proxy statement documents that we file with the SEC. This means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this proxy statement, and later information that we file with the SEC will update and supersede that information. We incorporate by reference the documents listed below and any documents filed by us pursuant to Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this proxy statement and before the date of the special meeting: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm">Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2025, filed with the SEC on March&#160;9, 2026</a>; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1087294/000108729426000025/cpix-20260309.htm">Proxy Statement for the annual meeting of our shareholders held on April&#160;21, 2026, filed with the SEC on Schedule&#160;14A on March&#160;9, 2026</a>; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1087294/000108729426000049/cpix-20260331.htm">Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2026, filed with the SEC on May&#160;8, 2026</a>; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Current Reports on Form 8-K filed with the SEC on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1087294/000108729426000011/cpix-20260204.htm">February&#160;4, 2026</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1087294/000108729426000015/cpix-20260303.htm">March&#160;3, 2026</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1087294/000110465926047335/tm2611622d1_8k.htm">April&#160;23, 2026</a> and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1087294/000108729426000043/cpix-20260421.htm">April&#160;24, 2026</a>. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the foregoing, information furnished under Items&#160;2.02, 7.01 and 8.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference in this proxy statement. In addition, statements contained in this proxy statement, or in any document incorporated in this proxy statement by reference, regarding the contents of any contract or other document, are only summaries of the material terms and as such we encourage you to carefully read in its entirety that contract or other document filed as an exhibit with the SEC. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="OTIN">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:188pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">OTHER INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Shareholder Proposals and Nominations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the Company&#8217;s annual meeting each year, the Board of Directors submits to shareholders its nominees for election as directors. The Board of Directors may also submit other matters to the shareholders for action at the Annual Meeting. Any proposal which a shareholder intends to present in accordance with Rule&#160;14a-8 of the Exchange Act at our next annual meeting of shareholders to be held in 2027 must be received by Cumberland Pharmaceuticals Inc., no later than 5:00&#160;p.m. Central Time on November&#160;12, 2026. Only proposals conforming to the requirements of Rule&#160;14a-8 of the Exchange Act that are timely received by the Company will be included in the proxy statement and proxy in 2027. Any such proposal should be directed to our Corporate Secretary at our principal executive offices located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To comply with the universal proxy rules, shareholders who intend to solicit proxies in support of director nominees, other than the Company&#8217;s nominees, at our next annual meeting of shareholders to be held in 2027 must provide notice that sets forth the information required by Rule&#160;14a-19 under the Exchange Act no later than February&#160;20, 2027. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Householding</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements and other special meeting materials with respect to two or more shareholders sharing the same address by delivering a proxy statement or other special meeting materials addressed to those shareholders. This process, which is commonly referred to as householding, potentially provides extra convenience for shareholders and cost savings for companies. Shareholders who participate in householding will continue to be able to access and receive separate proxy cards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you share an address with another shareholder and have received multiple copies of our proxy materials, you may write or call us at the address and phone number below to request delivery of a single copy of the proxy statement and, if applicable, other proxy materials in the future. We undertake to deliver promptly upon written or oral request a separate copy of the proxy materials, as requested, to a shareholder at a shared address to which a single copy of the proxy materials was delivered. If you hold stock as a record shareholder and prefer to receive separate copies of our proxy materials either now or in the future, please contact us at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203, Attn: Corporate Secretary, or by telephone at (615) 255-0068. If your stock is held through a brokerage firm or bank and you prefer to receive separate copies of our proxy materials either now or in the future, please contact your brokerage firm or bank. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">63</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="WYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:220pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public at the website maintained by the SEC at www.sec.gov. The reports and other information that we file with the SEC are also available in the Investor Relations section of our corporate website at https://www.cumberlandpharma.com/. The information located on, or hyperlinked or otherwise connected to, our website is not, and shall not be deemed to be, a part of this proxy statement or incorporated into any other files that we make with the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may request a copy of our reports and other documents filed with the SEC at no cost upon written request to Cumberland Pharmaceuticals Inc., 1600 West End Avenue, Suite 1300, Nashville, TN 37203, Attention: Secretary of the Corporation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you have questions about the special meeting or the Transaction, need additional copies of this document, have questions about the process for voting or need a replacement proxy card, you should contact: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sodali &amp; Co</font> <br ><font style="letter-spacing:0.2pt;">430 Park Ave, 14th Floor</font> <br ><font style="letter-spacing:0.2pt;">New York, NY 10022</font> <br ><font style="letter-spacing:0.2pt;">Phone: (203) 658-9400</font> <br ><font style="letter-spacing:0.2pt;">Email: CPIZ@info.sodali.com </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Shareholders should not rely on information that purports to be made by or on behalf of the Company other than that contained in this proxy statement. The Company has not authorized anyone to provide information on behalf of the Company that is different from that contained in this proxy statement. This proxy statement is dated May&#160;26, 2026. No assumption should be made that the information contained in this proxy statement is accurate as of any date other than that date, and the mailing of this proxy statement will not create any implication to the contrary. Notwithstanding the foregoing, in the event of any material change in any of the information previously disclosed, the Company will, where relevant and if required by applicable law, update such information through a supplement to this proxy statement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have not authorized anyone to give you any information or to make any representation about the proposed Transaction or the Company that is different from or adds to the information contained in this proxy statement. Therefore, if anyone does give you any different or additional information, you should not rely on it. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">64</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="MAOM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:552pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">MISCELLANEOUS AND OTHER MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">We know of no other matters to be submitted to the special meeting. If any other matters properly come before the special meeting, it is the intention of the person named in the enclosed proxy card to vote the shares they represent as our Board of Directors may recommend. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Dated: May&#160;26, 2026</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">65</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="ANA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:right; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Annex A</font>&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:right; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Execution Version</font>&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ASSET PURCHASE AGREEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">by and among</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CUMBERLAND PHARMACEUTICALS INC.,</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NUVO PHARMACEUTICALS (IRELAND) DAC,</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">and</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">APOTEX INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dated as of April&#160;22, 2026 </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Table of Contents</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:625pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:422.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sAPA"><font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">ASSET PURCHASE AGREEMENT</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.2pt;"><a href="#sAPA">A-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sARID"><font style="letter-spacing:-0.2pt;">ARTICLE I DEFINITIONS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.2pt;"><a href="#sARID">A-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1DA"><font style="letter-spacing:0.2pt;">Section&#160;1.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1DA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Definitions </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1DA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1DA">A-1</a></font><a href="#sS1DA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1I"><font style="letter-spacing:0.2pt;">Section&#160;1.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1I">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Interpretation </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1I">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1I">A-9</a></font><a href="#sS1I"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1CA"><font style="letter-spacing:0.2pt;">Section&#160;1.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1CA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Currency </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1CA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1CA">A-10</a></font><a href="#sS1CA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sAIAP"><font style="letter-spacing:-0.2pt;">ARTICLE II SALE AND PURCHASE OF ACQUIRED ASSETS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.2pt;"><a href="#sAIAP">A-10</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS2SA"><font style="letter-spacing:0.2pt;">Section&#160;2.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS2SA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Sale and Purchase of Acquired Assets </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS2SA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS2SA">A-10</a></font><a href="#sS2SA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS2EA"><font style="letter-spacing:0.2pt;">Section&#160;2.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS2EA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Excluded Assets </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS2EA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS2EA">A-10</a></font><a href="#sS2EA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS2AL"><font style="letter-spacing:0.2pt;">Section&#160;2.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS2AL">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Assumed Liabilities </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS2AL">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS2AL">A-10</a></font><a href="#sS2AL"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS2EL"><font style="letter-spacing:0.2pt;">Section&#160;2.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS2EL">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Excluded Liabilities </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS2EL">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS2EL">A-10</a></font><a href="#sS2EL"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS2DO"><font style="letter-spacing:0.2pt;">Section&#160;2.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS2DO">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Designation of Affiliates; Performance Obligations by Affiliates </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS2DO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS2DO">A-10</a></font><a href="#sS2DO"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS2TO"><font style="letter-spacing:0.2pt;">Section&#160;2.6</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS2TO">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Treatment of Contracts that Require Third Party Consents to Transfers </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS2TO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS2TO">A-10</a></font><a href="#sS2TO"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sAIP"><font style="letter-spacing:-0.2pt;">ARTICLE III PURCHASE PRICE</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.2pt;"><a href="#sAIP">A-11</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS3PP"><font style="letter-spacing:0.2pt;">Section&#160;3.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS3PP">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Purchase Price </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS3PP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS3PP">A-11</a></font><a href="#sS3PP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS3MA"><font style="letter-spacing:0.2pt;">Section&#160;3.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS3MA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Manner and Place of Payment </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS3MA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS3MA">A-11</a></font><a href="#sS3MA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS3AO"><font style="letter-spacing:0.2pt;">Section&#160;3.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS3AO">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Allocation of Purchase Price </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS3AO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS3AO">A-11</a></font><a href="#sS3AO"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS3CT"><font style="letter-spacing:0.2pt;">Section&#160;3.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS3CT">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Consistent Treatment </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS3CT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS3CT">A-11</a></font><a href="#sS3CT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS3W"><font style="letter-spacing:0.2pt;">Section&#160;3.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS3W">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Withholding </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS3W">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS3W">A-12</a></font><a href="#sS3W"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sAIC"><font style="letter-spacing:-0.2pt;">ARTICLE IV THE CLOSING</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.2pt;"><a href="#sAIC">A-12</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS4CD"><font style="letter-spacing:0.2pt;">Section&#160;4.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS4CD">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Closing Date </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS4CD">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS4CD">A-12</a></font><a href="#sS4CD"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS4CA"><font style="letter-spacing:0.2pt;">Section&#160;4.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS4CA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Closing Activities </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS4CA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS4CA">A-12</a></font><a href="#sS4CA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS4FA"><font style="letter-spacing:0.2pt;">Section&#160;4.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS4FA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Further Assurances </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS4FA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS4FA">A-12</a></font><a href="#sS4FA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sAVAW"><font style="letter-spacing:-0.2pt;">ARTICLE V REPRESENTATIONS AND WARRANTIES OF CUMBERLAND</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.2pt;"><a href="#sAVAW">A-13</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5OG"><font style="letter-spacing:0.2pt;">Section&#160;5.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5OG">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Organization; Good Standing </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5OG">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5OG">A-13</a></font><a href="#sS5OG"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5BA"><font style="letter-spacing:0.2pt;">Section&#160;5.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5BA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Board Approval </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5BA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5BA">A-13</a></font><a href="#sS5BA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5AE"><font style="letter-spacing:0.2pt;">Section&#160;5.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5AE">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Authority; Execution and Delivery </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5AE">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5AE">A-13</a></font><a href="#sS5AE"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5NV"><font style="letter-spacing:0.2pt;">Section&#160;5.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5NV">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">No Violation; Consents </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5NV">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5NV">A-13</a></font><a href="#sS5NV"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5TT"><font style="letter-spacing:0.2pt;">Section&#160;5.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5TT">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Title to Acquired Assets </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5TT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5TT">A-14</a></font><a href="#sS5TT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5LT"><font style="letter-spacing:0.2pt;">Section&#160;5.6</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5LT">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Litigation </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5LT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5LT">A-14</a></font><a href="#sS5LT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5RM"><font style="letter-spacing:0.2pt;">Section&#160;5.7</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5RM">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Regulatory Matters; Compliance with Law </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5RM">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5RM">A-14</a></font><a href="#sS5RM"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5C"><font style="letter-spacing:0.2pt;">Section&#160;5.8</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5C">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Contracts </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5C">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5C">A-15</a></font><a href="#sS5C"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5IP"><font style="letter-spacing:0.2pt;">Section&#160;5.9</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5IP">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Intellectual Property </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5IP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5IP">A-17</a></font><a href="#sS5IP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5IA"><font style="letter-spacing:0.2pt;">Section&#160;5.10</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5IA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Inventory </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5IA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5IA">A-18</a></font><a href="#sS5IA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5OC"><font style="letter-spacing:0.2pt;">Section&#160;5.11</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5OC">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Ordinary Course of Business </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5OC">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5OC">A-18</a></font><a href="#sS5OC"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5NB"><font style="letter-spacing:0.2pt;">Section&#160;5.12</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5NB">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">No Brokers </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5NB">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5NB">A-18</a></font><a href="#sS5NB"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5CA"><font style="letter-spacing:0.2pt;">Section&#160;5.13</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5CA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Customers and Suppliers </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5CA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5CA">A-18</a></font><a href="#sS5CA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5TW"><font style="letter-spacing:0.2pt;">Section&#160;5.14</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5TW">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Transactions with Affiliates </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5TW">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5TW">A-18</a></font><a href="#sS5TW"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5SI"><font style="letter-spacing:0.2pt;">Section&#160;5.15</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5SI">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Sales Information; No Undisclosed Liabilities </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5SI">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5SI">A-19</a></font><a href="#sS5SI"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5T"><font style="letter-spacing:0.2pt;">Section&#160;5.16</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5T">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Taxes </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5T">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5T">A-19</a></font><a href="#sS5T"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5LA"><font style="letter-spacing:0.2pt;">Section&#160;5.17</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5LA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Labor and Employment </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5LA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5LA">A-20</a></font><a href="#sS5LA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5EB"><font style="letter-spacing:0.2pt;">Section&#160;5.18</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5EB">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Employee Benefit Plan </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5EB">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5EB">A-21</a></font><a href="#sS5EB"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5SI1"><font style="letter-spacing:0.2pt;">Section&#160;5.19</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5SI1">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Solvency </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5SI1">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5SI1">A-21</a></font><a href="#sS5SI1"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="TOC3">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:655pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5IC"><font style="letter-spacing:0.2pt;">Section&#160;5.20</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5IC">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Investigation </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5IC">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5IC">A-22</a></font><a href="#sS5IC"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS5NO"><font style="letter-spacing:0.2pt;">Section&#160;5.21</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS5NO">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">No Other Representations </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS5NO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS5NO">A-22</a></font><a href="#sS5NO"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sAVAW1"><font style="letter-spacing:-0.2pt;">ARTICLE VI REPRESENTATIONS AND WARRANTIES OF APOTEX</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.2pt;"><a href="#sAVAW1">A-23</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS6AO"><font style="letter-spacing:0.2pt;">Section&#160;6.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS6AO">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Apotex&#8217;s Organization; Good Standing </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS6AO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS6AO">A-23</a></font><a href="#sS6AO"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS6AE"><font style="letter-spacing:0.2pt;">Section&#160;6.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS6AE">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Authority; Execution and Delivery </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS6AE">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS6AE">A-23</a></font><a href="#sS6AE"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS6NV"><font style="letter-spacing:0.2pt;">Section&#160;6.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS6NV">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">No Violations; Consents </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS6NV">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS6NV">A-23</a></font><a href="#sS6NV"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS6LT"><font style="letter-spacing:0.2pt;">Section&#160;6.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS6LT">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Litigation </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS6LT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS6LT">A-23</a></font><a href="#sS6LT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS6NB"><font style="letter-spacing:0.2pt;">Section&#160;6.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS6NB">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">No Brokers </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS6NB">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS6NB">A-23</a></font><a href="#sS6NB"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS6CN"><font style="letter-spacing:0.2pt;">Section&#160;6.6</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS6CN">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Consents </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS6CN">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS6CN">A-23</a></font><a href="#sS6CN"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS6FC"><font style="letter-spacing:0.2pt;">Section&#160;6.7</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS6FC">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Financial Capacity </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS6FC">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS6FC">A-23</a></font><a href="#sS6FC"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS6SI"><font style="letter-spacing:0.2pt;">Section&#160;6.8</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS6SI">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Solvency </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS6SI">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS6SI">A-23</a></font><a href="#sS6SI"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS6IA"><font style="letter-spacing:0.2pt;">Section&#160;6.9</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS6IA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Investigation </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS6IA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS6IA">A-24</a></font><a href="#sS6IA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS6NO"><font style="letter-spacing:0.2pt;">Section&#160;6.10</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS6NO">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">No Other Representations </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS6NO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS6NO">A-24</a></font><a href="#sS6NO"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sAVCA"><font style="letter-spacing:-0.2pt;">ARTICLE VII CERTAIN COVENANTS AND AGREEMENTS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.2pt;"><a href="#sAVCA">A-25</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7RC"><font style="letter-spacing:0.2pt;">Section&#160;7.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7RC">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Regulatory Commitments </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7RC">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7RC">A-25</a></font><a href="#sS7RC"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7IP"><font style="letter-spacing:0.2pt;">Section&#160;7.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7IP">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Intellectual Property Commitments </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7IP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7IP">A-25</a></font><a href="#sS7IP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7BT"><font style="letter-spacing:0.2pt;">Section&#160;7.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7BT">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Bulk Transfer Laws </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7BT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7BT">A-26</a></font><a href="#sS7BT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7MO"><font style="letter-spacing:0.2pt;">Section&#160;7.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7MO">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Marketing of Acquired Assets </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7MO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7MO">A-27</a></font><a href="#sS7MO"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7CO"><font style="letter-spacing:0.2pt;">Section&#160;7.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7CO">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Conduct of Business Prior to the Closing </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7CO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7CO">A-27</a></font><a href="#sS7CO"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7CA"><font style="letter-spacing:0.2pt;">Section&#160;7.6</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7CA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Cooperation and Commercially Reasonable Efforts </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7CA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7CA">A-28</a></font><a href="#sS7CA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7EC"><font style="letter-spacing:0.2pt;">Section&#160;7.7</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7EC">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Employee Covenants </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7EC">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7EC">A-29</a></font><a href="#sS7EC"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7GP"><font style="letter-spacing:0.2pt;">Section&#160;7.8</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7GP">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Government Price Reporting </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7GP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7GP">A-29</a></font><a href="#sS7GP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7RM"><font style="letter-spacing:0.2pt;">Section&#160;7.9</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7RM">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Regulatory Matters </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7RM">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7RM">A-30</a></font><a href="#sS7RM"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7E"><font style="letter-spacing:0.2pt;">Section&#160;7.10</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7E">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Exclusivity </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7E">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7E">A-31</a></font><a href="#sS7E"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7PS"><font style="letter-spacing:0.2pt;">Section&#160;7.11</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7PS">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Proxy Statement and Other Required SEC Filings </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7PS">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7PS">A-34</a></font><a href="#sS7PS"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7SM"><font style="letter-spacing:0.2pt;">Section&#160;7.12</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7SM">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Stockholder Meeting </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7SM">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7SM">A-35</a></font><a href="#sS7SM"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7WP"><font style="letter-spacing:0.2pt;">Section&#160;7.13</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7WP">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Wrong Pockets </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7WP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7WP">A-35</a></font><a href="#sS7WP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7PF"><font style="letter-spacing:0.2pt;">Section&#160;7.14</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7PF">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Payments from Third Parties </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7PF">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7PF">A-36</a></font><a href="#sS7PF"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7NO"><font style="letter-spacing:0.2pt;">Section&#160;7.15</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7NO">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Notice of Certain Events </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7NO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7NO">A-36</a></font><a href="#sS7NO"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7TM"><font style="letter-spacing:0.2pt;">Section&#160;7.16</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7TM">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Tax Matters </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7TM">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7TM">A-36</a></font><a href="#sS7TM"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7RC1"><font style="letter-spacing:0.2pt;">Section&#160;7.17</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7RC1">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Restrictive Covenants </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7RC1">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7RC1">A-37</a></font><a href="#sS7RC1"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7AA"><font style="letter-spacing:0.2pt;">Section&#160;7.18</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7AA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Access and Reports </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7AA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7AA">A-38</a></font><a href="#sS7AA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7VA"><font style="letter-spacing:0.2pt;">Section&#160;7.19</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7VA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Vibativ Award Milestone </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7VA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7VA">A-39</a></font><a href="#sS7VA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7DO"><font style="letter-spacing:0.2pt;">Section&#160;7.20</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7DO">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Delivery of Certain Work Product </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7DO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7DO">A-39</a></font><a href="#sS7DO"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS7LR"><font style="letter-spacing:0.2pt;">Section&#160;7.21</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS7LR">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Lien Releases </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS7LR">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS7LR">A-39</a></font><a href="#sS7LR"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sAVTC"><font style="letter-spacing:-0.2pt;">ARTICLE VIII CONDITIONS TO CLOSING</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.2pt;"><a href="#sAVTC">A-39</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS8CT"><font style="letter-spacing:0.2pt;">Section&#160;8.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS8CT">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Conditions to Obligations of Apotex </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS8CT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS8CT">A-39</a></font><a href="#sS8CT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS8CT1"><font style="letter-spacing:0.2pt;">Section&#160;8.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS8CT1">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Conditions to Obligations of Cumberland </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS8CT1">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS8CT1">A-40</a></font><a href="#sS8CT1"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sARIX"><font style="letter-spacing:-0.2pt;">ARTICLE IX INDEMNIFICATION</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.2pt;"><a href="#sARIX">A-41</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS9SA"><font style="letter-spacing:0.2pt;">Section&#160;9.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS9SA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Survival </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS9SA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS9SA">A-41</a></font><a href="#sS9SA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS9IB"><font style="letter-spacing:0.2pt;">Section&#160;9.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS9IB">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Indemnification by Cumberland </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS9IB">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS9IB">A-41</a></font><a href="#sS9IB"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS9IB1"><font style="letter-spacing:0.2pt;">Section&#160;9.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS9IB1">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Indemnification by Apotex </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS9IB1">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS9IB1">A-41</a></font><a href="#sS9IB1"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS9L"><font style="letter-spacing:0.2pt;">Section&#160;9.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS9L">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Limitations </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS9L">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS9L">A-42</a></font><a href="#sS9L"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS9P"><font style="letter-spacing:0.2pt;">Section&#160;9.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS9P">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Procedure </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS9P">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS9P">A-43</a></font><a href="#sS9P"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="TOC4">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:400pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS9TT"><font style="letter-spacing:0.2pt;">Section&#160;9.6</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS9TT">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Tax Treatment of Indemnification Payments </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS9TT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS9TT">A-44</a></font><a href="#sS9TT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS9ME"><font style="letter-spacing:0.2pt;">Section&#160;9.7</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS9ME">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Mitigation </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS9ME">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS9ME">A-44</a></font><a href="#sS9ME"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sARXT"><font style="letter-spacing:-0.2pt;">ARTICLE X TERMINATION</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.2pt;"><a href="#sARXT">A-45</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1TT"><font style="letter-spacing:0.2pt;">Section&#160;10.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1TT">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Termination </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1TT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1TT">A-45</a></font><a href="#sS1TT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1EO"><font style="letter-spacing:0.2pt;">Section&#160;10.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1EO">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Effect of Termination </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1EO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1EO">A-45</a></font><a href="#sS1EO"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1EO1"><font style="letter-spacing:0.2pt;">Section&#160;10.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1EO1">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Event of Termination </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1EO1">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1EO1">A-47</a></font><a href="#sS1EO1"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sAXP"><font style="letter-spacing:-0.2pt;">ARTICLE XI GENERAL PROVISIONS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.2pt;"><a href="#sAXP">A-47</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1NP"><font style="letter-spacing:0.2pt;">Section&#160;11.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1NP">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">No Punitive Damages </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1NP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1NP">A-47</a></font><a href="#sS1NP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1EE"><font style="letter-spacing:0.2pt;">Section&#160;11.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1EE">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Expenses </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1EE">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1EE">A-47</a></font><a href="#sS1EE"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1CI"><font style="letter-spacing:0.2pt;">Section&#160;11.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1CI">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Confidential Information </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1CI">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1CI">A-47</a></font><a href="#sS1CI"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1AA"><font style="letter-spacing:0.2pt;">Section&#160;11.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1AA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Amendments and Waivers </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1AA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1AA">A-48</a></font><a href="#sS1AA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1NA"><font style="letter-spacing:0.2pt;">Section&#160;11.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1NA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Notices </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1NA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1NA">A-48</a></font><a href="#sS1NA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1HT"><font style="letter-spacing:0.2pt;">Section&#160;11.6</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1HT">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Headings </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1HT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1HT">A-49</a></font><a href="#sS1HT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1SI"><font style="letter-spacing:0.2pt;">Section&#160;11.7</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1SI">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Severability </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1SI">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1SI">A-49</a></font><a href="#sS1SI"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1CT"><font style="letter-spacing:0.2pt;">Section&#160;11.8</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1CT">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Counterparts </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1CT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1CT">A-50</a></font><a href="#sS1CT"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1EA"><font style="letter-spacing:0.2pt;">Section&#160;11.9</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1EA">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Entire Agreement </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1EA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1EA">A-50</a></font><a href="#sS1EA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1TP"><font style="letter-spacing:0.2pt;">Section&#160;11.10</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1TP">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Third Party Beneficiaries </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1TP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1TP">A-50</a></font><a href="#sS1TP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1GL"><font style="letter-spacing:0.2pt;">Section&#160;11.11</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1GL">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">GOVERNING LAW; CHOICE OF LAW </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1GL">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1GL">A-50</a></font><a href="#sS1GL"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1DS"><font style="letter-spacing:0.2pt;">Section&#160;11.12</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1DS">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Disclosure Schedules </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1DS">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1DS">A-50</a></font><a href="#sS1DS"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1DR"><font style="letter-spacing:0.2pt;">Section&#160;11.13</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1DR">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Dispute Resolution; WAIVER OF JURY TRIAL </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1DR">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1DR">A-50</a></font><a href="#sS1DR"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1SP"><font style="letter-spacing:0.2pt;">Section&#160;11.14</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1SP">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Specific Performance </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1SP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1SP">A-52</a></font><a href="#sS1SP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1WN"><font style="letter-spacing:0.2pt;">Section&#160;11.15</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1WN">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Waiver </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1WN">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1WN">A-52</a></font><a href="#sS1WN"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1A"><font style="letter-spacing:0.2pt;">Section&#160;11.16</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1A">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Assignment </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1A">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1A">A-52</a></font><a href="#sS1A"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1AO"><font style="letter-spacing:0.2pt;">Section&#160;11.17</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1AO">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Advice of Counsel </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1AO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1AO">A-52</a></font><a href="#sS1AO"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1PR"><font style="letter-spacing:0.2pt;">Section&#160;11.18</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1PR">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Press Release </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1PR">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1PR">A-52</a></font><a href="#sS1PR"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1NR"><font style="letter-spacing:0.2pt;">Section&#160;11.19</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1NR">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">No Recourse </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1NR">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1NR">A-52</a></font><a href="#sS1NR"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.96pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:70pt;white-space:nowrap;">
                <a href="#sS1GB"><font style="letter-spacing:0.2pt;">Section&#160;11.20</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#sS1GB">
                  <!--blacklining:none;-->
                  <font style="letter-spacing:0.2pt;">Guarantee </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#sS1GB">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sS1GB">A-53</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:70pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:72pt;">
              <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Exhibits</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:10pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:350pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Exhibit&#160;A </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Bill of Sale and Assignment and Assumption Agreement </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Exhibit&#160;B </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">IP Assignment Agreement </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Exhibit&#160;C </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Form of Stockholder Support Agreement </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Exhibit&#160;D </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Transition Services Agreement</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:145pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;" colspan="4">
              <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Disclosure Schedules</font>
            </td>
            <td style="padding:0pt;min-width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;5.4 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">No Violation; Consents </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;5.5(b) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Title to Acquired Assets </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;5.7(b) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Regulatory Matters, Compliance with Law </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;5.8(a) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Material Contracts </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;5.9(a) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Business IP </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;5.9(c) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">IP Claims and Disputes </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;5.11 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Ordinary Course of Business Exceptions </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;5.13(a) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Material Customer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;5.13(b) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Material Suppliers </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-iii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:338pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:160pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;5.14 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:10pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Transactions with Affiliates </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;5.15(b) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">No Undisclosed Liabilities </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;5.17(a) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Transferred Business Employees </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;5.17(c) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Employment Loss </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;5.18(a) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Employee Benefit Plans </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;7.5 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Conduct of Business Prior to the Closing </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;7.5(t) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">RedHill Biopharma / Talicia Holdings Arrangements </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;7.7(a) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Designated Employees </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;7.19 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Vibativ Award Milestone </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;8.1(f) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Conditions to Obligations of Apotex&#8201;&#8212;&#8201;Material Contracts </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;8.2(d) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Governmental Approvals</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:100pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:72pt;">
              <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Annexes</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Annex 2.1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Acquired Assets </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Annex 2.1(A) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Description of Products </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Annex 2.1(B) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Inventory </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Annex 2.1(C) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Additional Intellectual Property </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Annex 2.2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Assumed Liabilities </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Annex 2.3 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:10pt;">
              <font style="letter-spacing:0.2pt;">&#8212;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;">
              <font style="letter-spacing:0.2pt;">Excluded Liabilities</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-iv</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sAPA">&#8203;</a><a name="sARID">&#8203;</a><a name="sS1DA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">ASSET PURCHASE AGREEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This ASSET PURCHASE AGREEMENT (this &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) is effective as of the 22nd day of April, 2026 (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Effective Date</font><font style="letter-spacing:0.2pt;">&#8221;), by and among Nuvo Pharmaceuticals (Ireland) DAC, an Ireland designated activity company (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Apotex</font><font style="letter-spacing:0.2pt;">&#8221;), solely for the purpose of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.20</font><font style="letter-spacing:0.2pt;"> (and any provision of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;I</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;XI</font><font style="letter-spacing:0.2pt;"> to give effect thereto), Apotex Inc., a corporation incorporated under the laws of the Province of Ontario (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Buyer Guarantor</font><font style="letter-spacing:0.2pt;">&#8221;), and Cumberland Pharmaceuticals Inc., a corporation organized under the laws of Tennessee, and having a principal place of business at 1600 West End Ave., Suite 1300, Nashville, TN 37203-7003 USA (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cumberland</font><font style="letter-spacing:0.2pt;">&#8221;). Apotex and Cumberland are referred to hereinafter individually as a &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Party</font><font style="letter-spacing:0.2pt;">&#8221; and together as the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Parties</font><font style="letter-spacing:0.2pt;">.&#8221; Capitalized terms used herein shall be as defined in this Agreement. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">RECITALS</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, Apotex wishes to acquire (or cause certain of its Affiliates to acquire) and Cumberland wishes to sell, certain assets (including the Transferred Equity Interests) of Cumberland and its Affiliates related to certain pharmaceutical products, and Apotex is willing to assume certain liabilities related thereto, in each case, upon the terms and subject to the conditions set forth herein; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, the board of directors of Cumberland (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Board</font><font style="letter-spacing:0.2pt;">&#8221;) has unanimously (i)&#160;approved and declared advisable and in the best interests of Cumberland and its Stockholders the entry into this Agreement and the consummation of the transactions contemplated hereby, upon the terms and subject to the conditions set forth in this Agreement and in accordance with the TBCA, and (ii)&#160;recommended that the Stockholders vote for the adoption of a resolution approving of the sale of substantially all of Cumberland&#8217;s assets pursuant to, and on the terms and conditions set forth in, this Agreement; and </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, on the date hereof, in order to induce Apotex to enter into this Agreement, simultaneously with the execution of this Agreement, Cumberland has delivered to Apotex fully executed Voting and Support Agreements in the form attached hereto as </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exhibit&#160;C</font><font style="letter-spacing:0.2pt;"> (each, a &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stockholder Support Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) from certain of the Stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">NOW, THEREFORE, in consideration of the foregoing recitals, mutual agreements, representations and warranties, covenants and closing conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE I</font>
          <br >
          <font style="letter-spacing:-0.2pt;">DEFINITIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;1.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Definitions</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;As used in this Agreement, the following terms shall have the meanings ascribed to them below: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">AAA</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.13(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Acceptable Confidentiality Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means an executed confidentiality agreement that is either (i)&#160;in effect as of the execution and delivery of this Agreement, as amended (if applicable) after the date hereof, or (ii)&#160;executed and delivered after the date hereof, in each case, with terms at least as restrictive in all material respects on such Person as the Confidentiality Agreement&#8217;s terms are (it being understood that such confidentiality agreement need not prohibit the making or amending of an Acquisition Proposal by such Person or contain any &#8220;standstill&#8221; provisions) and that does not contain provisions (a)&#160;that prohibit Cumberland (or any other Person) from providing information to Apotex or its Representatives as required pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;"> or (b)&#160;that otherwise prohibits Cumberland from complying with this Agreement, including </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Accounting Firm</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning assigned in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;"> of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Acquired Assets</font><font style="letter-spacing:0.2pt;">&#8221; shall mean the assets and other rights identified or described on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1(A)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1(B)</font><font style="letter-spacing:0.2pt;"> attached hereto. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp; &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Acquisition Proposal</font><font style="letter-spacing:0.2pt;">&#8221; means any offer or proposal (other than an offer or proposal by Apotex) to engage in an Acquisition Transaction. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Acquisition Transaction</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning assigned in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;"> of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Action</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.6</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Affiliate</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to any Person (as defined herein), any other Person that directly or indirectly Controls, is Controlled by or is under common Control with such first Person. A Person will be deemed to &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Control</font><font style="letter-spacing:0.2pt;">&#8221; another Person if such first Person has (i)&#160;direct or indirect ownership of more than fifty&#160;percent (50%) of the equity (or such lesser&#160;percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) having the power to vote on or direct the affairs of such other Person, or (ii)&#160;the power, directly or indirectly, to direct or cause the direction of the policies and management of the other Person, whether by the ownership of stock, by contract, or otherwise. Notwithstanding the foregoing, for the purposes of this Agreement, the term &#8220;Affiliate&#8221; when used with respect to Apotex shall not include, and no provision of this Agreement shall be applicable to, (x)&#160;SK Capital Partners, LP or any of its direct or indirect subsidiaries (collectively, &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">SK Capital Partners</font><font style="letter-spacing:0.2pt;">&#8221;), (y)&#160;investment funds or managed accounts advised by SK Capital Partners or (z)&#160;portfolio companies owned by such investment funds or managed accounts (other than Apotex Inc. and its controlled Affiliates). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Agreement</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning assigned in the preamble of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(j)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Allocation</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning assigned in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;"> of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(k)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Ancillary IP Rights</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to any Intellectual Property, (i)&#160;any and all claims and causes of action with respect thereto, whether accruing before, on or after Closing, and the right to seek and recover damages for the past, present or future infringement, misappropriation, dilution, or other violation thereof, (ii)&#160;all rights to proceeds, income, revenues and royalties with respect thereto, whether accruing before, on or after Closing, (iii)&#160;the goodwill of the Business appurtenant thereto, and (iv)&#160;all tangible embodiments thereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(l)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Anti-Corruption Laws</font><font style="letter-spacing:0.2pt;">&#8221; means all Laws relating to the prevention of corruption, money laundering, and bribery, including the U.S. Foreign Corrupt Practices Act of 1977, as amended. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(m)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Apotex</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning assigned in the preamble of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(n)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Apotex Fundamental Representations</font><font style="letter-spacing:0.2pt;">&#8221; means the representations and warranties made in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.1</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Apotex&#8217;s Organization; Good Standing</font><font style="letter-spacing:0.2pt;">), </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.2</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Authority; Execution and Delivery</font><font style="letter-spacing:0.2pt;">) and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.5</font><font style="letter-spacing:0.2pt;"> (No Brokers). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(o)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Applicable Rate</font><font style="letter-spacing:0.2pt;">&#8221; means a rate per annum equal to the rate of interest published by the Wall Street Journal as the &#8220;prime rate&#8221; at large U.S. money center banks on such date. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(p)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Arbitrable Dispute</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.13(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(q)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Arbitrator</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.13(c)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(r)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Assumed Liability(ies)</font><font style="letter-spacing:0.2pt;">&#8221; shall mean the liabilities and obligations set forth or described on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex&#160;2.2</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(s)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Benefit Plan</font><font style="letter-spacing:0.2pt;">&#8221; means any &#8220;employee benefit plan&#8221; as defined in Section&#160;3(3) of ERISA (whether or not subject to ERISA), any employment, severance, retention, change of control, bonus, incentive, equity or equity-based compensation, deferred compensation, pension, profit sharing, retirement, health, welfare, fringe benefit, disability, life insurance, vacation, paid time off or other employee benefit plan, program, policy, agreement, contract or arrangement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(t)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Bill of Sale and Assignment and Assumption Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means the Bill of Sale and Assignment and Assumption Agreement, in the form attached hereto as Exhibit&#160;A. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(u)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Board</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in the recitals of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Board Recommendation</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.2</font><font style="letter-spacing:0.2pt;"> hereto. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(w)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Business</font><font style="letter-spacing:0.2pt;">&#8221; means the business of researching, developing, obtaining and maintaining regulatory approval for, manufacturing, selling, licensing, marketing, promoting, commercializing, distributing, exporting, importing or offering the Products. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(x)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Business Day</font><font style="letter-spacing:0.2pt;">&#8221; means any day other than a Saturday, Sunday, or other day on which commercial banks are authorized or required by Law to be closed in the cities of New York, New York (United States), Dublin (Ireland) or Toronto, Ontario (Canada). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(y)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Business Employee</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.17(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(z)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Buyer Guarantor</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the preamble. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(aa)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Closing</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.1</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(bb)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Closing Date</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.1</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(cc)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">CMS</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.8</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(dd)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Code</font><font style="letter-spacing:0.2pt;">&#8221; shall mean the U.S. Internal Revenue Code of 1986, as amended. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ee)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Company Stock</font><font style="letter-spacing:0.2pt;">&#8221; means common stock, no par value, and preferred stock, no par value, of Cumberland. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ff)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Confidential Information</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.3(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(gg)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Confidentiality Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means that certain Mutual Confidentiality Agreement, entered into as of September&#160;12, 2025, by and between Buyer Guarantor and Cumberland. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(hh)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Contract</font><font style="letter-spacing:0.2pt;">&#8221; means any legally binding contract, agreement, instrument, license, lease or understanding of any kind to which a Person is a party or by which a Person or its assets is bound, whether oral or written, together with amendments, supplements and other modifications thereto. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Control</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.1</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(jj)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Controlling Party</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.5(b)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(kk) &nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Conveyance Taxes</font><font style="letter-spacing:0.2pt;">&#8221; means all sales, use, value added, transfer, stamp, stock transfer, documentary, registration (including motor vehicle registration), recording and similar transfer Taxes (including any penalties and interest added thereto) imposed by a Governmental Authority in connection with the Transactions; provided that Conveyance Taxes shall exclude any Taxes imposed in whole or in part on net income or gains. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ll)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cumberland</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in the preamble of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(mm)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cumberland Fundamental Representations</font><font style="letter-spacing:0.2pt;">&#8221; means the representations and warranties of Cumberland set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.1</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Organization; Good Standing</font><font style="letter-spacing:0.2pt;">), </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.2</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Board Approval</font><font style="letter-spacing:0.2pt;">), </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.3</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Authority; Execution and Delivery</font><font style="letter-spacing:0.2pt;">), </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.4</font><font style="letter-spacing:0.2pt;"> (other than with respect to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clause (b)</font><font style="letter-spacing:0.2pt;"> thereof) (</font><font style="font-style:italic;letter-spacing:0.2pt;">No Violation; Consents</font><font style="letter-spacing:0.2pt;">), </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5(a)</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Title to Acquired Assets</font><font style="letter-spacing:0.2pt;">), </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.12</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">No Brokers</font><font style="letter-spacing:0.2pt;">), and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.14</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Transactions with Affiliates</font><font style="letter-spacing:0.2pt;">). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(nn)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cumberland Sufficiency Representations</font><font style="letter-spacing:0.2pt;">&#8221; means the representations and warranties of Cumberland set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5(b)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.9</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(oo)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cumberland&#8217;s Knowledge</font><font style="letter-spacing:0.2pt;">&#8221; means the actual knowledge, after reasonable inquiry, of A.&#160;J.&#160;Kazimi and Adam Mostafa. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(pp)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cumberland SEC Documents</font><font style="letter-spacing:0.2pt;">&#8221; means each publicly available report, schedule, form, statement, prospectus, registration or other document filed with or furnished to the SEC by Cumberland during the period beginning on January&#160;1, 2025 and ending as of the date hereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(qq)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cumberland Systems</font><font style="letter-spacing:0.2pt;">&#8221; means computer systems, including software, computer hardware (whether general or special purpose), electronic data processing, record keeping, communications, telecommunications, networks, interfaces, platforms, servers, and computer systems, including any outsourced systems and processes that are related to the Business and used, owned, leased, licensed to, or relied on by Cumberland or any of its Affiliates. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(rr)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cumberland Work Product</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ss)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Data Protection Law</font><font style="letter-spacing:0.2pt;">&#8221; means all applicable Laws relating to (i)&#160;the collection, use, storage, disclosure and other processing (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Processing</font><font style="letter-spacing:0.2pt;">&#8221;) of Personal Data by the Business in the ordinary course of its operations, (ii)&#160;data privacy or data protection, (iii)&#160;cybersecurity to the extent relating to Personal Data, or (iv)&#160;the privacy of electronic communications, in each case to the extent applicable to the Business or Cumberland or any of its Affiliates in connection with the operation of the Business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(tt)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Data Privacy Requirements</font><font style="letter-spacing:0.2pt;">&#8221; means, collectively, to the extent applicable to the Business (or Cumberland and its Affiliates in connection with the operation of the Business) and with respect to Personal Data or other confidential information of the Business, the following: (i)&#160;Cumberland&#8217;s and its Affiliates&#8217; data privacy, information security, and cybersecurity policies and procedures; (ii)&#160;all applicable Data Protection Laws; and (iii)&#160;binding contractual obligations relating to data privacy or information security to which Cumberland or any Affiliate is a party. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(uu)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Data Room</font><font style="letter-spacing:0.2pt;">&#8221; means the electronic data room entitled &#8220;Cumberland Pharmaceuticals,&#160;Inc.&#160;&#8212;</font>&#8203;<font style="letter-spacing:0.2pt;">Business Matters,&#8221; hosted by Baker, Donelson, Bearman, Caldwell &amp; Berkowitz, P.C. </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(vv)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">De Minimis Threshold</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.4(e)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ww)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Deductible</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.4(e).</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(xx)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Designated Employee</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.7(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(yy)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Disclosure Schedule</font><font style="letter-spacing:0.2pt;">&#8221; means the disclosure schedules delivered to Apotex by Cumberland simultaneously with the execution and delivery of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(zz)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Effective Date</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in the preamble of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(aaa)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Encumbrance</font><font style="letter-spacing:0.2pt;">&#8221; means any mortgage, charge, lien (statutory or otherwise), license, claim, option, right of first refusal, first offer or first negotiation, title defect, priority, security interest, option, warrant, right, contract, commitment, demand, proxy, voting agreement, restriction on transfer, easement, right of way, pledge or encumbrance of any kind or character whatsoever. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(bbb)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Enforceability Exceptions</font><font style="letter-spacing:0.2pt;">&#8221; means any applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and other similar laws affecting creditors&#8217; rights generally from time to time in effect and to general principles of equity. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ccc)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exchange Act</font><font style="letter-spacing:0.2pt;">&#8221; shall mean the Securities Exchange Act of 1934. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ddd)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Ex-Im Laws</font><font style="letter-spacing:0.2pt;">&#8221; mean all Laws relating to export, reexport, transfer, and import controls, including the Export Administration Regulations, the customs and import Laws administered by U.S. Customs and Border Protection. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(eee)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Excluded Assets</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.2</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(fff)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Excluded Liabilities</font><font style="letter-spacing:0.2pt;">&#8221; means the liabilities and obligations set forth or described on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.3</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ggg)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Excluded Taxes</font><font style="letter-spacing:0.2pt;">&#8221; means (i)&#160;all Taxes of Cumberland and its Affiliates for any taxable period, including any Taxes imposed on Apotex or its Affiliates as a transferee or successor, by operation of law (including bulk transfer, bulk sales or similar laws) or otherwise, (ii)&#160;all Taxes arising out of, relating to, or in respect of, the Acquired Assets for all Pre-Closing Tax Periods, and (iii)&#160;all Taxes for which Talicia Holdings or any of its Subsidiaries is liable (including pursuant to Treasury Regulation&#160;Section&#160;1.1502-6 or any similar provision of state, local, or non-U.S. Law) as a result of being a member of an affiliated group with Cumberland or its Affiliates. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(hhh)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Final Determination</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.13(d)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Fraud</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to a Party, the fraud of such Person in making of a representation or warranty in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article</font><font style="letter-spacing:0.2pt;"> V or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article</font><font style="letter-spacing:0.2pt;"> VI of this Agreement or in any other Transaction Document with (a)&#160;actual knowledge that such representation is false or that the Person making such representation believes it to be false and (b)&#160;the intention to induce the other Person to whom such representation is made to enter into this Agreement or the Transactions or otherwise act or refrain from acting in reliance upon it. For the avoidance </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">of doubt, &#8220;Fraud&#8221; does not include, and no claim may be made by any Person in relation to this Agreement or the Transactions for, constructive fraud, negligent or reckless misrepresentation, or equitable fraud. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(jjj)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">General Cap</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.4(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(kkk)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Governmental Authority(ies)</font><font style="letter-spacing:0.2pt;">&#8221; means any federal, national, state, provincial or local governmental authority, public or private arbitrator or arbitral body or agency, including any which regulates the research, development, regulatory approvals, manufacture, sale, licensure, marketing, promotion, commercialization, distribution, exportation, importation or offering of pharmaceutical products. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(lll)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Guaranteed Obligations</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.20</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(mmm)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">INDs</font><font style="letter-spacing:0.2pt;">&#8221; means any investigational new drug applications (whether active, inactive, or withdrawn) associated with the Products. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(nnn)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Indemnified Party</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.5(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ooo)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Indemnifying Party</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.5(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ppp)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Intellectual Property</font><font style="letter-spacing:0.2pt;">&#8221; means all of the following and all rights therein and thereto: (i)&#160;inventions (whether or not patentable), all rights to inventions, patents, patent applications, petty patents, and issued patents, in each case, together with all reissues, reexaminations, divisionals, continuations, continuations-in-part, revalidations, substitutions, renewals, revalidations, supplementary protection certificates, and extensions of any of the foregoing, and patents or patent applications whether domestic or foreign claiming priority to any of the foregoing and any patent applications or patents that claim priority to a patent application or patent arising from any of the foregoing, including the right to claim priority to any of the foregoing (this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clause (i)</font><font style="letter-spacing:0.2pt;">, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Patents</font><font style="letter-spacing:0.2pt;">&#8221;); (ii)&#160;designs, design applications and design registrations, trademarks, trade mark applications, trade mark registrations, trade names, trade dresses, service marks, logos, product names, brand names, slogans and other designations of origin (whether registered or unregistered), and any trademark applications and registrations claiming priority thereto and any trademark registrations granted therefrom, including all goodwill associated with the use of and symbolized by any of the foregoing and the goodwill of the Business (this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clause (ii)</font><font style="letter-spacing:0.2pt;">, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Trademarks</font><font style="letter-spacing:0.2pt;">&#8221;); (iii)&#160;copyright, copyright applications and copyright registrations, and works of authorship (whether or not copyrightable), including the entire copyright and all other rights in the nature of copyright in any Trademarks; (iv)&#160;Internet domain names and social media accounts and handles; (v)&#160;Know-How; and (vi)&#160;registrations, applications for registrations and renewals in connection with any of the foregoing </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clauses (i)</font><font style="letter-spacing:0.2pt;">&#8201;&#8211;&#8201;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(vi)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(qqq)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Inventory</font><font style="letter-spacing:0.2pt;">&#8221; means all inventory owned by Cumberland or any of its Affiliates and used (or held for use) in the Business, including the Products and active pharmaceutical ingredients, spare parts, raw materials, containers, packaging and packaging supplies and work-in-process. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(rrr)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">IP Assignment Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means the IP Assignment Agreement, in the form attached hereto as Exhibit&#160;B. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(sss)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">IP Rights</font><font style="letter-spacing:0.2pt;">&#8221; means all Intellectual Property and Ancillary IP Rights included in the Acquired Assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ttt)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Know-How</font><font style="letter-spacing:0.2pt;">&#8221; means all technology, trade secrets, technical, scientific and other data, manufacturing information, pre-clinical and clinical data and sales data. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(uuu)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Law</font><font style="letter-spacing:0.2pt;">&#8221; means any laws, statutes, ordinances, rules, regulations, judgments, injunctions, orders and decrees of applicable Governmental Authorities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(vvv)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Liability</font><font style="letter-spacing:0.2pt;">&#8221; means any liability or obligation (whether known or unknown, whether asserted or unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated, unliquidated or otherwise, and whether due or to become due, and regardless of when or by whom asserted). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(www)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Loss</font><font style="letter-spacing:0.2pt;">&#8221; or &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Losses</font><font style="letter-spacing:0.2pt;">&#8221; means any actual losses, damages, Liabilities, costs, or expenses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xxx)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Material Adverse Effect</font><font style="letter-spacing:0.2pt;">&#8221; means a material and adverse effect, change, occurrence, development or circumstance (i)&#160;upon the Business or the Acquired Assets or (ii)&#160;upon the ability of Cumberland to execute </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">or deliver this Agreement, to perform any of its obligations under this Agreement or to consummate any of the Transactions; provided, however, that any effect, change, occurrence, development or circumstance arising or resulting from: (A)&#160;conditions generally affecting the general national, international or regional economy or generally affecting the industry or industries generally in which Cumberland operates; (B)&#160;national or international political or social conditions, including terrorism or the engagement by the United States in hostilities or acts of war; (C)&#160;any natural disaster or extreme weather conditions; (D)&#160;any epidemic, pandemic or disease outbreak; (E)&#160;any changes in applicable Law or U.S. GAAP, or accounting principles, practices or policies, in each case after the date hereof, that Cumberland is required to adopt, or the enforcement or interpretation thereof; (F)&#160;the announcement of the Transactions contemplated by this Agreement or any other Transaction Document; (G)&#160;actions taken or omitted following the date hereof at the written request or with the written consent of Apotex or (H)&#160;any failure to meet internal or published projections, estimates or forecasts of revenues, earnings, or other measures of financial or operating performance for any period (provided, that the underlying causes of such failures (subject to the other provisions of this definition) shall not be excluded), shall not be taken into account in determining whether a &#8220;Material Adverse Effect&#8221; has occurred, or would reasonably be expected to occur, with respect to Cumberland, except, in the case of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clauses (A)</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(B)</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(C)</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(D)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(E)</font><font style="letter-spacing:0.2pt;">, to the extent such matters had, or would reasonably be expected to have, a disproportionate adverse impact on Cumberland or the Business relative to other participants in the industries in which Cumberland or the Business operates. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(yyy)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Material Contracts</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.8(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(zzz)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Material Customers</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.13(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(aaaa)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Material Suppliers</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.13(b)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(bbbb)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">NDC</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.1(c)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(cccc)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Non-Controlling Party</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.5(b)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(dddd)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Notice of Arbitration</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.13</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(eeee)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Offer Employee</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.7(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ffff)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Order</font><font style="letter-spacing:0.2pt;">&#8221; means any order, writ, judgment, award, injunction or decree of any Governmental Authority. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(gggg)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Outside Date</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.1(c)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(hhhh)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Party/Parties</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in the preamble of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iiii)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Permitted Encumbrances</font><font style="letter-spacing:0.2pt;">&#8221; means (i)&#160;Encumbrances for Taxes not yet due and payable or that Cumberland is contesting in good faith by appropriate proceedings diligently conducted and for which appropriate reserves have been established on Cumberland&#8217;s financial statements in accordance with GAAP; (ii)&#160;statutory landlord&#8217;s, mechanic&#8217;s, carrier&#8217;s, workmen&#8217;s, repairmen&#8217;s or other similar liens arising or incurred in the ordinary course of business for amounts which are not due and payable as of the date hereof or that Cumberland is contesting in good faith by appropriate proceedings and, in each case, as to which adequate reserves have been established on Cumberland&#8217;s financial statements in accordance with GAAP; and (iii)&#160;non-exclusive licenses of IP Rights granted by Cumberland to customers in the ordinary course of business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(jjjj)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Person</font><font style="letter-spacing:0.2pt;">&#8221; means any individual, corporation, partnership, limited liability company, joint venture, trust, business association, organization, Governmental Authority or other entity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(kkkk)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Personal Data</font><font style="letter-spacing:0.2pt;">&#8221; means any data or information that identifies, relates to, describes, is reasonably capable of being associated with, or could reasonably be linked with, directly or indirectly, alone or in combination with other information, an identified or identifiable natural person, device or household, and any other information that is defined as &#8220;personal data,&#8221; &#8220;personally identifiable information,&#8221; &#8220;personal health information,&#8221; or &#8220;personal information&#8221; under any applicable Data Protection Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(llll)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Personnel Records</font><font style="letter-spacing:0.2pt;">&#8221; means the personnel records (including all human resources and other records) of the Transferred Business Employees. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(mmmm)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Pre-Closing Tax Period</font><font style="letter-spacing:0.2pt;">&#8221; means any taxable period ending on or before the Closing Date and the portion through the end of the Closing Date of any Straddle Period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(nnnn)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Prevailing Central Time</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to any particular time in question, Central Standard Time or Central Daylight Time in effect at such time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(oooo)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Product Records</font><font style="letter-spacing:0.2pt;">&#8221; means the books, data documents, records, and files required or primarily related to the Acquired Assets, including any (i)&#160;vendor lists of the Business, (ii)&#160;customer lists of the Business, (iii)&#160;a list of the distributors for the Products, (iv)&#160;pricing lists for the Products, (v)&#160;testing and clinical data, market research reports, marketing plans and other marketing-related information and materials of the Products, (vi)&#160;quality control, vigilance and regulatory records of the Products, (vii)&#160;copies and tangible embodiments of all IP Rights and all rights to INDs, in whatever form or medium, (viii)&#160;Tax Returns and associated work papers with respect to the Business and Acquired Assets, and (ix)&#160;other business records, to the extent such other business records are required to be transferred under applicable Law in connection with the Transactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(pppp)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Products</font><font style="letter-spacing:0.2pt;">&#8221; means (i)&#160;those certain pharmaceutical products with Regulatory Approvals or Regulatory Registrations identified on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1(A)</font><font style="letter-spacing:0.2pt;">, (ii)&#160;any analogs, tautomers, radioisomers, enantiomers, enantiomeric mixtures, salt forms, anhydrides, hydrates, polymorphs, metabolites, or ester forms of the products identified on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1(A)</font><font style="letter-spacing:0.2pt;">, and (iii)&#160;any dosage forms, substance, formulation, co-formulation, or compounded versions of any of the foregoing in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clauses (i)</font><font style="letter-spacing:0.2pt;">&#8201;&#8211;&#8201;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that the Parties acknowledge and agree that, other than as set forth in the Material Contracts, Cumberland does not directly own any rights or interests in and to the &#8220;Talicia&#8221; product (as identified on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1(A)</font><font style="letter-spacing:0.2pt;">) and that the only rights and interests in and to Talicia that shall transfer to Apotex pursuant to this Agreement are such rights and interests set forth in the Transferred Contracts. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(qqqq)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Purchase Price</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.1</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(rrrr)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Regulatory Approval</font><font style="letter-spacing:0.2pt;">&#8221; means any authorizations for research, development, obtaining and maintaining regulatory approvals for, manufacture, sale, licensure, marketing, promotion, commercialization, distribution, exportation, importation, distribution or otherwise offering of the Products that are part of the Acquired Assets in the name of Cumberland. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ssss)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Regulatory Registrations</font><font style="letter-spacing:0.2pt;">&#8221; means the INDs, new drug applications and abbreviated new drug applications and all subsequent supplements approved by the U.S. Food and Drug Administration (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">FDA</font><font style="letter-spacing:0.2pt;">&#8221;), and similar licenses, registrations, authorizations, permits, certifications, franchises, variances, exemptions, orders, approvals, amendments and renewals of the Products (including marketing authorizations and labeling approvals) issued by any Governmental Authority of any country and held or pending (including any applications) as of the Closing Date by Cumberland or any of its Affiliates with respect to the Business or third-party distributors (under rights of reservation of Cumberland or such Affiliates) that are required for the Business in any country. &#8220;Regulatory Registrations&#8221; include &#8220;Regulatory Approvals.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(tttt)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Representative</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to a particular Person, any director, officer, manager, shareholder, member, partner, owner, principal, employee, advisor, representative, consultant, counsel, accountant, investment banker or agent of such Person. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(uuuu)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Requisite Stockholder Approval</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.3</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(vvvv)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sanctioned Country</font><font style="letter-spacing:0.2pt;">&#8221; means any country or region or government that is, or has been since April&#160;24, 2019, the subject or target of a comprehensive embargo under Trade Controls (including Cuba, Iran, North Korea, the Crimea region of Ukraine, the so-called &#8220;Donetsk People&#8217;s Republic,&#8221; and the so-called &#8220;Luhansk People&#8217;s Republic&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(wwww)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sanctioned Person</font><font style="letter-spacing:0.2pt;">&#8221; means any Person that is the subject or target of sanctions or restrictions under Trade Controls including: (i)&#160;any Person listed on any U.S. or non-U.S. sanctions- or export-related restricted party list, including the U.S. Department of the Treasury Office of Foreign Assets Control&#8217;s (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">OFAC</font><font style="letter-spacing:0.2pt;">&#8221;) List of Specially Designated Nationals and Blocked Persons, or any other OFAC, U.S. Department of Commerce Bureau of Industry and Security, or U.S. Department of State sanctions- or export-related restricted party list; (ii)&#160;any Person located, organized, or ordinarily resident in a Sanctioned Country; (iii)&#160;any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Person that is, in the aggregate, fifty&#160;percent or greater owned, directly or indirectly, or otherwise controlled by a Person or Persons described in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clauses (i)</font><font style="letter-spacing:0.2pt;">&#8201;&#8211;&#8201;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">; or (iv)&#160;any national of a Sanctioned Country with whom U.S. persons are prohibited from dealing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xxxx)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sanctions</font><font style="letter-spacing:0.2pt;">&#8221; means all Laws relating to economic or trade sanctions, including the Laws administered or enforced by the United States (including by OFAC or the U.S. Department of State) and the United Nations Security Council. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(yyyy)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">SEC</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.11(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(zzzz)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Security Incident</font><font style="letter-spacing:0.2pt;">&#8221; means a (i)&#160;breach of security, unauthorized intrusion or unauthorized Processing of data, successful phishing incident, or ransomware or malware attack, or (ii)&#160;cyber or security incident with respect to any trade secrets or other confidential information or Personal Data. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(aaaaa)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Securities Act</font><font style="letter-spacing:0.2pt;">&#8221; means the Securities Act of 1933, as amended from time to time, and all rules and regulations promulgated thereunder, or any similar federal Law then in force. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(bbbbb)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stockholder</font><font style="letter-spacing:0.2pt;">&#8221; means each holder of Company Stock as of any applicable time of determination. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ccccc)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stockholder Meeting</font><font style="letter-spacing:0.2pt;">&#8221; means a meeting of the Stockholders (as promptly as reasonably practicable following the mailing of the Proxy Statement to the Stockholders) for the purpose of obtaining the Requisite Stockholder Approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ddddd)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stockholder Support Agreement</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in the recitals of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(eeeee)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Straddle Period</font><font style="letter-spacing:0.2pt;">&#8221; means any taxable period that includes (but does not end on) the Closing Date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(fffff)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Subsidiary</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to any Person, any entity of which securities or other ownership interests (a)&#160;having voting power to elect a majority of the board of directors or other persons performing similar functions or (b)&#160;representing more than fifty&#160;percent of such securities or ownership interests are at the time directly or indirectly owned by such Person. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ggggg)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Superior Proposal</font><font style="letter-spacing:0.2pt;">&#8221; means any bona fide unsolicited written Acquisition Proposal for an Acquisition Transaction on terms that the Board has determined in good faith (after consultation with its financial advisor and outside legal counsel) (i)&#160;is reasonably likely to be consummated in accordance with its terms, taking into account all legal, regulatory and financing aspects of the proposal (including certainty of closing) and the identity of the Person making the proposal and any other aspects of the Acquisition Proposal that the Board deems relevant (including the likelihood of consummation) and (ii), if consummated, would be more favorable from a financial point of view to Cumberland or the Stockholders than the Transactions (taking into account any revisions to this Agreement made or proposed in writing by Apotex in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;"> prior to the time of such determination). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(hhhhh)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Talicia Holdings</font><font style="letter-spacing:0.2pt;">&#8221; means Talicia Holdings, Inc., a Delaware corporation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iiiii)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Tax</font><font style="letter-spacing:0.2pt;">&#8221; means any foreign, federal, state or local income, gross receipts, franchise, estimated, alternative minimum, add-on minimum, sales, use, transfer, real property gains, registration, value added, excise, natural resources, severance, stamp, occupation, premium, windfall profit, environmental, real property, personal property, escheat, abandoned or unclaimed property, capital stock, social security, unemployment, disability, payroll, license, or employee or other withholding tax, or other tax, levy, duty (including customs duties), tariff, assessment, impost or other governmental charge, including any interest, penalties or additions to tax or additional amounts in respect of the foregoing, however denominated, in the nature of a tax, whether disputed or not. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(jjjjj)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Tax Return</font><font style="letter-spacing:0.2pt;">&#8221; means any return, statement, schedule, declaration, report, claim for refund, information return or other document (including any related or supporting schedule, statement or information and including any amendment thereof) filed or required to be filed with any Governmental Authority in connection with the determination, assessment or collection of any Tax of any party. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS1I">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(kkkkk)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Taxing Authority</font><font style="letter-spacing:0.2pt;">&#8221; means any Governmental Authority responsible for the determination, assessment, collection or imposition of any Tax. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(lllll)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">TBCA</font><font style="letter-spacing:0.2pt;">&#8221; means the Tennessee Business Corporation Act, as set forth in Title 48, Chapters 11 through 27 of the Tennessee Code Annotated, as the same may be amended, supplemented, or restated from time to time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(mmmmm)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Territory</font><font style="letter-spacing:0.2pt;">&#8221; means the fifty (50) states of the United States of America and its territories, commonwealths, possessions and associated states, including the District of Columbia, the Commonwealth of Puerto Rico, Armenia, Australia, Azerbaijan, Belarus, China, Georgia, Hong Kong, Jordan, Kazakhstan, Kyrgyzstan, Macau, Malaysia, Mexico, Moldova, New Zealand, Philippines, Russian Federation, Saudi Arabia, Singapore, Taiwan, Tajikistan, Thailand, Turkmenistan, Ukraine, Uzbekistan, Vietnam and shall include, solely with respect to shipments of Products to the U.S. Department of Defense, any specific remote ship-to location in the world to which such customer may require that Products be shipped, only if such sales are billed to a location within the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(nnnnn)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Third Party</font><font style="letter-spacing:0.2pt;">&#8221; means any Person other than Apotex, Buyer Guarantor, Cumberland, or their respective Affiliates. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ooooo)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Third Party Claim</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.5(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ppppp)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Transaction Documents</font><font style="letter-spacing:0.2pt;">&#8221; means this Agreement, the Bill of Sale and Assignment and Assumption Agreement, the IP Assignment Agreement, the Stockholder Support Agreements, the Transition Services Agreement, the Confidentiality Agreement and each of the other agreements, documents, certificates or instruments executed and delivered in connection with this Agreement, including any amendments thereto. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(qqqqq)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Transactions</font><font style="letter-spacing:0.2pt;">&#8221; means the transactions contemplated by this Agreement and the other Transaction Documents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(rrrrr)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Transferred Business Employee</font><font style="letter-spacing:0.2pt;">&#8221; means any Business Employee who commences employment with Apotex or its Affiliates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(sssss)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Transferred Contract(s)</font><font style="letter-spacing:0.2pt;">&#8221; means all Contracts exclusively or primarily related to the Business, including the Material Contracts required to be set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.8(a)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ttttt)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Transferred Equity Interests</font><font style="letter-spacing:0.2pt;">&#8221; means all issued and outstanding common stock of, and any rights convertible into or exercisable for any common stock of or other equity interests in, Talicia Holdings held by Cumberland and its Affiliates as of immediately prior to the Closing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(uuuuu)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Transition Services Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means the Transition Services Agreement substantially in the form attached hereto as </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exhibit&#160;D</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(vvvvv)&nbsp;&nbsp;&nbsp;&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Vibativ Milestone Payment Amount</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.19</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;1.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Interpretation</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;When used in this Agreement, the words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the words &#8220;without limitation&#8221; and, unless the context otherwise requires, &#8220;neither,&#8221; &#8220;nor,&#8221; &#8220;any,&#8221; &#8220;either&#8221; and &#8220;or&#8221; shall not be exclusive. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Any terms defined in the singular shall have a comparable meaning when used in the plural, and vice-versa. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;This Agreement shall be deemed drafted jointly by Apotex and Cumberland and shall not be specifically construed against either Party based on any claim that such Party or its counsel drafted this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;The headings and captions used in this Agreement, in any Schedule or Exhibit hereto, in the table of contents or in any index hereto are for convenience of reference only and do not constitute a part of this </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS1CA">&#8203;</a><a name="sAIAP">&#8203;</a><a name="sS2SA">&#8203;</a><a name="sS2EA">&#8203;</a><a name="sS2AL">&#8203;</a><a name="sS2EL">&#8203;</a><a name="sS2DO">&#8203;</a><a name="sS2TO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Agreement and shall not be deemed to limit, characterize or in any way affect any provision of this Agreement or any Schedule or Exhibit hereto. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Any capitalized terms used in any Schedule or Exhibit attached hereto and not otherwise defined therein shall have the meanings set forth in this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;Any reference to any Law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular. The definitions contained in this Agreement are applicable to the masculine as well as to the feminine and neuter genders of such terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;All references to materials being &#8220;made available&#8221; by Cumberland means documents posted and accessible to Apotex and its advisors in the Data Room no less than two (2)&#160;Business Days prior to the date of this Agreement and remain so posted and accessible continuously through the Closing and three (3) Business Days thereafter. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;1.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Currency</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;All currency amounts referred to in this Agreement are in United States Dollars (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">USD</font><font style="letter-spacing:0.2pt;">&#8221;) unless otherwise specified. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE II</font>
          <br >
          <font style="letter-spacing:-0.2pt;">SALE AND PURCHASE OF ACQUIRED ASSETS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;2.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sale and Purchase of Acquired Assets</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Upon the terms and subject to the conditions of this Agreement, at the Closing, Cumberland shall sell, assign, transfer, convey and deliver (or, where relevant, shall cause and procure its Affiliates the same) to Apotex (or its designated Affiliates), and Apotex (or its designated Affiliates) shall purchase, acquire and accept, all right, title and interest of Cumberland and its Affiliates in, to and under the Acquired Assets, in each case, free and clear of all Encumbrances (other than Permitted Encumbrances). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;2.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Excluded Assets</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Apotex and its Affiliates are not purchasing or acquiring, and the Acquired Assets will not include, any assets of any kind, nature, character or description (whether real, personal or mixed, whether tangible or intangible, whether absolute, accrued contingent, fixed or otherwise, and wherever situated) owned or held by Cumberland or its Affiliates that are not identified or described on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1(A)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1(B)</font><font style="letter-spacing:0.2pt;"> (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Excluded Assets</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;2.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Assumed Liabilities</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, at the Closing, Apotex will assume, and thereafter be responsible for and pay, perform or otherwise satisfy and discharge when due, the Assumed Liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;2.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Excluded Liabilities</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Notwithstanding anything in this Agreement to the contrary, neither Apotex nor any of its Affiliates shall assume or be obligated to pay, perform or otherwise discharge, pursuant to this Agreement or otherwise any Excluded Liability. All Liabilities of every form and nature of Cumberland and its Affiliates, other than Assumed Liabilities, shall be retained by and remain liabilities, obligations, and commitments of Cumberland and its Affiliates, and Cumberland and its Affiliates shall be responsible for and pay, perform, or otherwise satisfy and discharge when due the Excluded Liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;2.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Designation of Affiliates; Performance Obligations by Affiliates</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;To the extent that any of the Acquired Assets are under the control of any of Cumberland&#8217;s Affiliates, Cumberland shall direct and cause such Affiliate to promptly take such legal action as may be necessary to consummate the transfer to Apotex of such Acquired Assets under terms and conditions which are consistent with and subject to the terms of this Agreement. Notwithstanding the foregoing, this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.5</font><font style="letter-spacing:0.2pt;"> shall not be construed to relieve Cumberland from any of its obligations under this Agreement. Cumberland shall cause each of its applicable Affiliates to take or refrain from taking any action, or to fulfill any obligation, applicable to Cumberland under this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;2.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Treatment of Contracts that Require Third Party Consents to Transfers</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;If and to the extent that the transfer of the Transferred Contracts requires the consent or action of a Third Party, Cumberland and Apotex shall, for a period of twelve (12) months from and after the Closing, use their </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sAIP">&#8203;</a><a name="sS3PP">&#8203;</a><a name="sS3MA">&#8203;</a><a name="sS3AO">&#8203;</a><a name="sS3CT">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">reasonable efforts to obtain such consent or action as promptly as practicable. For the duration of the term of each such Contract until such consent or action is obtained, Cumberland shall, and shall cause its Affiliates to, provide Apotex (or its designated Affiliate) the rights and benefits under such Transferred Contracts as if the transfer of the respective Transferred Contracts had taken place in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.1</font><font style="letter-spacing:0.2pt;"> (e.g., enter into such suitable agreements (such as subcontracts, sublicenses or subleases or similar arrangements) so as to (partially) transfer the benefits and burdens arising out of the Transferred Contracts to Apotex) and, to the extent Cumberland provides such rights and benefits, Apotex shall assume the obligations and burdens thereunder. In these cases, Cumberland will, in respect of the external relationships, remain the party of the Contracts but will, in respect of the internal relationship between Cumberland and Apotex, continue to hold and be responsible for the relevant Transferred Contracts (or the relevant portion thereof) for the account of Apotex and act only in accordance with the directions of Apotex with respect to such Transferred Contract. In particular, (i)&#160;any enforcement by Cumberland of any right under the Transferred Contracts (or the relevant portion thereof) shall be for the account of Apotex, (ii)&#160;Cumberland shall manage and attend to the relevant Contracts (or the relevant portion thereof) with due care and in accordance with the instructions of Apotex and (iii)&#160;Cumberland shall indemnify Apotex and its Affiliates against any cost or liability arising from such Transferred Contract resulting from any breach or alleged breach as a result of the Transactions in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;IX</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE III</font>
          <br >
          <font style="letter-spacing:-0.2pt;">PURCHASE PRICE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;3.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Purchase Price</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp; Subject to the terms and conditions set forth herein, in consideration of the sale, assignment, conveyance, and delivery of the Acquired Assets and assumption of the Assumed Liabilities, Apotex will pay to Cumberland a cash payment of One Hundred Million Dollars (USD&#160;$100,000,000) (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Purchase Price</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;3.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Manner and Place of Payment</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;All payments owed under this Agreement shall be made by wire transfer in United States currency to the banks and accounts designated in writing by Cumberland. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;3.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Allocation of Purchase Price</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Purchase Price (plus Assumed Liabilities and any other amounts treated as consideration for U.S. federal income Tax purposes) shall be allocated among the Acquired Assets in accordance with Section&#160;1060 of the Code, the Treasury Regulations thereunder (such allocation, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Allocation</font><font style="letter-spacing:0.2pt;">&#8221;). A draft of the Allocation shall be delivered by Apotex to Cumberland within one hundred and twenty (120) days after the Closing Date, for Cumberland&#8217;s review and reasonable comment. Within forty-five (45) days thereafter, Cumberland may dispute Apotex&#8217;s draft of the Allocation by delivering written notice of objection with respect to the Allocation, setting forth in reasonable detail any items as to which Cumberland disagrees, the basis for the objections, and Cumberland&#8217;s proposed allocation of such items. Cumberland and Apotex shall thereafter work in good faith to resolve any disputes relating to the Allocation within twenty (20) days after Apotex&#8217;s receipt of Cumberland&#8217;s written notice. If Apotex and Cumberland are able to resolve such dispute within such period, the Allocation shall be adjusted to reflect such resolution. If, following any such negotiations, the Parties are unable to agree on the Allocation, disagreements regarding the Allocation shall be promptly referred to a neutral reputable accounting firm mutually agreed to by Apotex and Cumberland that will be jointly retained and reimbursed equally by Apotex and Cumberland (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Accounting Firm</font><font style="letter-spacing:0.2pt;">&#8221;) for resolution in accordance with this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;"> and the procedures set forth herein, provided that the Accounting Firm shall act in its capacity as expert and not arbitrator. The Allocation (if any) shall be final and binding on the Parties. Apotex and Cumberland agree not to treat Cumberland as having made any payment to Apotex in exchange for Apotex&#8217;s assumption of any liabilities hereunder under the principles of James M. Pierce Corp. v. Commissioner, 326 F.2d (8th Cir.&#160;1964). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;3.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Consistent Treatment</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Apotex and Cumberland shall file all Tax Returns (including Internal Revenue Service Form 8594) consistent with the Allocation. Neither Apotex nor Cumberland shall take any Tax position inconsistent with such Allocation; provided, however, that nothing contained herein shall prevent Apotex or Cumberland from settling any proposed deficiency or adjustment by any Taxing Authority based upon or arising out of the Allocation, and neither Apotex nor Cumberland shall be required to litigate before any court any proposed deficiency or adjustment by any Taxing Authority challenging such Allocation. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS3W">&#8203;</a><a name="sAIC">&#8203;</a><a name="sS4CD">&#8203;</a><a name="sS4CA">&#8203;</a><a name="sS4FA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;3.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Withholding</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Apotex and its Affiliates shall be entitled to deduct and withhold any Taxes from any amounts otherwise payable pursuant to this Agreement to the extent required by applicable Law; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that if Apotex or its Affiliates believe that any such deduction or withholding of Tax other than any deduction or withholding resulting from Cumberland&#8217;s failure to satisfy its obligations under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.2(a)(iii)</font><font style="letter-spacing:0.2pt;"> is required, Apotex or its Affiliates shall use commercially reasonable efforts to (i)&#160;provide written notice to Cumberland of its intent to withhold at least five (5)&#160;days prior to making such deduction or withholding and (ii)&#160;provide Cumberland with a written explanation substantiating the requirement to deduct or withhold. Each Party shall use its commercially reasonable efforts to cooperate with Cumberland to reduce or eliminate the requirement to deduct and withhold Tax to the extent permitted by applicable Law. Such withheld amounts shall be timely remitted to the appropriate Governmental Authority and shall be treated for all purposes of this Agreement as having been paid to Cumberland. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;In the event that Apotex assigns its rights under this Agreement and, solely by reason of such assignment, Apotex is required to deduct or withhold in respect of payments made hereunder to Cumberland under applicable Law, then </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.5(a)</font><font style="letter-spacing:0.2pt;"> shall not apply and all payments to Cumberland shall be made in full, without any set-off, counterclaim, deduction or withholding, regardless of any requirement under applicable Law or otherwise. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE IV</font>
          <br >
          <font style="letter-spacing:-0.2pt;">THE CLOSING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;4.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Closing Date</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The closing of the transactions contemplated by this Agreement (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Closing</font><font style="letter-spacing:0.2pt;">&#8221;) shall take place remotely via the electronic exchange of documents and signatures at 8:00&#160;a.m., Central Time, on the third (3</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">rd</font><font style="letter-spacing:0.2pt;">) Business Day following the date on which the conditions set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">ARTICLE&#160;VIII</font><font style="letter-spacing:0.2pt;"> have been satisfied or, to the extent permitted by applicable Law, waived (other than those conditions that by their nature are to be satisfied by action taken at the Closing, but subject to the satisfaction or waiver thereof at the Closing), or at such other date, time or place as Cumberland and Apotex may agree in writing. The date on which the Closing occurs is referred to in this Agreement as the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Closing Date</font><font style="letter-spacing:0.2pt;">.&#8221; </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;4.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Closing Activities</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;At the Closing, Cumberland shall, and shall cause its Affiliates to: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;deliver to Apotex a duly executed counterpart to all Transaction Documents to which Cumberland or any of its Affiliates is a party; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;deliver to Apotex evidence of the Requisite Stockholder Approval in form and substance reasonably satisfactory to Apotex; and </font>
        </div>
        <div style="text-indent:40pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;deliver to Apotex a duly completed and validly executed Internal Revenue Service Form&#160;W-9. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;At Closing, Apotex shall: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;deliver to Cumberland a duly executed counterpart to all Transaction Documents to which Apotex or any of its Affiliates is a party; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;pay or cause to be paid to Cumberland the Purchase Price by wire transfer of immediately available funds to an account designated by Cumberland not less than two Business Days prior to the Closing Date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;4.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Further Assurances</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;At the request and expense of the other Party, each Party shall, within fifteen (15) days of such request, execute and deliver such additional instruments and documents, or initiate other ministerial actions, as may be reasonably necessary to effectuate the transfer of the Acquired Assets and consummate the Transactions as contemplated by this Agreement. Any such instruments or documents shall be in form and substance reasonably agreed by the Parties, customary for the applicable jurisdiction, and solely intended to evidence or give effect to the terms of this Agreement. In the event of any inconsistency between this Agreement and any such instrument or document, this Agreement shall control. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sAVAW">&#8203;</a><a name="sS5OG">&#8203;</a><a name="sS5BA">&#8203;</a><a name="sS5AE">&#8203;</a><a name="sS5NV">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE V</font>
          <br >
          <font style="letter-spacing:-0.2pt;">REPRESENTATIONS AND WARRANTIES OF CUMBERLAND</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cumberland hereby represents and warrants to Apotex that, except as set forth in the Disclosure Schedules or as expressly disclosed in any Cumberland SEC Document (other than any cautionary or forward-looking information contained in the &#8220;Risk Factors&#8221; or &#8220;Forward Looking Statements&#8221; of any such Cumberland SEC Documents) to the extent that such disclosure specifically references any of the Products as follows: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Organization; Good Standing</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Cumberland is a corporation duly organized, validly existing and in good standing under the laws of Tennessee. Cumberland has the requisite corporate power and authority to own, lease and operate the Acquired Assets and carry on the Business as it is currently being conducted. Cumberland is duly qualified to conduct business and is in good standing in every jurisdiction where the Business conducted by it makes such qualification necessary, except where the failure to so qualify or be in good standing would not be material to the Business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Board Approval</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Board has unanimously (i)&#160;determined that this Agreement, the sale of the Acquired Assets and the transactions contemplated hereby are fair to and in the best interest of Cumberland and its Stockholders and declared it advisable to enter into this Agreement with Apotex and Buyer Guarantor, and (ii)&#160;adopted resolutions approving this Agreement, the sale of the Acquired Assets and the consummation of the other transactions contemplated hereby and recommending to the Stockholders to vote for the adoption of a resolution approving the sale of substantially all of Cumberland&#8217;s assets pursuant to, and on the terms and conditions set forth in, this Agreement at a meeting duly called and held (such recommendation by the Board, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Board Recommendation</font><font style="letter-spacing:0.2pt;">&#8221;) pursuant to the TBCA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Authority; Execution and Delivery</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Cumberland has the requisite corporate power and authority to enter into this Agreement. Except for the affirmative vote (in person or by proxy) of the Stockholders holding a majority of all of the shares of Company Stock then outstanding (at the Stockholder Meeting) in favor of the Transactions (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Requisite Stockholder Approval</font><font style="letter-spacing:0.2pt;">&#8221;), no vote of the holders of Company Stock or the equity interest of any Affiliates of Cumberland is necessary pursuant to applicable Law, their respective organizational documents, the applicable rules of any stock exchange, or otherwise to approve this Agreement and the other Transaction Documents to which they are or will be a party and the Transactions. The execution and delivery of this Agreement, the other Transaction Documents and the consummation of the Transactions have been and, assuming the receipt of the Requisite Stockholder Approval, will be prior to the Closing duly and validly authorized and no additional corporate or shareholder authorization or consent is required in connection with the execution, delivery and performance by Cumberland and its Affiliates of this Agreement and the other Transaction Documents. This Agreement and the other Transaction Documents have been duly executed and delivered by Cumberland and, assuming the due authorization, execution and delivery of this Agreement and the transaction documents by Apotex, will constitute legal, valid and binding obligations of Cumberland, enforceable against it in accordance with their terms, subject to the Enforceability Exceptions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Violation; Consents</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.4</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules, the execution, delivery and performance of obligations under this Agreement and the consummation of the Transactions do not and will not: (i)&#160;materially violate any Law applicable to Cumberland or the Acquired Assets; (ii)&#160;conflict with, result in the breach of, constitute a default under or result in the termination, cancellation or acceleration (whether after the giving of notice of the lapse of time or both) of any right or obligation of Cumberland under any contract to which it is a party or to which its assets or liabilities are subject, or result in the creation or imposition of any encumbrance upon any Acquired Asset, or result in the cancellation, modification, revocation or suspension of any authorization from any Governmental Authority in respect of the Acquired Assets, or the creation of any Encumbrance (other than Permitted Encumbrances thereon); (iii)&#160;require any approval, authorization, consent, license, exemption, filing or registration with any Person, other than required notices to the FDA with respect to ownership of and legal responsibility for the Regulatory Registration and Regulatory Approval of each Product and for the INDs, and to ClinicalTrials.gov for transfer of any clinical trials to Apotex; or (iv)&#160;conflict with or violate in any material respect any provisions of the organizational documents of Cumberland, except with respect to the foregoing </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clauses (ii)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(iii)</font><font style="letter-spacing:0.2pt;">, for such breaches, violations, conflicts, defaults, terminations, accelerations, which would not be material to the Business or the Transactions. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS5TT">&#8203;</a><a name="sS5LT">&#8203;</a><a name="sS5RM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Title to Acquired Assets</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Each of Cumberland and its Affiliates, as applicable, owns and has the right to transfer (and upon the Closing, Apotex will exclusively own) all right, title and interest in and to all of the Acquired Assets and has good, valid, enforceable and marketable title in and to all Acquired Assets, free and clear of any Encumbrances, other than Permitted Encumbrances, and, at the Closing, shall convey to Apotex (or one of its designated Affiliates) each of the Acquired Assets free and clear of any Encumbrances, other than Permitted Encumbrances. Except as expressly identified as an Assumed Liability, Cumberland has not granted rights to any of the Acquired Assets to any Third Party. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The Acquired Assets are sufficient for the continued conduct of, and constitute all of the material assets and properties used by Cumberland and its Affiliates in the operation of, the Business as conducted by it during the twelve (12) months prior to the Closing. On the Closing Date, except (i)&#160;as set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5(b</font><font style="letter-spacing:0.2pt;">) of the Disclosure Schedules and (ii)&#160;taking into account any services to be provided by any Offer Employees or pursuant to the Transition Services Agreement, Apotex will own or have the right to use (including by means of ownership of rights pursuant to licenses or other contracts), all of the material assets, properties, and rights that are used in the Business as it is presently conducted by Cumberland. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Litigation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;There is, and during the past three (3)&#160;years there has been, no claim, action, suit, charge, complaint, audit, inquiry, proceeding, investigation, hearing, arbitration, judgment, decree, infringement action, injunction, rule or order (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Action</font><font style="letter-spacing:0.2pt;">&#8221;) pending or in progress, threatened in writing or, to Cumberland&#8217;s Knowledge, threatened orally, whether relating to the Business (including by or against any Business Employee), the Acquired Assets or the Assumed Liabilities. There are, and during the past three (3)&#160;years there have been, no material orders, unsatisfied judgments, stipulations, injunctions, decrees, or awards, whether relating to the Business (including by or against any Business Employee) Acquired Assets or the Assumed Liabilities. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.7&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Regulatory Matters; Compliance with Law</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Solely with respect to the Acquired Assets, Cumberland possesses, and at all times during the past three (3)&#160;years has possessed, all material registrations, permits, licenses, certificates, accreditations, Regulatory Approvals and Regulatory Registrations of the Products in the United States and, to the Knowledge of Cumberland, any applicable jurisdiction outside of the United States for which Cumberland owns and manages the Products as such activities were conducted by Cumberland as of immediately prior to the Closing and Cumberland has not received notice of noncompliance with respect thereto from any Governmental Authority. Cumberland has complied with and is in compliance in all material respects with all Laws applicable to the research, development, obtaining and maintaining regulatory approvals for, manufacture, sale, licensure, marketing, promotion, commercialization, distribution, exportation, importation of the Acquired Assets as such activities were conducted by Cumberland as of immediately prior to the Closing. Other than the Regulatory Registrations and Regulatory Approvals for the product Talicia (as described on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1(A)</font><font style="letter-spacing:0.2pt;">) which are legally and beneficially owned by Talicia Holdings, Cumberland is the legal and beneficial owner of the Regulatory Registrations and Regulatory Approvals in the United States for the Products, and the Regulatory Registrations and Regulatory Approvals for all of the Products in the United States and, to the Knowledge of Cumberland, any applicable jurisdiction outside of the United States for which Cumberland owns and manages the Products are in full force and effect except to the extent noted on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1(A)</font><font style="letter-spacing:0.2pt;">. Cumberland has not received any notice in writing from the applicable Governmental Authorities related to the Products, and to Cumberland&#8217;s Knowledge, there are no facts, which have, or reasonably should have, led Cumberland to believe that the Product Regulatory Registrations and Regulatory Approvals are not currently in good standing with the Governmental Authorities that issue the applicable Regulatory Registrations and Product Regulatory Approvals. Cumberland has not, nor, to Cumberland&#8217;s Knowledge, has any of Cumberland&#8217;s employees or contractors been debarred or are deemed subject to debarment pursuant to Section&#160;306 of the United States Federal Food, Drug, and Cosmetic Act or any equivalent applicable Law nor are any such Persons the subject of a conviction thereunder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Except as set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.7(b)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedule, none of Cumberland nor any of its Affiliates (i)&#160;has received, during the past three (3)&#160;years, written or, to the Knowledge of Cumberland, oral, notice of any violation of or non-compliance with, or alleged violation of or non-compliance with any Laws, in any material respect, with respect to its ownership or operation of the Acquired Assets or otherwise </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS5C">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">relating to the Business, and (ii)&#160;is or has been during the past three (3)&#160;years, in violation of or non-compliance with any Laws, in any material respect, with respect to its ownership or operation of the Acquired Assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Neither Cumberland nor any of its officers, directors or employees, nor to Cumberland&#8217;s Knowledge, any agent or other third party Representative acting on behalf of Cumberland, (i)&#160;is currently, or has been since April&#160;24, 2019: (A)&#160;a Sanctioned Person; (B)&#160;engaging in any dealings or transactions with or for the benefit of any Sanctioned Person or in any Sanctioned Country; (C)&#160;engaging in any export, reexport, transfer or provision of any goods, software, technology, data or service without, or exceeding the scope of, any required or applicable licenses or authorizations under all applicable Ex-Im Laws; or (D)&#160;otherwise in violation of Sanctions, Ex-Im Laws, or applicable anti-boycott Laws (collectively, &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Trade Controls</font><font style="letter-spacing:0.2pt;">&#8221;); or (ii)&#160;has at any time (A)&#160;made or accepted any unlawful payment or given, received, offered, promised, or authorized or agreed to give or receive, any money, advantage or thing of value, directly or indirectly, to or from any employee or official of any Governmental Authority or any other Person in violation of Anti-Corruption Laws; or (B)&#160;otherwise been in violation of any Anti-Corruption Laws. Cumberland has not received from any Governmental Authority or any Person any notice, inquiry, or internal or external allegation; made any voluntary or involuntary disclosure to a Governmental Authority; or conducted any internal investigation or audit concerning any actual or potential violation or wrongdoing in each case, related to Trade Controls or Anti-Corruption Laws. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.8&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Contracts</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.8(a)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules sets forth the following contracts to which Cumberland or any of its Affiliates is party (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Material Contracts</font><font style="letter-spacing:0.2pt;">&#8221;) as of the Effective Date: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;any joint venture, strategic alliance, partnership, material research and development, pre-clinical or clinical trial, limited liability company or other similar agreements or arrangements with respect to the Acquired Assets, Products or Business; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;any Contract that obligates Cumberland to develop any product or related technology included in the Acquired Assets, or that obligates Cumberland to develop any of the Products for new indications or other purposes; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;any Contract that involves the payment by Cumberland to any Third Party or by any Third Party to Cumberland of royalties or other amounts calculated upon the revenues, profits or income of any Product(s) or the Business or income, profits or revenues related to any Product or Intellectual Property of the Business; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iv)&nbsp;&nbsp;&nbsp;any Contract that includes a right of first refusal, right of first negotiation, option to purchase, option to license or any other similar rights with respect to the Acquired Assets; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;any Contract that limits Cumberland&#8217;s ability to use, enforce, or disclose any Business IP, or arise out of an Intellectual Property-related dispute involving the Acquired Assets; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(vi)&nbsp;&nbsp;&nbsp;any agreement or series of related agreements, including any option agreement, relating to the acquisition or disposition of any of the Acquired Assets; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">(vii)&nbsp;&nbsp;&nbsp;any Contract that (A)&#160;materially limits the freedom of Cumberland or its Affiliates to operate the Business or with any Person or in any area or any line of business or any sales channel (including customary exclusive distribution agreements for the Products), (B)&#160;contains exclusivity obligations or restrictions or &#8220;most favored nation&#8221; pricing or similar terms with respect to the Products, (C)&#160;contains minimum purchase conditions or other similar requirements with respect to the Products or (D)&#160;contains failure to supply or similar penalties related to the Products; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">(viii)&nbsp;&nbsp;&nbsp;any sales, distribution, agency or other similar agreement providing for the sale by the Business of the Products, and materials, supplies, goods, services, equipment or other assets related thereto; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ix)&nbsp;&nbsp;&nbsp;any agreement under which the Business has (A)&#160;granted an Encumbrance (other than a Permitted Encumbrance) on any Acquired Asset or (B)&#160;provided for the sale of any Acquired Asset, or granted any preferential rights to purchase any Acquired Asset, in each case with a value in excess of $250,000; </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(x)&nbsp;&nbsp;&nbsp;any agreement with any (x)&#160;Material Customer or (y)&#160;Material Supplier; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(xi)&nbsp;&nbsp;&nbsp;any material settlement, conciliation or similar agreement (including, for the avoidance of doubt, any contract that is a settlement, conciliation or similar agreement with any Governmental Authority) that is related to the Business or the Acquired Assets; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(xii)&nbsp;&nbsp;&nbsp;any indemnification agreement, indemnity or similar agreement with a surety that is related to the Business or the Acquired Assets; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(xiii)&nbsp;&nbsp;&nbsp;any Contract with any Governmental Authority that is related to the Business or the Acquired Assets; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(xiv)&nbsp;&nbsp;&nbsp;any Contract that grants any Third Party any license or other right with respect to, or permits the use of, any Intellectual Property used in the Business or related to the Products, other than non-exclusive licenses granted to Cumberland, or its employees, contractors, consultants, customers or suppliers that are entered into in the ordinary course of business; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(xv)&nbsp;&nbsp;&nbsp;any Contract that grants Cumberland or any of its Affiliates any license or other right with respect to, or permits the use of any Intellectual Property that is necessary for or useful to the operation of the Business, other than shrink-wrap, click-wrap, and off-the-shelf software licenses, and other non-exclusive licenses of unmodified, commercially available software, in each case, with annual aggregate fees of less than $100,000; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(xvi)&nbsp;&nbsp;&nbsp;any Contract that relates to the acquisition, divestiture, or development of any Intellectual Property necessary for the conduct of the Business or the development, manufacture, or commercialization of the Products (other than agreements with employees, contractors, consultants, customers or suppliers that are materially consistent with the standard form of Cumberland or its Affiliates entered in the ordinary course of business, which form has been made available to Apotex) for or on behalf of the Business; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(xvii)&nbsp;&nbsp;&nbsp;any Contract that adversely affects Cumberland&#8217;s or any of its Affiliates&#8217; ability to disclose, enforce, use or exploit any IP Rights related to the Business or Products or that arises out of any Intellectual Property-related dispute involving the Business or the Products, including settlement agreements, coexistence agreements, and covenants not to sue relating to Intellectual Property that impose ongoing material obligations on Cumberland or the Business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Cumberland has not received written notice that it is in default under, or in breach of, any Material Contract and, to Cumberland&#8217;s Knowledge, no counterparty has threatened or intends to send such notice. To Cumberland&#8217;s Knowledge, no other party to any such Material Contract is (with or without the lapse of time or the giving of notice, or both) in material breach or default in any respect thereunder. Each Material Contract is a valid and binding agreement of Cumberland and, to Cumberland&#8217;s Knowledge, each other party thereto (subject to applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and other similar laws affecting creditors&#8217; rights generally from time to time in effect and to general principles of equity), and is in full force and effect, and neither Cumberland nor any of its Affiliates or, to Cumberland&#8217;s Knowledge, any other party thereto has provided or received any notice of any intention to terminate, not renew, materially decrease any usage of services or products or challenge the validity or enforceability of any such Material Contract and, to Cumberland&#8217;s Knowledge, no event or circumstance has occurred during the past three (3)&#160;years that, with or without notice of lapse of time or both, would constitute an event of default thereunder or result in a termination thereof or would cause or permit the acceleration of or other changes of or to any right or obligation or the loss of any benefit thereunder that has not been cured or waived. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS5IP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.9&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Intellectual Property</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.9(a)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules sets forth a correct and complete list of Business IP that is owned or purported to be owned by Cumberland: (i)&#160;all live registrations and pending applications for Trademarks; (ii)&#160;active issued and pending applied for patents; (iii)&#160;registered copyrights; (iv)&#160;domain name registrations and social media accounts and handles; and (v)&#160;material unregistered Intellectual Property, in each case, included in the Acquired Assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Cumberland owns or has the right to use (and upon the Closing, Apotex will own or have the right to use) all Intellectual Property used in, relied upon, or necessary for the operation of the Business as currently conducted (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Business IP</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Except as disclosed in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.9(c)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules, none of Cumberland or any of its Affiliates (in connection with the operation of the Business), the Products, or the Business, (i)&#160;infringes, misappropriates, violates, or otherwise conflicts with, or has infringed, misappropriated, violated, or otherwise conflicted with the Intellectual Property of any Third Party; and (ii)&#160;neither Cumberland nor any of its Affiliates has received any written notice from any Third Party of a claim (and there is no claim, action, suit, proceeding, investigation, hearing, arbitration, judgment, decree, infringement action, injunction, rule or order pending asserting) (A)&#160;that Cumberland or any of its Affiliates (in connection the operation of the Business), any Product, or the Business is or has been so infringing, misappropriating, violating, or conflict with any Intellectual Property of any Third Party or would be infringed by Cumberland or any of its Affiliates (in connection the operation of the Business), any Product, or the development, manufacture, distribution, marketing, or sale of the Products or other engagement in the Business, or (B)&#160;asserting the invalidity, misuse, unregisterability or unenforceability of any Business IP (including any opposition or cancellation action or proceeding) or claims of ownership over any Business IP. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;The IP Rights constitute all of the material Intellectual Property necessary for, used in, or relied upon for the conduct of the Business as presently conducted by Cumberland and its Affiliates (including the research, development, obtaining and maintaining Regulatory Approvals and Regulatory Registrations for, manufacture, sale, licensure, marketing, promotion, commercialization, distribution, exportation, importation or offering of the Products). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Cumberland and its Affiliates take and have taken commercially reasonable steps to protect and maintain the secrecy, confidentiality and value of all material Know-How included in the Acquired Assets, and there has been no unauthorized Processing of any such Know-How that was or is material to the Business. Each Person who has participated in the authorship, conception, creation, reduction to practice, or development of any Intellectual Property material to the Business for, on behalf of, or under the direction or supervision of Cumberland or any of its Affiliates, has executed and delivered to Cumberland a valid and enforceable written contract providing for (i)&#160;the confidentiality and non-disclosure by such Person of all such Know-How and (ii)&#160;the assignment by such Person (by way of present grant of assignment) to Cumberland of all right, title and interest in and to such Intellectual Property. No such Know-How has been disclosed or authorized to be disclosed to any Person, other than in the ordinary course of business consistent with past practice and subject to a written confidentiality and non-disclosure agreement materially consistent with Cumberland&#8217;s standard form(s). To the Knowledge of Cumberland, no Person is in material breach of any Contract referenced in this section. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;During the past three (3)&#160;years, there has been no Security Incident impacting any Cumberland System used in connection with the Business. During the past three (3)&#160;years, there has been no written complaint to, or Action against, the Business or Cumberland or its Affiliates relating to the Business with respect to (i)&#160;the privacy, data protection, or security of Personal Data, (ii)&#160;the confidentiality, availability, or integrity of any Cumberland System used in the Business or Personal Data contained in the Acquired Assets, (iii)&#160;the violation of any Data Privacy Requirement, in any material respect, or (iv)&#160;any Security Incident. During the past three (3)&#160;years: (A)&#160;Cumberland or any of its Affiliates have not been required by applicable Law to provide any notice to any Person in connection with a Security Incident relating to the Business or Data Privacy Requirements; and (B)&#160;Cumberland and its Affiliates are, and have been, in compliance in all material respects with all Data Privacy Requirements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;No funding, facilities, personnel, or other resources or Intellectual Property of any educational institution or Governmental Authority were used, directly or indirectly, to author, conceive, create, reduce </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS5IA">&#8203;</a><a name="sS5OC">&#8203;</a><a name="sS5NB">&#8203;</a><a name="sS5CA">&#8203;</a><a name="sS5TW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">to practice, or develop, in whole or in part, any IP Rights or Product, and no educational institution or Governmental Authority has any rights thereto as a result of the use of such funding, facilities, personnel, or other resources. The IP Rights and any other Business IP that is material to the operation of the Business as currently conducted shall be available for use by Apotex immediately following the Closing Date on identical terms and conditions to those under which Cumberland and its Affiliates owned or used the IP Rights and, in connection with the Business, such Business IP, as applicable, immediately prior to the Closing Date without payment of any further consideration. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.10&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Inventory</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Any transferred Inventory has been manufactured in accordance with all applicable Laws and then current Good Manufacturing Practices pursuant to 21 CFR Parts 210 and 211. All Inventory has been or will be dispositioned, approved, and released by Cumberland&#8217;s quality assurance department and is usable in the ordinary course of business consistent with past practice. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.11&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Ordinary Course of Business</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Other than as set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.11</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules, Cumberland has conducted the Business in the ordinary course and in all material respects in the same manner as conducted in the twelve (12) months prior to the date hereof. There has not been any Material Adverse Effect in the past twelve (12) months. During the past twelve (12) months with respect to the Acquired Assets, the Assumed Liabilities or the Business, none of Cumberland nor any of its Affiliates have taken, or failed to take, any action (or authorized or agreed to take any material action) with respect to the Acquired Assets, the Assumed Liabilities or the Business which, if taken, or failed to be taken, after the date hereof, would require Apotex&#8217;s consent under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.5</font><font style="letter-spacing:0.2pt;"> and (b)&#160;the Business has not suffered any material damage, destruction or other casualty or condemnation loss not covered by insurance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.12&nbsp;&nbsp;&nbsp; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Brokers</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Cumberland has not entered into any agreement, arrangement or understanding with any Person which will result in the obligation of Apotex to pay any finder&#8217;s fee, brokerage commission or similar payment in connection with the transactions contemplated hereby. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.13&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Customers and Suppliers</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.13(a)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules sets forth the top ten (10) customers of the Products (based on the dollar amount of sales to such customer) for the fiscal year ended December&#160;31, 2025 (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Material Customers</font><font style="letter-spacing:0.2pt;">&#8221;). No Material Customer has provided written or, to Cumberland&#8217;s Knowledge, oral notice to Cumberland or any Affiliate of Cumberland that it intends, anticipates or otherwise expects to stop, decrease the volume of, or change, adjust or otherwise modify, any of the terms (whether related to payment, price or otherwise) with respect to purchasing Products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.13(b)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules sets forth the top ten (10) suppliers of the Products in the Territory (based on the dollar amount of purchases from such supplier) for the fiscal year ended December&#160;31, 2025 (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Material Suppliers</font><font style="letter-spacing:0.2pt;">&#8221;). No Material Supplier has provided written or, to Cumberland&#8217;s Knowledge, oral notice to Cumberland or any Affiliate of Cumberland that it intends, anticipates or otherwise expects to stop, decrease the volume of, or change, adjust, alter or otherwise modify any of the terms (whether related to payment, price or otherwise) with respect to supplying materials, products or services for the Business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.14&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Transactions with Affiliates</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.14</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules, there are no contracts or any other arrangements between or among Cumberland and any of its Affiliates involving any Acquired Asset or Assumed Liability or otherwise relating to the Business. No officer, partner, director, equityholder, employee, Subsidiary or Affiliate of Cumberland: (a)&#160;owns any property or right, whether tangible or intangible, which is developed for, used or held for use in, or necessary for, the operation or conduct of the Business; (b)&#160;owes any money to or is owed money from Cumberland or any of its Affiliates related to the operation or conduct of the Business; or (c)&#160;provides services or resources to the Business, other than pursuant to employment agreements entered into in the ordinary course of business. None of Cumberland nor any Representative or Affiliate of Cumberland has any material direct or indirect ownership or controlling interest in any customer or supplier of the Business, or any other Person with whom the Business has any material business relationship. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS5SI">&#8203;</a><a name="sS5T">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.15&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sales Information; No Undisclosed Liabilities</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The audited financial statements of Cumberland for the fiscal&#160;years ended December&#160;31, 2024 and December&#160;31, 2025, and the notes related thereto included in the Cumberland SEC Documents (collectively, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Financial Statements</font><font style="letter-spacing:0.2pt;">&#8221;), in each case, prepared based on the books and records of Cumberland and its Affiliates, have been prepared in accordance with GAAP, consistently applied and fairly present in all material respects in accordance with GAAP the financial condition and the results of operations, cash flows and equity of Cumberland and its Subsidiaries (on a consolidated basis) as of the respective dates of and for the periods referred to in the Financial Statements. There is not, and for the past three (3)&#160;years there has not been, (x)&#160;to Cumberland&#8217;s Knowledge, any significant deficiency or weakness in the system of internal accounting controls used by Cumberland or its Affiliates with respect to the Business, (y)&#160;any fraud or other wrongdoing that involves any of the management of the Business or other employees who have a role in the preparation of the Financial Statements or the internal accounting controls used by Cumberland or its Affiliates with respect to the Business or (z)&#160;any written, or to Cumberland&#8217;s Knowledge, oral claim or allegation regarding any of the foregoing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;There are no Liabilities of the Business except for (i)&#160;Liabilities disclosed on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.15(b)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules, (ii)&#160;Liabilities as disclosed, reflected or reserved against in the audited balance sheet included in the Financial Statements or the notes thereto, (iii)&#160;Liabilities incurred in the ordinary course of business since December&#160;31, 2025 (none of which is a Liability resulting from noncompliance with any applicable Law or licenses, breach of contract, breach of warranty, tort, infringement, misappropriation, dilution or claim), (iv)&#160;Excluded Liabilities, and (v)&#160;Liabilities that would not reasonably be expected to be, individually or in the aggregate, material to the Business. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.16&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Taxes</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;All Tax Returns filed or required to be filed by Cumberland with respect to the Acquired Assets and, to Cumberland&#8217;s Knowledge, all Tax Returns filed or required to be filed by Talicia Holdings and its Subsidiaries, have been timely filed (taking into account applicable extensions). All such Tax Returns of Cumberland, and to Cumberland&#8217;s Knowledge, all such Tax Returns of Talicia Holdings, are true, correct, and complete in all material respects and were prepared in substantial compliance with applicable Law, and all Taxes due and owing by Cumberland with respect to the Acquired Assets and, to Cumberland&#8217;s Knowledge, all Taxes due and owing by Talicia Holdings and its Subsidiaries have been timely paid in full (whether or not shown as due and owing on a Tax Return). Cumberland has, and to Cumberland&#8217;s Knowledge, Talicia Holdings and its Subsidiaries have, paid all material Taxes due and owing by them (whether or not shown as due and owing on a Tax Return). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Cumberland has not, with respect to the Acquired Assets, and to Cumberland&#8217;s Knowledge, Talicia Holdings and its Subsidiaries have not (x)&#160;requested, granted, or become the beneficiary of any extension or waiver of any statute of limitations period, which period (after giving effect to such extension or waiver) has not yet expired, or (y)&#160;consented to extend to a date later than the date hereof the time in which any Tax may be assessed or collected. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;There is no Tax action pending with respect to any Acquired Asset, and to Cumberland&#8217;s Knowledge, there is no Tax action pending with respect to Talicia Holdings and its Subsidiaries, in respect of any Tax or Tax Return, nor has any such Tax action been threatened in writing by any Governmental Authority. No deficiencies for any Taxes have been assessed or asserted, or to Cumberland&#8217;s Knowledge, proposed against Cumberland with respect to the Acquired Assets, Talicia Holdings or its Subsidiaries that are still pending. There are no requests for rulings or determinations in respect of any Tax pending between Cumberland, on the one hand, and any Governmental Authority, on the other hand, with respect to the Acquired Assets. To Cumberland&#8217;s Knowledge, there are no requests for rulings or determinations in respect of any Tax pending with respect to Talicia Holdings or its Subsidiaries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Cumberland is not and has not been a party, and to Cumberland&#8217;s Knowledge, Talicia Holdings and its Subsidiaries are not and have not been parties to any &#8220;reportable transaction&#8221; as defined in Section&#160;6707A(c)(1) of the Code and Treasury Regulations&#160;Section&#160;1.6011-4(b) or similar provisions of applicable state, local and non-U.S. law. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS5LA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Other than with respect to Talicia Holdings, there are no Encumbrances for Taxes on the Acquired Assets other than Encumbrances for Taxes not yet due and payable; and, to Cumberland&#8217;s Knowledge, there are no Encumbrances for Taxes on the assets of Talicia Holdings or its Subsidiaries other than Encumbrances for Taxes not yet due and payable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;Cumberland has, with respect to the Acquired Assets, and to Cumberland&#8217;s Knowledge, Talicia Holdings and its Subsidiaries have properly (i)&#160;collected and remitted sales, use, valued added and similar Taxes with respect to sales or leases made or services provided to its customers and (ii)&#160;for all sales, leases or provision of services that are exempt from sales, use, valued added and similar Taxes and that were made without charging or remitting sales, use, value added or similar Taxes, received and retained any appropriate Tax exemption certificates and other documentation qualifying such sale, lease or provision of services as exempt. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;No payment or benefit provided to any current or former employee, officer, stockholder, director or service provider of Cumberland or its Affiliates (including, for this purpose and to Cumberland&#8217;s Knowledge, Talicia Holdings and its Subsidiaries) as a result (alone or in combination with any other event) of the execution, delivery and performance of this Agreement and the consummation of the Transactions, would constitute an &#8220;excess parachute payment&#8221; for purposes of Section&#160;280G of the Code. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;To Cumberland&#8217;s Knowledge, Talicia Holdings is not and has not been at any time during the applicable period specified in Section&#160;897(c)(1)(A)(ii) of the Code, a &#8220;United States real property holding corporation&#8221; and the Transferred Equity Interests are not &#8220;United States real property interests&#8221;, in each case, as defined in Section&#160;897 of the Code. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;To Cumberland&#8217;s Knowledge, neither Talicia Holdings nor its Subsidiaries have been members of an affiliated group filing a consolidated federal income Tax Return (other than a group the common parent of which was Talicia Holdings or its Subsidiaries) or is liable for the Taxes of another Person under Treasury Regulation&#160;Section&#160;1.1502-6, as a transferee or successor, by Contract or otherwise (other than any Contract the principal purpose of which does not relate to Taxes). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(j)&nbsp;&nbsp;&nbsp;To Cumberland&#8217;s Knowledge, neither Talicia Holdings nor its Subsidiaries is a party to or bound by any Tax sharing, indemnification, allocation agreement or other similar Contract and neither Talicia Holdings nor its Subsidiaries has any contractual obligation to indemnify, gross-up, or otherwise reimburse any other Person with respect to Taxes (other than customary provisions contained in commercial agreements entered into in the ordinary course of business and which documents or agreements do not principally relate to Taxes). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(k)&nbsp;&nbsp;&nbsp;To Cumberland&#8217;s knowledge, neither Talicia Holdings nor its Subsidiaries will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any taxable period (or portion thereof) beginning after the Closing Date as a result of any: (i)&#160;change in, or use of an improper, method of accounting for a taxable period (or portion thereof) ending on or prior to the Closing Date or adjustment pursuant to Section&#160;481 of the Code (or any analogous provision of state, local or non-U.S. Law), (ii)&#160;any agreement (including a &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any corresponding or similar provision of state, local or non-U.S. Law)) with respect to Taxes executed with any Governmental Authority prior to the Closing, (iii)&#160;installment sale or open transaction disposition made prior to the Closing, (iv)&#160;any intercompany transactions entered into prior to the Closing or any excess loss account as of the Closing Date, each as described in Treasury Regulations under Section&#160;1502 of the Code (or any analogous provision of any other Law) or (v)&#160;prepaid amount received or deferred revenue accrued prior to the Closing outside the ordinary course of business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(l)&nbsp;&nbsp;&nbsp;To Cumberland&#8217;s Knowledge, neither Talicia Holdings nor its Subsidiaries have been either a &#8220;distributing corporation&#8221; or a &#8220;controlled corporation&#8221; in a distribution of stock qualifying for tax-free treatment under Section&#160;355 of the Code in the prior two (2)&#160;years. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.17&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Labor and Employment</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.17(a)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules sets forth a list of each employee and consultant of Cumberland or its Affiliates who provides services with respect to the Acquired Assets (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Business </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS5EB">&#8203;</a><a name="sS5SI1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Employees</font><font style="letter-spacing:0.2pt;">&#8221;) that includes, with respect to each Business Employee: (i)&#160;job title, (ii)&#160;base annual salary, (iii)&#160;bonus eligibility, and (iv)&#160;name. No Business Employee is paid on an hourly wage basis or has a non-exempt classification. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Neither Cumberland nor any of its Affiliates is party to or bound by any collective bargaining agreement or other contract with a union, labor organization or other employee representative covering any Business Employees (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Labor Agreement</font><font style="letter-spacing:0.2pt;">&#8221;), and no Business Employee is represented by any union, or other labor organization or employee representative body with respect to their employment with Cumberland or its Affiliates. To Cumberland&#8217;s Knowledge, in the past three&#160;years, there have been no labor organizing activities with respect to any Business Employees. In the past three&#160;years, there has been no actual or, to Cumberland&#8217;s Knowledge, threatened unfair labor practice charges, strikes, lockouts, work stoppages, slowdowns, picketing, hand billing or other material labor disputes by or with respect to the Business Employees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.17(c)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules sets forth, by termination date and work location, the title of each employee who will suffer an &#8220;employment loss&#8221; as that term is defined in the Worker Adjustment and Retraining Notification Act or any state or local law requiring advance notice of layoff at any site of employment where a Business Employee is located within the 90&#160;days up to the Closing Date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Cumberland and its Affiliates have reasonably investigated all sexual harassment, or other harassment, discrimination, retaliation or policy violation allegations against Business Employees that have been reported to Cumberland and its Affiliates or of which Cumberland or its Affiliates are otherwise aware. With respect to each such allegation (except those Cumberland or its applicable Affiliate reasonably deemed to not have merit), Cumberland or its applicable Affiliate has taken prompt corrective action reasonably calculated to prevent further improper action and does not anticipate any material liability with respect to any such allegations and is not aware of any such allegations, that, if known to the public, would bring the Acquired Assets into material disrepute. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.18&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Employee Benefit Plan.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.18(a)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules sets forth a true, complete and correct, in all material respects, list of all Benefit Plans currently covering any Business Employee(s). Each such Benefit Plan has been established, maintained, administered in all material respects and funded in compliance with, and complies with, its terms and all applicable Laws (including ERISA and the Code) in all material respects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;No such Benefit Plan is and neither Cumberland nor any ERISA Affiliate maintains, sponsors, contributes to, has any obligation to contribute to, or has any liability or potential liability under or with respect to (i)&#160;any &#8220;defined benefit plan&#8221; as defined in Section&#160;3(35) of ERISA or any other plan subject to the funding requirements of Section&#160;412 of the Code or Section&#160;302 of Title IV of ERISA, or (ii)&#160;any &#8220;multiemployer plan&#8221; as defined in Section&#160;3(37) or 4001(a)(3) of ERISA, Code). No Acquired Asset is or could reasonably be expected to be subject to any lien associated with any Benefit Plan under the Code, ERISA or other applicable Law, other than statutory liens and not yet due and payable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Each such Benefit Plan that constitutes in any part a &#8220;nonqualified deferred compensation plan&#8221; (as defined under Section&#160;409A(d)(1) of the Code) subject to Section&#160;409A of the Code has been operated and administered in all material respects in operational compliance with, and is in all respects in documentary compliance with, Section&#160;409A of the Code and all IRS guidance promulgated thereunder, and no amount under any such plan, agreement or arrangement is, has been or could reasonably be expected to be subject to any additional tax, interest or penalties under Section&#160;409A of the Code. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.19&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Solvency</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Immediately after giving effect to the consummation of the transactions contemplated by this Agreement, and assuming that the representations and warranties regarding Apotex contained in this Agreement are true and correct in all material respects (without regard to any knowledge, materiality, Material Adverse Effect or similar qualifiers) and the performance in all material respects of all covenants and agreements required by this Agreement to be performed and complied with at or prior to the Closing by Apotex, (a)&#160;the fair saleable value (determined on a going concern basis) of the assets of Cumberland will be greater than the total amount of its Liabilities (including all Liabilities, whether or not reflected in a balance sheet prepared in accordance with GAAP and whether direct or indirect, fixed or contingent, secured or unsecured, disputed or undisputed); (b)&#160;Cumberland will be able to pay its debts </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS5IC">&#8203;</a><a name="sS5NO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and obligations in the ordinary course of business as they become due; and (c)&#160;Cumberland will have adequate capital to carry on its business. Cumberland is not entering into the Transactions with the actual intent to hinder, delay, or defraud either present or future creditors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.20&nbsp;&nbsp;&nbsp; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Investigation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;CUMBERLAND ACKNOWLEDGES AND AGREES THAT IT HAS MADE ITS OWN INQUIRY AND INVESTIGATION INTO, AND, BASED THEREON, AND WITHOUT LIMITING ITS RELIANCE ON THE REPRESENTATIONS, WARRANTIES AND COVENANTS HEREIN AND IN THE OTHER TRANSACTION DOCUMENTS, HAS FORMED AN INDEPENDENT JUDGMENT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT AND THE TRANSACTION DOCUMENTS. EXCEPT FOR THE SPECIFIC REPRESENTATIONS AND WARRANTIES EXPRESSLY MADE BY APOTEX IN </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">ARTICLE VI</font><font style="letter-spacing:0.2pt;"> AND THE OTHER TRANSACTION DOCUMENTS, (a)&#160;CUMBERLAND ACKNOWLEDGES AND AGREES THAT (i)&#160;APOTEX IS NOT MAKING AND HAS NOT MADE ANY REPRESENTATION OR WARRANTY, EXPRESSED OR IMPLIED, AT LAW OR IN EQUITY, REGARDING APOTEX OR ITS AFFILIATES OR THE ACCURACY OF COMPLETENESS OF ANY CONFIDENTIAL INFORMATION MEMORANDA, MANAGEMENT PRESENTATION, DOCUMENTS, PROJECTIONS, MATERIAL OR OTHER INFORMATION (FINANCIAL OR OTHERWISE) FURNISHED TO CUMBERLAND OR ITS REPRESENTATIVES OR MADE AVAILABLE TO CUMBERLAND AND ITS REPRESENTATIVES IN ANY FORM IN EXPECTATION OF, OR IN CONNECTION WITH, THE TRANSACTIONS CONTEMPLATED HEREBY, OR IN RESPECT OF ANY OTHER MATTER WHATSOEVER AND (ii)&#160;NO OFFICER, AGENT, REPRESENTATIVE OR EMPLOYEE OF APOTEX OR ITS AFFILIATES HAS ANY AUTHORITY, EXPRESS OR IMPLIED, TO MAKE ANY REPRESENTATIONS, WARRANTIES OR AGREEMENTS NOT SPECIFICALLY SET FORTH IN THIS AGREEMENT OR THE OTHER TRANSACTION DOCUMENTS AND SUBJECT TO THE LIMITED REMEDIES HEREIN PROVIDED; (b)&#160;CUMBERLAND SPECIFICALLY DISCLAIMS THAT IT IS RELYING UPON OR HAS RELIED UPON ANY SUCH OTHER REPRESENTATIONS OR WARRANTIES THAT MAY HAVE BEEN MADE BY ANY PERSON, AND ACKNOWLEDGES AND AGREES THAT APOTEX HAS SPECIFICALLY DISCLAIMED AND DOES HEREBY SPECIFICALLY DISCLAIM ANY SUCH OTHER REPRESENTATION OR WARRANTY MADE BY ANY PERSON. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">SECTION 5.20</font><font style="letter-spacing:0.2pt;"> OR ANY OTHER TERM HEREIN OR IN ANY TRANSACTION DOCUMENT, NOTHING IN THIS </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">SECTION 5.20</font><font style="letter-spacing:0.2pt;"> OR IN ANY SUCH TERM SHALL LIMIT ANY RECOURSE CUMBERLAND OR ANY OF ITS AFFILIATES WOULD HAVE IN THE CASE OF FRAUD. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;5.21&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Other Representations</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY CONTAINED IN THIS </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">ARTICLE V</font><font style="letter-spacing:0.2pt;"> (AS MODIFIED BY THE CUMBERLAND SEC DOCUMENTS AND THE DISCLOSURE SCHEDULES, IF APPLICABLE) AND THE TRANSACTION DOCUMENTS, NEITHER CUMBERLAND NOR ANY OTHER PERSON MAKES ANY OTHER EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY WITH RESPECT TO CUMBERLAND OR ITS AFFILIATES, THE BUSINESS, THE PRODUCTS OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT AND THE TRANSACTION DOCUMENTS AND ANY RIGHTS OR OBLIGATIONS (INCLUDING THE ASSUMED LIABILITIES) TO BE TRANSFERRED HEREUNDER AND THEREUNDER OR PURSUANT HERETO OR THERETO, AND CUMBERLAND DISCLAIMS (ON BEHALF OF ITSELF AND ITS AFFILIATES) ANY OTHER REPRESENTATIONS OR WARRANTIES, WHETHER MADE BY CUMBERLAND OR ANY OF ITS AFFILIATES OR REPRESENTATIVES. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY CONTAINED IN THIS ARTICLE V (AS MODIFIED BY THE SEC DISCLOSURE DOCUMENTS AND THE DISCLOSURE SCHEDULES) AND THE OTHER TRANSACTION DOCUMENTS, CUMBERLAND HEREBY DISCLAIMS (ON BEHALF OF ITSELF AND ITS AFFILIATES) ALL LIABILITY AND RESPONSIBILITY FOR ANY REPRESENTATION, WARRANTY, PROJECTION, FORECAST, STATEMENT, OR INFORMATION MADE, COMMUNICATED, OR FURNISHED (ORALLY OR IN WRITING) TO APOTEX OR ITS AFFILIATES OR REPRESENTATIVES (INCLUDING ANY OPINION, INFORMATION, PROJECTION, OR ADVICE THAT MAY HAVE BEEN OR MAY BE PROVIDED TO APOTEX BY ANY REPRESENTATIVE OF CUMBERLAND OR ANY OF ITS AFFILIATES). WITHOUT LIMITING THE FOREGOING, EXCEPT AS EXPRESSLY SET FORTH IN </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">ARTICLE&#160;V</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sAVAW1">&#8203;</a><a name="sS6AO">&#8203;</a><a name="sS6AE">&#8203;</a><a name="sS6NV">&#8203;</a><a name="sS6LT">&#8203;</a><a name="sS6NB">&#8203;</a><a name="sS6CN">&#8203;</a><a name="sS6FC">&#8203;</a><a name="sS6SI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">OR IN THE OTHER TRANSACTION DOCUMENTS, CUMBERLAND MAKES NO REPRESENTATIONS OR WARRANTIES TO APOTEX REGARDING THE PROBABLE SUCCESS, VALUE OR PROFITABILITY OF THE PRODUCTS. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">SECTION 5.21</font><font style="letter-spacing:0.2pt;"> OR ANY OTHER TERM HEREIN OR IN ANY OTHER TRANSACTION DOCUMENT, NOTHING IN THIS </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">SECTION 5.21</font><font style="letter-spacing:0.2pt;"> OR IN ANY SUCH TERM SHALL LIMIT ANY RECOURSE APOTEX OR ANY OF ITS AFFILIATES WOULD HAVE IN THE CASE OF FRAUD. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE VI</font>
          <br >
          <font style="letter-spacing:-0.2pt;">REPRESENTATIONS AND WARRANTIES OF APOTEX</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Apotex hereby represents and warrants to Cumberland as follows: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;6.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Apotex&#8217;s Organization; Good Standing</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Apotex is a designated activity company duly organized, validly existing and in good standing under the laws of Ireland. Apotex has all company power and authority to carry on its business as it is currently being conducted. Apotex is duly qualified to conduct business and is in good standing in every jurisdiction where the nature of the business conducted by it makes such qualification necessary, except where the failure to so qualify or be in good standing would not prevent or materially delay the consummation of the Transactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;6.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Authority; Execution and Delivery</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp; Apotex has all company power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. The execution, delivery and performance of obligations under this Agreement by Apotex and the consummation of the transactions contemplated hereby have been duly authorized by all necessary company action(s). This Agreement has been duly executed and delivered by Apotex and, assuming the due authorization, execution and delivery of this Agreement by Cumberland, constitutes the legal, valid and binding obligation of Apotex, enforceable against Apotex in accordance with its terms, subject to Enforceability Exceptions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;6.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Violations; Consents</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp; The execution, delivery and performance of obligations under this Agreement do not, and the consummation of the transactions contemplated hereby and compliance with the terms hereof will not: (a)&#160;violate any applicable Law applicable to Apotex or conflict with any material contract to which Apotex is a party or by which it is otherwise bound, except for such violations or conflicts which would not materially interfere with Apotex&#8217;s performance of its obligations hereunder; or (b)&#160;except in connection with any filing with the SEC, require any approval, authorization, consent, license, exemption, filing or registration with any Person, except for such approvals, authorizations, consents, licenses, exemptions, filings or registrations which have been obtained or made prior to Closing or which, if not obtained or made, would not materially interfere with Apotex&#8217;s performance of its obligations hereunder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;6.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Litigation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;There is no suit, claim, action, investigation or proceeding in progress or, to the knowledge of Apotex, pending or threatened against Apotex, (a)&#160;relating to and adversely affecting this Agreement or the transactions contemplated hereunder or (b)&#160;that would materially delay the ability of Apotex to perform its obligations hereunder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;6.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Brokers</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Apotex has not entered into any agreement, arrangement or understanding with any Person which will result in the obligation of Cumberland to pay any finder&#8217;s fee, brokerage commission or similar payment in connection with the transactions contemplated hereby. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;6.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Consents</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;No notice to, filing with, authorization of, exemption by, or consent of, any Person, including any applicable Governmental Authority, is required by Apotex for Apotex to consummate the transactions contemplated herein. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;6.7&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Financial Capacity</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Apotex has and will have, from and after the Effective Date, sufficient funds on hand to consummate the transaction contemplated hereby at the Closing, including the payment of the Purchase Price. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;6.8&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Solvency</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Immediately after giving effect to the consummation of the transactions contemplated by this Agreement, and assuming that the representations and warranties regarding Cumberland and the Business contained in this Agreement are true and correct in all material respects </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS6IA">&#8203;</a><a name="sS6NO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(without regard to any knowledge, materiality, Material Adverse Effect or similar qualifiers) and the performance in all material respects of all covenants and agreements required by this Agreement to be performed and complied with at or prior to the Closing by Cumberland, (a)&#160;the fair saleable value (determined on a going concern basis) of the assets of Buyer Guarantor will be greater than the total amount of its Liabilities (including all Liabilities, whether or not reflected in a balance sheet prepared in accordance with International Financial Reporting Standards (IFRS), and whether direct or indirect, fixed or contingent, secured or unsecured, disputed or undisputed); (b)&#160;Buyer Guarantor will be able to pay its debts and obligations in the ordinary course of business as they become due; and (c)&#160;Buyer Guarantor will have adequate capital to carry on its business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;6.9&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Investigation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;APOTEX ACKNOWLEDGES AND AGREES THAT IT HAS MADE ITS OWN INQUIRY AND INVESTIGATION INTO, AND, BASED THEREON, AND WITHOUT LIMITING ITS RELIANCE ON THE REPRESENTATIONS, WARRANTIES AND COVENANTS HEREIN AND IN THE OTHER TRANSACTION DOCUMENTS, HAS FORMED AN INDEPENDENT JUDGMENT CONCERNING THE BUSINESS AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT AND THE TRANSACTION DOCUMENTS AND ANY OTHER ASSETS, RIGHTS OR OBLIGATIONS (INCLUDING THE ASSUMED LIABILITIES) TO BE TRANSFERRED HEREUNDER OR THEREUNDER OR PURSUANT HERETO OR THERETO. EXCEPT FOR THE SPECIFIC REPRESENTATIONS AND WARRANTIES EXPRESSLY MADE BY CUMBERLAND IN </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">ARTICLE</font><font style="letter-spacing:0.2pt;"> V AND THE OTHER TRANSACTION DOCUMENTS, (a)&#160;APOTEX ACKNOWLEDGES AND AGREES THAT (i)&#160;CUMBERLAND IS NOT MAKING AND HAS NOT MADE ANY REPRESENTATION OR WARRANTY, EXPRESSED OR IMPLIED, AT LAW OR IN EQUITY, IN RESPECT OF THE BUSINESS OR THE ACQUIRED ASSETS, OR CUMBERLAND&#8217;S OR ITS AFFILIATES&#8217; RESPECTIVE BUSINESSES, ASSETS, LIABILITIES, OPERATIONS, PROSPECTS, OR CONDITION (FINANCIAL OR OTHERWISE), INCLUDING WITH RESPECT TO MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY ACQUIRED ASSETS, THE NATURE OR EXTENT OF ANY ASSUMED LIABILITIES, THE PROSPECTS OF THE BUSINESS, THE EFFECTIVENESS OR THE SUCCESS OF ANY OPERATIONS, OR THE ACCURACY OF COMPLETENESS OF ANY CONFIDENTIAL INFORMATION MEMORANDA, MANAGEMENT PRESENTATION, DOCUMENTS, PROJECTIONS, MATERIAL OR OTHER INFORMATION (FINANCIAL OR OTHERWISE) REGARDING THE BUSINESS, THE ACQUIRED ASSETS OR ASSUMED LIABILITIES, OR CUMBERLAND OR ITS AFFILIATES FURNISHED TO APOTEX OR ITS REPRESENTATIVES OR MADE AVAILABLE TO APOTEX AND ITS REPRESENTATIVES IN THE DATA ROOM, MANAGEMENT PRESENTATIONS OR IN ANY OTHER FORM IN EXPECTATION OF, OR IN CONNECTION WITH, THE TRANSACTIONS CONTEMPLATED HEREBY, OR IN RESPECT OF ANY OTHER MATTER WHATSOEVER AND (ii)&#160;NO OFFICER, AGENT, REPRESENTATIVE OR EMPLOYEE OF THE BUSINESS HAS ANY AUTHORITY, EXPRESS OR IMPLIED, TO MAKE ANY REPRESENTATIONS, WARRANTIES OR AGREEMENTS NOT SPECIFICALLY SET FORTH IN THIS AGREEMENT OR THE OTHER TRANSACTION DOCUMENTS AND SUBJECT TO THE LIMITED REMEDIES HEREIN PROVIDED; (b)&#160;APOTEX SPECIFICALLY DISCLAIMS THAT IT IS RELYING UPON OR HAS RELIED UPON ANY SUCH OTHER REPRESENTATIONS OR WARRANTIES THAT MAY HAVE BEEN MADE BY ANY PERSON, AND ACKNOWLEDGES AND AGREES THAT CUMBERLAND HAS SPECIFICALLY DISCLAIMED AND DOES HEREBY SPECIFICALLY DISCLAIM ANY SUCH OTHER REPRESENTATION OR WARRANTY MADE BY ANY PERSON AND (c)&#160;APOTEX IS ACQUIRING THE ACQUIRED ASSETS AND THE ASSUMED LIABILITIES IN &#8220;AS IS&#8221; CONDITION AND ON A &#8220;WHERE IS&#8221; BASIS, SUBJECT ONLY TO THE SPECIFIC REPRESENTATIONS AND WARRANTIES SET FORTH IN </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">ARTICLE</font><font style="letter-spacing:0.2pt;"> V (AS MODIFIED BY THE CUMBERLAND SEC DOCUMENTS AND BY THE DISCLOSURE SCHEDULES) AND THE TRANSACTION DOCUMENTS. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">SECTION 6.9</font><font style="letter-spacing:0.2pt;"> OR ANY OTHER TERM HEREIN OR IN ANY TRANSACTION DOCUMENT, NOTHING IN THIS </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">SECTION 6.9</font><font style="letter-spacing:0.2pt;"> OR IN ANY SUCH TERM SHALL LIMIT ANY RECOURSE APOTEX OR ANY OF ITS AFFILIATES WOULD HAVE IN THE CASE OF FRAUD. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;6.10&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Other Representations</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY CONTAINED IN THIS </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">ARTICLE VI</font><font style="letter-spacing:0.2pt;"> AND THE TRANSACTION </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sAVCA">&#8203;</a><a name="sS7RC">&#8203;</a><a name="sS7IP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">DOCUMENTS, NEITHER APOTEX NOR ANY OTHER PERSON MAKES ANY OTHER EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY WITH RESPECT TO APOTEX OR ITS AFFILIATES OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS AND ANY RIGHTS OR OBLIGATIONS HEREUNDER AND THEREUNDER OR PURSUANT HERETO OR THERETO, AND APOTEX DISCLAIMS (ON BEHALF OF ITSELF AND ITS AFFILIATES) ANY OTHER REPRESENTATIONS OR WARRANTIES, WHETHER MADE BY APOTEX OR ANY OF ITS AFFILIATES OR REPRESENTATIVES. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY CONTAINED IN THIS </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">ARTICLE VI</font><font style="letter-spacing:0.2pt;"> AND THE OTHER TRANSACTION DOCUMENTS, APOTEX HEREBY DISCLAIMS (ON BEHALF OF ITSELF AND ITS AFFILIATES) ALL LIABILITY AND RESPONSIBILITY FOR ANY REPRESENTATION, WARRANTY, PROJECTION, FORECAST, STATEMENT, OR INFORMATION MADE, COMMUNICATED, OR FURNISHED (ORALLY OR IN WRITING) TO CUMBERLAND OR ITS AFFILIATES OR REPRESENTATIVES (INCLUDING ANY OPINION, INFORMATION, PROJECTION, OR ADVICE THAT MAY HAVE BEEN OR MAY BE PROVIDED TO CUMBERLAND BY ANY REPRESENTATIVE OF APOTEX OR ANY OF ITS AFFILIATES). WITHOUT LIMITING THE FOREGOING, EXCEPT AS EXPRESSLY SET FORTH IN </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">ARTICLE VI</font><font style="letter-spacing:0.2pt;"> OR IN THE OTHER TRANSACTION DOCUMENTS, APOTEX MAKES NO REPRESENTATIONS OR WARRANTIES TO CUMBERLAND. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.10</font><font style="letter-spacing:0.2pt;"> OR ANY OTHER TERM HEREIN OR IN ANY OTHER TRANSACTION DOCUMENT, NOTHING IN THIS </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.10</font><font style="letter-spacing:0.2pt;"> OR IN ANY SUCH TERM SHALL LIMIT ANY RECOURSE CUMBERLAND OR ANY OF ITS AFFILIATES WOULD HAVE IN THE CASE OF FRAUD. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE VII</font>
          <br >
          <font style="letter-spacing:-0.2pt;">CERTAIN COVENANTS AND AGREEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Regulatory Commitments</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;From and after the Closing Date, other than as assumed or obligated to be performed by Cumberland and its Affiliates pursuant to the Transition Services Agreement, Apotex shall assume control of, and responsibility for, all obligations to any Governmental Authorities in connection with the Acquired Assets and Assumed Liabilities including all pharmacovigilance, safety, and medical information services for and in respect of the Acquired Assets and Assumed Liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;From and after the Closing Date, other than as assumed or obligated to be performed by Cumberland and its Affiliates pursuant to the Transition Services Agreement or as performed by Talicia Holdings prior to Closing (and which will continue to be performed by Talicia Holdings following the Closing), Apotex shall assume responsibility for (i)&#160;all correspondence and communication with Third Parties, including all Governmental Authorities, relating to the Acquired Assets, Assumed Liabilities, Regulatory Registrations and Regulatory Approvals and all obligations related thereto and (ii)&#160;all obligations of Cumberland with respect to the Regulatory Registrations and Regulatory Approvals (including INDs, NDAs, and ANDAs), including pharmacovigilance, safety, clinical studies, quality assurance, compliance with good manufacturing practices, good distribution practices, deficiency letters, corrective action plan agreements, product recalls and product returns. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Following the Closing, Cumberland permits Apotex to sell and distribute all Product Inventory transferred using the applicable Cumberland labeler code and National Drug Codes (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">NDC</font><font style="letter-spacing:0.2pt;">&#8221;) numbers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Following the Closing Date, Apotex and Cumberland each shall, as promptly as practicable, deliver or cause to be delivered to the other Party copies of all confirmations, acknowledgements, and other correspondence to and from the appropriate Governmental Authorities, including the FDA, that the transfer of ownership of the Product Regulatory Approvals to Apotex has been completed in full. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Intellectual Property Commitments</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;From and after the Closing Date, Apotex shall assume control of, and responsibility for, all Assumed Liabilities arising from or related to the IP Rights, including the assumption of any costs and obligations arising from prosecution, maintenance, enforcement and defense of the IP Rights and any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS7BT">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">liabilities and costs arising from any Intellectual Property infringement claims, lawsuits, or other Actions brought by any Third Party after the Closing Date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;From and after the Closing Date, Apotex shall assume responsibility for all prosecution, maintenance, enforcement and defense of the IP Rights, including without limitation responsibility for all correspondence and communication with Third Parties, including all Governmental Authorities, relating to the IP Rights, if such matter has been identified as an Assumed Liability. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;From and after the Closing Date, Apotex shall have responsibility for recording the IP Assignment Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;From and after the Closing Date, Cumberland covenants and agrees that, if Apotex is prosecuting, contesting or defending any Action by a Third Party in connection with the IP Rights, Cumberland shall, and shall use commercially reasonable efforts to cause its Affiliates to, if applicable, reasonably cooperate with Apotex and their respective counsel (at the expense of Apotex) in such prosecution, contest or defense, including making available its personnel and providing such testimony and access to its books and records (including lab notebooks) related to said IP Rights as shall be reasonably necessary or useful in connection with such prosecution, contest or defense in a manner that does not materially interfere with the conduct of the business of Cumberland or its applicable Affiliates, including that Apotex shall take commercially reasonable efforts to minimize the frequency of such requirements and impact on said personnel&#8217;s time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;From and after the Closing Date, Cumberland, on behalf of itself and its Affiliates, hereby grants Apotex in connection with the Business a non-exclusive, sublicensable, non-transferable, non-assignable, worldwide royalty-free license to continue to use any Trademark owned or controlled as of the Closing by Cumberland or any of its Affiliates with regard to the Business or Products, including &#8220;Cumberland&#8221;, &#8220;Cumberland Pharmaceuticals&#8221;, and &#8220;Cumberland Assured Products&#8221; or any variations or derivatives thereof (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Retained Names</font><font style="letter-spacing:0.2pt;">&#8221;) for a period of twelve (12) months following the Closing. Subject to Cumberland&#8217;s reasonable rights to exercise quality control over any use of, or other acts to protect the validity and enforceability of any Intellectual Property rights in, the Retained Names, Apotex shall have the right to use the Retained Names at all times after the Closing (i)&#160;as required by applicable Law and as may be required to perform any contractual obligations, (ii)&#160;on internal business and legal documents and items, (iii)&#160;in a neutral, non-trademark manner to describe the history of the Business, and (iv)&#160;as otherwise as permitted by &#8220;fair use&#8221; principles or as does not constitute trademark infringement or unfair competition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;From and after the Closing Date, Cumberland hereby grants (and hereby causes its Affiliates to grant) to Apotex and its Affiliates, effective as of the Closing, a worldwide, fully paid-up, royalty-free, irrevocable, non-terminable, perpetual, sublicensable (through one or multiple tiers), transferrable, non-exclusive license under and to all Intellectual Property (other than Retained Names) that (i)&#160;are owned or controlled as of the date hereof or the Closing by Cumberland or any of its Affiliates and (ii)&#160;are related to, used or held for use in, or necessary for the conduct of the Business as of the date hereof or the Closing (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Licensed Business IP</font><font style="letter-spacing:0.2pt;">&#8221;) in connection with (A)&#160;the operation of the Business and any natural evolutions or organic growth thereof, including to make, have made, use, sell, offer to sell, import and export any Product, and to use, reproduce, make derivative works of, distribute, display and perform any such Intellectual Property, or (B)&#160;the business of Apotex or any of its Affiliates (or any product or service thereof) only as necessary for continuing to operate the Business and natural evolutions or organic growth thereof and to the extent any such Licensed Business IP is used, implemented, incorporated, or otherwise exploited in connection therewith. At the Closing and otherwise upon Apotex&#8217;s request, Cumberland shall deliver, and shall cause its Affiliates to deliver, to Apotex, copies and tangible embodiments (if applicable) of all Licensed Business IP, in whatever form or medium. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;At the Closing, Cumberland shall deliver or cause to be delivered to Apotex or its designee as set forth in writing all access and administrative credentials (e.g., passwords, account names, keys, tokens) for all of the Internet domain names and social media handles and accounts included in the Acquired Assets as set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.09(a)(iv)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Bulk Transfer Laws</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Each Party hereby acknowledges that the other Party has not taken, and does not intend to take, any action required to comply with the provisions of any so-called &#8220;bulk </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS7MO">&#8203;</a><a name="sS7CO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">sale law&#8221;, &#8220;bulk transfer law&#8221; or similar laws of any jurisdiction in connection with the sale of the Acquired Assets to Apotex. Nothing in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.3</font><font style="letter-spacing:0.2pt;"> shall affect whether or not any particular liability constitutes an Excluded Liability. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Marketing of Acquired Assets</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;From and after the Effective Date through the Closing Date, Cumberland shall maintain the Regulatory Registrations and Regulatory Approvals for the Acquired Assets, and shall maintain the INDs, in good standing and in full force and effect, including making all timely payments of fees (including any user fees required to be paid to FDA) and timely filing of all regulatory updates, reports, acknowledgments and other similar submissions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Conduct of Business Prior to the Closing</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;From the Effective Date until the earlier of the Closing or the termination of this Agreement in accordance with its terms, except as (i)&#160;required by applicable Law or a Governmental Authority, (ii)&#160;expressly and specifically required by any of the Transaction Documents, (iii)&#160;set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.5</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules or (iv)&#160;consented to in writing by Apotex in advance (which consent shall not be unreasonably withheld, conditioned or delayed), Cumberland shall, and shall cause its Affiliates to, (1)&#160;conduct the Business and the Acquired Assets in the ordinary course of business consistent with past practice and in compliance with applicable Laws and (2)&#160;use commercially reasonable efforts to preserve the business organization, rights, goodwill, relationships and ongoing operations of Cumberland with respect to the Acquired Assets and the related customers, licensors, licensees, suppliers, distributors and other material business relations of the Business. Without limiting the foregoing, from the Effective Date until the earlier of the Closing Date or the termination of this Agreement in accordance with its terms, except as otherwise expressly and specifically provided in this Agreement or consented to in writing by Apotex (which consent shall not be unreasonably withheld, conditioned or delayed), Cumberland shall not, and shall cause its Affiliates not to, with respect to Acquired Assets: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;waive or release any material right or material claim arising out of or in connection with the Business or the Acquired Assets other than in the ordinary course of business consistent with past practice; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;distribute, sell, assign, abandon, let lapse or expire, transfer, lease, convey, license (other than non-exclusive licenses granted in the ordinary course of business consistent with past practice), pledge, encumber or otherwise dispose of any of the Acquired Assets other than (i)&#160;the sale of Inventory or granting of non-exclusive licenses to Business IP to Cumberland Affiliates in the ordinary course of business consistent with past practice; (ii)&#160;as necessary to comply with any Material Contract in effect as of the date hereof to which Cumberland or an Affiliate thereof is a party and has been disclosed on the Disclosure Schedules; or (iii)&#160;the expiration of Intellectual Property in accordance with its maximum statutory term under applicable Law; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;enter into, amend, waive, modify or terminate any Material Contract constituting an Acquired Asset, or consent to the entry, amendment, waiver, modification or termination of any of Cumberland&#8217;s rights thereunder; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;initiate, settle, agree to settle, waive or compromise any material claim, action, suit, or proceeding related to the Acquired Assets or affecting the Business; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;permit the lapse, abandonment, or expiration of any of the IP Rights necessary for or useful to the conduct of the Business as currently conducted, other than (i)&#160;the expiration of IP Rights at the end of their respective maximum statutory term unless impacted by terminal disclaimers under applicable Law, or (ii)&#160;the abandonment of immaterial IP Rights in the ordinary course of business; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;fail to take any commercially reasonable action reasonably necessary to protect or maintain the IP Rights that are necessary for or useful to the continuation of the Business as presently conducted in all material respects; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;disclose any Know-How included in the Acquired Assets to any Person other than pursuant to (i)&#160;a written confidentiality and non-disclosure agreement entered into in the ordinary course of business, (ii)&#160;as required by applicable Law provided that Cumberland undertakes commercially reasonable efforts to ensure confidential protection for any disclosed Know-How in the Acquired Assets, or (iii)&#160;to professional advisors on Law and Tax who are subject to confidentiality obligations or a professional duty not to disclose such Know-How in the Acquired Assets; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS7CA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;terminate, cancel, permit to lapse, amend, waive or modify any material approval or permit with respect to the Acquired Assets; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;change inventory levels of the Business in any manner (other than in the ordinary course of business consistent with past practice); </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(j)&nbsp;&nbsp;&nbsp;load distribution channels of the Business inconsistent with past practice over the twelve (12) month period preceding the Effective Date or engage in channel stuffing with respect thereto; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(k)&nbsp;&nbsp;&nbsp;enter into any Labor Agreement, or recognize or certify any labor union, labor organization, or group of employees as the bargaining representative for any Business Employees; </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(l)&nbsp;&nbsp;&nbsp;implement or announce any reductions in force affecting Business Employees; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(m)&nbsp;&nbsp;&nbsp;(i)&#160;increase or otherwise change any compensation or benefits payable to any Business Employees or (ii)&#160;take any action to cause to accelerate the payment, funding, right to payment or vesting of any compensation or benefits payable to any Business Employees; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(n)&nbsp;&nbsp;&nbsp;hire, promote or engage, or otherwise enter into any employment, consulting or other agreement, arrangement or commitment, with any Business Employee, former employee, officer, director or other service provider (or any of their respective dependents or beneficiaries); </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(o)&nbsp;&nbsp;&nbsp;encourage any Business Employee to reject an offer of employment by Apotex or its Affiliates; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(p)&nbsp;&nbsp;&nbsp;waive or release any noncompetition, nonsolicitation, nondisclosure or other restrictive covenant obligation of any Business Employee; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(q)&nbsp;&nbsp;&nbsp;(i)&#160;make, change or revoke any income or other material Tax election, (ii)&#160;file any income or other material amended Tax Return, (iii)&#160;settle or compromise any Tax proceeding, (iv)&#160;enter into any closing (or similar) agreement with a Governmental Authority with respect to Taxes; (v)&#160;request or consent to any extension or waiver of the limitation period applicable to any income or other material Tax claim or assessment, or (vi)&#160;adopt or change any Tax accounting method, in each case, to the extent reasonably expected to adversely affect Apotex or the Acquired Assets in a taxable period beginning after the Closing Date; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(r)&nbsp;&nbsp;&nbsp;fail to maintain or interfere with the Regulatory Registrations or Regulatory Approval of each Product; </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(s)&nbsp;&nbsp;&nbsp;fail to maintain or interfere with the INDs; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(t)&nbsp;&nbsp;&nbsp;terminate, modify in any respect or fail to comply with the arrangements set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.5(t)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedule; or </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(u)&nbsp;&nbsp;&nbsp;agree or commit to do any of the foregoing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cooperation and Commercially Reasonable Efforts</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;From the Effective Date until the earlier of the Closing Date or the termination of this Agreement in accordance with its terms, subject to the terms and conditions of this Agreement, each of Cumberland and Apotex shall cooperate, and shall use commercially reasonable efforts, to (i)&#160;take, or cause to be taken, all actions and (ii)&#160;do, or cause to be done, all things necessary for it to do, under applicable Law to consummate and make effective the Transactions, including all actions and all things necessary for it to (A)&#160;comply promptly with all applicable Law that may be imposed on it with respect to this Agreement and the transactions contemplated hereby (which actions shall include furnishing all information required by applicable Law in connection with approvals, reporting to, audits, or filings with, any Governmental Authority), (B)&#160;assist with meeting its obligations with respect to filing true, accurate, and complete disclosures regarding the Transactions as required by applicable Laws and securities exchange requirements and (C)&#160;obtain any consent, authorization, order or approval of, or any exemption by any Governmental Authority or other public or private Third Party required to be obtained or made by Cumberland or Apotex in connection with the Transactions, in each case, as soon as reasonably practicable following the date hereof; provided, however, that, except as otherwise set forth in this Agreement, no Party shall have any obligation to pay money or make any concessions to obtain such consents. Subject </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS7EC">&#8203;</a><a name="sS7GP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">to appropriate confidentiality protections and applicable Law, each Party will furnish to the other Party such necessary information and reasonable assistance as such other Parties may reasonably request in connection with the foregoing. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.7&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Employee Covenants</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;From the Effective Date until thirty (30) days following the Closing, Cumberland shall make the Business Employees reasonably available to Apotex for purposes of conducting interviews and shall reasonably cooperate with Apotex in connection with scheduling and conducting such interviews. Apotex shall consult in good faith with Cumberland regarding the employment of all Business Employees for positions with Apotex that are substantially similar in duties and responsibilities to their positions with the Business, and it is the intent of the Parties that Apotex will use good faith efforts to extend offers of employment to all Business Employees (any such Business Employee who receives an offer of employment from Apotex or its Affiliates, an &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Offer Employee</font><font style="letter-spacing:0.2pt;">&#8221;). Within thirty (30) days following the Closing, Apotex or one of its Affiliates shall extend a formal job offer letter to each Business Employee set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.7(a)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules (each, a &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Designated Employee</font><font style="letter-spacing:0.2pt;">&#8221;) for a position that is substantially similar to such Designated Employee&#8217;s position with Cumberland immediately prior to the Closing, to be performed in the same geographic location in which such Designated Employee was employed by Cumberland immediately prior to the Closing, with base salary, incentive compensation, and employee benefits generally consistent with Apotex&#8217;s policies and practices. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;All Designated Employees and any other Offer Employees that accept a position with Apotex or its Affiliates shall be terminated by Cumberland or its applicable Affiliate effective no later than ten (10) Business Days following the date on which Apotex extends such offers. Promptly following the Closing, Cumberland and its Affiliates shall fully and timely pay all accrued unused vacation and other paid time off to each Designated Employee and each other Offer Employee that accepts a position with Apotex or its Affiliates, in each case to the extent required by Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Cumberland and its Affiliates agree that, notwithstanding the terms of any noncompetition, customer non-solicit, or other restrictive covenant obligation between Cumberland and its Affiliates and a Designated Employee or any other Offer Employee that accepts a position with Apotex or its Affiliates, such Designated Employee or other Offer Employee shall be permitted to provide services to Apotex and its Affiliates following the Closing, and Cumberland and its Affiliates will not seek to enforce the terms of any such restrictive covenant following the Closing with respect to such Designated Employee&#8217;s or such Offer Employee&#8217;s services to Apotex or its Affiliates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;During the period prior to the Closing Date, Cumberland and its Affiliates shall use commercially reasonable efforts to make individual natural person independent contractors related to the servicing of the Acquired Assets and engaged by Cumberland or its Affiliates available to Apotex for the purpose of allowing Apotex or its Affiliates to interview each such contractor and determine the nature and extent of each such person&#8217;s continuation with Apotex or its Affiliates, if any. Cumberland or its Affiliates shall provide to Apotex or its Affiliates contact information for third-party service providers providing contingent personnel to service the Acquired Assets and reasonably cooperate in identifying and transferring such contingent work force to the extent requested by Apotex or its Affiliates. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.8&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Government Price Reporting</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;For three (3)&#160;years following the Closing, Cumberland will deliver to Apotex the following government price reporting information for the Acquired Assets and Assumed Liabilities following the Closing: transactional detail that is necessary to perform post-Closing government price calculations such as &#8220;Average Manufacturer Price&#8221; or &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">AMP</font><font style="letter-spacing:0.2pt;">&#8221; &#8203;(as defined in 42 U.S.C. &#167;&#160;1396r-8(k)(1) and 42 C.F.R. &#167;&#160;447.500 et seq., as may be amended from time to time), Medicare Part&#160;B ASP (as defined in Section&#160;1847A of the Social Security Act and detailed in 42 CFR Part&#160;414 Subpart J), &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Best Price</font><font style="letter-spacing:0.2pt;">&#8221; &#8203;(as defined in 42 U.S.C. &#167;&#160;1396r-8(c)(1)(C) (relating to the definition of Best Price) and 42 C.F.R. &#167;&#160;447.500 et seq., as may be amended from time to time), and the &#8220;Non-Federal Average Manufacturer Price&#8221; or &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Non-FAMP</font><font style="letter-spacing:0.2pt;">&#8221; and &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Federal Ceiling Price</font><font style="letter-spacing:0.2pt;">&#8221; or &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">FCP</font><font style="letter-spacing:0.2pt;">&#8221; &#8203;(as such terms are defined in 38 U.S.C. &#167;&#160;8126(h)(5)) including: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;with respect to AMP and Best Price: (A)&#160;calendar quarter in which baseline AMP was established; (B)&#160;baseline AMP; (C)&#160;all other baseline information submitted by Cumberland to the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS7RM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Centers for Medicare &amp; Medicaid Services (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">CMS</font><font style="letter-spacing:0.2pt;">&#8221;) in connection with the Medicaid drug rebate program (including&#160;units per package size, market start date, etc.); and (D)&#160;transactional data reasonably necessary for Apotex to calculate AMP and Best Price (inclusive of all commercial rebate and fee arrangements) for the quarters and&#160;months (as applicable) beginning with the AMP and Best Price submissions due on or after the Closing Date; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;with respect to the Veterans Health Care Act of 1992: (A)&#160;the applicable FCP (as such figure is calculated pursuant to 38 U.S.C. &#167;&#160;8126(a) and the VA Master Agreement); (B)&#160;any commercial sales data reasonably necessary to perform quarterly and annual Non-FAMP calculations and (C)&#160;any price lists applicable for purposes of sales under any applicable contract with the U.S. Department of Veterans Affairs under Federal Supply Schedule&#160;65IB for Drugs, Pharmaceuticals, &amp; Hematology Related Products; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;with respect to Medicaid Drug Rebate Program, complete Medicaid Rebate Payment history including supporting payment documentation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Apotex acknowledges and agrees that it is responsible for submitting complete and accurate government price reporting calculations for applicable Products, utilizing Apotex government pricing methodology, in a timely manner. During the term of the Transition Services Agreement, Cumberland will assist Apotex so that it can be identified as a delegate in the Medicaid Drug Program System to report AMP and Best Price directly to CMS for the applicable Products and Apotex will report AMP and Best Price directly to CMS via the Medicaid Drug Program System. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Apotex shall be responsible for and shall pay to the relevant Governmental Authority any rebates owed under the Medicaid drug rebate agreement, Medicare Part&#160;D Coverage Gap Discount Agreement and any similar government agreements with respect to Products utilization after the Closing Date as set forth in the Transition Services Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;If applicable, Apotex shall be obligated to honor Cumberland calculated 340B Ceiling Price for all 340B Covered Entities as well as the Federal Ceiling Price for the &#8220;Big Four&#8221; &#8203;(Coast Guard, Department of Defense, Department of Veterans Affairs and the Public Health Service) as well as any other entities entitled to purchase of the Federal Supply Schedule at the Federal Ceiling Price or other discounted price applicable under a contract with the U.S. Department of Veterans Affairs under Federal Supply Schedule&#160;65IB for Drugs, Pharmaceuticals, &amp; Hematology Related Products after the Closing Date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;During the term of the Transition Services Agreement, Cumberland will cooperate with Apotex and assist and provide any other available information required for compliance with government reporting, which may include information needed from pre-close periods. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;Any information or data delivered by Cumberland to Apotex pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.8</font><font style="letter-spacing:0.2pt;"> shall only be disclosed or published by Apotex for the government price reporting purposes contemplated herein, and shall otherwise be treated as Confidential Information subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.3</font><font style="letter-spacing:0.2pt;"> of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.9&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Regulatory Matters</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Cumberland shall use commercially reasonable efforts to assign to Apotex as of the Closing Date Cumberland&#8217;s right, title, and interest existing in and to the approvals and permits of Governmental Authorities necessary for researching, developing, obtaining and maintaining the Regulatory Registrations and Regulatory Approvals for, manufacturing, selling, licensing, marketing, promoting, commercializing, distributing, exporting, importing or offering the Acquired Assets, that are freely transferable, and Apotex shall assume such right, title, obligations and interest under said approvals and permits. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Apotex and Cumberland shall promptly give written notice to the other upon becoming aware of any action by, or notification or other information which it receives (directly or indirectly) from, any Governmental Authority (together with copies of correspondence related thereto), which (A)&#160;raises any material concerns regarding the safety or efficacy of the Acquired Assets, (B)&#160;which indicates or suggests a reasonably likely potential material liability for either Party to third parties arising in connection with the Acquired Assets, or (C)&#160;which indicates a reasonable potential for a need to initiate a recall, market </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS7E">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">withdrawal or similar action; in each case with respect to the Acquired Assets manufactured or sold by Cumberland on or prior to the Closing Date. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.10&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exclusivity</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Solicitation or Negotiation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to the terms of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10(b)</font><font style="letter-spacing:0.2pt;">, immediately upon the execution of this Agreement and until the earlier of the Closing Date or the termination of this Agreement in accordance with its terms, Cumberland shall, and shall cause its Subsidiaries, its Affiliates and its and their respective Representatives to, cease any and all existing activities, discussions, or negotiations with any Person other than Apotex and its Affiliates and Representatives with respect to, and to deal exclusively with Apotex and its Affiliates and Representatives regarding, any and all Acquisition Proposals and shall not, and shall not permit any of its Affiliates, Subsidiaries, or Representatives to, directly or indirectly (i)&#160;solicit, initiate, encourage, entertain or respond to any inquiries or proposals, discuss or negotiate with, provide any information to, consider the merits of any inquires or proposals from, or otherwise engage in any negotiations, discussions, or other communications with, any Person (other than Apotex) relating to any transaction or series of related transactions involving the direct or indirect purchase, license or other acquisition by any Person or &#8220;group&#8221; &#8203;(as defined pursuant to Section&#160;13(d) of the Exchange Act) of Persons, in whole or in part, of the Business, the Acquired Assets or the Products or that would otherwise compromise the ability of Cumberland to consummate the Transactions (any such transaction described in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clause (i)</font><font style="letter-spacing:0.2pt;">, an &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Acquisition Transaction</font><font style="letter-spacing:0.2pt;">&#8221;), (ii)&#160;provide or furnish information or documentation to any other Person with respect to the Business or the Acquired Assets or otherwise in furtherance of any Acquisition Proposal; or (iii)&#160;enter into any letter of intent, arrangement, contract, agreement, understanding, or commitment with any other Person in respect of any Acquisition Proposal (each, other than an Acceptable Confidentiality Agreement, an &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Alternative Transaction Agreement</font><font style="letter-spacing:0.2pt;">&#8221;). Cumberland agrees that the rights and remedies for noncompliance with this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;"> shall include having such provision specifically enforced by a court having equity jurisdiction, it being acknowledged that any such breach or threatened breach would cause irreparable injury to Apotex and that money damages will not provide an adequate remedy to Apotex. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Fiduciary Exceptions</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10(a)</font><font style="letter-spacing:0.2pt;"> (but subject to the provisos in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10(b)</font><font style="letter-spacing:0.2pt;">), from the date of this Agreement until Cumberland&#8217;s receipt of the Requisite Stockholder Approval, Cumberland and the Board may, directly or indirectly through one or more of their Representatives, participate or engage in discussions or negotiations with, furnish any non-public information relating to Cumberland or its Subsidiaries to, or afford access to the business, properties, assets, books, records or other non-public information, or to any personnel, of Cumberland or its Subsidiaries, in each case pursuant to an Acceptable Confidentiality Agreement to any Person or its Representatives that has made, renewed or delivered to Cumberland, after the date of this Agreement, an unsolicited Acquisition Proposal that did not result from any breach of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10(b)</font><font style="letter-spacing:0.2pt;">; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, in each case, that the Board has determined in good faith (after consultation with its financial advisor and outside legal counsel) that such Acquisition Proposal either constitutes a Superior Proposal or is reasonably likely to lead to a Superior Proposal, and the Board has determined in good faith (after consultation with its financial advisor and outside legal counsel) that the failure to take the actions contemplated by this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10(b)</font><font style="letter-spacing:0.2pt;"> would be inconsistent with its fiduciary duties pursuant to applicable Law; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">further</font><font style="letter-spacing:0.2pt;">, that Cumberland promptly (and in any event within twenty-four (24) hours), subject to applicable Law, makes available to Apotex any non-public information concerning Cumberland or its Subsidiaries that is provided to any such Person or its Representatives that was not previously made available to Apotex. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Change in Board Recommendation or Entry into an Alternative Transaction Agreement</font><font style="letter-spacing:0.2pt;">.&#8201; &#8201;Except as provided by </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10(d)</font><font style="letter-spacing:0.2pt;">, at no time after the date hereof may the Board (or any committee thereof): (i)&#160;(A)&#160;withhold, withdraw, amend, qualify or modify, or publicly propose to withhold, withdraw, amend, qualify or modify, the Board Recommendation in a manner adverse to Apotex; (B)&#160;publicly adopt, approve, endorse, recommend or otherwise declare advisable an Acquisition Proposal; (C)&#160;fail to publicly reaffirm the Board Recommendation within ten (10) Business Days after Apotex so requests in writing (it being understood that Cumberland will have no obligation to make such reaffirmation on more than two separate occasions, plus one time more each time that an Acquisition Proposal or material modification thereto shall have become publicly known); (D)&#160;make any recommendation in support of or fail to make a recommendation against a tender or exchange offer that constitutes or would be reasonably likely to lead to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">an Acquisition Proposal, other than a recommendation against such offer or a &#8220;stop, look and listen&#8221; communication by the Board (or a committee thereof) to Cumberland&#8217;s Stockholders pursuant to Rule&#160;14d-9(f) promulgated under the Exchange Act (or any substantially similar communication); (E)&#160;fail to include the Board Recommendation in the Proxy Statement (any action described in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clauses (A)</font><font style="letter-spacing:0.2pt;"> through&#160;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(E)</font><font style="letter-spacing:0.2pt;">, a &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Board Recommendation Change</font><font style="letter-spacing:0.2pt;">&#8221;); or (ii)&#160;cause or permit Cumberland to enter into any letter of intent, arrangement, contract, agreement, understanding, or commitment with any other Person in respect of any Acquisition Proposal (other than an Acceptable Confidentiality Agreement in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10(b)</font><font style="letter-spacing:0.2pt;">). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Board Recommendation Change; Entry into Alternative Transaction Agreement</font><font style="letter-spacing:0.2pt;">.&#8201; &#8201;Notwithstanding anything to the contrary set forth in this Agreement, at any time prior to obtaining the Requisite Stockholder Approval: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;the Board (or a committee thereof) may effect a Board Recommendation Change pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clause (A)</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(C)</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(E)</font><font style="letter-spacing:0.2pt;"> of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10(c)(i)</font><font style="letter-spacing:0.2pt;"> in response to any positive material event, change, effect, condition, occurrence or development or material change in circumstances with respect to Cumberland and its Subsidiaries (taken as a whole) or the Business that was (A)&#160;not actually known to, or reasonably foreseeable to, the Board as of the date hereof (or if known to the Board as of the date hereof, the consequences of which were not known or reasonably foreseeable to the Board, as of the date hereof); and (B)&#160;does not relate to any Acquisition Proposal; provided that in no event shall the following constitute or be taken into account in determining the existence of an Intervening Event: (x)&#160;the mere fact, in and of itself, that Cumberland or the Business meets or exceeds any internal or published or third party projections, forecasts, estimates or predictions of revenue, earnings or other financial or operating metrics for any period ending on or after the date hereof; or (y)&#160;changes after the date hereof in the market price or trading volume of Company Stock or the credit rating of Cumberland (it being understood that the underlying cause of any of the foregoing in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clauses (x)</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(y)</font><font style="letter-spacing:0.2pt;"> may be considered and taken into account) (each such event, an &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Intervening Event</font><font style="letter-spacing:0.2pt;">&#8221;), if the Board determines in good faith (after consultation with its financial advisor and outside legal counsel) that the failure to do so would be inconsistent with its fiduciary duties pursuant to applicable Law and if and only if: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(A)&nbsp;&nbsp;&nbsp;Cumberland has provided prior written notice to Apotex at least five (5)&#160;Business Days in advance to the effect that the Board (or a committee thereof) has so determined and resolved to effect a Board Recommendation Change pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10(d)(i)</font><font style="letter-spacing:0.2pt;">, which notice will specify the applicable Intervening Event in reasonable detail; and </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(B)&nbsp;&nbsp;&nbsp;prior to effecting such Board Recommendation Change Cumberland and its Representatives, during such five-Business Day period, must have negotiated with Apotex and its Representatives in good faith (to the extent that Apotex requests to so negotiate) to make such adjustments to the terms and conditions of this Agreement such that the Board no longer determines that the failure to make a Board Recommendation Change in response to such Intervening Event would be inconsistent with its fiduciary duties pursuant to applicable Law; or </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;if Cumberland has received a bona fide Acquisition Proposal that the Board has determined in good faith (after consultation with its financial advisor and outside legal counsel) constitutes a Superior Proposal, then the Board may (x)&#160;effect a Board Recommendation Change with respect to such Acquisition Proposal and/or (y)&#160;authorize and cause Cumberland to terminate this Agreement and enter into an Alternative Transaction Agreement with respect to such Acquisition Proposal, in each case if and only if: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(A)&nbsp;&nbsp;&nbsp;the Board determines in good faith (after consultation with its financial advisor and outside legal counsel) that the failure to do so would be inconsistent with its fiduciary duties pursuant to applicable Law; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(B)&nbsp;&nbsp;&nbsp;Cumberland, its Subsidiaries, and its and their respective Representatives have complied in all material respects with its obligations pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;"> with respect to such Acquisition Proposal; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(C)&nbsp;&nbsp;&nbsp;(I)&#160;Cumberland has provided prior written notice to Apotex at least five Business Days in advance (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Notice Period</font><font style="letter-spacing:0.2pt;">&#8221;) to the effect that the Board (or a committee thereof) has </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(1)&#160;received a bona fide Acquisition Proposal that has not been withdrawn; (2)&#160;concluded in good faith that such Acquisition Proposal constitutes a Superior Proposal; and (3)&#160;resolved to effect a Board Recommendation Change or to terminate this Agreement pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.1(g)</font><font style="letter-spacing:0.2pt;"> absent any revision to the terms and conditions of this Agreement, which notice will specify the basis for such Board Recommendation Change or termination, including the identity of the Person or &#8220;group&#8221; of Persons making such Acquisition Proposal, the status of discussions relating to such Acquisition Proposal, the material terms and conditions thereof and unredacted copies of all relevant written agreements (including, among others, all financing commitments) relating to such Acquisition Proposal; (II)&#160;prior to effecting such Board Recommendation Change or termination, Cumberland, during the Notice Period, must have negotiated with Apotex and its Representatives in good faith (to the extent that Apotex requests to so negotiate) to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal would cease to constitute a Superior Proposal; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, however, that in the event of any material revisions, updates or supplements to such Acquisition Proposal, Cumberland will be required to deliver a new written notice to Apotex and to comply with the requirements of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10(d)(ii)(C)</font><font style="letter-spacing:0.2pt;"> with respect to such new written notice (it being understood that the &#8220;Notice Period&#8221; in respect of such new written notice will be three (3)&#160;Business Days); and (III)&#160;at the end of the applicable Notice Period, the Board determines in good faith (after taking into account any revisions to the terms and conditions of this Agreement proposed by Apotex) that such Acquisition Proposal remains a Superior Proposal; and </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(D)&nbsp;&nbsp;&nbsp;in the event of any termination of this Agreement in order to cause or permit Cumberland to enter into an Alternative Transaction Agreement with respect to such Acquisition Proposal which constitutes a Superior Proposal, Cumberland will have validly terminated this Agreement in accordance with its terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Notice</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;From the Effective Date until the earlier to occur of the termination of this Agreement pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">ARTICLE</font><font style="letter-spacing:0.2pt;"> X and the Closing, Cumberland will promptly (and, in any event, within twenty-four (24) hours from the receipt thereof) notify Apotex in writing if any inquiries, offers or proposals that constitute an Acquisition Proposal are received by Cumberland, its Subsidiaries, or its or their respective Representatives or any non-public information is requested from, or any discussions or negotiations are sought to be initiated or continued with, Cumberland, its Subsidiaries, or its or their respective Representatives with respect to an Acquisition Proposal. Any such notice shall include (i)&#160;the identity of the Person or &#8220;group&#8221; of Persons making such offers or proposals (unless, in each case, such disclosure is prohibited pursuant to the terms of any confidentiality agreement with such Person or &#8220;group&#8221; of Persons that is in effect on the date of this Agreement) and (ii)&#160;a summary of the material terms and conditions of such offers or proposals. Thereafter, Cumberland shall keep Apotex reasonably informed, on a prompt basis, of the status (and supplementally provide the terms) of any such offers or proposals (including any amendments thereto) and the status of any such discussions or negotiations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Certain Disclosures</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Nothing in this Agreement will prohibit Cumberland or the Board (or a committee thereof) from (i)&#160;taking and disclosing to the Stockholders a position contemplated by Rule&#160;14e-2(a) promulgated under the Exchange Act or complying with Rule&#160;14d-9 promulgated under the Exchange Act, including a &#8220;stop, look and listen&#8221; communication by the Board (or a committee thereof) to the Stockholders pursuant to Rule&#160;14d-9(f) promulgated under the Exchange Act (or any substantially similar communication); (ii)&#160;complying with Item&#160;1012(a) of Regulation&#160;M-A promulgated under the Exchange Act; (iii)&#160;informing any Person of the existence of the provisions contained in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;">; (iv)&#160;complying with Cumberland&#8217;s disclosure obligations under U.S. federal or state Law with regard to an Acquisition Proposal; or (v)&#160;making any disclosure to the Stockholders (including regarding the business, financial condition or results of operations of Cumberland and its Subsidiaries) unrelated to an Acquisition Proposal that the Board (or a committee thereof) has determined to make in good faith; it being understood that (A)&#160;any such statement or disclosure made by the Board (or a committee thereof) pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10(f)</font><font style="letter-spacing:0.2pt;"> must be subject to the terms and conditions of this Agreement and will not limit or otherwise affect the obligations of Cumberland or the Board (or any committee thereof) and the rights of Apotex under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;">, and (B)&#160;that nothing in the foregoing will be deemed to permit Cumberland or the Board (or a committee thereof) to effect a Board Recommendation Change other than in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10(d)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS7PS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Breach by Representatives</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Cumberland agrees that any violation of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;"> by any Representative of Cumberland or any of its Subsidiaries will be deemed to be a breach of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;"> by Cumberland. Cumberland shall not authorize, direct or knowingly permit any consultant or employee of Cumberland or its Subsidiaries or Affiliates to violate this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;">, and upon becoming aware of any violation or threatened violation of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;"> by a consultant or employee of Cumberland, shall use its commercially reasonable efforts to stop such violation or threatened violation. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.11&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Proxy Statement and Other Required SEC Filings</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Proxy Statement</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;As promptly as reasonably practicable (but in no event later than twenty-five&#160;(25) days following the Effective Date), Cumberland will prepare and file with the United States Securities and Exchange Commission (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">SEC</font><font style="letter-spacing:0.2pt;">&#8221;) a preliminary proxy statement relating to the Stockholder Meeting (as amended or supplemented, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Proxy Statement</font><font style="letter-spacing:0.2pt;">&#8221;). Subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;">, the Proxy Statement will include the Board Recommendation, and the Board consents to such inclusion. Cumberland will use its commercially reasonable efforts to have the Proxy Statement cleared by the SEC as promptly as reasonably practicable, to cause the Proxy Statement to comply as to form in all material respects with the applicable requirements of the Exchange Act and the rules of the SEC and the NASDAQ, and take other actions to enable it to duly call and give notice of a Stockholder Meeting. Cumberland may not file the Proxy Statement with the SEC without first providing Apotex and its counsel a reasonable opportunity to review and comment thereon, and Cumberland will give due consideration to all reasonable additions, deletions or changes suggested thereto by Apotex or its counsel. On the date of filing, the date of mailing to the Stockholders (if applicable) and at the time of the Stockholder Meeting, the Proxy Statement will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not false or misleading. Notwithstanding the foregoing, no covenant is made by Cumberland with respect to any information supplied by Apotex or any of its Affiliates for inclusion or incorporation by reference in the Proxy Statement. Apotex shall cause the information relating to Apotex or any of its Affiliates supplied by Apotex for inclusion in the Proxy Statement or any amendments or supplement thereto not to, at the date the Proxy Statement is filed with the SEC or mailed to the stockholders of Cumberland or at the time of the Stockholder Meeting, or at the time of any amendment or supplement thereof (except to the extent revised or superseded by amendments or supplements contemplated hereby), contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading. If there shall occur any event that should be set forth in an amendment or supplement to the Proxy Statement, including correcting any information that has become false or misleading in any material respect, Cumberland will promptly prepare and deliver to Apotex such an amendment or supplement. Cumberland will timely notify its Stockholders once it is informed by the SEC staff that it does not plan to provide comments or it has no further comments on the preliminary form of the proxy statement, and take all necessary action, including establishing a record date and completing other actions required by the Exchange Act to permit the foregoing. The proxy statement shall include the notice of the Stockholder Meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Consultation Prior to Certain Communications</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Cumberland and its Affiliates may not communicate in writing with the SEC or its staff with respect to the Proxy Statement (including in response to any notice or request contemplated by </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.11(</font><font style="letter-spacing:0.2pt;">c)), without first providing Apotex and its Affiliates a reasonable opportunity to review and comment on such written communication, and Cumberland will give due consideration to all reasonable additions, deletions or changes suggested thereto by Apotex and its Affiliates or its and their respective counsel. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Notices</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Cumberland will advise Apotex, and supply Apotex with copies, promptly after it receives notice thereof, of (i)&#160;any receipt of a request by the SEC or its staff for any amendment or revisions to the Proxy Statement; (ii)&#160;any receipt of comments from the SEC or its staff on the Proxy Statement; or (iii)&#160;any receipt of a request by the SEC or its staff for additional information in connection therewith. Without limiting the application of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.11(b</font><font style="letter-spacing:0.2pt;">), Cumberland and Apotex, as applicable, shall use their respective commercially reasonable efforts to respond to as promptly as practicable, and resolve, any comments or requests from the SEC or its staff. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Dissemination of Proxy Statement</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to applicable Law, Cumberland will use its commercially reasonable efforts to cause the Proxy Statement to be disseminated to the Stockholders as </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS7SM">&#8203;</a><a name="sS7WP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">promptly as reasonably practicable (and in any event within five (5)&#160;Business Days) following the filing thereof with the SEC and confirmation from the SEC that it will not review, or that it has completed its review of, the Proxy Statement, which confirmation will be deemed to occur if the SEC has not affirmatively notified Cumberland prior to the tenth calendar day after initially filing the Proxy Statement that the SEC will or will not be reviewing the Proxy Statement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.12&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stockholder Meeting</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Broker Search; Call of Stockholder Meeting</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to the provisions of this Agreement, Cumberland will, within five (5)&#160;Business Days after the date of this Agreement, conduct a &#8220;broker search&#8221; in accordance with the Exchange Act and will take all action necessary in accordance with the TBCA, the organizational documents of Cumberland and the rules of the NASDAQ to establish a record date for (and Cumberland will not change the record date without the prior written consent of Apotex), duly call, give notice of, convene and hold the Stockholder Meeting as promptly as reasonably practicable following the mailing of the Proxy Statement to the Stockholders for the purpose of obtaining the Requisite Stockholder Approval. Subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;">, and unless there has been a Board Recommendation Change in compliance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;">, Cumberland will use its best efforts to solicit proxies to obtain the Requisite Stockholder Approval. Unless there has been a Board Recommendation Change in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10)</font><font style="letter-spacing:0.2pt;">, obtaining the Requisite Stockholder Approval shall be the only matter (other than a customary adjournment proposal) that Cumberland shall propose to be acted on by the Stockholders at the Stockholder Meeting without the prior written consent of Apotex (such consent not to be unreasonably withheld, conditioned or delayed). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Adjournment of Stockholder Meeting</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in this Agreement, Cumberland may (and, if requested by Apotex on no more than two (2)&#160;occasions, shall for a reasonable period of time not to exceed ten (10) Business Days in the aggregate) postpone or adjourn the Stockholder Meeting if (i)&#160;there are holders of an insufficient number of shares of the Company Stock present or represented by proxy at the Stockholder Meeting to constitute a quorum at the Stockholder Meeting; (ii)&#160;to allow reasonable additional time for any supplemental or additional disclosure required to be disseminated to the Stockholders to be so disseminated and reviewed by the Stockholders; (iii)&#160;Cumberland is required to postpone or adjourn the Stockholder Meeting by applicable Law, Order or a request from the SEC or its staff; or (iv)&#160;to allow additional solicitation of votes, if proxies granted by the time of the Stockholder Meeting are insufficient to obtain the Requisite Stockholder Approval; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that in no event shall Cumberland postpone or adjourn the Stockholder Meeting more than two times pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clauses&#160;(i)</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(iv)</font><font style="letter-spacing:0.2pt;"> or for an aggregate period of time in excess of thirty (30) days from the date on which the Stockholder Meeting was originally scheduled, in each case without the prior written consent of Apotex (which consent will not be unreasonably withheld, conditioned or delayed). In the event that the date of the Stockholder Meeting as originally called is for any reason adjourned or postponed or otherwise delayed, Cumberland agrees that, without the prior written consent of Apotex (which consent will not be unreasonably withheld, conditioned or delayed), it shall use commercially reasonable efforts to implement such adjournment or postponement or other delay in such a way that Cumberland does not establish a new record date for the Stockholder Meeting, as so adjourned, postponed or delayed, except as required by applicable Law. Unless this Agreement is validly terminated in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;X</font><font style="letter-spacing:0.2pt;">, Cumberland will submit this Agreement and the transactions contemplated hereby to the Stockholders at the Stockholder Meeting even if the Board (or a committee thereof) has effected a Board Recommendation Change. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.13&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Wrong Pockets</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;For a period of up to three (3)&#160;years after the Closing Date, if either Apotex or Cumberland becomes aware that any of the Acquired Assets or any other asset primarily related to the Products or the Business has not been transferred to Apotex or that any of the Excluded Assets has been transferred to Apotex, it shall promptly notify the other and the Parties shall, as soon as reasonably practicable and, subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.3</font><font style="letter-spacing:0.2pt;">, ensure that such property is transferred, and with any necessary prior third-party consent or approval, to: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Apotex, in the case of any such assets which was not transferred to Apotex at the Closing (and until such time as such assets are transferred to Apotex, Cumberland and each of its applicable Affiliates shall hold such assets in trust on behalf of the Business, and Cumberland, on behalf of itself and its applicable Affiliates, hereby grants and hereby causes each of its Affiliates to grant, to Apotex and its Affiliates, effective as of the Closing, a worldwide, fully paid-up, royalty-free, irrevocable, non-terminable, perpetual, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS7PF">&#8203;</a><a name="sS7NO">&#8203;</a><a name="sS7TM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">transferable, exclusive license under and to such assets for any and all uses, with the right to sublicense (through one or multiple tiers)); or </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Cumberland, in the case of any Excluded Asset which was transferred to Apotex at the Closing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;The Parties acknowledge and agree there is no right of offset regarding any transfer contemplated by this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.13, each such transfer shall occur for no additional consideration and a Party may not withhold any asset to be transferred pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.13 in the event there is a dispute regarding any other issue under this Agreement or under any Transaction Document. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.14&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Payments from Third Parties</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as expressly provided in any Transaction Document, in the event that, on or after the Closing Date, either Party shall receive any payments or other funds due to the other pursuant to the terms of this Agreement or of any Transaction Document, then the Party receiving such funds shall promptly forward such funds to the proper Party. The Parties acknowledge and agree there is no right of offset regarding such payments and a party may not withhold funds received from third parties for the account of the other Party in the event there is a dispute regarding any other issue under this Agreement or of any Transaction Document. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.15&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Notice of Certain Events</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;From the Effective Date until the earlier of the Closing Date or the termination of this Agreement in accordance with its terms, Cumberland shall promptly notify Apotex of any of the following: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;any written notice from any Person alleging that the consent of such Person is or may be required in connection with the Transactions, if the failure to obtain such consent would, individually or in the aggregate, reasonably be expected to be materially adverse to consummation of the Transactions; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;any damage or destruction by fire or other casualty of any material Asset or part thereof; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that the delivery of any notice pursuant to this Section shall not limit or otherwise affect the remedies available hereunder to Apotex. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Each Party shall promptly notify the other Party of any written notice or communication received by such Party from any Governmental Authority in connection with the Transactions to the extent permitted by applicable Law. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.16&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Tax Matters</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;All Conveyance Taxes shall be borne 100% by Apotex. The Person required by applicable Law to file any Tax Returns reporting any Conveyance Taxes shall prepare and file such Tax Returns and the other Party shall reasonably cooperate therewith. Apotex and Cumberland agree to use commercially reasonable efforts, to the extent otherwise consistent with this Agreement, to reduce or eliminate any Conveyance Taxes (including by completing and executing any documents or other certificates that would reduce or eliminate any Conveyance Taxes). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Apotex and Cumberland shall use their commercially reasonable efforts to cooperate, as and to the extent reasonably requested by the other Party, in connection with the preparation and filing of Tax Returns and any action, audit, litigation, or other proceeding with respect to Taxes, in each case with respect to the Acquired Assets or Assumed Liabilities; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that in providing such information, assistance and access, each Party shall be entitled to redact information that is not related to the Acquired Assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Any Taxes attributable to a Straddle Period required to be apportioned under this Agreement shall be apportioned as follows: (a)&#160;the amount of property, ad valorem, and other periodic Taxes allocable to the Pre-Closing Tax Period shall be equal to (i)&#160;the amount of such Taxes for the entire Straddle Period multiplied by (ii)&#160;a fraction, the numerator of which is the number of calendar days during the Straddle Period that are in the Pre-Closing Tax Period and the denominator of which is the number of calendar days in the entire Straddle Period; and (b)&#160;all Taxes not allocated under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clause (a)</font><font style="letter-spacing:0.2pt;"> shall, if applicable, be allocated to the Pre-Closing Tax Period on the basis of a &#8220;closing of the books,&#8221; as if such taxable period ended as of the end of the day on the Closing Date; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that, exemptions, allowances or deductions that are calculated on an annual basis (including depreciation and amortization deductions) shall be allocated between </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS7RC1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the period ending on the Closing Date and the period beginning after the Closing Date in proportion to the number of calendar days in each period (other than for property placed in service after the Closing Date). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.17&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Restrictive Covenants</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Apotex Employee Non-Solicitation/Non-Hire</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;From and after the Closing Date, Cumberland shall not, and shall cause each of its Subsidiaries to not, for a period of eighteen (18) months after the Closing Date, directly or indirectly, (i)&#160;encourage, induce, or solicit any Transferred Business Employee to leave employment with Apotex or any of its Affiliates or (ii)&#160;hire, employ, or attempt to hire or employ any Transferred Business Employee; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that the foregoing </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clause (i)</font><font style="letter-spacing:0.2pt;"> shall not preclude Cumberland or any of its Subsidiaries from (A)&#160;posting a general solicitation through a public medium or general or mass mailing by or on behalf of Cumberland or any of its Subsidiaries, as applicable, that is not targeted at employees of Apotex or its Affiliates or any Transferred Business Employee or (B)&#160;soliciting any terminated employee of Apotex or its Affiliates so long as such former employee has been terminated from employment with Apotex or its Subsidiaries or Affiliates for more than twelve (12) months. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cumberland Employee Non-Solicitation/Non-Hire</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;From and after the Closing Date, Apotex shall not, and shall cause each of its Subsidiaries to not, for a period of eighteen (18) months after the Closing Date, directly or indirectly, (i)&#160;encourage, induce, or solicit any employee of Cumberland with whom Apotex and its Subsidiaries have had material interactions in connection with the Transactions and that is not a Transferred Business Employee to leave employment with Cumberland or any of its Affiliates or (ii)&#160;hire, employ, or attempt to hire or employ any such employee of Cumberland that is not a Transferred Business Employee; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that the foregoing </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clause (i)</font><font style="letter-spacing:0.2pt;"> shall not preclude Apotex or any of its Subsidiaries from (A)&#160;posting a general solicitation through a public medium or general or mass mailing by or on behalf of Apotex or any of its Subsidiaries, as applicable, that is not targeted at employees of Cumberland or its Affiliates or (B)&#160;soliciting any terminated employee of Cumberland or its Affiliates so long as such former employee has been terminated from employment with Cumberland or its Subsidiaries or Affiliates for more than twelve (12) months. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Business Relations Non-Interference</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;For a period of four (4)&#160;years after the Closing Date, Cumberland shall not, and it shall each cause its Subsidiaries and Affiliates to not, directly or indirectly through a third party (i)&#160;induce or attempt to induce such Person to cease doing business with Apotex or any of its Affiliates with respect to the Products, or (ii)&#160;in any way intentionally interfere with the relationship between any such customer, supplier, licensee, licensor or other business relation of Apotex or any of its Affiliates with respect to the Products in a manner harmful to Apotex or any of its Affiliates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Competing Products</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;For a period of four (4)&#160;years after the Closing Date, Cumberland shall not, and shall cause its Subsidiaries and Affiliates to not, (i)&#160;engage in any business in the Territory that manufactures, promotes, markets, distributes, commercializes, imports, exports or sells any products that compete with the Products, or (ii)&#160;grant any rights to or enter into any arrangement with a third party to launch, manufacture, promote, market, distribute, commercialize, import, export or sell a product that competes with the Products in the Territory; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that nothing herein shall prohibit Cumberland or any of its Affiliates from (A)&#160;being a passive owner of not more than 5% of the outstanding equity securities of any class of a Person so long as none of Cumberland nor any of its Affiliates has any active participation in the business of such Person or (B)&#160;performing its obligations under the Transition Services Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Non-Disparagement</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;For a period of three (3)&#160;years after the Closing Date, Cumberland shall not, and shall cause its Affiliates not to, directly or indirectly, make any disparaging statement concerning the Business, the Products or the Acquired Assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Certain Acknowledgements</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Cumberland agrees and acknowledges that Cumberland and its Affiliates are familiar with the trade secrets and other information of a confidential or proprietary nature of the Business, the Products and the other Acquired Assets, and their respective business relations. Cumberland also agrees and acknowledges that Apotex, its Affiliates, the Business, the Products and the other Acquired Assets would be irreparably damaged if Cumberland or its Affiliates were to provide products or services or to otherwise engage in any activity in violation of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.17 and that any such action would result in a significant loss of goodwill by Apotex and its Affiliates in respect of such businesses. Cumberland agrees and acknowledges that the covenants and agreements set forth in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.17 were a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS7AA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">material inducement to Apotex to enter into this Agreement and to perform its obligations hereunder, and that Apotex and its Affiliates would not obtain the benefit of the bargain set forth in this Agreement as specifically negotiated by the parties if Cumberland or its Affiliates breached any of the provisions of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.17 with respect to the Products in the Territory. Cumberland acknowledges and agrees that the promises and restrictive covenants that Cumberland and its Affiliates are providing in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.17 are reasonable with respect to period, geographical area and scope and are necessary for the protection of legitimate interests in Apotex&#8217;s investment in the Business, the Products and the other Acquired Assets (including customer relationships, trade secrets and goodwill) pursuant to this Agreement, and that such limitations would not impose any undue burden upon Cumberland or its Affiliates. In the event that any such period, geographical area or scope limitation is deemed to be invalid, prohibited or unenforceable by a court of competent jurisdiction, Apotex and Cumberland agree to the reduction of any or all of said period, geographical area or scope limitations to such a period, geographical area or scope as said court shall deem reasonable or enforceable under the circumstances. If such partial enforcement is not possible in such jurisdiction, the provision shall be deemed severed as to such jurisdiction, and the remaining provisions of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.17 shall remain in full force and effect. Cumberland acknowledges and agrees that irreparable injury will result to Apotex, the Business, the Products or the other Acquired Assets if Cumberland or its Affiliates breaches any of the terms of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.17, and that in the event of Cumberland&#8217;s or its Affiliates&#8217; actual or threatened breach of any of the provisions contained in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.17, Apotex will have no adequate remedy at law. Cumberland accordingly agrees that in the event of any actual or threatened breach by Cumberland or its Affiliates of any of the provisions contained in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.17, Apotex shall be entitled to such injunctive and other equitable relief as may be deemed necessary or appropriate by a court of competent jurisdiction without proving the inadequacy of a remedy at law or irreparable harm and without the requirement to post a bond with respect thereto. Nothing contained herein shall be construed as prohibiting Apotex from pursuing any other remedies available to it for such breach or threatened breach, including the recovery of any damages which it is able to prove. In addition, because the protection of the goodwill of the Business requires that Cumberland comply with the covenants in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.17 for the full periods of restriction discussed herein, Cumberland agrees that, if it is determined by a court of competent jurisdiction that Cumberland has breached this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.17, any such period will be extended for a period of time (if any) equal to the time period that Cumberland is determined by such court of competent jurisdiction to have breached any of the covenants in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.17, such that Cumberland is ultimately foreclosed from engaging in the restricted activities under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.17 for a time period equal to the full periods of restriction. Cumberland shall be liable for any breaches of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 7.17 by any of its Affiliates and Representatives. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.18&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Access and Reports</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;From the Effective Date until the Closing or the earlier termination of this Agreement in accordance with its terms, upon reasonable prior written notice from Apotex, subject to applicable Law, Cumberland shall afford Apotex&#8217;s officers and other authorized Representatives reasonable access, during normal business hours throughout the period prior to the Closing, to the Business&#8217; and Cumberland&#8217;s officers, employees, properties, facilities, books, records, ledgers, financial statements, tangible data, disks, tapes, other media-storing data and files or other similar information, whether in hardcopy or computer format (or any other format) and whether stored in network facilities or otherwise, and Transferred Contracts, and any other contracts, documents, information and data to the extent (and only to the extent) related to the Acquired Assets, the Assumed Liabilities or the Business; and, during such period, Cumberland shall furnish promptly to Apotex all information concerning the Business as may reasonably be requested; provided, that, the foregoing shall not require Cumberland (i)&#160;to permit any inspection, or to disclose any information, that in the reasonable judgment of Cumberland, upon the reasonable advice of its counsel, would result in the disclosure of any trade secrets or violate any of its obligations with respect to confidentiality; (ii)&#160;to permit any inspection, or to disclose any information that exclusively relates to the Excluded Assets; (iii)&#160;to provide any access or furnish any information that, upon the commercially reasonable advice of Cumberland&#8217;s counsel, would be in violation of applicable Law; or (iv)&#160;to disclose any information that, upon the reasonable advice of Cumberland&#8217;s counsel, would jeopardize any attorney-client or other legal privileges; provided, further, that Cumberland shall use commercially reasonable efforts to provide access to such information in a manner that would not result in disclosure of trade secrets, violate confidentiality obligations, violate applicable Laws or destroy attorney-client or other legal privileges. All requests for access or information made pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.18</font><font style="letter-spacing:0.2pt;"> shall be directed to an officer of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS7VA">&#8203;</a><a name="sS7DO">&#8203;</a><a name="sS7LR">&#8203;</a><a name="sAVTC">&#8203;</a><a name="sS8CT">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cumberland, or other Person designated by Cumberland. All such information shall be governed by the terms of the Confidentiality Agreement, which (subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.3(a)</font><font style="letter-spacing:0.2pt;">) shall survive the execution and delivery of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.19&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Vibativ Award Milestone</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In the event that, (a)&#160;prior to the two (2)&#160;year anniversary of the Closing, either Apotex or its Affiliates is awarded a Contract by the U.S. Department of Health and Human Services (or any division thereof) for the supply of Vibativ (as described in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1(A)</font><font style="letter-spacing:0.2pt;">) for the uses set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.19</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Vibativ Contract</font><font style="letter-spacing:0.2pt;">&#8221;) (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">First Vibativ Milestone</font><font style="letter-spacing:0.2pt;">&#8221;) and (b)&#160;prior to the ten (10) year anniversary of the Closing, Apotex and its Affiliates realize cumulative net sales in excess of $100&#160;million pursuant to the Vibativ Contract (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Second Vibativ Milestone</font><font style="letter-spacing:0.2pt;">&#8221; and, together with the First Vibativ Milestone, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Vibativ Milestones</font><font style="letter-spacing:0.2pt;">&#8221;), then no later than thirty (30) days following Apotex&#8217;s good faith determination and delivery of notice to Cumberland that the Second Vibativ Milestone has been achieved, Apotex shall pay to Cumberland an amount equal to the Vibativ Milestone Payment Amount by wire transfer of immediately available funds to the account(s) designated by Cumberland not less than two (2)&#160;Business Days prior to such date. In the event that the First Vibativ Milestone is achieved, within thirty (30) days following each one-year anniversary of the Closing subsequent to the achievement of the First Vibativ Milestone, Apotex shall provide Cumberland with a detailed report of cumulative net sales under the Vibativ Contract, until the earlier of (i)&#160;the achievement of the Second Vibativ Milestone or (ii)&#160;the ten-year anniversary of the Closing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.20&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Delivery of Certain Work Product</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Parties acknowledge and agree that the failure of Cumberland to deliver to Apotex the Cumberland Work Product at or prior to the Closing shall not, in and of itself, be deemed to be a failure of Cumberland to cause the conditions to Closing set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.1</font><font style="letter-spacing:0.2pt;"> to be satisfied; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that, in the event that Cumberland fails to deliver to Apotex all such Cumberland Work Products at the Closing, Cumberland shall promptly and, in no event later than ninety (90) days following the Closing, deliver to Apotex all such Cumberland Work Product that was not delivered to Apotex at the Closing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;7.21&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Lien Releases</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Cumberland shall, prior to Closing, (a)&#160;obtain from each holder of indebtedness of Cumberland and its Affiliates a payoff letter (or release letter or other similar agreement) which shall be in form and substance reasonably satisfactory to Apotex and which shall (i)&#160;provide that any lien on the Acquired Assets securing any borrowings, guarantees and other obligations in respect of such indebtedness shall be unconditionally released upon the occurrence of the Closing and (ii)&#160;include as attachments, where appropriate, customary releases and/or terminations of all security interests (including UCC-3 termination statements, mortgage releases and terminations and releases of USPTO and USCO security interest filings or similar releases in any relevant jurisdiction) against the Acquired Assets with respect to such indebtedness, and which authorize the filing of such terminations and releases and which when filed will release and satisfy any and all recorded Encumbrances on the Acquired Assets (collectively, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Lien Release Letters</font><font style="letter-spacing:0.2pt;">&#8221;), (b)&#160;provide Apotex with a copy of such Lien Release Letters at least five&#160;(5) Business Days prior to the Closing Date, and (c)&#160;pay any and all such amounts due and payable under such Lien Release Letters and file all such UCC-3 termination statements, mortgage releases and terminations and releases of USPTO and USCO and other security interest filings necessary to release any and all Encumbrances on the Acquired Assets effective as of or prior to the Closing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE VIII</font>
          <br >
          <font style="letter-spacing:-0.2pt;">CONDITIONS TO CLOSING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;8.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Conditions to Obligations of Apotex</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The obligations of Apotex to consummate the Closing shall be subject to the fulfillment or Apotex&#8217;s waiver, at or prior to the Closing, of each of the following conditions: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;(i)&#160;Each of the representations and warranties of Cumberland contained in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article</font><font style="letter-spacing:0.2pt;"> V (other than those representations and warranties addressed in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clauses (ii)</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(iii)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(iv)</font><font style="letter-spacing:0.2pt;"> of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.1(a)</font><font style="letter-spacing:0.2pt;">) shall be true and correct (without giving effect to any &#8220;materiality&#8221;, &#8220;material Adverse Effect&#8221; or similar qualifiers therein) as of the Effective Date and as of the Closing Date as though made on the Closing Date, except to the extent that any failure to be so true and correct would not, individually or in the aggregate, have a Material Adverse Effect (other than any such representations and warranties made as of a specific date, which such representations and warranties shall have been true and correct as of such date, except to the extent that </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS8CT1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">any failure to be so true and correct would not, individually or in the aggregate, have a Material Adverse Effect); (ii)&#160;each of the Cumberland Fundamental Representations (other than those representations and warranties addressed in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clause (iv)</font><font style="letter-spacing:0.2pt;"> of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.1(a)</font><font style="letter-spacing:0.2pt;">) shall be true and correct in all material respects (without giving effect to any &#8220;materiality&#8221;, &#8220;Material Adverse Effect&#8221; or similar qualifiers therein) as of the Effective Date and as of the Closing Date as though made on the Closing Date (other than any such representations and warranties made as of a specific date, which such representations and warranties shall have been true and correct in all material respects as of such date); (iii)&#160;the representations and warranties contained in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.9(b)</font><font style="letter-spacing:0.2pt;"> shall be true and correct in all respects as of the Effective Date and as of the Closing Date as though made on the Closing Date; and (iv)&#160;each of the Cumberland Fundamental Representations in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.1</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5(a)</font><font style="letter-spacing:0.2pt;"> shall be true and correct in all respects (without giving effect to any &#8220;materiality&#8221;, &#8220;Material Adverse Effect&#8221; or similar qualifiers therein) other than </font><font style="font-style:italic;letter-spacing:0.2pt;">de minimis</font><font style="letter-spacing:0.2pt;"> inaccuracies as of the Effective Date and as of the Closing Date as though made on the Closing Date, other than any such Cumberland Fundamental Representations made as of a specific date, which such representations and warranties shall have been true and correct in all respects other than </font><font style="font-style:italic;letter-spacing:0.2pt;">de minimis</font><font style="letter-spacing:0.2pt;"> inaccuracies as of such date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Cumberland shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by this Agreement to be performed or complied with prior to or on the Closing Date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Cumberland shall have delivered to Apotex a certificate dated as of the Closing Date and duly executed by an executive officer of Cumberland certifying that each of the conditions set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.1(a)</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.1(b)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.1(d)</font><font style="letter-spacing:0.2pt;"> has been satisfied in all respects as of the Closing. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;There shall not have occurred a Material Adverse Effect. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Receipt of any and all required approvals of Governmental Authorities as set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.2(d)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;Cumberland shall have obtained and delivered, in form and substance reasonably satisfactory to Apotex, written consent from, or evidence of notice to, as applicable, the applicable counterparty as required for the assignment and assumption by Apotex (or its designated Affiliate) of each Material Contract or other Acquired Asset set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.1(f)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;Requisite Stockholder Approval shall have been obtained. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;There shall not be any applicable Law in effect prohibiting the consummation of the Transactions or any Action pending before any Governmental Authority that, if adversely determined, would prohibit the consummation of the Transactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;8.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Conditions to Obligations of Cumberland</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The obligations of Cumberland to consummate the Closing shall be subject to the fulfillment or Cumberland&#8217;s waiver, at or prior to the Closing of each of the following conditions: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The representations and warranties of Apotex contained in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article</font><font style="letter-spacing:0.2pt;"> VI shall be true and correct (without giving effect to any &#8220;materiality,&#8221; &#8220;in all material respects,&#8221; &#8220;Material Adverse Effect&#8221; or other materiality-based qualifiers therein) in all material respects as of the Closing Date with the same effect as though made at and as of such date (except those representations and warranties that address matters only as of a specified date, which shall be true and correct in all respects as of that specified date). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Apotex shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by this Agreement be performed or complied with by it prior to or on the Closing Date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Apotex shall have delivered to Cumberland a certificate dated as of the Closing Date and duly executed by an executive officer of Apotex certifying that each of the conditions set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.2(</font><font style="letter-spacing:0.2pt;">a) and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.2(</font><font style="letter-spacing:0.2pt;">b) has been satisfied in all respects as of the Closing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Receipt of any and all required approvals of Governmental Authorities as set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.2(d)</font><font style="letter-spacing:0.2pt;"> of the Disclosure Schedules. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sARIX">&#8203;</a><a name="sS9SA">&#8203;</a><a name="sS9IB">&#8203;</a><a name="sS9IB1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Requisite Stockholder Approval shall have been obtained. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;There shall not be any applicable Law in effect prohibiting the consummation of the Transactions or any Action pending before any Governmental Authority that, if adversely determined, would prohibit the consummation of the Transactions. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE IX</font>
          <br >
          <font style="letter-spacing:-0.2pt;">INDEMNIFICATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;9.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Survival</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;(a)&#160;The representations and warranties of Cumberland set forth in this Agreement (other than the Cumberland Fundamental Representations, the Cumberland Sufficiency Representations and the representations set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.16</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Taxes</font><font style="letter-spacing:0.2pt;">)), and any corresponding indemnification obligations, shall survive until 11:59&#160;pm. (Prevailing Central Time) on the date that is twelve (12) months following the Closing Date (the date of expiration of such period, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Expiration Date</font><font style="letter-spacing:0.2pt;">&#8221;); (b)&#160;the Cumberland Fundamental Representations, the Cumberland Sufficiency Representations and the representations set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.16</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Taxes</font><font style="letter-spacing:0.2pt;">) and, in each case, any corresponding indemnification obligations, shall survive until sixty (60) days following the expiration of the applicable statute of limitations; (c)&#160;the representations and warranties of Apotex set forth in this Agreement (other than the Apotex Fundamental Representations), and any corresponding indemnification obligations, shall survive until 11:59&#160;p.m. (Prevailing Central Time) on the Expiration Date; (d)&#160;the Apotex Fundamental Representations, and any corresponding indemnification obligations, shall survive until sixty (60) days following the expiration of the applicable statute of limitations; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that all representations and warranties of Cumberland or Apotex and corresponding indemnification obligations shall survive beyond the Expiration Date or other survival periods specified above with respect to any inaccuracy therein or breach thereof if a claim is made hereunder prior to the expiration of the applicable survival period for such representation and warranty, in which case such representation and warranty and corresponding indemnification obligations shall survive as to such claim until such claim has been finally resolved. Notwithstanding the foregoing, (i)&#160;each covenant of Cumberland or Apotex contained herein which, by its terms, is required to be performed prior to the Closing shall terminate at the Closing and (ii)&#160;each covenant of Cumberland or Apotex contained herein which, by its terms, is required to be performed after the Closing shall survive the Closing and will remain in full force and effect thereafter until fully performed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;9.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Indemnification by Cumberland</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.4</font><font style="letter-spacing:0.2pt;">, Cumberland hereby agrees that, from and after the Closing Date, Cumberland shall indemnify and hold harmless Apotex and its Affiliates and their respective successors and permitted assigns and each of their respective directors, officers, agents and employees (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Apotex Indemnified Parties</font><font style="letter-spacing:0.2pt;">&#8221;) against, and hold them harmless from, and pay and reimburse such parties for, any Losses, without duplication, to the extent such Losses result or arise from or in connection with: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;the ownership and operation of the Acquired Assets by Cumberland and the research, development, obtaining and maintaining regulatory approvals for, manufacture, sale, licensure, marketing, promotion, commercialization, distribution, exportation, importation or offering of the Products and INDs by Cumberland through the Closing Date (in each instance including actions taken by licensees of Cumberland or its Affiliates); </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;any breach of any representation or warranty of Cumberland contained in this Agreement or the certificate delivered pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.1(c)</font><font style="letter-spacing:0.2pt;">; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;a breach of, default in, or failure to perform, any of the covenants given or made by Cumberland in this Agreement, the IP Assignment Agreement or the Bill of Sale and Assignment and Assumption Agreement; </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;any and all Excluded Assets and Excluded Liabilities; or </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;any business(es) of Cumberland other than the Business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;9.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Indemnification by Apotex</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.4</font><font style="letter-spacing:0.2pt;">, Apotex hereby agrees that, from and after the Closing Date, Apotex shall indemnify and hold harmless Cumberland and its Affiliates and their respective successors and permitted assigns and each of their respective directors, officers, agents and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS9L">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">employees (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cumberland Indemnified Parties</font><font style="letter-spacing:0.2pt;">&#8221;) against, and hold them harmless from, and pay and reimburse such parties for, any Losses, without duplication, to the extent such Losses result or arise from or in connection with: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;the ownership and operation of the Acquired Assets by Apotex and the research, development, obtaining and maintaining Regulatory Registrations and Regulatory Approvals for, manufacture, sale, licensure, marketing, promotion, commercialization, distribution, exportation, importation or offering of the Products and INDs by Apotex after the Closing Date; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp; any breach of any representation or warranty of Apotex contained in this Agreement or the certificate delivered pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.2(c)</font><font style="letter-spacing:0.2pt;">; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;a breach of, default in, or failure to perform, any of the covenants given or made by Apotex in this Agreement, the IP Assignment Agreement or the Bill of Sale and Assignment and Assumption Agreement; or </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;any and all Assumed Liabilities. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;9.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Limitations</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Subject to the last sentence of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.4(d)</font><font style="letter-spacing:0.2pt;">, the aggregate amount the Apotex Indemnified Parties, as a group, may recover under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.2(b)</font><font style="letter-spacing:0.2pt;"> (other than in respect of the Cumberland Fundamental Representations, the Cumberland Sufficiency Representations and the representations set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.16</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Taxes</font><font style="letter-spacing:0.2pt;">)) shall be limited to a dollar amount equal to ten&#160;percent (10%) of the Purchase Price (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">General Cap</font><font style="letter-spacing:0.2pt;">&#8221;). Notwithstanding anything to the contrary set forth herein, the foregoing provisions of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.4(a)</font><font style="letter-spacing:0.2pt;"> will not apply in respect of claims for breach of any Cumberland Fundamental Representations, the Cumberland Sufficiency Representations or the representations set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.16</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Taxes</font><font style="letter-spacing:0.2pt;">)); provided, that in no event shall the aggregate liability of Cumberland in respect of claims for indemnification pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.2(b)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.2(c)</font><font style="letter-spacing:0.2pt;"> exceed the Purchase Price, subject to the last sentence of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.4(d)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Subject to the last sentence of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.4(d)</font><font style="letter-spacing:0.2pt;">, the aggregate amount the Cumberland Indemnified Parties, as a group, may recover under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3(b)</font><font style="letter-spacing:0.2pt;"> shall be limited to a dollar amount equal to the General Cap. Notwithstanding anything to the contrary set forth herein, in no event shall the aggregate liability of Apotex in respect of claims for indemnification pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3(b)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3(c</font><font style="letter-spacing:0.2pt;">) exceed the Purchase Price, subject to the last sentence of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.4(d)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;The amount of any Losses for which either Cumberland or Apotex, as the case may be, is liable under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;IX</font><font style="letter-spacing:0.2pt;"> shall be reduced by any amounts an Indemnified Party actually received (net of any costs of recovery, taxes and increased premiums) from any Third Party (whether before or after the Indemnifying Party shall have made a payment to any Indemnified Party hereunder), and the Indemnified Party shall promptly notify the Indemnifying Party and provide such information as the Indemnifying Party may require relating to any such recovery by the Indemnified Party in connection therewith. In any case where an Indemnified Party recovers any amount contemplated by the immediately preceding sentence in respect of a matter for which such Indemnified Party was previously indemnified pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;IX</font><font style="letter-spacing:0.2pt;">, in each case to the extent not already taken into account pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.4</font><font style="letter-spacing:0.2pt;">, such Indemnified Party shall promptly (and in any event within ten (10) Business Days after receipt)) pay over to the applicable Indemnifying Party an amount equal to the amount which, had such insurance or other recovery been made by such Indemnified Party prior to being indemnified hereunder, such Indemnified Party would not have been entitled to receive from the Indemnifying Party pursuant to the terms of the immediately preceding sentence (net of any costs of recovery, taxes and increased premiums), but not in excess of the sum of any amount previously so paid to or on behalf of such Indemnified Party in respect of such matter. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Subject to the last sentence of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.4(d)</font><font style="letter-spacing:0.2pt;">, from and after the Closing, the rights of the Apotex Indemnified Parties and the Cumberland Indemnified Parties under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;IX</font><font style="letter-spacing:0.2pt;"> shall be the sole and exclusive remedy of the Apotex Indemnified Parties and the Cumberland Indemnified Parties, as the case may be, with respect to any and all matters arising out of, related to or in connection with this Agreement and the Transactions. In furtherance of the foregoing, from and after the Closing, except in the case of Fraud, each Party (on behalf of itself and its Affiliates) hereby waives, to the fullest extent permitted by </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS9P">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Law, any and all rights, claims and causes of action such Party may have against the other Parties or any of their respective Affiliates arising under or based upon this Agreement, other than pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">ARTICLE IX</font><font style="letter-spacing:0.2pt;"> or any right or permitted claim under the Transition Services Agreement. Notwithstanding anything in this Agreement to the contrary, (i)&#160;nothing in this Agreement shall limit the liability of, and this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;IX</font><font style="letter-spacing:0.2pt;"> shall not be the sole and exclusive remedy of, any Person in connection with any claim of Fraud and (ii)&#160;nothing in this Agreement shall be deemed a waiver by any Party of, or any limitation on, any right or permitted claim under the Transition Services Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp; No Indemnifying Party shall be obligated to indemnify any Indemnified Party with respect to claims under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.2(b)</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3(a)</font><font style="letter-spacing:0.2pt;"> unless and until the aggregate amount of Losses from all claims under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.2(b)</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3(a)</font><font style="letter-spacing:0.2pt;">, as applicable, exceeds $1,000,000 in the aggregate (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Deductible</font><font style="letter-spacing:0.2pt;">&#8221;), and then only to the extent such aggregate amount exceeds the Deductible. In addition, no Indemnified Party shall be entitled to recover for any Losses under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.2(b)</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3(a)</font><font style="letter-spacing:0.2pt;"> that arises from any individual item, occurrence or circumstance or related group of events thereof unless and until the amount of all Losses resulting from such individual item, occurrence or circumstance or related group of events thereof exceeds $50,000 (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">De Minimis Threshold</font><font style="letter-spacing:0.2pt;">&#8221;), but any Losses below the De Minimis Threshold shall be taken into account for purposes of determining whether the Deductible has been exceeded. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;Neither the Apotex Indemnified Parties nor the Cumberland Indemnified Parties shall be entitled to recover for the same Loss more than once under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;IX</font><font style="letter-spacing:0.2pt;"> or otherwise under this Agreement (or any other Transaction Document) even if a claim for indemnification or otherwise in respect of such Loss has been made as a result of a breach of more than one covenant, agreement or representation or warranty contained in this Agreement (or any other Transaction Document). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;For purposes of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;IX</font><font style="letter-spacing:0.2pt;"> only, when determining whether or not a breach of any representation or warranty has occurred and for the purposes of calculating the amount of any Loss arising therefrom that is subject to indemnification hereunder, the determination of such breach of a representation or warranty or such Loss shall be deemed to be made without (and regardless of whether otherwise qualified by or limited in scope as to) any materiality or Material Adverse Effect or similar qualification or limitation; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, however, that, notwithstanding the foregoing, the words materiality, Material Adverse Effect or similar qualification shall not be ignored with respect to the word &#8220;Material&#8221; in the defined term &#8220;Material Contracts.&#8221; </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;9.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Procedure</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Any Person seeking indemnification provided for under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;IX</font><font style="letter-spacing:0.2pt;"> (an &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Indemnified Party</font><font style="letter-spacing:0.2pt;">&#8221;) in respect of, arising out of or involving a claim made by any Person (other than a Party) against an Indemnified Party (a &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Third Party Claim</font><font style="letter-spacing:0.2pt;">&#8221;), shall promptly notify the Party obligated to indemnify such Indemnified Party (such notified party, an &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Indemnifying Party</font><font style="letter-spacing:0.2pt;">&#8221;) in writing of the Third Party Claim stating the amount of the Loss claimed, if known, and method of computation thereof, the facts and circumstances giving rise to such claim in reasonable detail, and containing a reference to the provisions of this Agreement in respect of which such right of indemnification is claimed to arise within fifteen (15) Business Days after receipt by such Indemnified Party of written notice of the Third Party Claim; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that failure to give such notice shall not affect the right to indemnification provided hereunder except to the extent the Indemnifying Party shall have been actually and materially prejudiced as a result of such failure and then only to the extent of such prejudice. Thereafter, the Indemnified Party shall deliver to the Indemnifying Party, as promptly as reasonably practicable following such Indemnified Party&#8217;s receipt thereof; copies of all written notices and documents (including any court papers) received by such Indemnified Party relating to the Third Party Claim. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;If a Third Party Claim is made against an Indemnified Party, the Indemnifying Party shall be entitled at its election, by written notice to the Indemnified Party within fifteen (15) Business Days following receipt of the notice of the applicable claim therefor, and its cost to assume the defense of such Third Party Claim with counsel selected by the Indemnifying Party; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that the Indemnifying Party shall not be entitled to assume the defense if such Third Party Claim (i)&#160;involves criminal liability or any admission of wrongdoing of the Indemnified Party, (ii)&#160;seeks injunctive relief or specific performance that cannot (upon advice of the Indemnified Party&#8217;s external counsel) be reasonably separated from any non-equitable remedy or (iii)&#160;involves a claim that, if successful, would reasonably be expected to require the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS9TT">&#8203;</a><a name="sS9ME">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">payment of monetary damages to the third party claimant in excess of the applicable limitations contained in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.4(a)</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.4(b)</font><font style="letter-spacing:0.2pt;">; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">further</font><font style="letter-spacing:0.2pt;">, that, if Cumberland is the Indemnifying Party, Cumberland shall not be entitled to assume the defense if the defense of such Third Party Claim by Cumberland would be reasonably be expected to adversely affect the Business&#8217; relationship with its material customers or suppliers; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">further</font><font style="letter-spacing:0.2pt;">, that, if, following any such election, the Indemnifying Party determines that it will contest its obligation to indemnify the Indemnified Party, it may do so only if the cessation of its control of the defense can be effected in a manner that does not materially prejudice the Indemnified Party&#8217;s ability to conduct a defense of such matter (the party that conducts the defense and prosecution of any such Third Party Claim, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Controlling Party</font><font style="letter-spacing:0.2pt;">&#8221;, and the other party, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Non-Controlling Party</font><font style="letter-spacing:0.2pt;">&#8221;). The Non-Controlling Party shall have the right to receive copies of all pleadings, notices and communications with respect to any Third Party Claim to the extent that receipt of such documents does not affect any privilege relating to the Controlling Party, subject to the execution of a standard non-disclosure agreement, and shall be entitled to participate in (at its expense) the defense of such Third Party Claim. If the Indemnifying Party assumes such defense, the Indemnified Party shall nonetheless have the right to employ counsel separate from the counsel employed by the Indemnifying Party. If the Indemnifying Party chooses to defend a Third Party Claim or prosecute a claim in connection therewith, each Indemnified Party shall provide all cooperation as is reasonably requested by the Indemnifying Party in such defense or prosecution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.5</font><font style="letter-spacing:0.2pt;">, the Indemnifying Party, whether or not the Controlling Party, may not settle, compromise, discharge or enter into a judgment with respect to such Third Party Claim without the prior written consent of the Indemnified Party (not to be unreasonably withheld, conditioned or delayed) unless (i)&#160;all applicable Indemnified Parties are given a full and complete release (in a form satisfactory to such Indemnified Parties) of any and all Liability by all relevant parties to such Third Party Claim, (ii)&#160;such settlement, compromise, discharge or judgment does not involve any finding or admission of any violation of Law or admission of any wrongdoing by any Indemnified Party, (iii)&#160;such action does not impose an injunction or other equitable or other non-monetary relief upon any Indemnified Party and (iv)&#160;the Indemnifying Party shall pay directly to the applicable third party on behalf of, the applicable Indemnified Parties, the amount of all Losses based upon, arising from or relating to such to Third Party Claim as set forth in and concurrently with the effectiveness of such settlement, compromise, discharge or judgment. The Indemnified Party, whether or not the Controlling Party, shall not pay or settle any third-party claim without the prior written consent of the Indemnifying Party (not to be unreasonably withheld, conditioned or delayed); it being understood that it would be unreasonable for an Indemnifying Party to withhold consent where an Indemnified Party or its insurers are expected to bear Losses, in the aggregate, that are greater than the Losses to be indemnified by such Indemnifying Party with respect to such claim; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that, notwithstanding the foregoing, the Indemnifying Party may pay or settle a Third Party Claim without the consent of the Indemnifying Party if and only if the Indemnified Party irrevocably and unconditionally waives in writing any and all rights to indemnity by the Indemnifying Party for all Losses related to such Third Party Claim (in which case the Indemnifying Party shall have no further liability or obligation in respect of or related to such Third Party Claim to the Indemnified Party). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Within five (5)&#160;Business Days after final determination that an Indemnified Party has suffered Losses and is entitled to indemnification from an Indemnifying Party pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;IX</font><font style="letter-spacing:0.2pt;">, the amount of such Losses shall be paid by the Indemnifying Party, in cash by wire transfer immediately available funds, to such Indemnified Party. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;9.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Tax Treatment of Indemnification Payments</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Cumberland and Apotex agree to treat any indemnification payment made pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;IX</font><font style="letter-spacing:0.2pt;"> as an adjustment to the Purchase Price for U.S. federal, state, local and non-U.S. income tax purposes to the extent permitted by applicable law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;9.7&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Mitigation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Each Party shall, and shall cause its applicable Affiliates and Representatives to, take commercially reasonable efforts to mitigate their respective Losses as required by applicable Law upon and after becoming aware of any fact, event, circumstance or condition that has given rise to or would reasonably be expected to give rise to, any Losses for which it would have the right to seek indemnification hereunder. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sARXT">&#8203;</a><a name="sS1TT">&#8203;</a><a name="sS1EO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE X</font>
          <br >
          <font style="letter-spacing:-0.2pt;">TERMINATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;10.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Termination</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement may be terminated at any time prior to the Closing: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;by the mutual written consent of Cumberland and Apotex; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;by Apotex or Cumberland in the event that there shall be in effect any applicable Law or final, non-appealable Order permanently enjoining or otherwise making the consummation of the Transactions illegal or prohibited; provided, that, the right to terminate this Agreement pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.1(b)</font><font style="letter-spacing:0.2pt;"> shall not be available to any Party if such Party is in breach of, or has breached, in any material respect, any of its obligations under this Agreement, which such breach has proximately caused the imposition, or failure to be lifted, of such Law or Order; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;by Cumberland or Apotex if the Closing has not occurred on or before 5:00&#160;p.m., Central Time, on the date that is 120&#160;days following the Effective Date, which date may be extended from time to time by mutual written consent of Cumberland and Apotex (such date, as so extended from time to time, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Outside Date</font><font style="letter-spacing:0.2pt;">&#8221;); </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that the right to terminate this Agreement under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.1(c)</font><font style="letter-spacing:0.2pt;"> will not be available to either Cumberland or Apotex if such party&#8217;s material breach of its obligation under this Agreement has been the proximate cause of, or has directly resulted in, the failure of the Closing to occur by the Outside Date; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;by Cumberland if (i)&#160;any of the representations and warranties of Apotex contained in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article</font><font style="letter-spacing:0.2pt;"> VI fail to be true and correct such that the condition set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.2(</font><font style="letter-spacing:0.2pt;">a) would not be satisfied on the Closing Date or (ii)&#160;Apotex shall have breached or failed to comply with any of its obligations under this Agreement such that the condition set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.2(</font><font style="letter-spacing:0.2pt;">b) would not be satisfied on the Closing Date and such failure or breach with respect to any such representation, warranty or obligation (A)&#160;cannot be cured or (B)&#160;if curable, shall continue unremedied at the Outside Date or, if earlier, by the 10</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> Business Day following written notice by Cumberland to Apotex of such breach; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;by Cumberland, upon written notice to Apotex, at any time prior to receiving the Requisite Stockholder Approval if (i)&#160;Cumberland has received a Superior Proposal; (ii)&#160;the Board (or a committee thereof) has authorized Cumberland to enter into an Alternative Transaction Agreement to consummate the Acquisition Transaction contemplated by such Superior Proposal; and (iii)&#160;Cumberland has complied with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.10</font><font style="letter-spacing:0.2pt;">; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;by Apotex if (i)&#160;any of the representations and warranties of Cumberland contained in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article</font><font style="letter-spacing:0.2pt;"> V fail to be true and correct such that the condition set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.1(a)</font><font style="letter-spacing:0.2pt;"> would not be satisfied on the Closing Date or (ii)&#160;Cumberland shall have breached or failed to comply with any of its obligations under this Agreement such that the condition set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.1(b)</font><font style="letter-spacing:0.2pt;"> would not be satisfied on the Closing Date and such failure or breach with respect to any such representation, warranty or obligation (A)&#160;cannot be cured or (B)&#160;if curable, shall continue unremedied at the Outside Date or, if earlier, by the 10</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> Business Day following written notice by Apotex to Cumberland of such breach; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp; by Cumberland or Apotex, upon written notice to the other, if Cumberland fails to obtain the Requisite Stockholder Approval at the Stockholder Meeting (or any adjournment or postponement thereof) at which a vote is taken on the approval of the Transaction, except that the right to terminate this Agreement pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.1(</font><font style="letter-spacing:0.2pt;">g) will not be available to any Party whose action or failure to act (which action or failure to act constitutes a breach by such Party of this Agreement) has been the primary cause of, or primarily resulted in, the failure to obtain the Requisite Stockholder Approval at the Stockholder Meeting (or any adjournment or postponement thereof); or </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;by Apotex, upon written notice to Cumberland, if at any time prior to the receipt of the Requisite Stockholder Approval, the Board (or a committee thereof) has effected a Board Recommendation Change. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;10.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Effect of Termination</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in this Agreement, in the event of the valid termination of this Agreement pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 10.1, this Agreement shall forthwith become void and of no effect and there shall be no liability or obligation on the part of any Party, except as provided in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 10.2 </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(</font><font style="font-style:italic;letter-spacing:0.2pt;">Effect of Termination</font><font style="letter-spacing:0.2pt;">) and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;XI</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">Miscellaneous</font><font style="letter-spacing:0.2pt;">) and with respect to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 11.3 (</font><font style="font-style:italic;letter-spacing:0.2pt;">Confidential Information</font><font style="letter-spacing:0.2pt;">) (solely with respect to Confidential Information disclosed prior to termination of this Agreement and the Confidentiality Agreement (including any related defined terms)), each of which shall survive in accordance with its terms; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that no such termination shall relieve any Party of any liability resulting from such Party&#8217;s fraud occurring prior to the termination of this Agreement or Willful Breach. For the purpose of this Agreement, &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Willful Breach</font><font style="letter-spacing:0.2pt;">&#8221; means a material breach of any representation or warranty set forth herein or any material breach or material failure to perform any of the covenants or other agreements contained in this Agreement, in each case, that is a consequence of a voluntary and intentional act (or failure to act) by the breaching or non-performing Party with actual knowledge that such Party&#8217;s act (or failure to act) would constitute a breach of, or failure of, performance under this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The Parties agree that (i)&#160;in the event this Agreement is validly terminated pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.1(c)</font><font style="letter-spacing:0.2pt;"> (an &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Applicable Termination</font><font style="letter-spacing:0.2pt;">&#8221;); (ii)&#160;following the execution and delivery of this Agreement and prior to an Applicable Termination, Cumberland has received an Acquisition Proposal (and such Acquisition Proposal has not subsequently been irrevocably withdrawn prior to the Applicable Termination) or an Acquisition Proposal has been publicly made or disclosed (and not publicly withdrawn or otherwise publicly abandoned at least four (4)&#160;Business Days prior to the Stockholder Meeting (or an adjournment or postponement thereof) at which a vote is taken on the Transactions); and (iii)&#160;within twelve (12) months following such Applicable Termination, an Acquisition Transaction is consummated or Cumberland enters into a definitive agreement with respect to an Acquisition Transaction (which Acquisition Transaction is subsequently consummated), then Cumberland will, concurrently with the consummation of such Acquisition Transaction, pay to Apotex an amount equal to $4,000,000 (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cumberland Termination Fee</font><font style="letter-spacing:0.2pt;">&#8221;). If this Agreement is validly terminated pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.1(f)</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.1(g)</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.1(h)</font><font style="letter-spacing:0.2pt;">, Cumberland shall promptly, but in no event later than ten (10) Business Days after the date of such termination, pay to Apotex the Cumberland Termination Fee. If this Agreement is validly terminated pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.1(e)</font><font style="letter-spacing:0.2pt;">, then Cumberland shall prior to or concurrently with such termination pay to Apotex the Cumberland Termination Fee. Any payments made pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.2(b)</font><font style="letter-spacing:0.2pt;"> shall be made to Apotex by wire transfer of immediately available cash funds, in accordance with the payment instructions provided to Cumberland by Apotex not less than two (2)&#160;Business Days prior to such date, or as further updated by written notice by Apotex from time to time. In no event shall Cumberland be required to pay the Cumberland Termination Fee on more than one occasion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;The Parties agree that (i)&#160;in the event this Agreement is validly terminated by either Cumberland or Apotex pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.1(c),</font><font style="letter-spacing:0.2pt;"> and (A)&#160;all the conditions set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;VIII</font><font style="letter-spacing:0.2pt;"> have been satisfied or are capable of being satisfied prior to the Closing (other than conditions that by their nature can only be satisfied on the Closing Date), or waived by the applicable Party as of the date of such termination, (B)&#160;Cumberland has irrevocably confirmed in writing to Apotex that Cumberland stands ready, willing and able to consummate the Closing, (C)&#160;Apotex failed to consummate the Closing within three (3)&#160;Business Days after the later of (x)&#160;Cumberland&#8217;s delivery of such notice and (y)&#160;the date when it is required to consummate the Closing as provided in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.1</font><font style="letter-spacing:0.2pt;"> and (ii)&#160;at all times during the periods contemplated by the foregoing clause (i), Cumberland stood ready, willing and able to consummate the Closing, then Apotex shall promptly, but in no event later than five (5)&#160;Business Days after the date of such termination, pay or cause to be paid to Cumberland (or its designee(s)) by wire transfer of same day funds an amount equal to $4,000,000 (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Purchaser Termination Fee</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;The Parties acknowledge that the agreements contained in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.2</font><font style="letter-spacing:0.2pt;"> are an integral part of the transactions contemplated by this Agreement, and that, without these agreements, such Parties would not enter into this Agreement, and that the Cumberland Termination Fee and the Purchaser Termination Fee are not penalties and instead constitute liquidated damages. Accordingly, if Cumberland or Apotex, as applicable, fails to promptly pay the amount due pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.2(b)</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.2(c)</font><font style="letter-spacing:0.2pt;"> and, to obtain such payment, the other Party commences a suit or other enforcement action that results in a judgment against Cumberland or Apotex for the Cumberland Termination Fee or the Purchaser Termination Fee, as applicable, or any portion thereof, Cumberland or Apotex, as applicable, shall pay to the other Party its costs and expenses (including attorneys&#8217; fees) in connection with such suit or enforcement action, plus interest on the amount of the Cumberland Termination Fee or Purchaser Termination Fee, as applicable, or portion thereof from the date any such payment should have otherwise been made pursuant to this Agreement at a rate of five (5)&#160;percentage points above the 1 Month Secured Overnight Financing Rate (SOFR), as published </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS1EO1">&#8203;</a><a name="sAXP">&#8203;</a><a name="sS1NP">&#8203;</a><a name="sS1EE">&#8203;</a><a name="sS1CI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">by </font><font style="font-style:italic;letter-spacing:0.2pt;">The Wall Street Journal</font><font style="letter-spacing:0.2pt;"> (U.S. Internet edition), at 12:01&#160;a.m. on the first day in which such payments should have otherwise been made through the date of the payment (collectively, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Recovery Costs</font><font style="letter-spacing:0.2pt;">&#8221;). The Parties acknowledge and agree that, from and after a valid termination of this Agreement pursuant to an applicable termination event under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">ARTICLE X</font><font style="letter-spacing:0.2pt;">, the right of any Party to receive the Purchaser Termination Fee or the Cumberland Termination Fee, as applicable, and the Recovery Costs shall be the sole and exclusive remedy of Cumberland and its Affiliates or Apotex and its Affiliates, as applicable, for any and all Losses suffered or incurred by Cumberland, Apotex or any of their respective Affiliates in connection with this Agreement, the other Transaction Documents, and the Transactions (and the abandonment or termination thereof) or any matter forming the basis for such termination. In such circumstances, neither Cumberland, Apotex, nor any other Person shall be entitled to bring or maintain any Action against the other Parties or any of their respective Affiliates or Representatives arising out of or in connection with this Agreement, the other Transaction Documents, or the Transactions (or the abandonment or termination thereof) or any matter forming the basis for such termination other than the payment of the Purchaser Termination Fee or the Cumberland Termination Fee, as applicable and the Recovery Costs associated therewith. For the avoidance of doubt, either Party may simultaneously pursue (i)&#160;a grant of specific performance pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.14</font><font style="letter-spacing:0.2pt;"> and (ii)&#160;payment of the Cumberland Termination Fee or the Purchaser Termination Fee pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;X</font><font style="letter-spacing:0.2pt;">; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that in no event shall Cumberland, Apotex or their respective Affiliates be entitled to receive both a grant of specific performance and payment of all or any portion of the Cumberland Termination Fee or the Purchaser Termination Fee. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;10.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Event of Termination</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;If the transactions contemplated by this Agreement are terminated as provided herein: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Apotex will return to Cumberland or destroy all documents and other material received from Cumberland relating to the Products or the Acquired Assets, whether so obtained before or after the execution hereof, except (i)&#160;Apotex and its Representatives may retain copies of documents and other material in accordance with their retention policies or otherwise to the extent required by applicable Law and (ii)&#160;Apotex and its Representatives are not required to delete or destroy any electronic back-up files that have been created solely by its automatic or routine archiving and back-up procedures, to the extent created and retained in a manner consistent with their standard archiving and back-up procedures; and </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;all Confidential Information received by Apotex with respect to Cumberland and its Affiliates in connection with the Business, the Products or the Acquired Assets will be treated in accordance with the Confidentiality Agreement as modified by this Agreement, which will remain in full force and effect in accordance with its terms notwithstanding the termination of this Agreement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE XI</font>
          <br >
          <font style="letter-spacing:-0.2pt;">GENERAL PROVISIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Punitive Damages</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;EXCEPT IN THE CASE OF FRAUD OR WILLFUL BREACH, NO PARTY TO THIS AGREEMENT SHALL BE LIABLE TO OR OTHERWISE RESPONSIBLE TO ANY OTHER PARTY HERETO OR ANY AFFILIATE OF ANY OTHER PARTY HERETO FOR TREBLE OR PUNITIVE DAMAGES, EXCEPT TO THE EXTENT ANY SUCH TREBLE OR PUNITIVE DAMAGES ARE PAYABLE TO THIRD PARTIES THAT MAY BE IMPOSED OR OTHERWISE INCURRED. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Expenses</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as otherwise specified in this Agreement, all costs and expenses (including fees and disbursements of counsel, financial advisors and accountants) incurred in connection with this Agreement and the transactions contemplated hereby will be paid by the Party incurring such costs and expenses, whether or not the Closing will have occurred. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Confidential Information</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Each Party acknowledges that the information being provided to it in connection with the Transactions is subject to the terms of the Confidentiality Agreement and that it shall keep confidential, and shall use commercially reasonable efforts to cause its respective Representatives and Affiliates who actually receive Confidential Information to keep confidential, all information relating to this Agreement, the Business, the Products, the Acquired Assets (including, for the avoidance of doubt, with respect to trade </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS1AA">&#8203;</a><a name="sS1NA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">secrets in perpetuity and any confidential information transferred to Apotex pursuant to the terms of this Agreement), the Assumed Liabilities, the financial information and operations of Cumberland which have not been publicly disclosed, or liabilities or obligations excluded from Assumed Liabilities (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Confidential Information</font><font style="letter-spacing:0.2pt;">&#8221;), except (i)&#160;as may be required to comply with the requirements of applicable Laws, and the rules and regulations of each stock exchange upon which the securities of the Parties are listed (including, for the avoidance of doubt, filings required by the Exchange Act and the Securities Act of 1933, each as amended), (ii)&#160;as necessary to defend or prosecute any indemnification claim or any litigation or dispute, (iii)&#160;as required by the transition and license obligations hereunder, or (iv)&#160;for information that is lawfully made available to the public on the Closing Date, or thereafter becomes available to the public other than as a result of a breach of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.3</font><font style="letter-spacing:0.2pt;">. Notwithstanding anything herein to the contrary, no Person shall be deemed to have been provided with Confidential Information as a result of its employees or directors, or the employees or directors of its affiliated investment funds or related management and advisor entities (collectively, &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Investment Personnel</font><font style="letter-spacing:0.2pt;">&#8221;), serving as officers or on the board of directors (or equivalent body) of such other Person so long as the Investment Personnel do not (i)&#160;disclose Confidential Information to any other directors, officers or employees of such Person (excluding other affiliated Investment Personnel) or (ii)&#160;use (or direct the portfolio company or other Person to use) Confidential Information in breach of this Agreement for the benefit of such Person. The covenants of each Party in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.3</font><font style="letter-spacing:0.2pt;"> shall terminate the later of (a)&#160;three (3)&#160;years following the Closing Date and (b)&#160;the date on which the Products are no longer marketed by Apotex; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that effective upon, and only upon, the Closing, Apotex&#8217;s and its Affiliates&#8217; obligations pursuant to the Confidentiality Agreement and otherwise with respect to the Business, the Acquired Assets and the Assumed Liabilities shall terminate other than with regards to any Confidential Information that remains a trade secret under applicable Law, which shall remain confidential until it is no longer considered a trade secret under applicable Law. Each Party shall treat and will cause its Affiliates and its and their respective Representatives to treat, the Confidential Information as confidential, using the same degree of care as such Party normally employs to safeguard its own confidential information from unauthorized use or disclosure, but in no event less than a reasonable degree of care. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;In the event either Party is required to disclose any of the Confidential Information pursuant to any Governmental Authority or judicial, administrative order, subpoena, discovery request, regulatory request or similar method in contravention of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.3(</font><font style="letter-spacing:0.2pt;">a), then the disclosing Party shall promptly notify the other in writing of such demand for disclosure so that the non-disclosing Party, at its sole expense, may seek to make such disclosure subject to a protective order or other appropriate remedy to preserve the confidentiality of the Confidential Information. Each Party will cooperate in all reasonable respects, in connection with any actions to be taken for the foregoing purpose. In the case of such compelled disclosure, the disclosing Party shall disclose Confidential Information only to the extent necessary in the written opinion of its counsel to satisfy such compelled disclosure herein described, and the disclosing Party shall undertake commercially reasonable efforts to ensure confidential protection for any disclosed Confidential Information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Notwithstanding anything herein to the contrary, promptly following the date hereof and prior to the Closing, Cumberland and Apotex shall cooperate in good faith to agree in writing on the method and content of the notifications to partners, customers and suppliers involved in the manufacture, marketing, and sale of the Products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Amendments and Waivers</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement may not be amended except by an instrument in writing signed by authorized signatories on behalf of each Party. By an instrument in writing, Apotex or Cumberland may waive compliance by the other Party with any term or provision of this Agreement that such other Party was or is obligated to comply with or perform. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Notices</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;All notices, requests, instructions or other communications or documents to be given or made hereunder by any Party to the other Party shall be in writing and (a)&#160;served by personal delivery upon the Party for whom it is intended, (b)&#160;sent by an internationally recognized overnight courier service to the Party for whom it is intended or (c)&#160;sent by email unless the sender receives a failure of transmission in connection therewith: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS1HT">&#8203;</a><a name="sS1SI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(a)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Apotex</font><font style="letter-spacing:0.2pt;">, to: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:40pt; margin-top:6pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Nuvo Pharmaceuticals (Ireland) DAC </font> <br ><font style="letter-spacing:0.2pt;">88 Harcourt St. </font> <br ><font style="letter-spacing:0.2pt;">Dublin 2, D02 DK18 </font> <br ><font style="letter-spacing:0.2pt;">Attention: Gary McCloskey </font> <br ><font style="letter-spacing:0.2pt;">E-mail: gmccloskey@nuvopharm.eu </font></div>
        <div style="margin-left:40pt; margin-top:6pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with a copy to (which shall not constitute notice): </font>
        </div>
        <div style="margin-left:40pt; margin-top:6pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Apotex Inc.</font> <br ><font style="letter-spacing:0.2pt;">150 Signet Drive</font> <br ><font style="letter-spacing:0.2pt;">Toronto, Ontario Canada, M9L 1T9,</font> <br ><font style="letter-spacing:0.2pt;">Attn: Francesco Tallarico; Andrew Teehan </font> <br ><font style="letter-spacing:0.2pt;">Email: ftallarico@apotex.com; ateehan@apotex.com </font></div>
        <div style="margin-left:40pt; margin-top:6pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">and </font>
        </div>
        <div style="margin-left:40pt; margin-top:6pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Kirkland &amp; Ellis LLP</font> <br ><font style="letter-spacing:0.2pt;">98 S.E. 7</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> Street, Suite 700 </font> <br ><font style="letter-spacing:0.2pt;">Miami, Florida 33131 </font> <br ><font style="letter-spacing:0.2pt;">Attention: Matthew S. Arenson, P.C.; Ngozi Nezianya </font><br ><font style="letter-spacing:0.2pt;">Email: matthew.arenson@kirkland.com; ngozi.nezianya@kirkland.com </font></div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cumberland</font><font style="letter-spacing:0.2pt;">, to: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:40pt; margin-top:6pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Cumberland Pharmaceuticals Inc. </font> <br ><font style="letter-spacing:0.2pt;">1600 West End Ave., Suite 1300 </font> <br ><font style="letter-spacing:0.2pt;">Nashville, TN 37203-7003 USA </font> <br ><font style="letter-spacing:0.2pt;">Attn: Chief Executive Officer </font></div>
        <div style="margin-left:40pt; margin-top:6pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with a copy to (which shall not constitute notice): </font>
        </div>
        <div style="margin-left:40pt; margin-top:6pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Baker, Donelson, Bearman, Caldwell &amp; Berkowitz, P.C. </font> <br ><font style="letter-spacing:0.2pt;">1600 West End Ave., Suite 2000 </font> <br ><font style="letter-spacing:0.2pt;">Nashville, TN 37203-7003 USA </font> <br ><font style="letter-spacing:0.2pt;">Attn: Tonya Mitchem Grindon, Esq. </font> <br ><font style="letter-spacing:0.2pt;">Email: tgrindon@bakerdonelson.com</font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">or to such other Person or address as has been designated in writing by the Party to receive such notice provided above. Any notice, request, instruction or other communications or document given as provided above shall be deemed given to the receiving party (x)&#160;upon actual receipt, if delivered personally, (y)&#160;on the second (2</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">nd</font><font style="letter-spacing:0.2pt;">) Business Day after deposit with an overnight courier, if sent by an overnight courier, or (z)&#160;upon a successful email transmission and such email shall be deemed successfully transmitted provided sender does not receive notice of failed transmission. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Headings</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.7&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Severability</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced under any applicable Law, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties hereto as closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible. The Parties hereto intend that each representation, warranty and covenant contained herein shall have independent significance. If any Party hereto has breached any representation, warranty or covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless of the relative levels of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS1CT">&#8203;</a><a name="sS1EA">&#8203;</a><a name="sS1TP">&#8203;</a><a name="sS1GL">&#8203;</a><a name="sS1DS">&#8203;</a><a name="sS1DR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">specificity) which such Party has not breached shall not detract from or mitigate the fact that such Party is in breach of the first representation, warranty or covenant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.8&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Counterparts</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each Party and delivered by each Party to the other Party, it being understood that all Parties hereto need not sign the same counterpart. Counterpart signature pages to this Agreement may be delivered by electronic delivery (i.e., by email of a portable document format (PDF) signature page), and each such counterpart signature page will constitute an original for all purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.9&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Entire Agreement</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement, together with the Schedules and Exhibits attached hereto, and the other Transaction Documents constitute the entire agreement and supersede all prior agreements and understandings (including any letter of intent or non-binding transaction proposal), both written and oral, between or among the Parties with respect to the subject matter hereof. The Exhibits, Schedules, certificates, and notices specifically referred to herein, and delivered pursuant hereto, are an integral part of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.10&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Third Party Beneficiaries</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as specifically provided herein, this Agreement is intended solely for the benefit of each Party and their respective successors or permitted assigns and it is not intended to confer upon any Person other than the Parties any rights or remedies hereunder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.11&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">GOVERNING LAW; CHOICE OF LAW</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;ALL ISSUES AND QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, INTERPRETATION AND ENFORCEABILITY OF THIS AGREEMENT, THE SCHEDULES ATTACHED HERETO AND THE OTHER TRANSACTION DOCUMENTS, AND THE PERFORMANCE OF THE OBLIGATIONS IMPOSED HEREUNDER OR THEREUNDER SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE. ANY AND ALL ACTIONS AND CAUSES OF ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER TRANSACTION DOCUMENT, WHETHER SOUNDING IN CONTRACT, TORT OR STATUTE, SHALL BE GOVERNED BY THE LAWS OF THE STATE OF DELAWARE, INCLUDING ITS STATUTES OF LIMITATIONS (EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN), WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW OR CONFLICT OF LAW RULES OR PROVISIONS (WHETHER OF THE STATE OF DELAWARE OR ANY OTHER JURISDICTION) THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OR STATUTE OF LIMITATIONS OF A JURISDICTION OTHER THAN THE STATE OF DELAWARE. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.12&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Disclosure Schedules</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Any disclosure with respect to a Section of the Disclosure Schedule shall be deemed to be disclosed for purposes of other Sections of the Disclosure Schedule to the extent that the relevance of such disclosure would be apparent on its face to a reasonable reader of as an exception to any representations and warranties herein. Matters reflected in any Section of the Schedules are not necessarily limited to matters required by this Agreement to be so reflected and such additional matters are set forth for informational purposes and do not necessarily include other matters of a similar nature. No reference to or disclosure of any item or other matter in any Section of this Agreement, including any Section of the Schedules, shall be construed as an admission of Liability or an indication that such item or other matter is material. Without limiting the foregoing, no such reference to or disclosure of a possible breach or violation of any contract, Law or Order shall be construed as an admission or indication that breach or violation exists or has actually occurred. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.13&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Dispute Resolution; WAIVER OF JURY TRIAL</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Except as expressly provided elsewhere in this Agreement, any Action arising under or relating to this Agreement or any other Transaction Document (other than the Transition Services Agreement) or any breach or threatened breach hereof or thereof (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Arbitrable Dispute</font><font style="letter-spacing:0.2pt;">&#8221;) shall be resolved by final and binding arbitration administered by American Arbitration Association (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">AAA</font><font style="letter-spacing:0.2pt;">&#8221;); </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that nothing in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 11.13 shall prohibit (i)&#160;Apotex and its Affiliates from having the right to specifically enforce </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;">&#160;7.17 and the restrictive covenants therein by way of specific performance, restraining order, injunction or other equitable relief in any court of competent jurisdiction, (ii)&#160;a Party from instituting litigation to enforce any Final Determination in any court of competent jurisdiction or (iii)&#160;any Party from seeking </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">remedies under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 11.14, in each case of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clauses (i)</font><font style="letter-spacing:0.2pt;">&#8201;&#8211;&#8201;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(iii)</font><font style="letter-spacing:0.2pt;">, without complying with the procedures in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.13(b</font><font style="letter-spacing:0.2pt;">)&#8201;&#8211;&#8201;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(d)</font><font style="letter-spacing:0.2pt;">. Except as otherwise provided in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.13(a)</font><font style="letter-spacing:0.2pt;"> or in the rules and procedures of AAA as in effect from time to time, the arbitration procedures and any Final Determination hereunder shall be governed by and shall be enforced pursuant to the Uniform Arbitration Act and applicable provisions of Delaware Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;In the event that any Party asserts that there exists an Arbitrable Dispute, such Party shall deliver a written notice to each other Party involved therein specifying the nature of the asserted Arbitrable Dispute and requesting a meeting to attempt to resolve the same. If no such resolution is reached within thirty (30) days after such delivery of such notice, the Party delivering such notice of Arbitrable Dispute may, within forty-five (45) days after delivery of such notice, commence arbitration hereunder by delivering to each other Party involved therein a notice of arbitration (a &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Notice of Arbitration</font><font style="letter-spacing:0.2pt;">&#8221;) and by filing a copy of such Notice of Arbitration with the New York, New York office of AAA. Such Notice of Arbitration shall specify the matters as to which arbitration is sought, the nature of any Arbitrable Dispute and the claims of each Party to the arbitration and shall specify the amount and nature of any damages, if any, sought to be recovered as a result of any alleged claim, and any other matters required by the rules and procedures of AAA as in effect from time to time to be included therein, if any. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Within twenty (20) days after receipt of the Notice of Arbitration, the Parties shall use their best efforts to agree on an independent arbitrator expert in the subject matters of the Arbitrable Dispute (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Arbitrator</font><font style="letter-spacing:0.2pt;">&#8221;). If the Parties cannot agree on the identity of the Arbitrator, each of the parties to the Arbitrable Dispute shall select one independent arbitrator expert in the subject matter of the Arbitrable Dispute. In the event that any Party fails to select an independent arbitrator as set forth herein within twenty (20) days after delivery of a Notice of Arbitration, then the matter shall be resolved by the arbitrator(s) selected by the other Party(ies). The arbitrators selected by the parties to the Arbitrable Dispute shall select the Arbitrator, and the Arbitrator shall resolve the matter according to the procedures set forth in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section</font><font style="letter-spacing:0.2pt;"> 11.13. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;The arbitration shall be conducted under the rules and procedures of AAA as in effect from time to time, except as otherwise set forth herein or as modified by the agreement of all of the parties. The arbitration shall be conducted in New York, New York. The Arbitrator shall conduct the arbitration so that a final result, determination, finding, judgment or award (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Final Determination</font><font style="letter-spacing:0.2pt;">&#8221;) is made or rendered as soon as practicable, but in no event later than sixty (60) days after the delivery of the Notice of Arbitration nor later than ten (10) days following completion of the arbitration. The Final Determination must be agreed upon and signed by the Arbitrator. The Final Determination shall be final and binding on all parties hereto and there shall be no appeal from or reexamination of the Final Determination, except for fraud, perjury, evident partiality or misconduct by an arbitrator or to correct manifest clerical errors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Apotex and Cumberland each may enforce any Final Determination in any court of competent jurisdiction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;Each Party hereby irrevocably consents to the service of process by registered mail or personal service. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;If any Party shall fail to pay the amount of any damages, if any, assessed against it within five (5) days after the delivery to such Party of such Final Determination, the unpaid amount shall bear interest from the date of such delivery at the Applicable Rate. Interest on any such unpaid amount shall be compounded monthly, computed on the basis of a three hundred sixty-five (365) day year and shall be payable on demand. In addition, such Party shall promptly reimburse the other Party for any and all costs or expenses of any nature or kind whatsoever (including all attorneys&#8217; fees and expenses) incurred in seeking to collect such damages or to enforce any Final Determination. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY ACTION, SUIT OR PROCEEDING (I)&#160;ARISING UNDER THIS AGREEMENT OR ANY OTHER TRANSACTION DOCUMENT OR ANY OF THE TRANSACTIONS (II)&#160;IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY OF THE TRANSACTIONS RELATED HERETO OR THERETO, IN EACH CASE WHETHER NOW </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS1SP">&#8203;</a><a name="sS1WN">&#8203;</a><a name="sS1A">&#8203;</a><a name="sS1AO">&#8203;</a><a name="sS1PR">&#8203;</a><a name="sS1NR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY OR OTHERWISE (INCLUDING, FOR THE AVOIDANCE OF DOUBT, ANY SEEKING EQUITABLE RELIEF). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.14&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Specific Performance</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof or thereof and that the Parties may be entitled to seek a temporary injunction or injunctions to prevent breaches of this Agreement or to enforce specifically the performance of the terms and provisions hereof, or to seek a permanent injunction in addition to any other remedy to which they are entitled at law or in equity without being required to prove irreparable harm or the inadequacy of monetary damages or other remedy at law or post a bond. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.15&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Waiver</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;No waiver by either Party of any term or condition of this Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of the same or any other term or condition of this Agreement on any future occasion. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.16&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Assignment</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;No Party may assign any or all of its rights or obligations under this Agreement without the other Party&#8217;s prior written consent; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that (i)&#160;either Apotex or Cumberland may assign any or all of its rights or obligations under this Agreement to an Affiliate of such Party, and (ii)&#160;Apotex may assign all or any portion of its rights or obligations under this Agreement to (A)&#160;a Third Party to which all or a substantial portion of the Acquired Assets or Business have been sold and (B)&#160;any of its debt financing sources for collateral security purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Any assignment to an Affiliate of a Party shall not release the assigning or transferring Party of its obligations hereunder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;This Agreement shall be binding upon and inure to the benefit of the Parties, and their respective successors and permitted assigns. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.17&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Advice of Counsel</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The language in all parts of this Agreement shall be deemed to be the language mutually agreed by the Parties. The Parties hereto and their counsel have cooperated in the drafting and preparation of this Agreement, and this Agreement therefore shall not be construed against any Party by virtue of its role as the drafter thereof. No drafts of this Agreement or any other similar or related document exchanged by the Parties prior to the Closing Date shall be offered by a Party, nor shall any draft be admissible in any proceeding, to explain or construe this Agreement or for any other purpose. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.18&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Press Release</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Notwithstanding anything herein to the contrary, each of the Parties hereby agrees that it shall not issue any press release or make any public announcements with respect to the Transactions and shall not make any filings or provide any notices to any third party or any Governmental Authority (including any national securities exchange or interdealer quotation service), except (a)&#160;with the prior written consent of the other Party, (b)&#160;as may be required to comply with the requirements of any applicable Laws, and the rules and regulations of each stock exchange upon which the securities of one of the Parties is listed, (c)&#160;if such press release or public announcement is explicitly contemplated by this Agreement (</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that, in the case of clauses (a)&#160;and (b), such Party, to the extent permitted by applicable Law, will consult with the other Party with respect to the content thereof and reasonably incorporate any comments received), (d)&#160;as consistent with previous press releases relating to this Agreement or the Transactions that were previously approved by the Parties or (e)&#160;solely to the extent related to a Superior Proposal, Intervening Event or Board Recommendation Change. Notwithstanding anything to the contrary in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.18</font><font style="letter-spacing:0.2pt;"> or otherwise in this Agreement, nothing herein shall prevent Apotex or its Affiliates from making customary disclosures to its direct or indirect investors or other </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> financing sources (in each case, whether current or prospective) on a confidential basis in connection with normal fund raising, marketing or informational or reporting activities of Apotex or any such Affiliate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.19&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Recourse</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement may only be enforced against, and any dispute, controversy, matter or claim based on, related to, or arising out of this Agreement, or the negotiation, performance, or consummation of this Agreement, may only be brought against, the Persons that are expressly named as Parties, and then only with respect to the specific obligations set forth herein with respect to such Party. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="sS1GB">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:176pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;11.20&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Guarantee</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Buyer Guarantor hereby absolutely, irrevocably and unconditionally guarantees to Cumberland the due and punctual payment in full of any payments (including the Purchase Price) required hereunder or under any other Transaction Document by Apotex, indemnification obligations of Apotex hereunder or under any other Transaction Document and the payment of any other obligations of Apotex hereunder or under any other Transaction Document (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Guaranteed Obligations</font><font style="letter-spacing:0.2pt;">&#8221;), as and when due and payable pursuant to any provision of this Agreement or any other Transaction Document; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that (i)&#160;the liabilities and obligations become performable or are due in accordance therewith, (ii)&#160;Buyer Guarantor&#8217;s liabilities and obligations under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.20</font><font style="letter-spacing:0.2pt;">, with respect to the obligations and liabilities of Apotex shall not exceed or otherwise extend beyond the liabilities and obligations of Apotex, and (iii)&#160;the remedies available against Buyer Guarantor under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.20</font><font style="letter-spacing:0.2pt;"> shall not exceed or otherwise extend beyond those remedies available to Cumberland in relation to such obligations and liabilities of Apotex, as the case may be, subject to any defenses available to Apotex or such other Person in accordance herewith or therewith. Buyer Guarantor hereby agrees that the obligations of Buyer Guarantor hereunder shall not be released or discharged, in whole or in part, in each case, or otherwise affected by: (a)&#160;the failure or delay on the part of Cumberland to assert any claim or demand or to enforce any right or remedy against Apotex or Buyer Guarantor; (b)&#160;any change in time, place or manner of payment of any of the Guaranteed Obligations or (c)&#160;any insolvency, bankruptcy, reorganization or other similar proceeding instituted by or against Apotex or any other Person now or hereafter liable with respect to the Guaranteed Obligations. Buyer Guarantor hereby waives promptness, diligence, presentment, demand for payment, notice of non-performance, default, dishonor and protest, notice of any Guaranteed Obligations incurred and all other notices of any kind, all defenses which may be available by virtue of any stay, moratorium or other similar law now or hereafter in effect or any right to require the marshaling of assets of Apotex or any other Person now or hereafter liable with respect to the Guaranteed Obligations. To the fullest extent permitted by Law, Buyer Guarantor hereby irrevocably and unconditionally waives any and all rights or defenses arising by reason of any Law which would otherwise require any election of remedies by Cumberland. Buyer Guarantor represents and warrants to Cumberland that the guarantee hereunder constitutes the legal, valid and binding agreement of Buyer Guarantor enforceable against Buyer Guarantor in accordance with the terms of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;11.20</font><font style="letter-spacing:0.2pt;">, subject to the Enforceability Exceptions. Buyer Guarantor is a legal entity duly organized, validly existing and in good standing under the laws of Ontario, Canada. Buyer Guarantor has the requisite corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder. Buyer Guarantor has taken all actions or proceedings required to be taken by or on the part of Buyer Guarantor to authorize and permit the execution and delivery by Buyer Guarantor of this Agreement and the performance by Buyer Guarantor of its obligations hereunder. This Agreement has been duly executed and delivered by Buyer Guarantor. Buyer Guarantor will have at the Closing sufficient funds to satisfy all of Apotex&#8217;s obligations under this Agreement to be satisfied at the Closing, including the payment in full of the Purchase Price. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">[</font><font style="font-style:italic;letter-spacing:0.2pt;">Signature Pages Follow</font><font style="letter-spacing:0.2pt;">] </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be signed by their respective representatives thereunto duly authorized, all as of the date hereof. </font>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:14pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt; width:0pt;" colspan="7">
              <font style="letter-spacing:-0.2pt;">Nuvo Pharmaceuticals (Ireland) DAC</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:14.38pt;">
              <font style="letter-spacing:0.2pt;">By: </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Gary McCloskey</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:225.63pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:14.38pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 0.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">Name:&#8194; Gary McCloskey</font>
              </div>
              <div style=" float:left; line-height:10pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Title:</font>
                <br >
              </div>
              <div style=" margin-top:4pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:36pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:225.63pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:16.5pt 0pt 0.5pt 0pt; width:0pt;" colspan="7">
              <font style="letter-spacing:-0.2pt;">Apotex Inc.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:14.38pt;">
              <font style="letter-spacing:0.2pt;">By: </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Francesco Tallarico </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:225.63pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:14.38pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 0.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">Name: &#8194;Francesco Tallarico </font>
              </div>
              <div style=" float:left; line-height:10pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Title:</font>
                <br >
              </div>
              <div style=" margin-top:4pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:36pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">Secretary </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:225.63pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:16.5pt 0pt 0.5pt 0pt; width:0pt;" colspan="7">
              <font style="letter-spacing:-0.2pt;">Cumberland Pharmaceuticals Inc.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:14.38pt;">
              <font style="letter-spacing:0.2pt;">By: </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ A.J. Kazimi </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:225.63pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:14.38pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 0.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">Name: &#8194;A.J. Kazimi </font>
              </div>
              <div style=" float:left; line-height:10pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Title:</font>
                <br >
              </div>
              <div style=" margin-top:4pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:36pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">Chief Executive Officer </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:225.63pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXHIBIT A</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Bill of Sale and Assignment and Assumption Agreement </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">[Omitted]</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXHIBIT B</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">IP Assignment Agreement </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">[Omitted]</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">EXHIBIT C</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Form of Stockholder Support Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">[Omitted]</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">EXHIBIT D</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Transition Services Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">[Omitted]</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:right; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Final Version</font>&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">ANNEX 2.1</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Acquired Assets</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Acquired Assets shall mean all of Cumberland&#8217;s and its Affiliates&#8217; respective right, title, and interest in, to and under the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the Products, as specifically identified on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1(A)</font><font style="letter-spacing:0.2pt;">; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the Transferred Contracts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the Inventory, including as set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.1(B)</font><font style="letter-spacing:0.2pt;">; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iv)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">(A) the Intellectual Property primarily related to, developed for, used with or held for use in connection with the Products and the Business, and all Ancillary IP Rights with respect thereto, (B)&#160;the Intellectual Property in or to the formulations of the Products and all Ancillary IP Rights with respect thereto, (C)&#160;the Intellectual Property set forth in Section&#160;5.9(a) of the Disclosure Schedules and all Ancillary IP Rights with respect thereto, and (D)&#160;the Intellectual Property set forth on Annex 2.1(c) and all Ancillary IP Rights with respect thereto; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(v)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the INDs, whether active, inactive, or withdrawn; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(vi)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the Product Records; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(vii)</font>
          <br >
        </div>
        <div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the FDA Product NDA and ANDA Approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(viii)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the permits granted to Cumberland or any of its Affiliates by a Governmental Authority exclusively in connection with the operation of the Business prior to the Closing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ix)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Prescription Drug User Fee Act (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">PDUFA</font><font style="letter-spacing:0.2pt;">&#8221;) or Generic Drug User Fee Amendment (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">GDUFA</font><font style="letter-spacing:0.2pt;">&#8221;) fees with respect to the Business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(x)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">brand marketing and promotional literature currently used by Cumberland and specifically related to, and any corresponding marketing and regulatory authorizations to sell and distribute, the Products and all Intellectual Property therein or thereto, and Ancillary IP Rights with respect thereto; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(xi)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">only to the extent in Cumberland&#8217;s or its Affiliates&#8217; possession, any material (a)&#160;written correspondence and reports related to the Products or the Business submitted to or received from Governmental Authorities (including minutes and official contact reports relating to any communications with any Governmental Authority) and relevant supporting documents with respect thereto, including all regulatory drug lists, final advertising and promotion documents, adverse event files and complaints (including clinical and pre-clinical reports) contained in any of the foregoing, (b)&#160;(I)&#160;all clinical reports, final publications (abstracts, posters, manuscripts), (II)&#160;all audit reports, manufacturing documents (including master batch records and deviation reports), and process validation reports, (III)&#160;all scientific reports underlying the Regulatory Registration and Regulatory Approval, including pre-clinical, clinical, post-marketing and other reports characterizing the Product, (IV)&#160;post-marketing reports and filings concerning complaints, (V)&#160;current wholesaler acquisition pricing list, and (VI)&#160;promotional and medical materials concerning the Product prepared for health care professionals, in each case of clauses&#160;(a)&#160;and (b), to the extent arising, generated, received or filed during the three (3)&#160;year period immediately preceding the Closing Date, (c)&#160;records of all serious adverse drug experiences known to Cumberland, to the extent arising, generated, received or filed during the ten (10) year period immediately preceding the Closing Date, and (d)&#160;without regard to the time limitation set forth in the foregoing clauses (a), (b)&#160;and (c), (I)&#160;a copy of each applicable Regulatory Registration, Regulatory Approval, dossiers and submissions to and from the Governmental Authorities responsible for the grant of the applicable Regulatory Registration and all annexes thereto, and (II)&#160;all reports submitted annually to any Governmental Authority in connection with the Products, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:488pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:44pt; width:412pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">in each case of clauses (a), (b)&#160;and (c)&#160;whether generated by Cumberland, acquired by Cumberland in the course of acquiring one of the Products from another entity, or generated by another entity as a third party contractor to help develop or manage the development of a Product (clause&#160;(xi), collectively, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cumberland Work Product</font><font style="letter-spacing:0.2pt;">&#8221;); </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(xii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the Regulatory Registrations and Regulatory Approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(xiii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the Transferred Equity Interests; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(xiv)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the Personnel Records related solely to the Business Employees; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(xv)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other properties, assets (including contracts) and goodwill exclusively related to the Products or the Business. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:209.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Annex 2.1(A)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Description of Products</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;min-height:11.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 4.5pt 0pt; width:205.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Drug and Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 4.5pt 0pt; width:72.68pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Product IND Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 4.5pt 0pt; width:153.38pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Status </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:31.25pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.917pt 0pt 2.833pt 0pt; width:205.94pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Acetadote</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">acetylcysteine</font><font style="letter-spacing:0.2pt;">) injection, for the treatment of acetaminophen poisoning; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.917pt 0pt 2.833pt 0pt; width:72.68pt;">
              <font style="letter-spacing:0.2pt;">NDA 021539 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.917pt 0pt 2.833pt 0pt; width:153.38pt;">
              <font style="letter-spacing:0.2pt;">Active </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:37pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:205.94pt;">
              <font style="letter-spacing:0.2pt;">Caldolor</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">ibuprofen</font><font style="letter-spacing:0.2pt;">) injection, for the treatment of pain and fever; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:72.68pt;">
              <div>
                <font style="letter-spacing:0.2pt;">NDA 022348</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">IND 062605 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:153.38pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Active</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">Withdrawn </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:43pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:205.94pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">lactulose</font><font style="letter-spacing:0.2pt;">) oral solution, a prescription laxative for the treatment of constipation; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:72.68pt;">
              <font style="letter-spacing:0.2pt;">ANDA 074712 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:153.38pt;">
              <font style="letter-spacing:0.2pt;">Active </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:55pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:205.94pt;">
              <font style="letter-spacing:0.2pt;">Sancuso</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">granisetron</font><font style="letter-spacing:0.2pt;">) transdermal for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:72.68pt;">
              <div>
                <font style="letter-spacing:0.2pt;">NDA 022198</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">IND 070582</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">IND 171452 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:153.38pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Active</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">Active</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">No Application made yet </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:43pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:205.94pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Talicia</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">omeprazole/amoxicillin/rifabutin</font><font style="letter-spacing:0.2pt;">) for the treatment of Helicobacter pylori (H. pylori) infections, which occur in the stomach; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:72.68pt;">
              <font style="letter-spacing:0.2pt;">NDA 213004 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:153.38pt;">
              <font style="letter-spacing:0.2pt;">Active </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:73pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:205.94pt;">
              <font style="letter-spacing:0.2pt;">Vaprisol</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">conivaptan</font><font style="letter-spacing:0.2pt;">) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:72.68pt;">
              <div>
                <font style="letter-spacing:0.2pt;">NDA 021697</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">NDA 022016</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">IND 056813</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">IND 057065 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:153.38pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Active</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">Inactive; bundled into NDA 021697</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">Inactive</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">Inactive </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4.167pt 0pt 0.5pt 0pt; width:205.94pt;">
              <font style="letter-spacing:0.2pt;">Vibativ</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (</font><font style="font-style:italic;letter-spacing:0.2pt;">telavancin</font><font style="letter-spacing:0.2pt;">) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 0.5pt 0pt; width:72.68pt;">
              <div>
                <font style="letter-spacing:0.2pt;">NDA 022110</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">NDA 022407</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">IND 060237 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 0.5pt 0pt; width:153.38pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Active</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">Inactive; bundled with NDA 022110</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">Active</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:572pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Annex 2.1(B)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Inventory</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">[Inventory Lists Omitted]</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">A-2-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:572pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Annex 2.1(C)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Additional Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">[Additional Intellectual Property List Omitted]</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">A-2-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:116pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">ANNEX 2.2</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">ASSUMED LIABILITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Assumed Liabilities mean the following liabilities and obligations of Cumberland and its Affiliates, in each case, to the extent arising out of or to the extent related to the Acquired Assets and first arising after the Closing: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">all obligations under the Transferred Contracts and any purchase orders for the supply of Products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">all obligations with respect to Regulatory Registrations, Regulatory Approvals and INDs, including, without limitation, post-marketing activities, pharmacovigilance, safety, clinical studies, quality assurance, compliance with good manufacturing practices, good distribution practices, deficiency letters, corrective action plan agreements, and any other obligations described in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.1(b)</font><font style="letter-spacing:0.2pt;"> of the Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">all Liabilities arising from any patent infringement claim or Proceeding brought by any Third Party, including any Governmental Authority, at or after the Closing to the extent arising out of the conduct of the Business after the Closing or any activities of Apotex or any of its Affiliates with respect to the Business, Product or any Acquired Asset after the Closing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iv)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">all Liabilities arising from any Governmental Authority action or notification filed by a Governmental Authority, in each case, at or after the Closing to the extent arising out of the conduct of the Business after the Closing or any activities of Apotex or any of its Affiliates with respect to the Business, the Product or any Acquired Asset after the Closing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(v)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">all Liabilities arising out of the Product made or sold at or after the Closing, including all Liabilities for product warranty claims or Product Liabilities arising after the Closing relating to such Products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(vi)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">all Liabilities for Taxes to the extent arising out of Apotex&#8217;s or any of its Affiliates&#8217; conduct of the Business for all taxable periods (or portions thereof) beginning on or after the Closing Date (determined in the case of a Straddle Period in accordance with Section&#160;7.16(c)); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(vii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any Liability relating to the Transferred Regulatory Documentation solely to the extent arising out of the conduct of the Business after the Closing or any activities of Apotex or any of its Affiliates with respect to the Business, the Product or any Acquired Asset after the Closing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(viii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any Liability of Apotex under the Transition Services Agreement (including in the event such Liability falls within one or more of the categories of Excluded Liabilities set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.3</font><font style="letter-spacing:0.2pt;">); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ix)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other Liability occurring at or after the Closing solely to the extent arising out of the conduct of the Business after the Closing or any activities of Apotex or any of its Affiliates with respect to the Business, the Product or any Acquired Asset after the Closing. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:324pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">ANNEX 2.3</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">EXCLUDED LIABILITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Excluded Liabilities mean all liabilities and obligations of Cumberland and its Affiliates that are not specifically and expressly Assumed Liabilities set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex 2.2</font><font style="letter-spacing:0.2pt;">, including the following liabilities and obligations of Cumberland or any of its Affiliates: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">all Liabilities for Excluded Taxes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any Liabilities to the extent related to any Excluded Asset; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any obligations of Cumberland under the Agreement and the Transaction Documents (other than the Transition Services Agreement, which is addressed by the following clause (vi)); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iv)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any Liability arising or occurring prior to the Closing to the extent relating to the Business, the Products or any Acquired Asset or any activities of Cumberland or any of its Affiliates with respect to the Business, the Products or any Acquired Asset; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(v)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any excise taxes, duties, other government taxes or charges on the sales and any other allowances or adjustments for Product sold by Cumberland or any of its Subsidiaries prior to Closing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(vi)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any Liability of Cumberland under the Transition Services Agreement (including in the event such Liability falls within one or more of the categories of Assumed Liabilities set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Annex&#160;2.2</font><font style="letter-spacing:0.2pt;">); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(vii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:44pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any cost or Liability arising or resulting from any breach or alleged breach of any Transferred Contract as a result of the Transactions, in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.6</font><font style="letter-spacing:0.2pt;"> of the Agreement.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="ANB">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:right; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Annex B</font>&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">VOTING AND SUPPORT AGREEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This Voting and Support Agreement (this &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) is made and entered into as of April&#160;21, 2026, by and among Cumberland Pharmaceuticals Inc., a Tennessee corporation (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221;), Nuvo Pharmaceuticals (Ireland) DAC, an Ireland designated activity company (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Buyer</font><font style="letter-spacing:0.2pt;">&#8221;), and [&#8226;] (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stockholder</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RECITALS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, concurrently with the execution and delivery of this Agreement, Buyer and the Company are entering into an Asset Purchase Agreement (as it may be amended, supplemented or otherwise modified from time to time, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Purchase Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) that, among other things and subject to the terms and conditions set forth therein, provides for the sale of substantially all of the assets of the Company to Buyer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, as of the date hereof, the Stockholder is the record and/or &#8220;beneficial owner&#8221; &#8203;(within the meaning of Rule&#160;13d-3 under the Securities Exchange Act of 1934 (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exchange Act</font><font style="letter-spacing:0.2pt;">&#8221;, as amended), which meaning will apply for all purposes of this Agreement; provided, that all options, warrants, restricted stock&#160;units and other convertible securities are included even if not exercisable within sixty (60) days of the date hereof) of the number of shares of Company common stock, no par value (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Company Stock</font><font style="letter-spacing:0.2pt;">&#8221;), as set forth next to the Stockholder&#8217;s name on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;A</font><font style="letter-spacing:0.2pt;"> hereto, being all of the shares of Company Stock owned of record or beneficially by the Stockholder as of the date hereof (with respect to the Stockholder, the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Owned Shares</font><font style="letter-spacing:0.2pt;">&#8221; and, the Owned Shares together with the Stockholder&#8217;s Additional Shares (as defined herein), the Stockholder&#8217;s &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Covered Shares</font><font style="letter-spacing:0.2pt;">&#8221;); </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, the Board has, by unanimous vote of the directors, (a)&#160;determined that the terms of the Purchase Agreement and the Transactions are fair to, and in the best interests of, the Company and its stockholders, (b)&#160;determined that it is in the best interests of the Company and its stockholders and declared it advisable to enter into the Purchase Agreement, (c)&#160;approved the execution and delivery by the Company of the Purchaser Agreement, the performance by the Company of its covenants and agreements contained therein and the consummation of the Transactions upon the terms and subject to the conditions contained therein, (d)&#160;resolved to recommend that its stockholders vote to approve the Transactions, in each case on the terms and subject to the conditions set forth in the Purchase Agreement and (e)&#160;directed that the Purchase Agreement be submitted to the Company&#8217;s stockholders for their approval; and </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, as an inducement and condition for Buyer to enter into the Purchase Agreement, the Stockholder has agreed to enter into this Agreement with respect to the Stockholder&#8217;s Covered Shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth below and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">1.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Definitions</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Purchase Agreement. When used in this Agreement, the following terms shall have the meanings assigned to them in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Additional Shares</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to the Stockholder, any additional shares of Company Stock or other voting securities of the Company that the Stockholder may acquire record and/or beneficial ownership of after the date hereof (including by way of stock dividend or distribution, split-up, recapitalization, combination, exchange of shares or issued upon the exercise of any options, the settlement of any restricted stock or other conversion of any convertible securities). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exempt Transfer</font><font style="letter-spacing:0.2pt;">&#8221; means any transfer of Covered Shares (i)&#160;if the Stockholder is a natural person, (a)&#160;by will or intestacy, to the legal representative, heir, beneficiary or a member of the immediate family of the Stockholder, (b)&#160;to any immediate family member (for purposes of this Agreement, &#8220;immediate family&#8221; shall mean any spouse, lineal descendant or antecedent, brother or sister, adopted child or grandchild, or the spouse of any child, adopted child, grandchild or adopted grandchild of the Stockholder) or (c)&#160;to any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">trust the beneficiaries of which include only the Stockholder or the immediate family of the Stockholder for bona fide estate planning purposes, (ii)&#160;if the Stockholder is a corporation, partnership, limited liability company, trust or other business entity, to another corporation, partnership, limited liability company, trust or other business entity that is a controlled Affiliate of the Stockholder, or (iii)&#160;that has received the prior written approval of Buyer; provided that (A)&#160;any transfer pursuant to the foregoing clause (i)&#160;or (ii)&#160;of this definition shall be permitted only if prior to, and as a condition to, such Exempt Transfer becoming effective, such transferee executes a joinder to this Agreement in form and substance reasonably satisfactory to Buyer and which shall bind such transferee to all of the obligations of the Stockholder herein and (B)&#160;in the case of a transfer pursuant to the foregoing clause (i)&#160;or (ii)&#160;of this definition the transferor Stockholder shall remain liable for any failure of such transferee to comply with or perform its obligations under this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Expiration Time</font><font style="letter-spacing:0.2pt;">&#8221; means the earlier to occur of (a)&#160;the Closing, (b)&#160;such date and time as the Purchase Agreement shall be validly terminated pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;X</font><font style="letter-spacing:0.2pt;"> thereof or (c)&#160;with respect to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2</font><font style="letter-spacing:0.2pt;"> only, receipt by the Company of the Requisite Stockholder Approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Lien</font><font style="letter-spacing:0.2pt;">&#8221; means any lien, encumbrance, hypothecation, adverse claim, charge, mortgage, security interest, pledge or option, proxy, right of first refusal or first offer, preemptive right, deed of trust, servitude, voting agreement, voting trust, transfer restriction or any other similar restriction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Permitted Lien</font><font style="letter-spacing:0.2pt;">&#8221; means (a)&#160;any Lien arising under this Agreement, (b)&#160;any applicable restrictions on transfer under the Securities Act, or (c)&#160;proxies granted by the Stockholder in connection with the Company&#8217;s annual meeting of shareholders to be held on April&#160;21, 2026 and any adjournment thereof (which shall exclude, for the avoidance of doubt, any proxy with respect to any Acquisition Proposal). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Representative</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to a particular Person, any director, officer, manager, shareholder, member, partner, owner, principal, employee, advisor, representative, consultant, counsel, accountant, investment banker or agent of such Person. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Transfer</font><font style="letter-spacing:0.2pt;">&#8221; means (i)&#160;any direct or indirect offer, sale, assignment, encumbrance, pledge, gift, hedge, hypothecation, disposition, loan or other transfer (including pursuant to a margin call), or entry into any option or other contract, arrangement or understanding with respect to any offer, sale, assignment, encumbrance, pledge, gift, hedge, hypothecation, disposition, loan or other transfer (whether by merger, consolidation, division, conversion, operation of law or otherwise), of any Covered Shares or any interest in any Covered Shares (in each case other than this Agreement), (ii)&#160;the deposit of such Covered Shares into a voting trust, the entry into a voting agreement or arrangement (other than this Agreement) with respect to such Covered Shares or the grant of any proxy or power of attorney with respect to such Covered Shares or (iii)&#160;any contract or commitment (whether or not in writing) to take any of the actions referred to in the foregoing clauses (i)&#160;or (ii)&#160;of this definition. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Agreement to Vote the Covered Shares</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.1&nbsp;&nbsp;&nbsp;From the execution and delivery of this Agreement until the Expiration Time, at every meeting of the Company&#8217;s stockholders at which any of the following matters are to be voted on (and at every adjournment or postponement or recess thereof), and in any other circumstance, however called, including in connection with any request for an action by consent of the stockholders in lieu of a meeting, the Stockholder shall vote (including by providing proxy) or execute and deliver a consent with respect to, all of the Stockholder&#8217;s Covered Shares (or cause the holder(s) of record on any applicable record date to vote (including by providing proxy) or execute and deliver a consent with respect to all of the Stockholder&#8217;s Covered Shares): </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;in favor of the approval of the Purchase Agreement and the Transactions; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;in favor of the approval of any amended and restated Purchase Agreement or amendment to the Purchase Agreement recommended by the Board or pursuant to any reaffirmation of the Board Recommendation. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;in favor of the approval of any proposal to adjourn or postpone the meeting to a later date if there are not sufficient votes present for there to be a quorum or for the approval of the Purchase </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Agreement (or any amendment thereto) on the date on which such meeting is held, or if Buyer proposes or requests such adjournment or proposal, in each case, in accordance with the Purchase Agreement; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;against any Acquisition Proposal or any action or proposal in furtherance of any Acquisition Proposal (other than a Superior Proposal). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2.2&nbsp;&nbsp;&nbsp;From the execution and delivery of this Agreement until the Expiration Time, at every meeting of the Company&#8217;s stockholders (and at every adjournment or postponement or recess thereof), the Stockholder shall appear in person at such meeting or shall cause the Stockholder&#8217;s Covered Shares to be represented by proxy and shall otherwise cause all of the Stockholder&#8217;s Covered Shares to be counted for the purposes of establishing a quorum at such meeting (or, with respect to any such Covered Shares that the Stockholder owns beneficially but not of record, the Stockholder shall cause the holder(s) of record of such shares as of any applicable record date for determining the Stockholders entitled to vote at the meeting to be represented in person or by such proxy at such meeting as provided herein and to be counted as present for purposes of establishing a quorum). The Stockholder hereby appoints the Company and any designee of the Company, and each of them individually, until the Expiration Time (at which time this proxy shall automatically be revoked), as its proxy and attorney-in-fact, with full power of substitution and re-substitution, to vote or act by written consent during the term of this Agreement with respect to the Covered Shares in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.1</font><font style="letter-spacing:0.2pt;"> hereof in the event the Stockholder fails to comply with its obligation under this Agreement or attempts or purports to vote (or provide consent with respect to), or cause any other Person to vote or provide consent with respect to, the Stockholder&#8217;s Covered Shares in a manner inconsistent with the terms of this Agreement. This proxy and power of attorney is given to secure the performance of the duties of the Stockholders under this Agreement. The Stockholder shall take such further action or execute such other instruments as may be necessary to effectuate the intent of this proxy. This proxy and power of attorney granted by the Stockholder shall be irrevocable during the term of this Agreement, shall be deemed to be coupled with an interest sufficient in law to support an irrevocable proxy, and shall revoke any and all prior proxies granted by the Stockholder with respect to the Covered Shares (other than proxies granted by the Stockholder in connection with the Company&#8217;s annual meeting of shareholders to be held on April&#160;21, 2026 and any adjournment thereof (which shall exclude, for the avoidance of doubt, any proxy with respect to any Acquisition Proposal)). The power of attorney granted by the Stockholder herein is a durable power of attorney and shall survive the bankruptcy, death or incapacity of the Stockholder. The proxy and power of attorney granted hereunder shall terminate upon the termination of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">3.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Transfers</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Beginning on the date hereof until the Expiration Time, the Stockholder hereby covenants and agrees that, (a)&#160;except as expressly contemplated pursuant to this Agreement, the Stockholder shall not, and shall direct its Affiliates and their respective Representatives not to, directly or indirectly (i)&#160;tender any Covered Shares into any tender or exchange offer, (ii)&#160;except for an Exempt Transfer, Transfer or enter into any contract, option, agreement, understanding or other arrangement with respect to the Transfer of, any Covered Shares or beneficial ownership, voting power or any other interest thereof or therein (including by operation of law), (iii)&#160;enter into any hedge, swap or other transaction or contract which is designed to (or is reasonably expected to lead to or result in) a transfer of the economic consequences of ownership of any Covered Shares (whether any such transaction is to be settled by delivery of Covered Shares, in cash or otherwise), (iv)&#160;grant any proxies (other than proxies granted by the Stockholder in connection with the Company&#8217;s annual meeting of shareholders to be held on April&#160;21, 2026 and any adjournment thereof (which shall exclude, for the avoidance of doubt, any proxy with respect to any Acquisition Proposal)) or powers of attorney, deposit any Covered Shares into a voting trust or enter into a voting agreement with respect to any Covered Shares or (v)&#160;commit or agree to take any of the foregoing actions and (b)&#160;the Stockholder shall not, and shall direct its Affiliates and their respective Representatives not to, directly or indirectly take any action that would reasonably be expected to prevent or materially impair or materially delay the consummation of the transactions contemplated by this Agreement. Without limiting the foregoing, the Stockholder agrees that it shall not, and shall cause each of its Affiliates not to, become a member of a &#8220;group&#8221; &#8203;(as defined under Section&#160;13(d) of the Exchange Act) with respect to any securities of the Company for the purpose of opposing or competing with or taking any actions inconsistent with the Transactions. Any Transfer in violation of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3</font><font style="letter-spacing:0.2pt;"> shall be void </font><font style="font-style:italic;letter-spacing:0.2pt;">ab initio</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">4.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Fiduciary Duties</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Stockholder is entering into this Agreement solely in its capacity as the record holder and/or beneficial owner of the Stockholder&#8217;s Covered Shares. Without limiting the terms of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the Purchase Agreement in any respect, nothing in this Agreement shall in any way attempt to limit or affect any actions taken by the Stockholder or its Affiliates&#8217; designee(s) or beneficial owner(s) serving on the Board (in any such director&#8217;s capacity as such) or any the Stockholder, in his or her capacity as a director, officer or employee of the Company or any of its Affiliates, from complying with his or her fiduciary obligations to the extent (and solely to the extent) acting in such designee&#8217;s or beneficial owner&#8217;s capacity as a director, officer or employee of the Company. No action taken (or omitted to be taken) by the Stockholder in any such capacity as a director, officer or employee of the Company shall be deemed to constitute a breach of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Representations and Warranties of the Stockholder</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Stockholder hereby represents and warrants that: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Due Authority</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Stockholder has the full power and capacity to make, enter into and carry out the terms of this Agreement and the other definitive documentations contemplated hereby. If an entity, the Stockholder is duly organized, validly existing and in good standing (to the extent such concept exists) in accordance with the laws of its jurisdiction of formation, as applicable. The execution and delivery of this Agreement, the performance of the Stockholder&#8217;s obligations hereunder, and the consummation of the transactions contemplated hereby have been validly authorized. This Agreement has been duly and validly executed and delivered by the Stockholder, and this Agreement constitutes a valid and binding obligation of the Stockholder enforceable against it in accordance with its terms, except as enforcement may be limited by applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar applicable Laws affecting or relating to creditors&#8217; rights generally and equitable remedies of specific performance and injunctive and other forms of equitable relief may be subject to equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Ownership of the Covered Shares</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;(a)&#160;The Stockholder is, as of the date hereof, the beneficial and/or record owner of the Stockholder&#8217;s Covered Shares, all of which are free and clear of any Liens, other than Permitted Liens, and (b)&#160;subject only to community property laws, if applicable, the Stockholder has sole voting power over all of the Stockholder&#8217;s Covered Shares and no person (other than the Stockholder and any person under common control with the Stockholder) has a right to acquire any of the Covered Shares held by the Stockholder. The Stockholder has not entered into any agreement to Transfer any Covered Shares (other than any proxies granted by the Stockholder in connection with the Company&#8217;s annual meeting of shareholders to be held on April&#160;21, 2026 and any adjournment thereof (which shall exclude, for the avoidance of doubt, any proxy with respect to any Acquisition Proposal)). As of the date hereof, the Stockholder does not own, beneficially or of record, any shares of Company Stock or other voting shares of the Company (or any securities convertible, exercisable or exchangeable for, or rights to purchase or acquire, any shares of Company Stock or other voting shares of the Company) other than the Owned Shares. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Conflict: Consents</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The execution and delivery of this Agreement by the Stockholder does not, and the performance by the Stockholder of its obligations under this Agreement does not and will not: (i)&#160;violate any Laws applicable to the Stockholder or (ii)&#160;result in any breach of or constitute a default under any contract or obligation to which the Stockholder is a party or by which the Stockholder is subject or (iii)&#160;if an entity, violate the certificate of incorporation, bylaws, operating agreement, limited partnership agreement or any equivalent organizational or governing documents of the Stockholder, in each case of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clauses (i)</font><font style="letter-spacing:0.2pt;"> through </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(iii)</font><font style="letter-spacing:0.2pt;">, except for such violations, breaches or defaults as would not materially delay or materially impair the ability of the Stockholder to perform its obligations under this Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;No consent, approval, order or authorization of, or registration, declaration or filing with any Governmental Authority or any other Person is required by or with respect to the Stockholder in connection with the execution and delivery of this Agreement or the performance by the Stockholder of its obligations under this Agreement, except (i)&#160;as required by the rules and regulations promulgated under the Exchange Act, the Securities Act, or state securities, takeover and &#8220;blue sky&#8221; laws or (ii)&#160;the applicable rules and regulations of the SEC or any applicable stock exchange. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Absence of Litigation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;As of the date hereof, there is no legal action pending against, threatened in writing against, or, to the knowledge of the Stockholder, threatened orally against or affecting the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;min-height:637.08pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Stockholder that would reasonably be expected to prevent, materially delay or materially impair the ability of the Stockholder to perform its obligations under this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Brokers</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;No broker, finder, financial advisor, investment banker or other agent is entitled to any brokerage, finder&#8217;s, financial advisor&#8217;s, investment banking or other similar fee or commission payable by the Company or any of its Subsidiaries in connection with the transactions contemplated hereby based upon arrangements made by or, to the knowledge of the Stockholder, on behalf of the Stockholder (it being understood that arrangements made by the Company shall not be deemed to be an arrangement of the Stockholder). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">6.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Representations and Warranties of the Company</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Company hereby represents and warrants that: (a)&#160;the Company has the full power and capacity to make, enter into and carry out the terms of this Agreement; (b)&#160;the Company is duly organized, validly existing and in good standing in accordance with the laws of its jurisdiction of formation; (c)&#160;the execution and delivery of this Agreement and the performance of the Company&#8217;s obligations hereunder have been validly authorized, and assuming the accuracy of the representations and warranties set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.3(b)</font><font style="letter-spacing:0.2pt;">, no other consents or authorizations are required to give effect to this Agreement; and (d)&#160;this Agreement has been duly and validly executed and delivered by the Company, and this Agreement constitutes a valid and binding obligation of the Company enforceable against it in accordance with its terms, except as enforcement may be limited by general principles of equity whether applied in a court of law or a court of equity and by bankruptcy, insolvency and similar applicable Laws affecting creditors&#8217; rights and remedies generally. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">7.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Representations and Warranties of Buyer</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Buyer hereby represents and warrants that: (a)&#160;Buyer has the full power and capacity to make, enter into and carry out the terms of this Agreement; (b)&#160;Buyer is duly organized, validly existing and in good standing in accordance with the laws of its jurisdiction of formation; (c)&#160;the execution and delivery of this Agreement and the performance of Buyer&#8217;s obligations hereunder have been validly authorized, and assuming the accuracy of the representations and warranties set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.3(b)</font><font style="letter-spacing:0.2pt;">, no other consents or authorizations are required to give effect to this Agreement; and (d)&#160;this Agreement has been duly and validly executed and delivered by Buyer, and this Agreement constitutes a valid and binding obligation of Buyer enforceable against it in accordance with its terms, except as enforcement may be limited by general principles of equity whether applied in a court of law or a court of equity and by bankruptcy, insolvency and similar applicable Laws affecting creditors&#8217; rights and remedies generally. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">[Restrictive Covenants.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">2</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">8.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Employee Non-Solicitation/Non-Hire</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;For a period of eighteen (18) months from and after the Closing Date, the Stockholder shall not, and shall cause each of his Affiliates to not, directly or indirectly, (i)&#160;encourage, induce, or solicit any Transferred Business Employee to leave employment with Buyer or any of its Affiliates or (ii)&#160;hire, employ, or attempt to hire or employ any Transferred Business Employee; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that the foregoing clause (i)&#160;shall not preclude Stockholder or any of his Affiliates from (A)&#160;posting a general solicitation through a public medium or general or mass mailing by or on behalf of Stockholder or his Affiliates, as applicable, that is not targeted at employees of Buyer or its Subsidiaries or Affiliates or any Transferred Business Employee or (B)&#160;soliciting any terminated employee of Buyer or its Affiliates so long as such former employee has been terminated from employment with Buyer or its Affiliates for more than twelve (12) months. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">8.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Business Relations Non-Interference</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;For a period of four (4)&#160;years from and after the Closing Date, the Stockholder shall not, and shall each cause of his Affiliates to not, directly or indirectly through a third party, (i)&#160;induce or attempt to induce any Person to cease doing business with Buyer or any of its Affiliates with respect to the Products, or (ii)&#160;in any way intentionally interfere with the relationship between any such customer, supplier, licensee, licensor or other business relation of Buyer or any of its Affiliates with respect to the Products in a manner harmful to Buyer or any of its Affiliates. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">8.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Competing Products</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;For a period of four (4)&#160;years from and after the Closing Date, the Stockholder shall not, and shall cause his Affiliates to not, (i)&#160;engage in any business in the Territory </font>
        </div>
      </div>
      <div style="margin-top:4.49999999999989pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7.5pt;">
          <font style=" position:relative; bottom:4.25pt;letter-spacing:0.15pt;">2</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:7.5pt;">
          <!--blacklining:none;-->
          <font style="font-size:10pt;letter-spacing:0.2pt;">Section&#160;8 is included only in A.J Kazimi&#8217;s Voting and Support Agreement.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:1.92000000000007pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">that manufactures, promotes, markets, distributes, commercializes, imports, exports or sells any products that compete with the Products, or (ii)&#160;grant any rights to or enter into any arrangement with a third party to launch, manufacture, promote, market, distribute, commercialize, import, export or sell a product that competes with the Products in the Territory; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that nothing herein shall prohibit the Stockholder from being a passive owner of not more than 5% of the outstanding equity securities of any class of a Person so long as none of the Stockholder nor any of his Affiliates has any active participation in the business of such Person. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">8.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Non-Disparagement</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;For a period of three (3)&#160;years from and after the Closing Date, the Stockholder shall not, and shall cause his Affiliates not to, directly or indirectly, make any disparaging statement concerning the Business, the Products or the Acquired Assets. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">8.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Certain Acknowledgements</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Stockholder agrees and acknowledges that he is familiar with the trade secrets and other information of a confidential or proprietary nature of the Business, the Products and the other Acquired Assets, and their respective business relations. The Stockholder also agrees and acknowledges that Buyer, its Affiliates, the Business, the Products and the other Acquired Assets would be irreparably damaged if the Stockholder or his Affiliates were to provide products or services or to otherwise engage in any activity in violation of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;"> and that any such action would result in a significant loss of goodwill by Buyer and its Affiliates in respect of such businesses. The Stockholder agrees and acknowledges that the covenants and agreements set forth in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;"> were a material inducement to Buyer to enter into this Agreement, the Purchase Agreement and the other Transaction Documents and to perform its obligations hereunder and thereunder, and that Buyer and its Affiliates would not obtain the benefit of the bargain set forth in this Agreement, the Purchase Agreement and the other Transaction Documents as specifically negotiated by the parties hereto and thereto, as applicable, if the Stockholder or his Affiliates breached any of the provisions of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;"> with respect to the Products in the Territory. The Stockholder acknowledges and agrees that the promises and restrictive covenants that the Stockholder and his Affiliates are providing in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;"> are reasonable with respect to period, geographical area and scope and are necessary for the protection of legitimate interests in Buyer&#8217;s investment in the Business, the Products and the other Acquired Assets (including customer relationships, trade secrets and goodwill) pursuant to the Purchase Agreement and the other Transaction Documents, and that such limitations would not impose any undue burden upon the Stockholder or his Affiliates. In the event that any such period, geographical area or scope limitation is deemed to be invalid, prohibited or unenforceable by a court of competent jurisdiction, Buyer and the Stockholder agree to the reduction of any or all of said period, geographical area or scope limitations to such a period, geographical area or scope as said court shall deem reasonable or enforceable under the circumstances. If such partial enforcement is not possible in such jurisdiction, the provision shall be deemed severed as to such jurisdiction, and the remaining provisions of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;"> shall remain in full force and effect. The Stockholder acknowledges and agrees that irreparable injury will result to Buyer, the Business, the Products or the other Acquired Assets if the Stockholder or his Affiliates breaches any of the terms of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;">, and that in the event of the Stockholder&#8217;s or his Affiliates&#8217; actual or threatened breach of any of the provisions contained in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;">, Buyer will have no adequate remedy at law. The Stockholder accordingly agrees that in the event of any actual or threatened breach by the Stockholder or his Affiliates of any of the provisions contained in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;">, Buyer shall be entitled to such injunctive and other equitable relief as may be deemed necessary or appropriate by a court of competent jurisdiction without proving the inadequacy of a remedy at law or irreparable harm and without the requirement to post a bond with respect thereto. Nothing contained herein shall be construed as prohibiting Buyer from pursuing any other remedies available to it for such breach or threatened breach, including the recovery of any damages which it is able to prove. In addition, because the protection of the goodwill of the Business requires that the Stockholder comply with the covenants in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;"> for the full periods of restriction discussed herein, the Stockholder agrees that, if it is determined by a court of competent jurisdiction that the Stockholder has breached this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;">, any such period will be extended for a period of time (if any) equal to the time period that the Stockholder is determined by such court of competent jurisdiction to have breached any of the covenants in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;">, such that the Stockholder is ultimately foreclosed from engaging in the restricted activities under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;"> for a time period equal to the full periods of restriction. The Stockholder shall be liable for any breaches of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;"> by any of his Affiliates and Representatives.] </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:120pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Miscellaneous</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Ownership Interest</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Nothing contained in this Agreement shall be deemed to vest in the Company any direct, indirect or beneficial ownership or incidence of ownership of or with respect to the Covered Shares. Without limiting this Agreement in any manner, rights, ownership and economic benefits of and relating to the Covered Shares shall remain vested in and belong to the Stockholder, and the Company shall have no authority to direct any Stockholder in the voting or disposition of any of the Covered Shares, except as expressly provided herein. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Certain Adjustments</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In the event of a stock split, stock dividend or distribution, or any change in the Company Stock by reason of any split-up, reverse stock split, recapitalization, combination, reclassification, exchange of shares or the like, the terms &#8220;Company Stock&#8221; and &#8220;Covered Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction. In the event of any such adjustment, or in the event the Stockholder acquires any Additional Shares, Schedule&#160;A shall be deemed amended accordingly, automatically and without further action of any Person to include such Additional Shares. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Amendments and Modifications</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement may not be modified, amended, altered or supplemented except upon the execution and delivery of a written agreement executed by all of the parties hereto. No waiver by any party of its rights hereunder shall be effective against such party unless the same shall be in writing. No waiver by any party hereto of any default, misrepresentation or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty, covenant or agreement hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence. For the avoidance of doubt, nothing in this Agreement shall be deemed to amend, alter or modify, in any respect, any of the provisions of the Purchase Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Expenses</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as otherwise provided, all costs and expenses incurred in connection with this Agreement shall be paid by the party hereto incurring such cost or expense. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Notices</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;All notices, requests, instructions or other communications or documents to be given or made hereunder by any party hereto to another party hereto shall be in writing and (a)&#160;served by personal delivery upon the party for whom it is intended, (b)&#160;sent by an internationally recognized overnight courier service to the party for whom it is intended or (c)&#160;sent by email unless the sender receives a failure of transmission in connection therewith: </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp; if to the Company or the Stockholder, to: </font>
        </div>
        <div style="margin-left:80pt; margin-top:8pt; width:376pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Cumberland Pharmaceuticals Inc. </font> <br ><font style="letter-spacing:0.2pt;">1600 West End Ave., Sute 1300 </font> <br ><font style="letter-spacing:0.2pt;">Nashville, TN 37203-7003 USA </font> <br ><font style="letter-spacing:0.2pt;">Attention: Chief Executive Officer </font></div>
        <div style="margin-left:80pt; margin-top:8pt; width:376pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Email: akazimi@cumberlandpharma.com </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:80pt; width:376pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with a copy (which shall not constitute notice) to: </font>
        </div>
        <div style="margin-left:80pt; margin-top:8pt; width:376pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Baker, Donelson, Bearman, Caldwell &amp; Berkowitz, PC </font>
          <br >
          <font style="letter-spacing:0.2pt;">1600 West End Avenue, Suite 2000 </font> <br ><font style="letter-spacing:0.2pt;">Nashville, TN 37203 </font> <br ><font style="letter-spacing:0.2pt;">Attention: Tonya Mitchem Grindon </font><br ><font style="letter-spacing:0.2pt;">E-mail: tgrindon@bakerdonelson.com </font></div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp; if to Buyer, to: </font>
        </div>
        <div style="margin-left:80pt; margin-top:8pt; width:376pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Nuvo Pharmaceuticals (Ireland) DAC </font> <br ><font style="letter-spacing:0.2pt;">88 Harcourt St. </font> <br ><font style="letter-spacing:0.2pt;">Dublin 2, D02 DK18 </font> <br ><font style="letter-spacing:0.2pt;">Attention: Gary McCloskey </font> <br ><font style="letter-spacing:0.2pt;">E-mail: gmccloskey@nuvopharm.eu </font></div>
        <div style="margin-left:80pt; margin-top:8pt; width:376pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with a copy to (which shall not constitute notice): </font>
        </div>
        <div style="margin-left:80pt; margin-top:8pt; width:376pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Apotex Inc. </font> <br ><font style="letter-spacing:0.2pt;">150 Signet Drive </font> <br ><font style="letter-spacing:0.2pt;">Toronto, Ontario Canada, M9L 1T9, </font> <br ><font style="letter-spacing:0.2pt;">Attn: Francesco Tallarico; Andrew Teehan </font><br ><font style="letter-spacing:0.2pt;">Email: ftallarico@apotex.com; ateehan@apotex.com </font></div>
        <div style="margin-left:80pt; margin-top:8pt; width:376pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">and </font>
        </div>
        <div style="margin-left:80pt; margin-top:8pt; width:376pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Kirkland &amp; Ellis LLP </font> <br ><font style="letter-spacing:0.2pt;">98 S.E. 7</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> Street, Suite 700 </font> <br ><font style="letter-spacing:0.2pt;">Miami, Florida 33131 </font> <br ><font style="letter-spacing:0.2pt;">Attention: Matthew S. Arenson, P.C.; Ngozi Nezianya </font><br ><font style="letter-spacing:0.2pt;">Email: matthew.arenson@kirkland.com; </font><br ><font style="letter-spacing:0.2pt;">ngozi.nezianya@kirkland.com</font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">or to such other Person or address as has been designated in writing by the party to receive such notice provided above. Any notice, request, instruction or other communications or document given as provided above shall be deemed given to the receiving party (x)&#160;upon actual receipt, if delivered personally, (y)&#160;on the second Business Day after deposit with an overnight courier, if sent by an overnight courier, or (z)&#160;upon a successful email transmission and such email shall be deemed successfully transmitted provided sender does not receive notice of failed transmission. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Specific Performance</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The parties hereto agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the parties hereto may be entitled to seek a temporary injunction or injunctions to prevent breaches of this Agreement or to enforce specifically the performance of the terms and provisions hereof, or to seek a permanent injunction in addition to any other remedy to which they are entitled at law or in equity without being required to prove irreparable harm or the inadequacy of monetary damages or other remedy at law or post a bond. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.7&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">GOVERNING LAW; CHOICE OF LAW</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;ALL ISSUES AND QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, INTERPRETATION AND ENFORCEABILITY OF THIS AGREEMENT AND SCHEDULE A ATTACHED HERETO AND THE PERFORMANCE OF THE OBLIGATIONS IMPOSED HEREUNDER SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">PROVIDED</font><font style="letter-spacing:0.2pt;"> THAT ALL ISSUES AND QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, INTERPRETATION AND ENFORCEABILITY OF </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">SECTION 8</font><font style="letter-spacing:0.2pt;"> OF THIS AGREEMENT AND THE PERFORMANCE OF THE OBLIGATIONS IMPOSED THEREIN SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF TENNESSEE. ANY AND ALL ACTIONS AND CAUSES OF ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT, WHETHER SOUNDING IN </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">CONTRACT, TORT OR STATUTE, SHALL BE GOVERNED BY THE LAWS OF THE STATE OF DELAWARE, INCLUDING ITS STATUTES OF LIMITATIONS (EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN), WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW OR CONFLICT OF LAW RULES OR PROVISIONS (WHETHER OF THE STATE OF DELAWARE OR ANY OTHER JURISDICTION) THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OR STATUTE OF LIMITATIONS OF A JURISDICTION OTHER THAN THE STATE OF DELAWARE. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.8&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Dispute Resolution; WAIVER OF JURY TRIAL</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Except as expressly provided elsewhere in this Agreement, any Action arising under or relating to this Agreement or any breach or threatened breach hereof or thereof (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Arbitrable Dispute</font><font style="letter-spacing:0.2pt;">&#8221;) shall be resolved by final and binding arbitration administered by American Arbitration Association (&#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">AAA</font><font style="letter-spacing:0.2pt;">&#8221;); </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that nothing in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">9.8</font><font style="letter-spacing:0.2pt;"> shall prohibit [(i) Buyer and its Affiliates from having the right to specifically enforce </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style=" text-decoration:underline #000000 solid; position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">3</font><font style="letter-spacing:0.2pt;"> and the restrictive covenants therein by way of specific performance, restraining order, injunction or other equitable relief in any court of competent jurisdiction,]</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">4</font><font style="letter-spacing:0.2pt;"> (ii)&#160;a party hereto from instituting litigation to enforce any Final Determination in any court of competent jurisdiction or (iii)&#160;any Party from seeking remedies under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.6</font><font style="letter-spacing:0.2pt;">, in each case of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">clauses [(i)</font><font style="letter-spacing:0.2pt;">&#8201;&#8211;&#8201;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(iii)]</font><font style="letter-spacing:0.2pt;">, without complying with the procedures in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">9.8(b)&#8201;&#8211;&#8201;(d)</font><font style="letter-spacing:0.2pt;">. Except as otherwise provided in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.8</font><font style="letter-spacing:0.2pt;"> or in the rules and procedures of AAA as in effect from time to time, the arbitration procedures and any Final Determination hereunder shall be governed by and shall be enforced pursuant to the Uniform Arbitration Act and applicable provisions of Delaware Law. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;In the event that any party hereto asserts that there exists an Arbitrable Dispute, such party shall deliver a written notice to each other party hereto involved therein specifying the nature of the asserted Arbitrable Dispute and requesting a meeting to attempt to resolve the same. If no such resolution is reached within thirty (30) days after such delivery of such notice, the party delivering such notice of Arbitrable Dispute may, within forty-five (45) days after delivery of such notice, commence arbitration hereunder by delivering to each other party involved therein a notice of arbitration (a &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Notice of Arbitration</font><font style="letter-spacing:0.2pt;">&#8221;) and by filing a copy of such Notice of Arbitration with the New York, New York office of AAA. Such Notice of Arbitration shall specify the matters as to which arbitration is sought, the nature of any Arbitrable Dispute and the claims of each party to the arbitration and shall specify the amount and nature of any damages, if any, sought to be recovered as a result of any alleged claim, and any other matters required by the rules and procedures of AAA as in effect from time to time to be included therein, if any. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Within twenty (20) days after receipt of the Notice of Arbitration, the parties shall use their best efforts to agree on an independent arbitrator expert in the subject matters of the Arbitrable Dispute (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Arbitrator</font><font style="letter-spacing:0.2pt;">&#8221;). If the parties cannot agree on the identity of the Arbitrator, each of the parties to the Arbitrable Dispute shall select one independent arbitrator expert in the subject matter of the Arbitrable Dispute. In the event that any party fails to select an independent arbitrator as set forth herein within twenty (20) days after delivery of a Notice of Arbitration, then the matter shall be resolved by the arbitrator(s) selected by the other party(ies). The arbitrators selected by the parties to the Arbitrable Dispute shall select the Arbitrator, and the Arbitrator shall resolve the matter according to the procedures set forth in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.8</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;The arbitration shall be conducted under the rules and procedures of AAA as in effect from time to time, except as otherwise set forth herein or as modified by the agreement of all of the parties. The arbitration shall be conducted in New York, New York. The Arbitrator shall conduct the arbitration so that a final result, determination, finding, judgment or award (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Final Determination</font><font style="letter-spacing:0.2pt;">&#8221;) is made or rendered as soon as practicable, but in no event later than sixty (60) days after the delivery of the Notice of Arbitration nor later than ten (10) days following completion of the arbitration. The Final Determination must be agreed upon and signed by the Arbitrator. </font>
        </div>
      </div>
      <div style="margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7.5pt;">
          <font style=" position:relative; bottom:4.25pt;letter-spacing:0.15pt;">3</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:7.5pt;">
          <!--blacklining:none;-->
          <font style="font-size:10pt;letter-spacing:0.2pt;">Section references are updated for Voting and Support Agreements that do not include Section&#160;8.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7.5pt;">
          <font style=" position:relative; bottom:4.25pt;letter-spacing:0.15pt;">4</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:7.5pt;">
          <!--blacklining:none;-->
          <font style="font-size:10pt;letter-spacing:0.2pt;">Included only in A.J. Kazimi&#8217;s Voting and Support Agreement.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:1.99000000000001pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Final Determination shall be final and binding on all parties hereto and there shall be no appeal from or reexamination of the Final Determination, except for fraud, perjury, evident partiality or misconduct by an arbitrator to correct manifest clerical errors. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;The parties hereto each may enforce any Final Determination in any court of competent jurisdiction. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;Each party hereto hereby irrevocably consents to the service of process by registered mail or personal service. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;If any party hereto shall fail to pay the amount of any damages, if any, assessed against it within five (5)&#160;days after the delivery to such party of such Final Determination, the unpaid amount shall bear interest from the date of such delivery at the Applicable Rate. Interest on any such unpaid amount shall be compounded monthly, computed on the basis of a three hundred sixty-five (365) day year and shall be payable on demand. In addition, such party shall promptly reimburse the other party(ies), as applicable, for any and all costs or expenses of any nature or kind whatsoever (including all attorneys&#8217; fees and expenses) incurred in seeking to collect such damages or to enforce any Final Determination. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY ACTION, SUIT OR PROCEEDING (I)&#160;ARISING UNDER THIS AGREEMENT OR (II)&#160;IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY OR OTHERWISE (INCLUDING, FOR THE AVOIDANCE OF DOUBT, ANY SEEKING EQUITABLE RELIEF). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">9.9&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Documentation and Information</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as required by applicable Law, the Stockholder shall not, and shall direct its Representatives not to, make any public announcement regarding this Agreement, the Purchase Agreement, or the Transactions without the prior written consent of Buyer and the Company. The Stockholder consents to and authorizes the publication and disclosure by the Company of the Stockholder&#8217;s identity and holding of the Covered Shares, and the terms of this Agreement (including, for the avoidance of doubt, the disclosure of this Agreement), and any other information that the Company reasonably determines is required to be disclosed by applicable Law, in any press release, the Proxy Statement and any other disclosure document required in connection with the Purchase Agreement and the Transactions. The Stockholder acknowledges that the Company, in its sole discretion, may file this Agreement or a form hereof with the U.S. Securities and Exchange Commission (the &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">SEC</font><font style="letter-spacing:0.2pt;">&#8221;) or any other Governmental Authority. The Stockholder agrees to promptly give the Company any information it may reasonably request for the preparation of any such disclosure documents. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">9.10&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Further Assurances</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Stockholder agrees, from time to time, at the reasonable request of the Company and without further consideration, to execute and deliver such additional documents and take all such further action as may be reasonably required to consummate and make effective, in the most expeditious manner practicable, the transactions contemplated by this Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">9.11&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Entire Agreement</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral, among the parties with respect to the subject matter hereof. For the avoidance of doubt, nothing in this Agreement shall be deemed to amend, alter or modify, in any respect, any of the provisions of the Purchase Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">9.12&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Reliance</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Stockholder understands and acknowledges that Buyer is entering into the Purchase Agreement in reliance upon the Stockholder&#8217;s execution and delivery of this Agreement. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.13&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Interpretation</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;When used in this Agreement, the words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the words &#8220;without limitation&#8221; and, unless the context otherwise requires, &#8220;neither,&#8221; &#8220;nor,&#8221; &#8220;any,&#8221; &#8220;either&#8221; and &#8220;or&#8221; shall not be exclusive. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; text-indent:20pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Any terms defined in the singular shall have a comparable meaning when used in the plural, and vice-versa. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;This Agreement shall be deemed drafted jointly by the parties hereto and shall not be specifically construed against any party based on any claim that such party or its counsel drafted this Agreement. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;The headings and captions used in this Agreement are for convenience of reference only and do not constitute a part of this Agreement and shall not be deemed to limit, characterize or in any way affect any provision of this Agreement. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Any reference to any Law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular. The definitions contained in this Agreement are applicable to the masculine as well as to the feminine and neuter genders of such term. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;References to Articles, Sections and Schedules are to Articles, Sections and Schedules of this Agreement unless otherwise specified. All Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. Capitalized terms used in any Schedule but not otherwise defined therein, shall have the meaning as defined in this Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">9.14&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Assignment</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the parties hereto in whole or in part (whether by operation of applicable Law or otherwise) without the prior written consent of the other parties, and any such assignment without such consent shall be null and void. This Agreement shall be binding upon, inure to the benefit of and be enforceable by the parties hereto and their respective successors and permitted assigns. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">9.15&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Severability</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Agreement, or the application of such provision to any Person or any circumstance, is invalid or unenforceable, (a)&#160;a suitable and equitable provision shall be substituted therefor to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b)&#160;the remainder of this Agreement and the application of such provision to other Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of such provision, or the application of such provision, in any other jurisdiction. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.16&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Counterparts</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each party hereto and delivered by each party to the other parties, it being understood that all parties hereto need not sign the same counterpart. Counterpart signature pages to this Agreement may be delivered by electronic delivery (i.e., by email of a portable document format (PDF) signature page), and each such counterpart signature page will constitute an original for all purposes. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.17&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Non-Survival of Representations and Warranties</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;None of the representations and warranties in this Agreement or in any schedule, instrument or other document delivered pursuant to this Agreement shall survive the Closing or the termination of this Agreement. This </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.17</font><font style="letter-spacing:0.2pt;"> shall not limit any covenant or agreement contained in this Agreement that by its terms is to be performed in whole or in part after the Closing or the termination of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.18&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Termination</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement shall automatically terminate without further action by any of the parties hereto and shall have no further force or effect as of the Expiration Time; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that the provisions of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9</font><font style="letter-spacing:0.2pt;"> shall survive any such termination. Notwithstanding the foregoing, termination of this Agreement shall not prevent any party hereto from seeking any remedies (at law </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:456pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">or in equity) against any other party for that party&#8217;s breach of any of the terms of this Agreement prior to the date of termination; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, however, that in no such event shall the Stockholder have any liability for any monetary damages resulting from a breach of this Agreement other than in connection with a Willful and Material Breach of this Agreement by the Stockholder. For purposes hereof, &#8220;Willful and Material Breach&#8221; means a material breach of this Agreement that results from a willful or deliberate act or failure to act by a Party that knows, or could reasonably be expected to have known, that the taking of such act or failure could result in such a material breach. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.19&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Agreement until Executed</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement shall not be effective unless and until (i)&#160;the Board has approved, for purposes of any applicable takeover Laws, and any applicable provision of the charter or bylaws of the Company, the Purchase Agreement, this Agreement and the Transactions, and following such approval, (ii)&#160;the Purchase Agreement is executed by all parties thereto and (iii)&#160;this Agreement is executed and delivered by all parties hereto. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">[Signature page follows]</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered as of the date first above written. </font>
        </div>
        <div style="margin-left:220pt; margin-top:8pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">COMPANY:</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:220pt; margin-top:12pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CUMBERLAND PHARMACEUTICALS INC. </font>
        </div>
        <div style=" float:left; margin-left:220pt; line-height:12pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:33pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">By:</font>
          <br >
        </div>
        <div style=" margin-top:12pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:253pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="white-space:nowrap; margin-left:253pt; margin-top:2.5pt; width:203pt;">
          <div style="margin-left: 0pt; width: 203pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:220pt; margin-top:2pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Name: </font>
        </div>
        <div style="margin-left:220pt; margin-top:2pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Title: </font>
        </div>
        <div style="margin-left:220pt; margin-top:8pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">BUYER:</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:220pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">NUVO PHARMACEUTICALS (IRELAND) DAC </font>
        </div>
        <div style=" float:left; margin-left:220pt; line-height:12pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:33pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">By:</font>
          <br >
        </div>
        <div style=" margin-top:12pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:253pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="white-space:nowrap; margin-left:253pt; margin-top:2.5pt; width:203pt;">
          <div style="margin-left: 0pt; width: 203pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:220pt; margin-top:2pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Name: </font>
        </div>
        <div style="margin-left:220pt; margin-top:2pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Title: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:220pt; width:236pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">STOCKHOLDER:</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:220pt; margin-top:12pt; width:236pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style=" float:left; margin-left:220pt; line-height:12pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:33pt;white-space:nowrap;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">By:</font>
          <br >
        </div>
        <div style=" margin-top:12pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:253pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="white-space:nowrap; margin-left:253pt; margin-top:2.5pt; width:203pt;">
          <div style="margin-left: 0pt; width: 203pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:220pt; margin-top:2pt; width:236pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Name: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Schedule&#160;A</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:32.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:340.36pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares of Common</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.167pt 0pt; width:340.36pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">[&#8226;]</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.345pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">[&#8226;]</td>
            <td style="padding:0pt;padding-left:27.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="ANC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:right; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Annex C</font>&#8203;</div>
        <div style="position:relative;margin-top:9.9pt; text-align:center; width:456pt;">
          <img src="lg_velocity-4c.jpg" alt="[MISSING IMAGE: lg_velocity-4c.jpg]" height="95" width="92" >
        </div>
        <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PERSONAL AND CONFIDENTIAL</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">April&#160;15, 2026 </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Board of Directors </font> <br ><font style="letter-spacing:0.2pt;">Cumberland Pharmaceuticals, Inc. </font> <br ><font style="letter-spacing:0.2pt;">1600 West End Ave #1300 </font> <br ><font style="letter-spacing:0.2pt;">Nashville, TN 37203 </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dear Members of the Board: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We understand that Cumberland Pharmaceuticals, Inc. (the &#8220;Company&#8221;) proposes to enter into an asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;) by and among Apotex Inc. a corporation incorporated under the laws of Ontario, Canada and Nuvo Pharmaceuticals (Ireland) DAC, an Ireland designated activity company (&#8220;Apotex&#8221;) and the Company, pursuant to which Apotex who will integrate its branded U.S. pharmaceutical business with the Company&#8217;s commercial operations by acquiring the rights and related assets and certain related liabilities of the Company&#8217;s portfolio of commercial brands (the &#8220;Transaction&#8221;), which includes Acetadote</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> </font><font style="font-style:italic;letter-spacing:0.2pt;">(acetylcysteine),</font><font style="letter-spacing:0.2pt;"> Caldolor</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> </font><font style="font-style:italic;letter-spacing:0.2pt;">(ibuprofen),</font><font style="letter-spacing:0.2pt;"> Kristalose</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> </font><font style="font-style:italic;letter-spacing:0.2pt;">(/actulose),</font><font style="letter-spacing:0.2pt;"> Sancuso</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> </font><font style="font-style:italic;letter-spacing:0.2pt;">(granisetron),</font><font style="letter-spacing:0.2pt;"> Vaprisol</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> (conivaptan), Vibativ</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> </font><font style="font-style:italic;letter-spacing:0.2pt;">(telavancin),</font><font style="letter-spacing:0.2pt;"> and Talicia</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> </font><font style="font-style:italic;letter-spacing:0.2pt;">(omeprazole, amoxicillin, and rifabutin)</font><font style="letter-spacing:0.2pt;"> (the &#8220;Products&#8221;). The consideration for the transaction includes a payment at of $100 Million in cash at the closing of the Transaction (the &#8220;Consideration&#8221;), plus reimbursement of inventory transferred, and for transition services provided. VelocityHealth Securities, Inc. (&#8220;VHS&#8221; or &#8220;We&#8221;) has been engaged by the Company to present a valuation of the Products to the Company in connection with the Transaction, and to assist the Company&#8217;s Board of Directors in its evaluation of the financial terms of the Transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">VHS, as part of its investment banking business, is regularly engaged in the valuation of businesses and product related assets in connection with mergers and acquisitions, private placements, product licenses, and other financial transactions. We have completed over 125 relevant transactions with over 100 in the specialty pharmaceutical sector, including M&amp;A, financings, valuations, and licensing transactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In conducting our analysis and arriving at the valuation, we have, among other things, (i)&#160;reviewed the draft Asset Purchase Agreement; (ii)&#160;reviewed data furnished to VHS by the Company&#8217;s management, including certain internal financial analyses, budgets, forecasts, reports and other information; (iii)&#160;held discussions with senior management of the Company concerning the Products and their prospects, including recent financial performance; (iv)&#160;reviewed the valuations of publicly available patented pharmaceutical product transactions that we deemed comparable in certain respects to the Products; and (v)&#160;prepared a discounted cash flow analysis of each Product on a stand-alone basis and as a basket of Products. In addition, we have conducted such other quantitative reviews, analyses and inquiries relating to the Products as we considered appropriate in preparing the valuation. It is understood that our valuation is solely for the use and benefit of the Company in its consideration of the Transaction. </font>
        </div>
        <div style="margin-top:60pt; text-align:center; width:456pt; line-height:10pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">VelocityHealth Securities, Inc. &#8226; 95 White Bridge Rd., Suite 409, Nashville, TN 37205 USA &#8226; VOICE: +1.615.352.9953 </font>
          <br >
          <font style=" text-decoration:underline #FC0014 solid;color:#FC0014;letter-spacing:0.16pt;">www.velocityhealth.com</font>
          <br >
          <font style="letter-spacing:0.16pt;">a member of FINRA/SIPC</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:389pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">VHS has assumed, without independent verification or any responsibility, the accuracy and completeness of the financial, legal, regulatory, tax, accounting, and data furnished to, discussed with, or reviewed by us for purposes of this valuation and have, relied upon such data as being complete and accurate. In that regard, we have assumed that the data, including the forecasts, have been reasonably prepared on the basis reflecting the best currently available estimates and judgments of the management of the Company. VHS has relied on the data for purposes of our analysis and this valuation. We express no view or opinion as to the data or the assumptions on which it is based. We are not legal, regulatory, tax or accounting advisors, and we express no opinion as to any legal, regulatory, tax or accounting matters. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based upon market multiples typical for acquisitions of branded pharmaceutical products, our valuation analysis, and subject to the foregoing, we are of the opinion as investment bankers that, as of the date hereof, the Consideration to be paid to the Company from the Buyer in the Transaction pursuant to the Asset Purchase Agreement is fair and reasonable to the Company, from a financial point of view. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Very truly yours, </font>
        </div>
        <div style="position:relative;margin-top:2pt; width:456pt;">
          <img src="sg_velocity-bw.jpg" alt="[MISSING IMAGE: sg_velocity-bw.jpg]" height="61" width="111" >
        </div>
        <div style="margin-top:5pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">VelocityHealth Securities, Inc.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">C-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.31pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="position:relative;padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:-8pt;margin-left:0pt;width:595.31pt;">
        <div style="position:relative;z-index:-1;margin-top:6pt; text-align:center; width:595.31pt;">
          <img src="px_26cumberlandproxy1pg01-bw.jpg" alt="[MISSING IMAGE: px_26cumberlandproxy1pg01-bw.jpg]" height="993" width="767" >
        </div>
        <div style="margin-top:13pt; width:595.31pt; line-height:3pt;color:#FFFFFF;font-family:Times New Roman, Times, serif ;font-size:1pt;">
          <font style="letter-spacing:0.02pt;">2026 2. To authorize the Board of Directors to adjourn and postpone the special meeting to a later date or dates, if necessary, to allow time for further solicitation of proxies if there are not sufficient votes present in person or represented by proxy at the special meeting to approve the Transaction Proposal (the &#8220;Adjournment Proposal&#8221;). NOTE: Such other business that properly may be brought before the special meeting or any adjournment or postponement thereof, including matters incidental to its conduct. The Board recommends a vote FOR Proposals 1 AND 2. Shareholders will be asked to consider the following proposals at the special meeting: 1. To authorize and approve the sale of the Company&#8217;s FDA-approved commercial products and related assets (the &#8220;Transaction&#8221;) as contemplated by the Asset Purchase Agreement, dated as of April 22, 2026 (the &#8220;Agreement&#8221;), by and among Nuvo Pharmaceuticals (Ireland) DAC (&#8220;Apotex&#8221;), Apotex Inc. (&#8220;Guarantor&#8221;), and the Company, which may be deemed under Tennessee law to be a sale of substantially all of the Company&#8217;s property and assets otherwise than in the usual and regular course of business (the &#8220;Transaction Proposal&#8221;). CUMBERLAND PHARMACEUTICALS INC. FOLD HERE &#8226; DO NOT SEPARATE &#8226; INSERT IN ENVELOPE PROVIDED Signature Signature, if held jointly Date 2026. Note: Signature should agree with name printed hereon. If shares are held in the name of more than one person, EACH joint owner should sign. Executors, administrators, trustees, guardians, and attorneys should indicate the capacity in which they sign. Attorneys should submit powers of attorney . Please mark your votes like this X CONTROL NUMBER PROXY THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; PROPOSALS 1 AND 2. PLEASE DO NOT RETURN THE PROXY CARD IF YOU ARE VOTING ELECTRONICALLY. FOR AGAINST ABSTAIN FOR AGAINST ABSTAIN YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. IMMEDIATE - 24 Hours a Day, 7 Days a Week or by Mail Vote by Internet, Smartphone or Tablet - QUICK EASY Your Mobile or Internet vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned your proxy card. Votes submitted electronically over the Internet must be received by 9:59 p.m., Central Time, on June 23, 2026. INTERNET www.cstproxyvote.com Use the Internet to vote your proxy. Have your proxy card available when you access the above website. Follow the prompts to vote your shares. MOBILE VOTING On your Smartphone/Tablet, open the QR Reader and scan the below image. Once the voting site is displayed, enter your Control Number from the proxy card and vote your shares. MAIL &#8211; Mark, sign and date your proxy card and return it in the postage-paid envelope provided.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.31pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="position:relative;padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:-8pt;margin-left:0pt;width:595.31pt;">
        <div style="position:relative;z-index:-1;margin-top:6pt; text-align:center; width:595.31pt;">
          <img src="px_26cumberlandproxy1pg02-bw.jpg" alt="[MISSING IMAGE: px_26cumberlandproxy1pg02-bw.jpg]" height="1003" width="775" >
        </div>
        <div style="margin-top:13pt; width:595.31pt; line-height:3pt;color:#FFFFFF;font-family:Times New Roman, Times, serif ;font-size:1pt;">
          <font style="letter-spacing:0.02pt;">2026 FOLD HERE &#8226; DO NOT SEPARATE &#8226; INSERT IN ENVELOPE PROVIDED PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS CUMBERLAND PHARMACEUTICALS INC. The undersigned hereby appoints A.J. Kazimi and Kenneth J. Krogulski, or either of them, as proxies, with full power of substitution, and hereby authorizes each of them to represent and vote, as designated on the reverse side, all of the shares of Common Stock of Cumberland Pharmaceuticals Inc., held of record by the undersigned on May 12, 2026 at the Special Meeting of Shareholders to be held at the Cumberland Pharmaceuticals Inc., 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203 on June 24, 2026, at 10:00 a.m. Central Time, or any adjournment(s) or postponement(s) thereof, with all powers which the undersigned would possess if personally present, upon and in respect of the following matters and in accordance with the instructions specified on the reverse side. THIS PROXY, WHEN EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED &#8220;FOR&#8221; PROPOSALS 1 AND 2. PLEASE SIGN, DATE AND RETURN THE PROXY IN THE ENVELOPE ENCLOSED TO CONTINENTAL STOCK TRANSFER &amp; TRUST COMPANY. THIS PROXY WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED STOCKHOLDER. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED &#8220;FOR&#8221; PROPOSALS 1 AND 2 AND WILL GRANT DISCRETIONARY AUTHORITY TO VOTE UPON SUCH OTHER MATTERS AS MAY PROPERLY COME BEFORE THE MEETING OR ANY ADJOURNMENTS THEREOF. THIS PROXY WILL REVOKE ALL PRIOR PROXIES SIGNED BY YOU. (Continued and to be marked, dated and signed on the other side) Important Notice Regarding the Internet Availability of Proxy Materials for the Special Meeting of Shareholders of Cumberland Pharmaceuticals Inc. to be held on June 24, 2026 To view the Proxy Statement please go to: https://www.cstproxy.com/cumberlandpharma/sm2026</font>
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>lg_cumberland-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_cumberland-4clr.jpg
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MQ #&  $  @(# 0$             !P@!!@0%"0(# 0$  P$! 0
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MQO[*!0*!08XT <10#P% N?"@S08-_"@S0*!08)(H,^%Z#'&@S0*!08)L*#-
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M(2L)]--R%/JXJ^UZO95K5W-->K$<T%M4WMF>2W#;:&DI;;2$-I 2A"19( X
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M,95Z>^X%^NA6/92XV&R"$\2?>N#7(I$UF?)RUYB\5\)2**B3,+^B:" \/O\
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<4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>lg_velocity-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_velocity-4c.jpg
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M%!04%!04_\  $0@ E "0 P$1  (1 0,1 ?_$ *D  0 !! ,!
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MW_Q.IGRWI:>\IN&[(ZD_M\\G\-E<0TM7!7#X5<>5ZTX>1N/<F6/-'!(Y5O\
M*Q]+71^KLZ?+J-V0[<J2!=2>8^BK^A\>KK/2L&10"@% * 4 H!0"@.+\/;Y4
M8()W(U9JW6>6D;:;7-H7DHW1^_:@>_\  QR5\+K(XK<3?X6D_$3[!4:Y6XZ1
M.DPH0Q+?W[OB?A1E>T^R.E=IXK\C&E>2U5DQ?.:EF@*FRU&Q*;_D:"A=+8Y>
MVML(*"HBFRLJ>1/>DR2P+"PX>ZMA$-..X/K8U9JE)/4GT([EN7%4=(_A7,9B
MI>?6?<N5^]P^UTK>]4JEE[%V''M5ZOR:N+;4"/')]JWBO[DU:X<=9P_,TZQA
MVF\ 38>'5YU9'"D);P]ONG]PTN9G&+1B=9%(/SB4VCRB+<)"4\>KP#@XCQN*
MAY&)&[I6AG6<&YCO83W)]^'175_+T=A2[':\S\5V1M1N$TN/K7"-W@/2%!2I
M>/;%DD+N?44@"_6#\2>/Y37C%NRK]N?B1[X]P^SNK,Q7O6;FO^%]?EK[43OU
M&UP+\.'&IYR!VH!0"@% * 4 H!0%FS4:?DV%P($A4$N_"_/;_P"XV@\PT#^<
MCDKDGGSHS;;:C+>>GJ.<#IK%:9@)Q>%CHBP$75T)3=:W%DJ4XXLDE:E$W)56
M$DE1"[=G=GO3=2\5DU"@-/NY6*MG4^:?6GI3/QL=:#Y^D@H-<[Q&-+J9]HY0
MFI8"6V+GZSOV(0K:=UIE"D?KY*/&0OQLPP5$?[Q5IB+0V<'S'*MR*[3;ZIQR
M9P4@T!BFI]!8K5#<5R2XN+F<<XF3B<Q&NF5$?0 .I"KV*56LMM5TJ' ^=:KE
MM2T[>DG8N;<L;R6F,_''9+X=I?,:[*4P&IP3\ZV 'B@$-K/+K3Y ^7A6XC74
MDZQU%PK!J% * 4 H!0"@% * 4 H!0&KO=A#/_KIPO^ICY3"EVX? M*K'V_%5
M+Q%T<=&L^J<D2_;O1KT>QEV[,L"<9LX,D1TG,Y29-_S):(BC[6C5AB*D#B^/
MW-[)I]*-C*E'/B@% * 4 H!0"@% * 4 H!0"@% #RH#7_NHB)7MTC+JX+C2"
MT?,)DMJX?6FJ[/A6"?0SON2KV[DSA]4&_099VY8Q[#[)Z-Q\E'0]\B7UI]LI
MYQX'Z0NI=A4@CD^*.N5/M)4K<5HH!0"@% * 4 H!0"@% * 4 H!0"@(@[D,0
M,AM!J $C_BI9E $?R.A!M;V+J+F:;39TW+5[[>?%?5&4?2F21IO'#%X#%8U)
MLF%#C1P+?V64H_A4B*I%(YVY)RG*3VLN]>C6* 4 H!0"@% * 4 H!0"@% *
M4 H#&M=X@9[2F6PZT]29;(:*>=[K2?X5XG&L*$S!N_:R(S^EF2(%DI'D *]D
M1ZSFA@4 H!0"@% * 4 H!0"@% * 4 H!0%/*M\NOKZNFWQ='X_9:L2,QJ5 K
/)@4 H!0"@% * 4 H#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>sg_velocity-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sg_velocity-bw.jpg
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M%!04%!04_\  $0@ 8 "L P$1  (1 0,1 ?_$ 'D  0$!  (# 0
M   (!P4& @,)! $! 0                    $0  (! P0! P,"! 0#"0
M  $" P0%!@ 1$@<((2(3,4$4,B-184(6<5(S%8%B<H)#4X,E%Q@H"1$!
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M0% :#&J-A/@W6$IY4M/&1NM5<(V ^29@0>#J#_F4+M'HJI0 !L/0#Z#1#0-
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M&Q/VT50^6Y;B75&%5&1Y)5K;L9L=.B<C[G(0".**-?J\CG954?4Z(DK#.O\
M,O,/,Z7M[MJ*2U]+6V9SAF&,64UL(.PEEXD;*Y ,LOUDVX)M& =%5;GV>89T
MY@U3E&1R1VW'+1$D%+24Z(K2,%XPTM+$"H+';BB#8 #<[*"01AW4/668]JYM
M3^1'>4#4]3%R;KO!)AO!9Z-SO'43HX&]2P 8;CD#LYV(1(BOV=M>1^4_WE+T
M_P"/6/KF79-,&%\KI!RM=I ]A$K\XU,B,1SYNJ(VRGDY**&E]&/W-+@XG[S6
MACS&:JE>&GH!&#%1%4^-)_@+1&3D'/[9(XE=_=OHCE,'[:PCL2_97C>+5KU5
MUPRM_P!MOD;Q/&BS<G3>-R.+KSBD3<'ZJ?ML2&9]T>875W3=VEQB=*O(\L@0
MM5VRTB-DI&X\E6IFD=50MO\ I4.RCU91Z;A@%I\[^Y<AOUCHK3UW;4M^676*
MW8U\[U>\ZB=(9HQ.71)'!D5?E5%1#^I6^FBOH%HB4_([L&_]D953>+74E21D
ME[7EGEZC]8;792H,L3L"/<Z./D&X]K+'ZM+[2J)P/";!UQA]HPG&8/@LMFIU
MIZ=3MS=MRTDLA  +R.6D<[>K$Z(['H&@ZOV/G%LZUP2_YU=_=0V.CDJC%OQ,
MLH]L4(.QV,LC)&O\VT&)>&W7]PM>%7'MS+"TV=]H5+7RNFE&S1T,CN],B[C<
M"0.TWIZ<60?TZ*V/MRQR9-U9FN/PQF6HN5CN--!&J"1C+)2R!.*G?<\MMOYZ
M(QGP-OL=W\=[30*5,MCN%PM\R@DD%IS5CD"3M[:@:#U>75@O.._V=Y"8A2M4
M9#UM7K)=XHO1I[#4^E0KD$$JI]IV'HDCMZ :*H3$LJLF<8S:LNQNI%78[Q3Q
MU=%./0E)!OQ8?TNIW5U/JK @^HT1RE34TU%335E9,E/24Z--45$S"....,%F
M=V8@*J@;DGZ:"0>J;C!WCW]E7D1=YDAZNZZIYK'A=94[0TS&-':IK2TBJ.*Q
MO)*S/L5$J _HT5P5HM]T\W>SWR*_13T7CC@]5)%9:'UB>\UPX@L[; [,H#2?
M^'&1&NSN[@+!R/(<8ZYQ&MR"]2PVC%<?I/DE*JL<4,$*A$CBC78;GVQQQJ/4
MD*HW(T1-/6^,7WR-RRF\@.X:);=UI:%>;K?#:MP8!$&)-SK58\22%#+R&S>A
M_P!-5YE=Q[,\GL'I['FEBZZN4F09=9K!<KBUQM"?DVVW2P0L(VJ*Q=XE;G^A
M5Y;L.)V)&@_/X3859L;Z-M&24H^?(,Q:6[7ZY2-\DTTPFEBC0N?7C&@_23^M
MG;ZL=$;W?[S28Y8KID-?R_!M-)45]3P&[?%2Q-*^P_CLIT'S7ZS[/R3K#I.M
MJ,/C>?N/N[(JA<:IH0KRP4<,@IFJE5M^3-4/-##R 4ONWK\;#17MRGJN+%;C
M:_'R"[*V69#"N6]Z9]4-S_$MD)_*:G$TOJ(8N)G<N=YY3$6(W"*&&=C]M?G=
ME4.2=8B3'L;PZ*"UX% %3Y:2BH=^$K!@P,TTC25$C-R;FYW)/KH+.7S'O57U
M-AF-X7PS+R*RRD%.::BB1H:*H+NAGJ$7:,2A5Y_%Z(/5WXQC9@VOQLZ&CZ8Q
M>IJ[].EV[+R24U^57P[R.TTIY_CI(WN9$8L2Q]9')8_TA2-NT#0-!'_G7=Y[
MW#UKTS0SE)\WR"#\R./?F8(I(Z>,'[<3)4!MC]T'\-%5O;K?16FWTEJML*TU
MNH88Z:DIX_1(X85"(B_R50 -$?IT'S^R;'^^O%SL',Z/IC&7O.'=E5,38W/3
MPM6I;JYG9PC1[-P:,22HOR^QTXL2>#*"KELM#=+AAUOMN=14M;>:JVPT^20Q
MH#1S5,L 2J54;<&-F+CB?Z=$2^.N^[/%ZZ7&X=+4?_N!T_7SO63X'42LERML
MDC;G\)_<77UV]JLQ'ZD+#Y-%=<R3(/(SRR^+ K5AU9U7U?4LHR>\782K55$2
M'=H4^2.!G4D;?'''[CZ2.$W&@]'DM36[$*3J[Q$P&L3%L3R2:'_?;G,_%S1O
M4_$/E<\%<RR_+-*-QS=57T4[:"M[+0X)T_A=JQJ.MH[!B]DIDI*62X5$-,O%
M 2SR22%%+N>3NW]3$G1$"]V>0([T[DMV&XM8J[..N,?E9[7C%M+Q)?+K$I J
M*HJCM^(C';Z#]L,=TYDJ5NEO\>.W^YXJ>N\CLK>SXXFQI.M<49*6BA1>01)Y
M8RZ-Q!V&QE/'T$@T%!6/J7K?&L-K>O[!CE';\2N4$M)<;?"A'Y,50ACD^:4D
MR2,58KS=RVWW]-$3%T7<\C\=.\JCQ@R*L-QP2_I->,"N$Q EA$OR2?&3Z#:3
MXI4=?I\R\E $AW*JOL/':K+L!RC%:&84];>[376VFG+%%26KIWB0EE!( +#?
M8?31$L^)'B9?NM+Q+V'VRD+9/0Q-1XU:Q.M6MOB/+Y9S(A9 [!F6-4)"JS$^
MYO:5U7R%ZKZCRCNR3L/+NW[/9L.ND-+3Y!9:6J$UVD-"B1&")*<R?MN(D+.Z
M^QOZ3Z:#D[OVSX.+<K<,>PZ?,+W:+<;'::.RVJJD)HBCQE E2T"2-M(W[SAI
M-VWY;Z#C^GZ*^X'65-5T7XXWJFOEP^2/^YLYN HWBI"P)B"31Q\4! ]L;<FV
M]2WIH-DI,-\N\U5FR[/['@%NJ/<UOQ>W_P"X5L:;_P"G\]6=D;^+QNV@UCK;
MKN3KRWU=-4Y5?<MK[A*L]7<,CK362!U7CQ@0*JPQ_P#(H_Q)T1W;0-!QMPQZ
MP7:NMUTNEKI*ZYVB1IK565,$<T])+(O%G@D=2T;$>A*$:#DM T#0- T#09AW
M1T'U]WM::2W9I3SQU=N9WMEVH)%AK*?Y0 ZJS*ZLC<5+*ZD>@^^@Q>T__GMU
M)$[39-?L@R&7U6(3544"(FWH/9$6)!._Z]OY:*Z%U-G?_P +DN77/;V$U4%O
MJ:^>IMO8-FITJ(;A3GB$65B5)X@;A>?).6QC'U(;#4>=WCC#31SQWVMJ)7!)
MI8K95B52/H"9$1-S]MG.@XM_.3$+N4INOL"R[+;A+_I14MO$<3#T]>:O*VW_
M )>@G_*>P^[NX?)S'+CB/6XL^=X'1&1,=N\W(Q03@R?/72-^-P4K4QE4W!]1
MMN6T&^S=<>:F:P(N2=H67#:6<\IJ3'J-I9XE)WXB5HXWW'_+/_Q.@\D\([/?
M9_S.S>RLMS*K(V<35OX\##Z;<'^=@/Y+(-!WG&_$+QWQF)4I\(I+A*IY&>ZO
M+<&8[[^JSNR?\ NB-:LF,8UC,)IL;LU#9Z<C8Q6^FAI4('\HE4:#E= T#0-
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09HAH&@:!H&@:!H&@:#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>px_26cumberlandproxy1pg01-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 px_26cumberlandproxy1pg01-bw.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !&
M  #_X0,Q:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 Y+C$M8S P,B W.2YF,S4T969C-S L(#(P,C,O,3$O
M,#DM,3(Z,#4Z-3,@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;7 Z
M0W)E871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<" R-2XU("A-86-I;G1O<V@I
M(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.D,T-D,R-4,V-$4W13$Q1C%!
M0T(X0C1%-C$R,D$Q0T$R(B!X;7!-33I$;V-U;65N=$E$/2)X;7 N9&ED.D,T
M-D,R-4,W-$4W13$Q1C%!0T(X0C1%-C$R,D$Q0T$R(CX@/'AM<$U-.D1E<FEV
M961&<F]M('-T4F5F.FEN<W1A;F-E240](GAM<"YI:60Z0S<S,#-#034T13=!
M,3%&,4%#0CA"-$4V,3(R03%#03(B('-T4F5F.F1O8W5M96YT240](GAM<"YD
M:60Z0S<S,#-#038T13=!,3%&,4%#0CA"-$4V,3(R03%#03(B+SX@/"]R9&8Z
M1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME
M="!E;F0](G(B/S[_[@ .061O8F4 9,     !_]L A  $ P,# P,$ P,$!@0#
M! 8'!00$!0<(!@8'!@8("@@)"0D)" H*# P,# P*# P-#0P,$1$1$1$4%!04
M%!04%!04 00%!0@'" \*"@\4#@X.%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 9R!/L# 1$  A$! Q$!
M_\0 L@ !  (# 0$! 0            8'! 4( P(!"0$! 0$
M      $"$  ! P,# @0"!08'" T' A<" 0,$  4&$1('(1,Q(A0(015183(C
M%D+2U!=7&'&!4C.45I9BDB14M'65-Y%R0W.STS1T)36U=CBAL=&"LE.3-@EC
M@X2D5<'BQ-4F&41E9^&BH\-%A:5F)Q$! 0$! 0$              !$!02$Q
M_]H # ,!  (1 Q$ /P#OZ@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@I?F_GN1PA<+&Y=<4>NF)W@T9<OL:6@+'?$M7&R
M85DM2[?W@?>#OT).FU5HN8E?(G+.,<><<O<DR71N%I-AEVTML.(*SW):(4<&
MB5%Z&B[E+1= 12T72@TV&\V1KOQ0]R]G-I_!F.(A/Q@?D^K=>B(H@VZB(RTJ
M*ZXNQH-JJ?E5.A)0BH0]Z-]NX2KIB'$%[OF+1B5#O /."(B/BIHQ#D-BJ)XI
MWNE%BY^&><L.YLL\B?CJN1+I 41N=GE[?4,;]=AHHJJ&V6B[33^-$7I1-QJ>
M)>>F>5,TS'#F["=J+$GC9*84I)"2%"0Y'U0$:;V:]O=]HJ$?O)?/+/'7)>&<
M='83N)Y>[&9&XC*1A(RR9:1=5:5H]^W7=]L?HH1'N7O<Z_Q?R%&X\M^$RLHN
MDN(S+C>BE*#SA/DXG;!@8[Q$J=O7HO\ %0B*N^]&78GXKF><57_&;-(=1KY@
M^IKHJ]5V@_&CH:HG7:AZT6.HK5=+??+9"O-ID#*M=Q8:EPI+?V'6'P0P--?@
M0JBT95'?^?V<8YQM/#E[Q\XT>^"R5LR-90JVZLD#1M.QVD5-7P)C^<\>M%B8
M\M<D6_B; [IG%QC+-"!V@8@"XC)R'WW1: $-1+3[6Y5VKH**NE$1NV\\V./P
M[#YCSF">,VN>)'$MG=2;)>0G#%@6M :W&\(=P1T1$'JJHB*J%BH@]Z61R83F
M0V_AV]2<,;55*_)(=[*-#]HU48)M)I\?OM/KHL6[8N>\?S/BVZ\D8';I5^F6
MEM?4XN";+B,E-/N2%L7?%%W"8"2$GAU140D4[=?>U?;#)B0[YQ#=[9,GKM@Q
MYLIR.X^NY!T:%R"*FNJHGE^*T6+$PKW"9-DL#++C?^,KOBT?&+/)O('<C=;&
M6<45-8X$[%9025$\?-_!1(@%F]Z&3Y%#^86#AN]76 AJTLJ ^]*9[@HBD.]J
M 0ZIJFJ:T6+=X<Y@R3E"7=HU]X_NF%!;6V7&'KIW=LE7B-%$.[&8ZCM15TU\
M:)N)IR'EPX#A%]S,X:SQLD1R8L(7$95WM_D[U$]NOT[5HB 8][BL:N'"I<UY
M%!<LMH WF?EP.),?-UM]8[;;:[6D(G"3IJB(/BJZ(JT6*K+WKWUJWADLCB&\
M-8.9H@Y"LESL*!+HA(JPD:55^"=[37IK18Z7P7-\?Y%Q6W9CC#Y/V>Y IM=P
M=CK9@2@;;@ZKM,"11)-53Z%5-%HRB_./+;?"V%AF#MH*]"<UF!Z,)"153O@X
M6_>K;OAV]--OQHN('RK[IXW&&/X+?G<6<N29M;?F@1QFBPL5.U'=[:EV'-Z_
M?Z:Z#X4(L?COE:S9_P 81N3T96W6XX\J3.BFXCQ1E@DX+PJ:"&NG;4D7:FJ:
M+05+P[[OXG+F?0<&8Q%VU%-;DNI/.>,A 2,T3NBMI';UW;=/M=*$8E\]X%U@
MYSD>#X_QC<LCFX[-DPWW+=*-XS"*\K/>5IJ(ZH"2HGBJ^/C0B0\7>ZVQ9YF@
M\>Y)C<_#<LD(J0XEP+>+CH@KBM$I-LFV:BFX-P:%X:ZZ(HC<<T^Y3%.()\3'
M&X+^29K-039L4$D @%Q=&^\YM/:KB_8 0(E\=---1F(%"]YIVF[PX/*?&UYP
M:VSE1&;E)5U]$1?RU;=BQ244_*[>Y?J6A%L<R<SP.)\ B<@1K>F1VZ=)C1XP
M1Y(L-FU+;-T'A=V.H0J(=-$ZZ^-#,5 'O$R]8(W8N%+^EG)I)/S!''U8].0[
MD=0_0(*BHKJA;M-/C0B?6CW)VK+.)[CR5@^.3[]<[5(9AS<3:U2>+SSC8JJ*
MRV]N! /N(8@NJ(NNBHN@BM)OO9OUMND6QW'B"[Q+U.VK"MLB2ZU*?0R4![31
MP4,]2143:GC18NCAOEK(>45O*7[ [GA/RKTW86Z=W_"O4=W=V^['8_F^VF[3
M7[2>%$0&W>\+%KAS&G%B68V[>=S<LK.2^K$FCDBJM J,=K[)O)VQ+N^"H7U4
M(O#/<K'!L+OV8'$6<-DA/3EAB?:5U&!4MF]1+;KIX[5HB <"^X&Q<Z6ZYNQ(
M"V6]VET1E6EU]))+'=3[M\#0&]PJJ$))M\JIU\4U+N,:Q>X%+[RGFO%\?&G?
M5X?!ESQFA*1Q9A1"9%&A91E% C5[IYB\/KH15]Z]ZV18U&:F9)P]>+/%>/M-
M/SY+L5LW--VT2>@BBKHFNB46+"XM]P66<BY7#QZY\6WG&+9+8=D)?)JO+&%&
MV^X":G$9%=_@*[_]FB1?%$4/S=[D3X>RZS8A&Q&1DT^]11DQ4BRNRZKAO&R+
M(-"P\1DJATT^G32BYB&![U LUTA1.1>-KWB%MF'L2?*5PU$?!31IV-'(Q'74
MMBJNG@BKTH18G+_N#A<57;"[<S95OT?,C)(TQF6,<&FT<8 31.TYO0D?0DZC
MX?70BYZ(H7FOW)N\0YI:,*B8?)R>X7B$W,B^DE=ITC=?=8%D&A8>(RU;UZ?3
MX47,1)?=GR%^PC)?_KK_ /!]".GF)8G ;G21]*),B^\+JZ=I%'<2$JZ:;?C1
M'//%7N\QOE#D?\ ,V-RUM24E?*+J[*1U)11M3$5:[0=M3:$C3SEHJ;>NM%BZ
M\^SK'^-L3N.99.Z35IMP"3@M#O><<<) ;;;'5-3,E04U5$^*JB(JT1S47O7O
MH6],E+B&\#@ZF@ID*R7$84%+:A:^B[6J_1W]->FM&HNYSFG')G#LWF3&V3NM
MGBPG9J0#)(S_ '&%VN,.+HX@&)(J+T)/BFJ*BT2*6M/O+RN_00N=CX8OESMK
MJD+<R$\_)8(@7:2(XW (55%Z+UHL7+PYRK?^4(]W?OV#W+"BMCC ,-W3N:R4
M>$U)0[C#"^3:FNB+XI1-?G.G+LGA;%(V6CCQ9! <F!"F W*2(L?N@1 XJJT[
MJ*D.SX=52AB<8KD<#+L9M&56Q?\ H^\PV)\=%5%40D-HYM+3\H==I?71%7<0
M^X2)R]D660+;8EM^+XLI:Y&],$VGT5TQ:7M]H-B&VV;JKW"VHG7QUHL0.Z>\
MQJX9#-L?%7'UUS]B JB_/A&XR!(BJB& -19)]M51=I&@:_10B9\/>YS%N4[V
M[A]PMDK%,Z90R^1W!=W=1I-QBTXHMJI@FI$!MB6WJFJ(6@B*9O[L,IPF[7V+
M,XBO3ECLDR1$6_&Z\Q#=:8>5D'T-81 (.:(H^=4ZIU6A'QAONURG,[A96H'$
M-Z2R7B6S%2^-.O/PVVW7D9-[N#"0"%OJI>=/!>J4(]<Q]VUQQSD:^<<V/CB?
MDURLKB@1VZ41NN-B &3G9;B.D(IO1%ZK0C-Q'W,9QDN46?'YO#5_L\.YRVHK
M]UD^H[,4'205=/?";3:/BNII0CHIYQ6F7'1!7" 2) 3Q)4371/X:(Y+O/O2R
M7'(@S\AX<O5I@D:,C*GR'HK*N$BJ@(;L 4W*@JNFOPHU$VXQ]Q^5\AY7:+#+
MXJO-@LUV!QU,ADD\<-ML(YO@:D4-H5%S:@BO<_*3QHD8&>>[NT6+,9&"<>XG
M/Y R"$9-30MQDVT+K:[7 ;5MF0;B@O0U1M!1?BM"/?COW:6/)\N9P+.\9G8#
ME<LQ9@QKD2N-./.+H#1&XU',#->@;F]I+TW:Z(HC;<Y^XU>&,AL6.M8J_DDN
M_,D[&2/*[#G<1U&A:%M&'E,B5>FG\%#,0C]]%RR38H<A<87[%+3)<1KYA(WE
MHJ^*HV_'C;M$354$E73P1:$=/VFZVV^VN'>K/)"9:K@RW)ARFEU!UET4("%?
MH5%HCGG,/>%B^(<MEQF_93D6^--C6ZXY&,L0:CN/[.Z79[2J0L*>T_O$742^
MCJ6)KSOS5<N$K;;+\N*.9!CTQTHLV<S,2,41]=%;$VU9<U1P4/:6Y$U':OBE
M#,26\<K8C:.,'>6?5)(Q9( W&,8*@F]W41&F$1?!TW"%K:OV3Z+IHM$:KA#E
M6Z<PXJ[E\G&#QRTN/DQ:U=EI+*6+6HNN"B,M;0$TV(O754+PTZEU9M$*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"L\_P"?.,.-+PW8,INK
M@7=6DE2(T2,_,*-&)=$=?[($@"JK\?-X+IHJ46/;,N=.,\&M5FO%YO'>BY"U
MZFS! :<FNR8R CA/"#(DJ-B*HJD6G^S0CVOG-G&F/X;;,]F7QM['+T0MV9V*
MVY(>F.DJIVVF0%7%)%%4-%%-JIH6BT(\K9SGQ?=<'G\B,7T&L8M3BL7-Z0VZ
MT_'D(J)V38(>YW"4D0105W:]-:$9_'7+.#\IQYSV(3C??MC@M7&#)9<BRF%<
M15!3:=02VFB+M).BZ*GBBT1-J!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!01+DOC^R\H85=<+O@HD:X-:,24%"
M.-)#S,OAX>8"1%TU\R:BO15H.!^.L(S_ )3SJS>WG-9@_A#C*5/D75IHUW*P
M$@0,!/<BN;C)&F2TU; R5.B:4;73[\W7;7QGB=BMH)%LIW1!*.RG;:$8D4Q9
M;01T1!1"70?#I]5$QU!AMHM-@Q.R6:Q--LVB%"CM0P:1$#MHVFA=/%2^TJ_%
M5UHRY,PZ-%QCWW9%:<;%&+9<H;QW&.RFC:'(@,S7=43IU?1#_A6C7'W[1?\
M79S-_P ]>_[1DT-??N:_\3/"O_.[=_VL-#$>]P5WR"P^[O%;OBMG6_Y!$MD4
MX-G$E!9!Z2T4=R=4T%5+^*AGQK,_Y6Y5]PEQ#@*?C%MPR]/RV7I87:0;3^YC
M[P1#O"*ZJBH:(V!$8_9Z+0=NX-B[.$X;8<0CO+):LD"/ 222;5=6.V@*>FJZ
M;E15T^%&7-_OBQ28&.XQRK9-6KQB-P;!V0">8&)!B;+BK_\ 0WVP0?K<6C6(
ME[DLV<YJ3A_C?&25LLU&)?Y@#YD929K':W:>*,_X2I_[6ACV]Y=OB1+IP[@
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MN%\FQ9EVRIYF>HV]T9$1N,V"]G8Z'D-2[A$I!Y=%315\:)NJYY]5?WO>(/\
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MO]/-90D E'XB0D0&G\DETZZ4,<\X_)][/&]D9P*#C%MR2'";2):+XXZR\K3
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MI&%WYFXE"#NS(J@XQ):;\-Y,O"![?[I!T^N@C,WW2\#P+3%O+N7L.0YCKC#
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M?5 H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M7],;'8;)C-KCV3'K?'M=HB#MCPHC8LL@BKJN@BB)JJKJJ^*KU7K1AL:#^?\
M*P' >1?=AR39>1+D5KLT=DYD>0$MJ"I206&V([WD5%\AFNU.O37X4:XZ"XEX
M:X,XXRX+Y@V3+/O[\=V$U$>NT66A@ZHF6UIL1)2391*C?O:S&9%PFR\96(3?
MR#-Y[;*1&?,ZY&C. J B)UU<?)D1^G0DH8H/E:!S ''.(MSN,'<3A<9BT</(
MV9(O.@/W8F9BB^)O"VZI=="^I5HKNC"N0F,QXMMO(UNBG,*7:UGG;HNBNE*8
M;)'HS>Y4121T#:'5?&C+E2U8/[9O<3$N>;VZ<YQQE0R7#N,+UT9E$<7SI)5A
M[R[#UUU94$W(OQHTEOLXS3*)]YSG )U_=RW$\9>!+)D#JF>HD\ZTB 3BF7;>
M%ON "DJ#M73HM#5S>X;&K-E'#&9Q;U'1]N#:Y=TAEX&U,@,F^RX!>**A#H6G
MB*J/@JT3%9>QO&[/;>("R*)'0;S?)\A+C*7J9A#-6F6T^@ 125$_E$2T-=-T
M0H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H*[P3
M@WC'C6_3\EPVR);KQ<FS8D/]]]Y$9<<1T@;!TR$!4A'H*)X)1:_.2."^,N5W
MF9F9649%TC@C3%SCN.190MHJJ@*;1#O%%5=$-%1->FE"MMQ[QA@_%MJ<L^$6
MENVQGR1R6[N-V0^8IHBNNN*1EIJNU-=!U71$UHB-XQ[=>)</RV7F=AL?I[M,
M!]IQDGW7(8MS$47A%@R4-IHJIM5%%$Z(B46M*Q[2N!H]^&_ABZ$8N=X;>Y)D
M' 1S777L$:BHZ_D+Y/AMTH5=@B(B@BB(*)HB)T1$2B*IR#VW<.Y1.O\ =+WC
MR2;IDCK<BXS5??1X7FE51-@D/[I>OF[>B$G0D5*+6QL&"XCP7A%V7CW&7I/I
MVCFOP(:E(N5P=:%=!WN*1&6FJ '@GY*=:"D.%<"R?-^?LCY[RW$9&(6M&U;L
M%LN#:LRCE.,C%5X@-!+5&@-3511%-SRJNBT776M&4'A\18% S>\<B1;<899?
M8YPKG-60^0N,.BV)"C2FH#JC0=1%%Z46OO#^*,&P3$Y^$8S;BB8W<R?<FQ2?
M>>(REM"P[]XX9&FH"B="Z41B0.$^-K=Q]+XNCV?=A,XC<D6]U]]U5<,Q<WHZ
M9JXA(8"0JA=%3I1:U5F]N7$5EPNX8 U8O5XU=)*3I;$Q]YYSU("@"ZVXI(39
M"*;4)M1737Z5H5]\=^WCBCBZZG?L4LJA>R$FVY\MYV6ZRV::$+7=)4#5/*I"
MFY4Z:Z4*D>-<889B.47_ #&PP"C9!DY]V\R2?>=%TU-7-4 S(0\Q*OD1*(_+
M9Q?A=GSZZ\FP(!-YE>HZ1+C/5]XA<91&4VHT1JV/\PWU$4\/K6@6+B_"L;R^
M^YU:+>3.2Y&.V[RB>><%T=R%HC9FH#U%/LBE! Y/M*X&E7Y;^>,(#A.=\[>U
M)D-P"<UU_F!-!0=?R!T#X::46IKR#Q)@7)UAB8YEMJ%^VV\A.W)',HIQE$=B
M(T32CH.WR[?L^'3HE$5ZYP);+?R+QO(Q:S-V[%<"BR'/G#DQUZ2ZKI/J$$6#
M4O\ =7RD&\7P7:FE%J[+O9[7?[9*LM[AM7"TS6U9EPY (XTXV7BA"71:(I1O
MV=< M7+YBF..D"'W$A'.EE&1===-O=W*GU*6E%JP;UQ%Q_?[OBU[GV@1FX60
M%C8QW'(S,7M$!@(M,D(*(JV&@D*ITH5[SN+\+N/(%NY0EP"/-+5'6'!G]]X1
M!D@=!4[2&C:]'W$U4=>OU)1&*[P]QY(RZ_9Q)M"/Y!DT K3?''7GC8DPC;::
M)HF%/MHBBRVFJ#KTH(5"]H_ L)F>Q^&5D-SA5O\ PF7*=6."DA:1U)S5M=43
MSIY].FNBK1:F$'ACCVWY-CF81[<ZN0XI;@LMDF'*D&K4%IMUD (2<435 >,=
MQHI?7T2A6/R7P5QKRW+@W#-;6<JX6X%9CRV'W8SO84E-6B5LDW#N5537JFJZ
M*FJT*H#!O;U;\JY5Y6A<BXC)#$'Y#28Q<GQ=8)&XSQ@VL62BH2_=H&O5=R:;
MJ+5_6[@;BVU8#/XT@V-&L4NI Y=&1>>21)<:,'!-R0A]Q50@'3S:)X)THE;*
M[<38+>^/XW&%QMQNX9$;CL,04D/@8MQ"0FD[HFCBZ**>)=?C1&'EO"'&6;XW
M:<5R2QA+MEBCMP[,XCCK<J*RT MB(/@2.:;0'<A$J%IUUHM..^$>->+&)@8=
M9AC2K@':FSWW')$MUI>NSNN*JB.O51#:BJB*J:T*S<*XFP7CW&+CA^*6XH=@
MNKCSTZ,4A]]3.2R+#B[W3(DU !3HM$:^#P5Q; P-_C0+"#V&R'REG D///$D
M@]/O >,U< TTZ$!HJ?QK1:P./?;KQ-QC>"R#%K(HWO:0,SYC[LMU@#3:2-=T
ME0-47:I(F[3IKI0JR+M:;9?;;*LUYB-3[5-;)F7#D CC3K9IHHD)=%2B*DL7
MM3X,QZ_MY%!QKN2F'$>BQI<F1)B,N(NY"%ETR%=%\$/<B46IP[QAAC_(+'*+
MD ES6-&6$S/[[R"C"@3:CVM_;7RF2:[=:(E]!#,CXKPC+,NL6<WVWE(R7'%
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M\<BCK_&CMJH=6G8_;_B;OMICWG'9$:P\@9/C\99637"6XRV\$UQF6[&<(SV
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M4(D-IN.P"JI*C;0H IJO5=$2B.?N3N"^2KKS!#Y=XNR>!9;LD$;?+;N;)/(
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MW512V"VYT)$UWCJB!V;1DH% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H/Q40D42345Z*B]45%H/YY<M<!\E<%\@_K+X?8DR<>:D'-@N6]M
M7W[;W55#C/,HA*;&TE!"VJ*AT/KXFJ\[I[TN;LAM)XS:+%#@9"^"L.S[?&DN
M3$54VJK+)F: ?UJA:?#2A%B>T7VX9'CE\7E7D6&<&Y VX%@M4I/\+%R0BB[*
M?%>H%L4@ "\WF)51-!U&ZE_O%X,R#DZS6K*L-CK.R+'Q=9D6L-$=DPGE0]6M
M?%QLAU0/RD)=.J(BDS5!81[N.7.*\>BX/?\ '&KC\I;2+!.ZM28DUIEI-H-.
M(FFY&T1!'44+3HJK18U5DPCESW7\HM91E%O=@V%PF0N-T[#D:!$MS*Z]B*KN
MJF:HI;10B7<6XE1-5HOQV-[K;=(D^WW*;=:XKDA[;;@8BQFR=-1"X1N@@"*J
MZ(G^Q1G%5>U?!YU]]M^=X9=X+T*1>IURC,MRVC8)"?MT8&W$1Q$Z(?5%^E*+
MKF[V\<89'>N:L1C7BR3HMMA3DN,QV5%>::%+<)24$U,41-QMB&B_3I1=67[T
MK#?;CS=:9ENM4R;$;L\$3>C1G7P0AER55-6Q+JB+X43%^^]6WS[GPL46VQ'Y
MLE;M")&8S1O'M%'=5V@BKHGTT3'*O%'-_-_#^+%B6-8:W*MQ2G9JNW"VW!Q[
MN/" DFK3K2:: FGEHU&;G_,?N4YKLBX2]B;\:U3G&_4Q;/:9H%([1H8BXX\3
MRH"$@DNBCX=>E".J_:APQ=>(<%E%DPBUE60OA+N$4"0TC,L@HL,$0JJ$8[C(
ME%=-2V]=-5,[KA^QW/D;C+EVX9YC6,R9=PAS[DD8)D"6Y'()2NLJJHWVR7RF
MJIH5&EP?OA^X_P#J+ _T5=/TFB1<7MRYXY6Y2S"Y6+/<;C6:V1;:<V/)CPIL
M52?!]EI 4Y#K@JBBX2Z>/3ZEHFXH"^8_?R]YS5T&TS2MGXP@N>L2*\K.Q'V4
M4]Z!IM3XEKIIUHO']"KS9[9D%IFV.\Q@F6FXLN19L5U-0<9=%1(5TZ]47Q3K
M1E_-J1B7(OM=YU"?CMMG7>SPG>[%>89<=;N%EE+H3+A-BHHYM10+5/*Z*&B:
M;:-_5U^]5Q_.>.<"O&+P9D^)-E.S&P;BO*\#3L=%3NM[=P$FNBB2>-$Q4W'O
MN+YYXVPZUX38\+8D6JTBX$=Z9;+B;Y(\\;R[R;>;%?,XNF@ITH1-K%[M_</<
M;W;;?+PB"W%ERF([[@VNYBHMNN"!*BK(5$T1?%4H1#_<9'S+FCW!CCMJM<]+
M-!E,8S;9917TCBHO;9,@B44':CIN*IZZ* HNNE#'9,;VX<'1HS,;\#VMWL@+
M?==90W#V(B;C)5ZDNFJK1*YX]WOMZQVSXC9\JXSQEN"_ EE%NT.U,$I.L2Q3
MMND :Z]LPVZHG^Z=?#H7-;K&LDOV7^S/([%=+?-')L?MYV4HSL=X7GF6B!8I
M@"CJ2=I1;73X@M#K(]AEINMIQ/+FKK!DP77+C'-L93+C"D/85-1WBFO\5#6N
M]['!TB^QXW*^*03DW>*C<+(HD9M7'7XZJ@,2$$$U(FU7MGT5=BCX("T,U^>P
M6T7>T0L]"ZV^5 )UVUDUZIAQC>B#+1=JN"FNGQT\/XZ&J/YKC9E8O<M?<SL-
MAES7;5>XMR@D4.0]&<<B"RX*%L1-P*0:+M+^.BIS(]VWN;N+)0X&&1HTIWRM
MO1K-<7'A5?B(NO."J_P@M$F-M[=_;?GV0<@-\N\Q1WXGII2W6/#N*;9TZXJ7
M<!UUKQ;;;/SZ$@JI(B(.W6ANNZJ,E H% H% H% H% H% H% H% H% H% H%
MH% H.9_?1_J39_SW"_X*11<17)>.O<CRIB6-\57YNS1L&82&_.S2,\I/3(K#
M:*SK&,D<1Q!5%,>V@DXB>81HJ>'PWE$+W*XEGMIBM)Q_C]A2RJ\<@.^':B26
M&Q1K[1=7 37^.B/OE_B3/BY-L7-W$9PW\MM<=8%SL=Q/M,38VACY3Z)N47%
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MUKE6.*$R_P"1Y":I' S$#1EH4UUT1UL5\I$I*O04%241X83[FKI%QWD./R;
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M@M-"1F7JK2N@BBJO1'-?A0\0#!^7/=3R1>'+#A.2W&[79J.<QR,!0F51AL@
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MT0SHT5IU,DAR30D(H[H.H0@N@%]V'70A+;Y2H8K_ -O?%626GF&=FV.8K=L
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MM7NOQF^P[1+=PFT8V%J2]J">G$V(3S(H1Z_:55%/X5HG'IRSA7(.%\X6GGO
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M)(3:9B&NFX7"+S?R:(Z1HA0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!04S[L/\
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MHKJ7_P";_1%P/+47JBW9O7^C!1-<\8-/'V\^YP6\F$HUJM%SE6^:ZHKHENG
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MU1:-<9GM7@3X?MDS:+*B/QY12+THL.-&#A;K:PB*(J**6O@FG\%#5:QL<O\
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MB:Z;B)=$U7:.@Z]*(E] H%!^;AUVZIN\=/C0?M H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M1,Q7"9=DBH$6@(:(*(6BKN3PHL;W+_<[8[#D]PQ'&<5O>97BQ!W,C2R,(^S
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MP(=74/MH6P=OW@T(G-]YILEFY9LG#T>VS+ED=X826Y(C=KTT1E>X2D\I&A=
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M[?>5ESVK8R8N-6UX!"/,=8>(D$U(2T15V^</#<J(7'W+D8'R-G.!V->4\IY
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M5Z(B)"=H*C]D:HO!41$7JESGHO\ ?C1=<ZX\X'ZA_<6NY-%O<+XI^5<D1/\
M9^%%2[F]&@]E?&0B@BA/6C1$T34E@RB+3ZUZJM#/J4>Z%&6[W[>VP00 ;JV@
M"FB(@"Y;4Z?4G2AB'Y.#^#^Z+-'LJS6?QW$R6.,JSY)&CMOLRHZBTJ,D3H'M
M$5;4-43[0:+XIJ.)MP->./\ 'Y?)?,D._9)?+5%;1N_WNZV^/&B3G6W%/O14
M8+<9(B:J) "B+B;DU6AKIO"LQLN?XO;LOQXG3LUT W(A/MJRXHMN$TNH%U3S
M M&4>YQQZ\Y5Q'F&/X^).7F;;7AB,-KH;Q!H:M#];B"H(GUT7',^(\\\5V/V
MLR\&N\A(^60K3<+&_C+C+B/NS9'>!"T4=NTB<WF2KY?-^4FBEGJM<QQ2]8I[
M;>++?E+!1Y$_)G[@W!DHHFU$D@NP3%?L[T3N:?#?UZZT%Y^\I03(N'-VF[\0
M'HJZ:[>[#U_B\-:&.KZ,E H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H,*YV:T7ID(]YM\:XQVS[C;
M4MEM\!-$5$)!<0D1=%5-:#\F6:SW&1%EW"WQI<N"6^$^^RVZXP>J+N;(A507
M4474?HH#EFL[MR:O+MOC'>&![;-P)ELI( J*FT753<B:$71%^*T&-<,5Q>[7
M"/=[K9($ZZQ-/2SI,5EZ0UHNJ;'#%2'1?H6@RXEHM,!Z7(@P(\5^>?=G.L,@
MV;[FJKN=44137S+U+7QH-7!P7"+9<?F]MQJU0[MKN]?'@QVI&J_'N "%_P"6
M@S+WC6.Y*TTQD=HA7=A@NXRU<(S4H /^4*.B2(O3Q2@V+++,=EN/';%IAH4;
M::;1!  %-$$43HB(G1$2@QI]IM5T["W.#'FK%<1Z-ZEH'NTZ/@8;T7:2?2G6
M@Q8N+XS!NS]^A6:#&ODK7U5S9BLMRW=WCO>$4,M?K6@^KWC6.9*RW'R.SPKP
MPTJDTU<(S4H 5=-5%'1)$5=/A09L*%"ML5J#;HS42$PFUF-' 6F@'QT$ 1$1
M/X$H/>@P8-FL]L>DR;;;XT.1-+N3'H[+;1O'JJ[G"!$4EU)5U+Z5H,6]8EBN
M2&TYD5CM]W<8_F#N$1F43?77RJZ!:=?HH-HW'CLL!%9:!N*V"- P H+8MHFB
M"@IT1$3II0:>UX9A]CFN7*R8_;;;<7=>[+APV([Q;O'<;8"2Z_PT'O>\8QK)
M6VV<CLT&\-,JJM!<(S,H05?%11T21-=/A0>ZV6S%;/DBVZ,MF04;2W*RWZ78
MBZH/:V[-$7KII0>K5NM[$%+8Q$9:MHMJR,,&Q%A&E3101M$V[=%TTTTH/RWV
MVW6F*,&U0V(,(%50C16P9:%27550 1$35>J]*#77+#,/O4]NZWC'[;<+HUIV
MILN&P^^.WPVN. I)I\.M!M946+-CN0YC#<B(\*@\P\ N-F"]%$A)%147Z%H-
M3'PO#H<!NU1,>MC%L:>]4U":A1P8&0B:=T6Q!!0]%TW::T&\H,.X6FU79&1N
MD&/.&.XCT=)+0/(VZ/@8;T7:2?2G6@Q8^+XU#N[V01+-!8OTE%21=&HK(2W$
M7QWO"*&6OUE04!S/Q'S+S3E47%KO,L]MX;@7!JX _&5WYH^ M;"$Q)#17!WN
MB&FP>NY=RHE%QTA%C1X49F'$;%F+' 66&0300;;1!$43Z$1-*(]:#37'$,3O
M%P9NUWL-NGW2/IV)TJ(P_(;T\-KA@I)I]2T&PGVZWW6*<&Z1&9T)S17(TEL'
MFB450DU T5%T5-4Z4'RY:[8];OE#L)ART]M&/0$T!1^T*(B!VU3;M1$Z)II0
M8UDQK',:9<C8Y:(5GCNJA.M6^,U% R3712%H115Z_&@\IV(8G=+FU>KG8;=,
MO+&G9N$B(P])#;X;73!233X:+0;F@UN10'[KC]UM<9123-AR(S*FJH"&\T0#
MN5$5=-5ZT%/\#<&KA'&L7$.2K;:+Y<85QE3HBJT,]AD9';T5M9+0J):AUVC1
M=U<EPLUGNT0(%UM\:=!;42;C2F6WFA($5!5 ,51%1%5$Z41^)9+*EQ"[I;HJ
M79H.RW/[#?J!;T5-B.;=R#HNFFM!]1[-:(D^1=8MOC,7.4FV5-:9;!]U.G0W
M!1"+P3Q6@\F,=Q^,U-CQK3#98N.OS!IN.T 2-VNO>1!1#UW+KNU\:"&<C<3V
MW/<=MF&,E%M&*,3F9=SAQX;?<=C,GWE9C&FU(Y..(F]P!UV[D^*T58M$*#0.
M8-A+MT^=NXW:SO6[?\Q*#'65OUUW=U0WZZ_'6@WCK33[1L/@+C+@J#C9HA"0
MDFBHJ+T5%3Q2@U-FQ+%,<>>D8]8K?:7Y/20[ B,13<377SJT J75/C09D>S6
MB)/D76+;XS%SE)ME36F6P?=3IT-P40B\$\5H$6S6B#+DW"#;XT:?-7=,E,LM
MMO/+KKJX8HA%U7\I:#7,8/A44YKD;'+6RY<DVW$VX4<"DBI(6CRH";TW(B^;
M7K0;9B!!C0AMT:*TS;P#M!$;;$&4;5--B B(*#I\-*#4Q,(PN!#EV^#CEKBP
M)Y"<Z*S"CMLOF!;A)T!!!-47JBDBZ+09J6"PC+B3TM<1)T!I(\&4D=KNL,BB
MHC;1[=0%$)4015$ZT&QH/-]AF2RY&DMB]'>$FW6G!0P,#30A(5U145%T5%H/
M"W6NV6>,D*TPF($-%4DCQ6@8:0B\5V@B)JM!BAB^--QI<(+-!&'/)')T<8K*
M-/FB[D)T4'0U1>NI:T'W)QZP3+>S:)=JAR+5'VK'@.QVCCM[$5!V-D*B.B*J
M)HE!]S;)9KD44[C;HLLX);X12&&W58)-.K:F*[%\J=1^B@\[UCF/9(P$7(K3
M"N\9M5)MFX1VI38DOQ071)$7I085\QM7L0G8SBXP;.3L8X\#N0FY$&.1^"K$
M\@&**NNU>FOC0>7'^%VWCO#+-A5I<-Z#9XZ, ^[_ #CAJ2FXX2)T13,B+1/#
M72@DM!HY.%X=,NHWV7CUL?O8*A#<G8;!RD)/!4=(%/7^.@S[E9K1>1:"[V^-
M< 8/N,C+9;?0#_E"CB+HOUI0+A9K1=BCG=+?&G'$/N12DLMO*T?3S IHNU>B
M=4H,V@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4',/+.9Y=:?=1QEBULO<R)C=SB,'<+4R\017
MR61+%5<!.A*J"*+K]"47BZ\?Y2P[)\SON VB6X[DN-INNL<V'&P!-PCY7"%!
M+J2>"T1KX7-O'L^3FL2-/>)_CYM]W)T6,\B,!%[J.*"J/WFG9/[&NM%B'3O=
M]P3 C6^4M^>D!/'N*$:(^Z<8%-019"(/W:KM54#[>WKMT5-1%AW_ )5X_P 8
MPR/R!>+XPSB<QMMR#/'<YZGOBIMBR (IF9(BKM0=4T7731="-!QO[@N+^4[F
M[9,6NAI?&FU>2VSF'(C[C2)JIMH::'HBZJ@DJHG732BQ+.0+AE5JPR]3\(MJ
M7;+6HQ)9X!$ B<DU0!4MY *B&N]1W)JB:?&B.0,T'W)<3X!;N9LDY(?*_O2V
M1N&&3606("22+:R@B:MD2(FIBVV&@Z[2\NJFEP<@Q^<>27\4+$[R''W'$VU,
MW7(+^VZVL]F0^SW5942)LT$$4111(4U4E)>B)1&O]K7(6<9'=LYPG*+R.7VO
M$I@QK5F#8H@R4)QT%!7!U1S5 1P%U)415\Q)MH:Z3HB@^7[?SUF7(-FPO YC
M^(<=E'5^\9A&1IQY7]#)6Q3N"ZB(B (H.W4B5571**@W&G*N=\>YYR=QMGE^
M7-[5@UDD9#&OAH@2-L1IEU6#+S*JFCZ"0D1*)BJ(JI15=!E_N%F\4RO<R&?.
MM-Q[EH.(@PGR[T/JABKH"DHZ(X6S:HJ6Q-W<W4%T9MDG-W*]JX['B7?C>+Y7
M!8N.2Y2RK3KD(WQU)@4(A<3M;2U4$3>JBFX4UU(CW'V<<A\7<Y7/B'.<M<S?
M&6[0]>?FLEO27"1AA9.KBJ1DFH"HJ!&2>8"3;JJ*5#K%DG.',]FNO)MNY+9P
ME]R<[%PC#5=9C,S?3;2)M3=,$/[: A&#FXT75!'2@[%PAW+'L3M)YU'8C9=V
M$&[M0S1QA7P514P5$1-#1$/:GV==/A1EOZ!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*"J.:.<+?PN[C!W>T/3;3D$PH<FYMNHVS!%M6]QN)L,B789&(CX[%HN8H
M?.<FQ_D#WB<8.X3<H]^C6Z$UZR5;W!D, K1S)!IW&U4546U0BT7IKIXT7C9<
M57VRX[[L^7PR"X1[4LIG='6<Z$87$$V'%VDXHHJ[%0]/Y/7P2AQ"N.[O;K_<
M/=9>K0^,JUS[==)$.2'4'67/F"@8_P!R2=4^J@W_ !_9[4/L2O\ (2$SWYD6
MZRY3B@*DY(CS#!IPETU4@%L$%?AHE#JM,M2Y-<5^VZX//QXV.,29J/S+BR4F
MVL2OF#9 4MI/MMH $NSX@)I]-!:;]LG9!SUQ]/R/DS&)F<6UUMV%!QVVRB<F
M6_4C=9=D,*XV.K0NH".FFT25=-%ZAUIE.36?#<=N64Y _P"FLUI8.5+>TU5
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M <<C8,>0LQU:!32Y)<"CHYW--RCL339KI0:;V_W7E_.K%8^1\TR>$=@ND%P
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MV+_91YPW$3<Z9"J;OLHB4$HY1X^ON98GBMDM+D8)EEO5FNDPI!F#:L6T]SJ
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M2-AFJ(1(6JKI]:^"4&5[?KW:<CSCF2\V.6W.M<G(8_II;)(;3HMQ!;4P).A
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M&S:U4Y .>8>ZU]:(J:4585Y9?+EC++QQEG,?#^0'X5I?RW&<FA@Y;YP-Q/\
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M)?"&:\FV&QY- Q/C-_*[2F47HTNK=X@6\>X4CS-]J2N_R_3X+K1K5F9_R!R
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M))7E)(7)$5!0U[H25'J*:[41=*%=!VFUPK):H-EMK2,VZW1VH<-E/ &(X(V
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MJJBB)CO4E01U1%754HL1K!_=9Q-G%_CXPT_.L=ZFD(6]B]QDB#(,UT 6S$W
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MN$-XAWB+K6XDT).HD)*B]>M$0?GCE2^\?7;!+?9;==I+-VO<<;H=L@A,23#
M7%.$T1K_ ,H=41(0'15 2\R47$>+F.7C?-V9VF?&R"^,OVFRRK#B%KB',E-*
MXR1RG$9W"VUM4@[I&X/F5$ZKHE!9=IYJP"Z8%<N1G)SEMQ^RN.QKVW<63CS(
M4R.HB<9YCJ2/;C 4 =5)21$UUH1A8USCCM^OL#'[E8[]BLR\H7R%W([>L"/<
M5 =Z@PXAN)OVIN0'-A*FG3K0B<91D$+$\:N^47+<MOLT*1<)*!]M6XK9.D@_
M6J#HGUT12.&\>YIRUCD'D//<]R*RS<A8&X6JPXM/6TP;="E(CD</(!$\YVU$
ME-WXKIHOC16QP7*\QQ_*,PX<S:[%>[K9K5\_Q?)" 6I<JTNJ32I($$0>ZP[H
M&]/M^*_6$&X>PU_/^,[#F.2\P9C"O=T9==F,1K\RPPV3;[C:;0<8,A3:"+U)
M:&K!]O.5W^^#FN/72^EEMHQ:\K;K)EAH&^9')M'";-QM$!PV57:3B?:W?1I0
MUX>XB;>!N/&UAMN17'&X609"EONLVTR4A2%C&P9*B.*A(FBIJFJ+0Q#.4[))
MXFPV9G6+\RY%*R"V$T<"U7ZZ1KK#GFKHHL;TR,@1$:*NBBO3Q\.J!<F2\LVG
M#X-@9NUMN$_+[^P+T/%++&6;<R46Q-Y>VI @@TJZ$;A"G^PM!ZXKR]AV4VJ^
MW(CDV)_%T4LGM5\96#.MH=M7D.0VJDB 0"I"8$0DB+HM$16/[E,/<*W39V/Y
M+:\3NSK3%NR^X6M6+,ZLDD%D^[W%<$'-R;#-H45.OA18DF9<P6'$+\WBL>TW
MC*,F6.DZ5:<<A>O?B1%7:+TC4VQ!"5-!'<IE\!ZIJ(@G#W+%ON%OY4S?(L@=
M+#+3D#Y095P[H)#@>G9(61:<%#!4(MO:V[M_1$4EH:E6/\\8S>KS;;-<K)?\
M8^>GVL>N&0V]8,.XNJBD+;#J&>AF*;@!U 4OAJJHE"/FX<_8C"S"9@D2U7R[
MY%;IS,"Y,6NW'+",,@&R"2\8EM!C5Q!W+YM=?+HFM"+5HA0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*#^?G(]]L^->^)B^WZ8W M$"5;W)DQW7MM!\M;34M$5?%4JKQU?^\IP
M3_7JV_WSGYE1$9Y7Y.P'D+A+D=K"K]&O3EOL[A3!C*2]I'M4!2W"GCM+_8JB
MUN/45,!Q5%Z*EGM_^2MU!)*"AO:XBC:^2!5-"3.[XBHOBB[FJ"^:"M^><%N?
M(W%E]QJQD@WY19FVI"5!0Y<%X) -JI:(G<V=M%+HF[5:+C06OW/\4K9?4Y;=
MOPQDL,-EZQJXLOMW"++ 4[C(L]M2<Z_84$7<FG@NJ((IK-K5>KCPYSIR[>K?
M(LZ9^]:EM%LF!VY06JTO,QHKKS?B!NB2DH+X)HO5%1:*MKGH&_D7%";$1 SO
M%^VB)H@^<TZ:>'1=*)B\3 7!(#%" D42$DU147HJ*BT1R#B5CN[G(EF]N,J,
MY^%N/LAFYCWR55!RQALDV=E27^<TDRR%T5Z>3^YZ&DWQ?,,:XGY8Y.MW(\YJ
MP.Y+/8OMBNUP7M19]O&,+2MM/DFU3CDB@K:KKYO*BT16MZ&7=./.1.4K=;I2
M89=LXM606Q$8,7'K5;GF!?N ,[4+MNJBGJHHNB*I>&M%3G.>3L+SWE7AV/AE
MR&]QX=[?>G7"&!G#8*1"<1EDWE% 1TT$R1O7<B"NY$Z41+/;Z@K>N83T\ZYW
M<Q4M.JH++&B:_0E#4]Y0O^6XKA5PR'"K0%^O5N5I\K2>]3>BBX/J$:1M457$
M;W$"?'3P5=$4CG'D"_>T?,,;F7^U)'AYZZV9V@+%&D6_(1NRHJ-"C$< 4G>Z
MJ"JN(HZ]==.M&O4F@CD_ZSO;M^.$(LN&P7U;JKJ(KJ2OE[*%O5.G<T70U3\K
M6B)9@.B^Y'F!=/,,#&41=.J(L5U51%H*CB9?=,2XR=<MQ1;9'N/)5VAS<MG0
MAN+-B;.6YI,1DTV[T7R@9^4=>OBE%>D&ZVJ;[A.*GX?(-QY$]._>H\^\O!'&
MS1I,BV'VF(I0V6V>\YIJX*&:Z;/"@MCVR" XOF*B*(I9I?U-43157U IJOT]
M$1*)J@K9E=@;]K>+6APUF7;#<J@%E%B%LBEL(Y>Y3PM&TJ(NYP!7:GQ\/&B]
M6]F^:XOS#F7%]BXTN3=\GVC((V47>="$R;@6J$TZC@2344[1/J8MHV>A:]%1
M.E$;[VZZ+)Y>+3JO(E]15TZJB!'Z4-4E@#@XYQM[>^2KHTX6$8K<,D9R!]ML
MWDB)='Y4>-)< 454;:<'S'IY=4^*T5:URRFP<J<\<;/<>RV[Y"PMN\3\BO<+
M[R%&9N,-(S#'?3R$XX?BV):HB:_!="-3Q$+9^T/($(447+?EG<33[6KTU.OQ
M7ITH=0J=!.UM\&YI>\BN>(X6>#0[(>36H6E2%<7([+H#(-YIX6VY ^1#V?:'
MJJ#JM%;BV9+AN.7_ #CE"QY?D&<W#$,5D0CRJXG".PD\^Z+T:VMNL,-$Z\3R
M@:*&X$W:*NNB4'0W$^)+@W&V,8JZ.V9;[>RD_KKNG.IWI1:_'<\;A?QT95+Q
M7/F6QCW!7*VV[YO<(>3WF1%M.BKZMYJ() QIHNO<)-GA\:*IG,\R;RCA"9,N
M7*DJZY%/M:.!QQC,*+"CP5%!)Z/*9:8<?&/%!"[ANN *H'15U1%*M&1G.)X=
MSM@]]R68W%LD[CIF+'N;B*L:.X_.;-MUUS31L#0>VAETW$B?&B-5DMPB9P[S
MOR1BZJ]@ZX:5@8NP"HQKE<(K+[CSK*JB=P6$5&M_A_)54HK!R""MESGCO,,A
MRFZ85B%VP*!88N46SLBTS<&G DK&E&^R\#3;H*AB9(FI#IKHBT&_Q&#CE]G\
MF7_%<AR3.IK&+R;&[DUP](=IDF8./!&B+'99)YUM==2%"%-^GQ'4B8\/<L<?
M6C@S"Y\Z^-I%@1[9C<TP:>=)F[K';'TQB#9$BHJ_:TV_70U=<YEV3"DQV#[3
MSS1MMN]?*1"J(73KT5:(YCXJY7P#C;A0<!S:0%IS3%VIMKN>)/MKZZ3*<>>(
M!CL[?OQD=P5$PU#S=5TZT5%[:\'#[WMJ+D8#@K;+?DR7!QT#,H*W!IE6U=%$
M511H71!U5Z-IKKT2BIA?'F^9N3,HN/&+X7"VVW KKC+V1QUTA/W:ZDIQHC;_
M $%SM_SI$"J(Z]5UHBN+5<\*:XEC8_D/*&7-WAJWMX_=>,(@PANBRNTD5V Q
M%<AD[L5=1 R5?)IJ6[I15N8I;&[-[CL8LP-R "V\4QXK83U;<E@C%S;;1'B;
M\BNH@Z&H=-==.E$;[C7:GN!YR1$ZZXHI?6ORMR@Q_<?=(5@/C'(KNZL6QVK,
MX$BY3E$B:89]/)'>XHHN@ZKIK0Q^<?2X=Q]Q?)-QA.!(B2;%CCT62'439>9<
M,2$OY)(J+05%E-ANMXPWEIVS-RB;LW*"7BZ-VT!<FK!BMQB?-@"11(V]W>1"
M14\NJT5MC=X^S')L&M5MY0RKDF>Y>(=YM]L@';W&X!02WI-G*L1I66VD+0P(
MA<7=Y1UH.E\]Q@<UPG(<1)U&%O=NE0 ?5%5&W)#1 !JB>.TE0M*,J+QGW!6;
MCGC)C%<QC#:^4,*@1[;*Q:YO?+EFA!$61?B2G -IP76@5QO:OF+R^"H2EC$X
MVRRU\O<J9QRI");?%MF+M8S:[+.)MJZDR[I<'I+L83(@;WD@-GU$^NB]%2@T
MW#?MSXKY)]OEAEW6R-1LFNT.3KD#"N)+;D!)>!MW3>@EMVCJ))H2=*+NK3]O
M>6..6FY<79#;8=CSO W?0W2W6]@8D63&/4H\Z.T B.Q\?,6U/M>;04,4HFM/
M[D[-:LAR#B.QWR($ZTS\I%B9$=U4'&SCFBB6U472AB/<F</8OPU/M?-O&N*1
M'F<:-%R?'E922+ML(DWRXG>4^S)CZ;D,-/+JJ]$5"%:[D&;:I',M@Y+DYI<<
M4X^RW%&K?8\RM79&.D@92REB27)##PLBX!(XBF@^9-/R2T!9;A:8#'*/(>"S
M;_R==+58PMKEVO81'['<#;)7>RP,=EDI'ID4B=TU11511>HJI5?<I95;KUQ:
MP\_R[+S2[25MLQS&;+$BQ;1#C-RF7'5G,1F%<;:9Z"WWG!+?LZ+07=;<KQWB
MSG3DF5R!.:LEOS1BS7/'+U,79#E,6V&49]E'E38CC9^#>[<HEJB=4U(J6:Q*
MY"XRYHNN(0II0RSAB]%"885J=(M["1GG'&V7A1=Y#_A(B8ZK\4UZ45()4GCW
M-KAA]JM_*>6\ASKC=85PM]B@%;B=AG%/NI,FHL-HF&V/]T0E$^O1/'0+2X?$
M/UO<WF@IW%NUI0BTZJB6]-$U^K5:(NRB% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H*7Y4]K_
M !GRYD 91D"3H-[[0,2)%M>!I) -IH"NBXVZBD*>5"'1=.BZZ)0J#?N'<.?_
M &2OW]*C?HM%NMA*]L5AX[XMY'L_&Y7&YWK*;3Z88DYYEQ3.,CA-@WL::1"+
M>2>9?HHE<68W/YDBWFTVZ_3\V@XPQ)CQ[D$([F+K$$'!%U&6]=$(&T7:.GC5
M:\2?E:[YPQFLP>)+WGDK"D!I8C\QZ\"7=4$[B!W4!S8A>&\=?XM*&1UU[.<8
MRG&^*'W<NB2(=RO5UDW5L)J$DIQE]ID4=<0_,BF0$7FZJG7XU$UT'1"@Q7;;
M;GY34Y^(R[-8_F9)M@3H?[4U35/XEH,AQMMT%;=%#;+[0DB*B_PHM -MMQ!0
MP$D%4(4)$70D\%37XI01'+,ZAV'(\;P81>#(\T"YMV.8C0O1&'K9%]012$5P
M"VZ$FU!1=WAT\:#5\:\?7O&KC?LNS6[M7S.\E*.$^7%96-#CPX(*$>-&;(B4
M13<1FNOF(NOAJI4\F0(-P;%J?%9E- 2&(/MBZ*&/@2(2*FJ?31'OHFFFG3PT
MH,>-;X$-H68D5F.R)JZ+;38@*.%XDB"B)JNOC0>X-MMJ2M@(J:[C441-27XK
MIXK0?5!B#:[:$Q;B$-@;@2:%+1H$>5%Z*BGIN_\ +006\\Q85:\(R'D9 DS[
M+BLQ^VS2CL(DA9#$@(KJ,H\3:$*&>F[<B+HM%3^.K+H#+:!!5\!-2T1"4535
M-53Z-:(_2BQC9<CFR!,.Z]UI110+=]K<.FBZ_&@^&($&,PU&C1FF8S"ZL,MM
MB -KUZB*(B)X_"@C8YS9&.1AXO;C/A?7+,62]\6P2)Z7U7I%%20]W=4^NFS3
M3X_"@UO*''*Y[98=LMTIJU28]XMUY?E=G>KORYY'=J[%%=RZ:(2KTHJ;QX4.
M(3QQ8[3!R#5V030""N.+XD:BB;B7Z5HB.V?-;+=,UR/!849YJ[XZU"EW%X@
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MFQ)T!+QV&J:HB_4M$0S*>/'LCY(P7.DG S%Q!N\-R+>;2FLI+O%".B(6Y$%
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M'>^MJ)21E44QVH>OVDUT^A:(C5WXERNWY5><IXNS/\*%DI"]?[7+MS=UA.3
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MHW&W6B5%3>!+HO1=.FI$YH% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M2'T9%'E7:VK8HH+IIJM"J_R1,/RG,LJ:N"9OR;>V;B_$B%BH2K=:;!VT1!A
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M-J6'JG'2;=;(/,H+H2=.B:ZD;GA6=.EX9R,Y*EO2'6,KR9EAQUTS)MMIU4
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MHDCN25 D7H0J,EQ"'75&P3XI0Q?N>9S&Y+]HMYS-G;W+G8M\QL?LMS&7!;D
MB?0+H$B?5HM$ZHG,P#]4'MG\J?\ 637P_E/M*O\ LT5WY1E^$0BFI*B)]?2@
M^>ZU_+'_ &4H#O5H_HVK_P":@X[]F#[V)I"L#SAE9\^L[F1VHG-$ +C:9KMO
MG,!])$VC#O\ M4HUK(F27<K]U&)YV;QK;&;Y=L0L3"CH!,6&UNE+>1? D*7(
M= 53X!0XN"Z9US-<KA?',*PJ!'QZPR7H:2<IER+;*N91OMNPVQ9(!95>C;KI
M[3^UTZHA&DN/N+F.X#QYF^*XL=TD9[<%M+%D=DBPZW+T?:04>4-FWOM:*X0H
MG;\VB4(T%[R>X6+E_ <MY8"!CD^W8YD;]W"-(61$:8:=;%HFW"1",S%>C8HI
M:KHFJKI07)QME&69E:G\BR&PCCMJFN;\>M[YD5R*#UVNS T06C<30D:%544\
M5UHB:T%&RN8.0\@R+++=QICMGN<3"Y;MOGP+K<G(EXGR(P";OI([;)B#:JNQ
MMQTMIKU3XHA69?,LASN1.%2NV(]B^Y"U>W8KMQ,VY]E<:MP.OMB >4E<3[L]
MW@B:I08,?F3D?)(EVS7 \,AW7C2SOR6&WI,\X]VNS4$R;?D0&A9-I $@+8+I
MH1[=$T5=$# #W"97*QSBVZ6C$V+I>>1TN#8VQN8K(L/0QU:5'#!4[?Y3Q*FH
MBBZ(2T(EV#\D9A)Y G<7\C62#;<F:M0Y!;IMFDN2X$F KZ1C3[YMMP#!Q=-"
M3K]2:*02[/LGNN)8V]=K'C\O)[RKC4:!9H**ANO/F@"KCFTD::'7<XZ2:"-$
M5_$Y.Y)QO.,8Q/DVP6>/#S!QZ-:Y]@GO23CRF&E>[<AJ0RT2H2)IO;\J+16!
M!Y9Y<RV\YC9\#PVUOAA]XEVM^X7.XN1V98QT%6VF!!HE[Y(NX]ZBV&H^9=>@
M90>X(+MQYAN38Q8')V79Y)<MMCQQY]&A"7%-QN4;S^WHPPK1$1H&I)IT35=!
M$4&Y9S.]R?'<+D"QP[9=H-IOAL3K5*.7;IC+[0:=KO--.@;:HHN":?%"1=%H
M+MY'SNV\:X=<<PN;+LIJ$C81X,?J])E2'!999#QZF9BFNG1-5^%$<^\MWSE2
M9,XKA\B8O;K7#E9W8)D&;:9YS4C/-NFGI)0N--_>D)DHN,J0+L5/HHJV+[F7
M+UPR2\6; ,/A-VFQ*V#M\RB1)@L3WG&^X0P098<4P#5!)TB05+I\*"J.4N4,
MIY!X(A9%8K7'MKRW^+:<DAOSG-69<.Y,M"VPZP.UYIQQ$0RU30%Z(JI069>N
M3,^:O=KXZQRP6R?R6Y;4O&1&_-=9L=MC$ZK(*KR,J\Z3AIH "VA(GF7I0;SC
MCD6YY1<[]A^6VINR9WC!1UN42*_ZJ%(C304V)45U1 B T%=1(=P+T+K0>N9<
M@3,.SC";%,@M%C&72)%K<NZF0G%N8M=V*THZ:$C^T@'X[DH-3?\ F6+C^:95
M:948%Q/!["W><GNP$I2&YLPB6+";:Z(IN-"KB*I==43I0B,R^9.5,:L,7D?-
M,(A0N-9"L.S&H<]R1?;="E$(MR)#!,BV>F\5-MHMPZ]?LK0B?V#D!Z]\F9-@
MPQ6DMUCMULN,6XMN*1O_ #)'%5%'31$38FBHM!!K[SY<K+B'*.4+96'2X]OC
M=G8C]\Q24R3T9LG"+:NT]'U5$1--41/KH18''M\Y"OS$V;G6.1<<8<5IVS1F
M)GK)*L.B1$,I$ 1!P/*B[55%77Z.I$3RSE+.8_*;G%&#XU#N=T.S,7MNZW&6
M<6%%;*0ZRXLE&VW#)/* @+2*2D77RHJT5JIG/5\L^$<@3+]C[$/D/CGTWS:S
M#))V#(:FJ*QY##Z A=MT%(D$AW"J:%0CUD\SYYC^.?B#*\*:C2\AF0;?Q]C\
M6<CL^=*N2.$#4PE#MQU 1$G#ZHFJIXIU$;&W<F9]CF5V'&>6<>MUNBY6Z42Q
MWNQ3'9<4)X@K@Q)0R&FC$S1%V&&HJO3Z50--<_</(Q9G)\=RRR"URC:);,/'
M<;AND8WT;D6R"]#(Q0E EU1[1%[>U=?,NVA$MM'(>11^1;7QUF=KBP)EXQ\;
MS"G0WC<8<N,<T"=##N(BDK2$C@E\0ZK0;#!L^EYME&;P8T)IO&,5N+=DA7,7
M")V5<&6D.<) J(@BR9BVFBKNZK]5$8.?\CWRS9/9^/,$L[-[SF]1GKBJ3I!1
M;? MT<D;*3*, <<5"->V MCJJ_Q(I6NC<HY[;+%E7XHX_G/Y?C"Q!C0[#W9D
M"\?,"V-'!?<: MK:K_A"$"JT/F77P0-<7*')^(Y-BULY-QNS1[-E\\+1 D6.
MXO2942:^)&T+[3[+?<%=NTC:\H^.O@BA^0>6N1\BY#R'#,6Q"$_:<4NS$.]7
MV9/6.V,*0VV:*TWVU(WD173)$\J"(IXE01V^<L<AYS@.59=BN'PYO%!1+G#C
MR7)Q-7J;$9!V.[.CQU95I&Q435&G#1PD'IU5$H+'X Z<)X%I_P#82%_P24-8
ME_S+EJ?DUWL/'V(0QMMC1I)%^RB1)@Q9SKS?<4( L,.*X+:+M-TB0=VH_#50
MBTGW%36>*X_(+>-*Y=X^0MXQ>;"U)%[22,CL/>E>!$%W7HK:]!55\>FJB-O;
MN4.1K-G>-8KR5BUNM<#,_4A99=HGN3CB28K2OK'F(XRTA$H)IO:\N[ZM= PC
MY8Y#RL,@O6 8A#NW'UBD2K:\_*GG&NET.'J$@[>T++C6T"U0.\:=S3IHO1 S
MO:J*![?\)1--/3R5Z?24U]5_\]#5QT0H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!7O*_V
M<*_[V6G_ -IRBX_<DS6[72[OX)QL+4K)VM!O5\?!7;98VC37<]M5.]*)%U9B
M"6OY3B@'V@U%NXRS# HR0N,LA:2WS1/YE#R%LY3+4UXE-RX1!CJTC9$2J1Q!
M0&"7[':Z[@\@PK)>+Y3^7XD_+RXK@C;F;6J<39W.XFT*CZR$\NQ >;'H,/46
M"#RM]HNI!YY[DUDRZT<=7S'Y8R[>_F5I'<B$#C;H*\)M.MFB&VX!(HFV8H0K
MT5*"X:(JOW(X]?,JX4RK'\;@.W.]36X@Q84=$5QQ0FL&6FY43RB)$O7P2BXY
MJY7X Y"R=OB);):I312L9M&,9FC*B'I A*P2K)3=U05-57Q_FOJ2BU8$_%^0
M<1YZY.S[&,6F2;>N(-VW%'8X-DR_<1:MS3+8(IHNUL@)2U_) OJU(T7%?L[<
MDX1$GYGE&2X_DUX[LB]VBVS&F&4[AD("ZBMN*1JWHIJ1+U54HM8>,\9<H8=Q
MMS+PLEBGW&QN]V7A5ST;4)8FX#9 B[DT,VT:<V(FB$CGQ\0\L\XWY,_5!PA#
MM.)S;E?L2D++NUJ;V"XTK)@8@:ZKMW[>BIK06[8.:N9[I?;9;+IPE<;5;9DM
MB/,N9W(' BL.N"!O$'IAW(V*J:IN372B19G(?&F'<IV9BP9M!.?:HTD9S+(/
MO1E1\&S;0MS!@2^5PDT5=*(K7]S?V^?U9>_TE/\ ^/HM79"MT:U6J/:8 *$.
M%'"+%;4E-1:9! !-Q*JKHB)U5:(Y6LO'_(^*\"<9Y!8L=</E7CV;/?9L<A$[
MSD2ZR94>0RJ"7@;;K3WC]D:-)=&XKOF*WC@&UV^$]-A8G\W<R:Y J&VU+GP=
M7734BU^^DN.*/C1$++#;A+R#(6N4.,[]R%R&_<I;N/W%Z0I8IZ$R_P $%#62
M#,=H!^V!LDXGUKJB%9N(<>YU;^.^#+%-L,MJZ8EE;K]^:+8OIXJ/S%1]20M%
M;4715%2@G/*?%4?D?F3#SR.PE=L)C66[1Y\DNC+,J0@HSJJ$BH?BH+IT+1?%
M*(R,(OO('&V$Y1C^86:;?W<!:,[!>P)L!O5H 5-C5PB7:^RVFQY"3P1.I+JM
M!;.-7H,CQVT9"TR4=N[PHT\(YJA$V,IH74!53HJCNT54HCG#DC'8MXR>]_K"
MXAN=YR#U1EA^88**LN.P]J#&]9)22V34AO[)D\!!T\HZ(.XK;V3".4(N0>WV
M5F .WB\8RSD297=D,7AC+-@]J,#SN[4ST46E--VXA5=5UU4,#"[AR#Q-Q_/X
MSLN(.Y)#MQ7/\)9?#F0_DAP'WWG^[/>-T29-A3-'&T E+;M'X*H:GBW&+_/L
M/MJN]OM[TBU65N]2+M,!$[<9N9&,6E/547SD6B:)15NO8]?"]R$7*D@._AMO
M"GK85ST3L^M.ZMO(SKKKNV#N\/"B/SW V[.+GA$5C"0FO@-TAN9-!M#R1KG*
ML0D7JV(CJJ.UPM1\"15'5/J48IBVX!%_6!QYE''?$MVQG'+7>=;[=KSTN[JR
M6#;0B:?DOO\ IVM=SCCA)JJIM3I15R<*X[?;!<^3GKU =@M7?,;A<;83VB(_
M#=;9$'@T5?*2BNE$U56,\=\@8YQKQ7E;&/OR<JX]N][EW#%3)MJ6_;;Q+E"\
MK*J6Q7A;,'&P4D0OIUT10ED.?FF?\X8-F181=\?PFS0+Q%&7>6V8\OU4MIM"
M5V.#KA-MKL 6E+J2[NFB4$[YQPB\9]QY-L^.DVF11)$2ZVEM]=K+LFWO@^+1
MKTT1Q!4$75$151572ABL,YR'D'E29@$"W<;7VRP;%EMENV3R[L,=D61B/+N&
M,@ND4AM-2,WQ1$1$3IJ7E#3Y!BTR;R#E:\L\>9)R))DW(G,$*W/*6/-6I1'T
M[#@+*898,2U[QOBNJ^9$_E!AV_CK/X?MUOF+_A-V-DENRWYHU8(I-H#T-BXL
M2U]$2EH;:!J+>NBKM7IX:E;+.\'C7S.87+V4<8W'+,3R"SLP[ECO:$K_ &>=
M%<+MN>E%\4<!P%VD(&I(O7ZB(G?!6(-6FYY#D,'CN)Q_CLU&(UABNB0WY]D-
M2>.<*/.MMBI[>TVGF3KK\%4:D7/>,GDW%M\6(^$2\V,!R"RSS5!]/.LY>K;-
M"+H.Y )M27P0EH8K;#>.KSR7P%E]PNI!#S'ELI%_4G-5;8%U16VQ]^BEV0::
M:TZ*J":^-!^99?>3.2>/#X?:X\NUERVYL1[7?+W<!8''XC($"2)#,H'C60BB
M*]L '=U^KS!M)S.3<2\L7+)HN)7?+,2O]CM=JCOV!MJ5+C2[3O;0'V7'&M ,
M3W=S7:G^SH$#O6 <GW?A_FZ#<<6>BY1EN0Q[I:[,PZU)4V''X3NT'0) -6@
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M. $07W <1BW$T;"=T20]15D-5UZ_&@E]!6,K@'C:7^+&SAR@@YJO<OUO;FR
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M7'$X$J[G?GV728]-W80I&<[C9@X)(Z*$V0+T)*+B9X=Q-AV%K<WX;,BZ76]
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MN?M!@?V>'].H'X8Y<_:# _L\/Z=0/PQRY^T&!_9X?TZ@?ACES]H,#^SP_IU
M_#'+GQY!@:?]WA_3J#.XFR:[9AQ[9<BOJM%=Y8/#+.,"M-$;$AQG<(*1*.Y
MUTW+1$TH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H*YY?_Y/A?\ WOLG_#K1<6-1"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4%:>W_\ U1X[_P#5O^72*+JRZ(4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@K
MGE__ )/A?_>^R?\ #K1<6-1',?O:R_*L-P/'9V)WJ;9)C]W[+[]O?<C.&UZ9
MTMI$VJ*J:HBZ47$$R_B[W"8/Q_)Y)MW--RNGRV$%T?MTHY#0JSL%PT%77W@,
MA1>@D";O#XZ45GYSS5F65>T6W<AQ+A(LF7+<6($^=;'#B$X<=\VB,5;45%'1
M$2(4Z:ZHG2A/72/#=QGW?B;";I=)+LVY3+) ?ERWS5QUUUR.!$9D6JJ2JNJJ
MM$U37O:R_*L-P/'9V)WJ;9)C]W[+[]O?<C.&UZ9TMI$VJ*J:HBZ4,:NW>W;G
M6XVZ'<!Y\O(#+8:?0-LPMO=!"TU]<FNFOC0KHCCS'+WB.&6O'LEO[V37J"+J
M2[[*0D>D=QXW!4MYN%Y!(034UZ#1'!67^X+E.3R9=N5<:NMQ/BNPY!$MXVUB
M28VYZ."&@ 3.[:OJ6V'#(M.BFG5/+1J.^[ME<:-@D[.+./S*&S:7;U  -?\
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MBLLCX.Q3)^4[)RW/F7!O(["TRS$C,N,C#(6"=,>X!-$:JJNEKHXGPHM2G/\
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MFFFTVB(BG1$1$HC+H*T]O_\ JCQW_P"K?\ND475ET0H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MO5-S8N^KC;U3P!' <!?]\HUC]]F=FF93=<^YTOC*!<LHN+T6"G54;:)SU4E
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M;>(;%PMSZ;7XDMH'V33Z"!Q%%?XTH(S8>)^,<7N"77'L0M%MN:+N"9&A,-O
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M.*?XAD/]F[W^AT#]<.*?XAD/]F[W^AT#]<.*?XAD/]F[W^AT#]<.*?XAD/\
M9N]_H= _7#BG^(9#_9N]_H= _7#BG^(9#_9N]_H= _7#BG^(9#_9N]_H= _7
M#BG^(9#_ &;O?Z'0/UPXI_B&0_V;O?Z'0/UPXI_B&0_V;O?Z'0/UPXI_B&0_
MV;O?Z'0/UPXI_B&0_P!F[W^AT#]<.*?XAD/]F[W^AT#]<.*?XAD/]F[W^AT#
M]<.*?XAD/]F[W^AT#]<.*?XAD/\ 9N]_H= _7#BG^(9#_9N]_H= _7#BG^(9
M#_9N]_H= _7#BG^(9#_9N]_H= _7#BG^(9#_ &;O?Z'0/UPXI_B&0_V;O?Z'
M0/UPXI_B&0_V;O?Z'0/UPXI_B&0_V;O?Z'0/UPXI_B&0_P!F[W^AT#]<.*?X
MAD/]F[W^AT#]<.*?XAD/]F[W^AT#]<.*?XAD/]F[W^AT#]<.*?XAD/\ 9N]_
MH= _7#BG^(9#_9N]_H= _7#BG^(9#_9N]_H= _7#BG^(9#_9N]_H= _7#BG^
M(9#_ &;O?Z'0/UPXI_B&0_V;O?Z'0/UPXI_B&0_V;O?Z'0/UPXI_B&0_V;O?
MZ'0/UPXI_B&0_P!F[W^AT#]<.*?XAD/]F[W^AT#]<.*?XAD/]F[W^AT#]<.*
M?XAD/]F[W^AT#]<.*?XAD/\ 9N]_H= _7#BG^(9#_9N]_H= _7#BG^(9#_9N
M]_H= _7#BG^(9#_9N]_H= _7#BG^(9#_ &;O?Z'0/UPXI_B&0_V;O?Z'0/UP
MXI_B&0_V;O?Z'0/UPXI_B&0_V;O?Z'0/UPXI_B&0_P!F[W^AT#]<.*?XAD/]
MF[W^AT#]<.*?XAD/]F[W^AT#]<.*?XAD/]F[W^AT#]<.*?XAD/\ 9N]_H= _
M7#BG^(9#_9N]_H= _7#BG^(9#_9N]_H= _7#BG^(9#_9N]_H= _7#BG^(9#_
M &;O?Z'0>?!D"?;>*L>B7.(_ FB,EQR)+;)A\$=EO.!O;-$(5421=%36BZL.
MB% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MRR7!DN(J=?"C7QT=[1.1/QYP[;8<MWN7K%R^2S45?,K3 HL8]/'165$-5\2
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M>-7%H1+<N/3A!RX/H2)HA1T: FU)4\QZ)U+J7$6OG#^5W/YS:+;:85NE/N9
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MHXQA6;GI=(S*D+#5R T?)LQ3IM=(>^WK^4AZ:(*4,;3W'?\ AGX/_P"91O\
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M[=OC2WH3 G/>574(H[3;BJT".CN,M%0=BH:B)->>3)YXOAF3XK:3DM91=K?
M>AW'6%(8C3%-'247-/O 4-$3JB^*:I01K%^9+W<K!$_$=JD6Z?+9BR[?=XZ1
MG&IL<[JQ;G32.3FYCJ^VJ"XNJ@2JGF';03'C_DUC/+A>;>%K<MCMI<V$U(D,
M%*1.X;>V1&$D>CN>3=L,--%30EH)[1"@KGEG_E''_P#WOMW_  $JBK&HCGWW
M8<W_ *J<(6RV*0@9QD@''MZ@7WD2+]EZ5TZHJ:[&O#SKN378J47,<\^W3VJQ
MN2./+]EN7[XKEZCN0\.-=R*RZV6JSB%%3</<'MB*^([_ *1*B[K0>W#DR[\
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M+MK@27O4LOPC0VG$?(R<(M=4)3(MR*J%KK08H\:88,>%$&W:1K>PD2(WW7=
M8&8S/0?M=?OF&RZ_1IX*J4'WCO'N-XS=Y%]@#)>N;['HFGYTI^84>%W%>],P
MKQDH-;UW;4^I/!!1 E5 H*YY9_Y1Q_\ ][[=_P !*HJQJ(J/./;5Q3R-D<G*
MLO@S+A>)*-@3BSY+;8--"@BVVV!H("FFN@IXJJ^*K1:M.WP(5J@1;7;6 BVZ
M$TW&B1FD06VF610  43P011$1*(K/D#VY\3<FY N49;9C?O1,A'=DQY+T7N
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MO!K^*'[A?VXUB2.ZY)O#DZ0\TRD40 D>WDJ,%MUV**[M!ZT:2?BO';OC/+N
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M9NU"(%<CB+!N*/EZ(XJ=:#-S#+ER7-,SY5XSM(9=8\;PAVQN2NP3UON%R?N
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M%0-9KB&(<O9P&57V#92F6^PE$2X2&XO>%M)J&K?=(=R"JHBZ>%%2?]<_$?\
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M$<<$--JE\=5Z4,1B8SB&;VZ)B?SODW)LEN3T5JZ8)/?=BC#-MT'3*:^_!;9
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M-,,E*>!7" 04DCLZ[!7KIJE"+0N_-F.Q[9C,C&($[*KSF,7U^/62V  R7(J
M)F\^3Y-@PV&Y!(G"^UT1%T701A.<^X]!Q+*,BOEGN=IN^%K&3(\9DMM?,&!F
M."#+K:BXK3K1[E(#!SJ@K\:$2CC_ #N1GD69<"QJZV"WMFVMM?N[0,+.C/"I
M \V F1"FB(JB:(J:I]>A&DR7E\K9E%QQ#%,5NF8WFQ,QY.1A:RC-!!;F 3C(
M*LEUKN.F J8MMHNJ?&BO*=SIC(8]C5WL=MN=[O&8=X<?QJ-'[5R=*(JI)[HO
MD - PJ:.F1[?B.Y.M"(CGW,!WOB[D>VL1+IA?(N-VE94FURR%F8TV]_-R8LB
M,X8.MJJ*/<;/HO1=.FH;FQ9UC5DR6^SK]>+P#UFQ.TW6])-?1VS-1R R[L=E
M-3]0:HO<73S^5$ZT&;8^<V;A=+'&OV(7O&+)E3PQL8OET".D>5(=!3::=!EU
MQR.XZ**K0NCYJ$57&Y;NUOL_#0X'%RN_XS?)UT.6=S>AR;Q<$BG+'TKK[KJ:
MDV8*XB;A'M"*;M4TH+2NW.)MS[VQB6$WS+;7C,AV%?[M;1C-L-2HR(K[+ 2'
MFW)#C6NABV'CX*M"(GE'-EXG<A\/+A,&Y7'"LLCW"X2&HH116>GI=&VU5YP2
M H9*KSXJHIX:*:II0C>63E;#\4QF^W1N1D%\?=RZY6*!;)A#/N4NZH]HL6WB
MA(@QAT56D,AV G7KXAN[+S1%DW"X6#*L<N>*95!MSUZ8M-P].[ZV#&15,HK\
M=TVG"'HA@I(0Z_0BJ@B.1/<W9I-FMN9.XAD$3CF<4=A_+9+,<(L9^28MIO;1
MY759!PNT3XALW]!W=-1%Y*J"BD2Z(G557PTHBEW?<9:_22<H@8E?;CQC"=-F
M3F\5EDX:BT:MN2&F%=20[& D+>\#>B;5Z+I18A.8Y+<\[]P./8FD/(W<'9LS
M=UA?(IS,.-))^:R(W4S9D KL,&SV**^?7[(=5U"\^2.0;+Q?B4K,\A;?=M$)
MV,U)2*(N.BDI\&$-!(AU05/<O773PZT1'+'S,Q-R2UX[DF+7C%/Q'W%Q:==@
M81F=V@[BMFC+IE'>4/,++XB2IT^UTHL:>P>XVP9 Y,FM8Y>8>(6CUX7_ "N8
MTTW;H+UM[A$V2BX1.*8@.WM"2ZN .FJKM$9%MY[BN2[.[D>(7S&<6R-]J)8<
MCN;<=(KKTG^8&0#3QN1N[_N:NCHOQTH1G3.=\1M-NS&3?XTRUW3"I 1;A97@
M YDE96B0CB"!DCH2E71I=4^.[:B:T(Q8F>XY!SN]W/()-ZLDN#B<*]WFU7)]
MLK1 BDZZ2[66B-?5HJ*+JAN0D1!'5:#\M/.[$J9:#O\ A]\QK&,C?:B6#(KF
MVPD9Y^3T8%]MITW8_>71&E=#1=>NE"/F[\\L0YM^.R8?>\AQC%)3UNR3(+<,
M96HTJ(B+(!MAUX'GNSK]ZH!HG736A%JVZ?%NMOB72":N0IK+<F,XHD"DT\*&
M"J)HA)JBIT)$5*(Y5Y(Y ELX/>+;A99=-:N6?R;'?+DLQCU48FYK+;\&"]W4
M-EEY"V1!$?*FY#4=>IIT3AT0<=P* U#M]TUB1#?;M5SD#,NV\MSW8<><=,2<
MW+M35W:G1-41*,N8/UQ9O,XOL&5Y!\[MSD/D.&-PG!L%9]M6=+%V"PS$/>:-
M T+3C1 B$7ANHTOW%^8FKQE88;DN,77#[S,B.W.SC>$CJW,B,*G<43CNNB#K
M:*A.-$NHI\:)&D7W%6I8SF3M8I?'N+VGE8<SH&6EA;1<[:R!C]SU)1D5.KR-
M?Q4(S;]SM!MN:3,"L.+7G*+_  F84QWY2VPY'6%-'=WT=-T100U%-"TW*7EU
M1%5!'E<>?(C+]UF6+$;YD.'8^^[%OF4VYMA8C3D9='U8;<=!V2#*HO<-H%1-
M%TW4(M.TW6W7VUPKW:) 2[5<6&Y<*4WKL=8>%# TUT7145%ZT16=WYL>"ZWJ
M!A^$WS+X6-2#A7ZYVP8S;#4ID4)UA@9#S;DAUM%3>#8>.G5=:+&/=_<5B4.'
MB$FRVJZY"_G4*5,QJ';(X./NNP^WO8<$C'82;UWEU$4 E5?I$>\OFU\IS5BQ
M["+W?<J8A1KCD-FC>D:*T!,#N-,RWGG@;208>8&1)25/HH1-L'S>R<@X^WD-
MB[S;"NNQ9<*8TL>9$EQC4'H\ADNK;K9)H0_QIJBHM$1/*>9XM@S61QU:,9N^
M29BW 9NC$*W PC)QGC-LC<?>= &A!11")S352%!U5:+'C&Y^PT\'F9G.B7&#
M(M]S7'9>-.1]]X6^(HH,%ID"5'73W(H;2T5.JJFBZ"/JT<T$_>4QC)L/O&,Y
M3,AR;ACULG>D<2[!$;5QQF*\R^37J!'12:<(=J*BJNE"-=[;<[RG/<%=N>60
MIP7 )TW2Z3$C@Q*%9L@$;8%DE44CH M&A *;D\JE0U(,PY57'\F#"L<QJXY=
MEB0TNLR!;BCL-Q8).*T+CKTIUH-QD)(#8ZDNGPZ:ACV_FW'+BQB3H6VYQG\L
MN;]C;A3(Z1Y,&=$;,W0E 9]-NQ4U;4J$968<HM8]D,["[=9I]VR=G'G<EC-0
MA847&6Y0P]@J\Z'G$C[BHO3:B]==$4.2;=DF7N<=X8AP,X?E9_>[>F27U+FR
M2W1IM)3JQ;:12D*/W5T5?*UJ(:*NFE%=#8QFV#<=-<@OS;CD7H\32SM7.)?)
M2W(67I,%M6(\!-YFKAJ:"ZA%YGEUUV]:(SW.9V982L>S+%L@PJ7=[5<9MB<?
M6.DB6Q"C$\^+#D=USL2VVT5Q&W=NFFNM"/BV<OVBSXM@]EQ>VW[,\FOUDCW.
MV6IPV';M\N1L!]9<Y+K@,MH1*@$Z1>=Q=!UH1E2O<+B5LPV^Y9>[;<[7*Q:9
M$M^38])9 ;E!=G.MMM&0(XH&T8N(XVX!JAA]GKTH1[6KFYN5DUNQJ^X??,<=
MR%N0[BTFY-,"%P6(TKQM*(.D4=U03<+;Z"OTZ+TH1J_;WR!EF<,Y?^*+;<F"
MAY!<FXDJ>D86F66WNV$ 48-5[D=!T/4=-5Z$5#5@'GEM9Y$;XWDQI#%UDVHK
MU FF@>DD--/=AUH"W;NZVJB1#M^RNM$1B[\[XG9SR5'8<^4./W6+C<;T;0/G
M=;Y+:1U8,$!/<;K:*@N(>Q$7XZ46/FT\T%(N<C&<@P^\8_F:P'[I9K%+6(XM
MU9C#N-N'(:?5DGA33>T9BHZZ^&JH(@G$//$\.%[5E7(4.Z7#()\YZ!;"998<
MD7R;)F2.VS!99--.T(=LNXC8CL^/BHBP;'S-;GIERM&;V2?@][MEN>OKD6[=
MEUIZUQ4U>?8?BFZV?:33N!KO'7P7K0C7V+G9NZ2["[<L-OEFQ;*WF8^-9');
MCO1I!RQW1^\W&><=81Y.K9.!I\5T37018V59#%Q+&+UE4YIQ^%9(,FY2&6$%
M73:B-$\0@A**;E0=$U5$HBL;?[A[3*"S7N?BU[M7'^0/,1+7F$UI@(BR)2[6
MU>9%TGF63)=@/F&PE5%UVKNHL9J<Z0I>=7# [+BM[NDVR7%JWW^Y,-,C;X++
MX@0277C=3R+N)=NF[:!EIX:B, O<3:O3.9,UBE\>XO9>5AS.FV65A;1<[:R!
MC]SU)1D).KR-?Q4(W.0\QC"R.=BV'8O<LUN=ECQIE_6T'%!J&S.!76$W2'F^
MZZXV.\&V]=1^-"/F=SGC(8YC5YLEMN=[NV8*\&/8U&C]JYO'%54D]P'R 6@8
M5/O7"+:GBBDFBT(Q5YZLL''\IN.1V*YV3(L-C-SKUC,H65F+%?+:V]&<!U67
MVB74=X.=%31=.FHCYMG/<"7>;#&NF*7RQXUED@(.,9+<666XLN4\*DR!-BZ3
MK/?1-6.X"*:==$3701K^%^1,MR_->1+9D%IN<>!;KNXS;GY:11C0FF&6!&$J
M,N$7=+>KVY$(5%>I:]*&KLHA0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!05E[AK?/NO"N9VZUQ'IUPD6]0CQ
M(S9//.%W 70 !%(E_@2BXA-_FR>/.8\>Y$OEIN4C$IN%!C3DRV0GYYQKBW.&
M6@OM,"3@B8KM%=OVNGTZ!7-ZMN5Y/8^4KJ>)W> =\R_&9T"VRX;B2G(+11OO
M%;%"\ '<Z**O;742T5%HJW.:79=DY'XES9RV3Y^/6*;>&KL];(KLYUA;C;_3
ML$33*$6U3\2TZ?PZ(I,>?$]FNUNQ+EMF9;Y$63/R[*94-MUDVSD,OZ=IUI"1
M%,3T\A#T+X4%/P,&N5D@<6YME,+)H>,L8<..7HL9.;#NMKE-R5E [):B:2"8
M<15$Q05VDB$7PU*]LIQ,+YQARI></QC*97KH-LMMJOF0RY\ZZ7AMJ:T\:,09
M0*\#3/Y)E]I%71$T*@[(93:TV*)M1!1-/#31*,N;.6(.,)R+<9^4V;*<2N2Q
MHPV#D#"3FON7(4#S1Y+<1EP0=:/R +H%O#\I$T2BL"QN\C8U-X]Y@Y#M%VNO
MI[;=K!?^W$1R[0X4B6CUOF284;<N\FP09"-HJAT4M2U2@PN08U\Y.D<C<CX_
MC]R:QMK!7<3LJRX3T>;=94B:DPW8\8Q1Y6FT'8FX$W$J[?CH4S#C?+,UD<C6
M"VP)#$FZ8-CC-N?>;)EEZ9;WBD%&%TT0-Y;.V2*7EU\VB419]MYENF5W#',?
MQ/#KHW>GI3/XL"^0)5OBV:$V*K(UD&V@./ZZ"P#:DA^*JB4(IS%;??</XTX(
MR&\8_=_1XO>;T[?8K$!Y^?%;F.3FV3<C"/<024Q77;X*GTIJ5GW*;?[]=,I@
M<B.9W)S-)TR-CV$XXDNW6*3;272(:2H@ T;9"2*\](D)IUU'IU#RQEB\XI:/
M;ADUUL-V6VXVS?K=?@9@/N2H<BX,>E9[T<1[@B1B7FVZ:=?BFH>EKQ?+<?<A
M<@_A^X3H^(<BY3.N%GCL&LQ^UW=%CI,C,DB*\C>J&*!KN'54Z:K02;(YTSF'
M.;1E6*6:YM8MA%CR)7;I<(3\#U\Z\P4BMQ(S,@ =-0V[S) VZ]/'34C#RW';
M^][*X6.QK1,=OXV>R-E:&X[A3.XW.B$X*L(._440B)-O31=:'72-X@+=;1/M
M8NJRLV,]&1X?$%>;4-R?P:ZT1S/9,QNV+\+.\*3L,O3_ ";$M<K'8UJCVYYZ
MWS">%QAN6$U!2.L91,7'#-P53S)ITHJ28#A5]Q+F#"[?.C.O1;'Q>S9)=U;;
M,H2SH\^.A-"\HH.[0%(17S;>NE!N/=6X\SPO='H\=);[=PLQM12Z(Z8W2,J
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M^CI1ESM<I]_O>097 Y(=SM[*&[E+C8QA6,C+M]EF6K72*:2X8"V0FB_?/2)
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M[M>CO]MFN17$M[\ H\9E%;E:=M3W:^377HOT+H%UT0H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MXV>A"*HNA)0B \89Y-O^,\-S,Z8O8Y%=)\QBV3TGM=BX*D-QXY4IMHEWM>(
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MGI,"Y1[K=)F93[U$@6<X:]P7023(<"3)$O*V (0KJNY=JZT'5-$5MSF_G<?
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M#N,71J^6](YB E*8 VQ1W<):AHXNJ)HOUT$EH% H% H% H% H% H% H% H%
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MUL>7?^H[#_WGQW_M6/0Q8%$*!08-Z_ZFN/\ S9[_ (,J".<2?ZK,(_S#;/\
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MM4\*$;G!^6+S?<SE<?9OB#^'96$#YS 8*:Q<X\JWHZC!$+\=!$7 ,D0F^O\
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M:D6F@I]-$<><8>W//LU_$G(V<9-D& 99D]SDN2;7:W?2F<,B0A1[JBJ.XC$
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M:ZZ;2%?XZ+UF\D\97^Q\NR>1+AB-_P KQ/)+/"COLXI+?BW&#/B,1V-K@1C
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MN/Y+"Q:58?6@[(-Z2#:N$VX+>PE0S5&M/*X.TM1UZ"-R_P L<E0W;9B,S#(
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MT:@ABZ&J G146@U;-DY@Q;+;+S#>K&WD]ZGV5^QY=C]E=8:D06/6E-AE%[Q
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MT45\-4THM2?'>+\KM-_X9G?A>VV./89613<C@V)S_ H'S*"3,855YPC=<7R
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M$73X]*"DK-PS=,1L*X8_PG9<NR>$KD>TYLZ]";M<IE37LR9[3AC)$FQ4>ZT
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MN NM",5S>;C0.#'-"-6C<1#UTZ_ 8K>+P_F1WG-+G9N/K?AMAR'C^[XS9K+
ME1%?2XO&A,K/5I1;5Y_<NAB9B "(D>M%JQ<SP'+KIPSA.)VZ"+N169_&7+A%
M[S0BVEK-A9*HX1();-A?97K\-:(Q;;:N3N*<AS"!B6)AEU@S"\R<DMEQ2X,0
M?0SKD()(9F@^J$K(F&\"8$RV]--VB4$KX$Q3(<(XGL.,Y8P,?(893SGM-N \
M&^3<)$A"0VU450A<0NGAKIXT-5MF7'F1R^4K_D.4\>?K1L\T8OX.5ZY1F(5K
M!II!>CO19;@@*&XG<)T&G=WT:JJ4&LQ+AWD6U6;%;?/L<*'(LW)+N2S&+:^R
M-O;M#K#B]V**J)"T!.=L&E%#1$^SI0JVFL2OX^X&3G2QA_"[F'LV49G<#<L\
M+FY(5OMZ[].V6N[;M^&NM!6#7$7(ML<NN86NW1G<ILW(UYRZQ6J1*;!NY66Z
M,@P;:/#N%AUP4505Q/*J>9.M"I')Q_D?D[,[5F&08TN(6K#[==VK-;)4R-+F
MW"YWB(L12/TQ&VVRV"KMU/<I+KIIX!AWCC'-IOM,:XOCVX2S9+3"AE;ED,B*
M/,RFG#'O*?;Z"*K]O3ZZ'62!YGAG)^=2^.[1 SB)?WK?*O=E;NL>VS['<TB"
MVA21?0MS$AM!<$A13Z%M!=.H9GM><N<C"\FFWE6#NDS+K[(F/P24X3KYR41T
MXQEU)E30D OHH:D7X1R#]X7\>>F'\*_@SY'ZSNAO^8?-?4]OM:[].WYM^FWX
M>-! KOPME5HYSQG*L/0#XU?NLG(+]:][+?H;P["<BNR&D/0R&2A I &[0T5=
M$32A6-%QKF/%+'G?&5BQ%BYP\EGWF;9\O<N4>/"9C7K>6DA@M7U>;4MJ" *)
M%IU044J#.O7&G(</A[C:1B$-AOE_CR-"]#%?<9(%5V'Z&=&5U31O:H'O5=^B
M]M-%H,NY\.7S$\2XQD8%'8NF4<8N&^MLD/)&;N8W!@F[D(/'J+;KIF3C9'Y4
M7QH-C:+)G?(/*&.<@Y?CBX?8\*BW!NS6V1+CS9\R==F@8>=/TI&VVR#8J(HI
M[E+KX+T#<\_8AD&<<=N6#&8@S;H5QMDE&#<;9%6HTQIUQ5)U1'H(JNGQ^%#%
ME-1H["J3+(-D7VE 4%5_AT2B*YP_$K_:>8N3,LGQA:L.1,6!NT24< U=*W17
MFW]0%5(-I&B>9$U^%%5!<^(^1QQIZ)(LAWBQ'G5ZOU\P^-<6X3EWL\\E6,7?
M%P0T!5[BQW#'?X+HNE![63B?*F<X+(K'QS;L)Q63B]XL3%MC28A3TER$$VGI
MQ,KL5751 ! <=V(FIDFNE!);GQIFDG@# L'9MPED]ED8^Y<H2OLHC0V^0V;Z
M]Q3V%L$57RDNOPUH)ID6)W^?S9A.7Q(J'CUGM5XB7&6KC8JV],[/:'MJ6\MV
MQ>HIHGQH*TS?BSDRX3.49EBBDL+(;Y8+@W 9GA!>O-HM\06IL(9 $A1E<)-N
MX]NNFG@M!AX_Q;?&.1<!RK&.*X."XM8)DP+JVLJ&[>7QG07(Z/.DP1HK+2EH
M(]\G%4M=B)UH-QBULYPXRPPN(L5Q9FY'!.3%QG/')T5N"U#E/FZV_+BN:O=U
MA'.K8-&)J*::IK0:NZ<17#&,QR.[W'C&W<L6_)G6KDU<C*!%N$2XJP#<EIT9
MRH/8=<%76^T2]O545%H5L)7&O(-FQS!,FM&+V,<FQ6^2;U.PS'T:M<0HD^.<
M96FG2T;<D--J&KA[4-=>JZ)N#.MN*<GYARA?<YR;'&<9M-UPF5C%KC'.9F2&
M7CF(\'JD9U1"/<9_=;A$41%7=JE!I<)XYY&DRN&X^3XO\G@\?QK]9+XX4^+)
M[T>7:VHL>2SV35=KIH0[--P::KTZT&QQ>%SS@>%1^(K!C$=Z;;E.!9>0BFQ?
MEC< G5)N4]#-5?[S8%M5E&R123754H--,XPRL,VR6=F''3'*%WN,WO8QE%TG
MQ@M,2 38 $=^$^9*R+)(1GV8YJYKTUT2@]^.>(N0L>;X7BW:VM,%@\W+5OLA
MI]@VFPNHR/1NM A(I@:NCH*)N%/M(E"M'DO%>?Y4017N-85EY6;F";?+5CN#
M%N@CL>W+.6.PX,DS)ORDTXT2J2ZZHG@5UJV)"V(F6\T1$(U1$W*B=5T3Z:,O
MJ@4%+\O8[?KQ?X_S7 (7)''CL-6OEP>ECWBW7%#55>:=E.-(33H*@JC9H2*F
MOAXE5!=\5Y P''N-8;4 4O)\@.7'%\5GW)926^V+"=[=L.:7<354 ]#'<(D?
MQZT595TP7,^:+]/N^8V,L+L4;'+MCMEARGX\VX.3+X -ORW$BN&V+30@@@"G
MN)?-T1=*(@]MXFO#-G@8M^HG'$S&.C,27F,]R')Q\FVM!.9V&W EN$X**O9[
M8JA+JJZ)15CA;N0N+,RRZ?C.(GF>+Y?(8NL0(,R+!DP;BW&",ZR\,LP%67.V
M) ;:KVTZ**^-$:I[ N9KO?K%D-XD16LM'%LC@/WR(;;<:W7.ZN <!H&T1#-&
M$1$5Q +<HJJ_#4*KOO!^67WC67BMFXAC6[/RC,K>LTO-TB394N5&<;<=."\3
MCSO=E$*^9SM  $0Z^"46NB,)Q3(;9R[R1E]RA)&LF21L>"U.]UMPS.WQ'FY
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MG@N"Y19,2Y2M5QB"U.R3(LEN5E;1YLT>B7-/\&-5$E0-_P#)+14^.E$0'/\
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MG&:[D&'CN0X9&LD*Z$X"H-TC7 Y8"30JKFQ/(I+MTTZ)UH5$H'&$Z:MKL[7
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MW=%;'1'1)$^'BM!*:!0>$N9$@1SESY#<6*WIW'WS%ML=RH*:D2HB:JJ)0>]
MH% 145-4ZHO@M H% H% H%!J%Q>PEDXYFL(/Q.$%;0-QU+N)!)Y'U9TUVZ=Q
M-VNW7ZZ#;T"@4&'=K7;[Y:YUENS RK7<H[L.=&-5078\@%;<!5%470A)4Z+0
M+3:[?8[7!LMI8&+:[;':AP8P*JBU'C@C;8(I*JZ"(HG5:#,H% H% H% H% H
M% H% H% H% H/'TL5)2S>PWZU6T963M'NJTA*2!OTUVZKKIKIK0>U H% H%
MH% H(CFW&&#<B^C++K2,V3;E)8$QIY^'+8[FB&C;\9QIQ!+3S#NT6@V&(87B
M^!V<;#B5M;MEK$R>)IM2,W'CTW..N.$3CAKHFIN$I=/&@WU H% H% H% H%
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M*[E557:BT1IW.?;S8[/?+)DEB8=Y8LMXMV-,66WODEON$Z^!W8#K+SR;FVG
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MFJ+0;&1R+R_EG(.;X-QO%QYB#BJ6M]F^WCU;@N-W2 ,H&>TP2;B,E)>XBH(
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M">=-NY#5.OPH*TS9<U_>DAL8 %O&]R\$[,J?=A==C0X0W@S-WM,DV;IJ: V
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M1$3Q6@BECY3XUR:[%8L>RVT72\)KI"B36'G3V]2V"!+OT^.W72@EU H% H%
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M(>!8]=F;%?LHM5LO3^WM6Z9.CL2"[G0/NW#0O-^3TZ_"@DM H% H% H% H%
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MN5:$3*1EG+_'-[Q5SD659L@QO*[I&L4I;-$?A/VNXW#48W;5UUQ'XZFFPR-
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M]R7>VJH$N&\L=U4U3Q15!P%3ZE2@W\2)$M\5F# 8;BPHP"S'C, +;3;8)M$
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MH5".NZ,E H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MV].LEJ@VV2\PI*T;L2.#)$"D@KM51Z:HBT14.2\-9_<CY:L-ODVE<9Y$;2=
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M=PCT\=*%= T0H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H%!7M_YTXCQ>[RK!D&70+?>8)($N&\1(XV1"A(A
M:"OP5%HL2?%\PQ;-K;\WQ*[Q;S;4)6RD0W1=$'$ZJ!HBZB6G70D1:(W= H%
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M;U+IR9/9;%ONON:;W#VHFXRT34EZK09% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M>"A;?$V377,^-,5RJ^,HQ=[M;8\J8(CL$G##JX(_ 7/MBGT+1$RH% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M;M[(Y(_%&WO7-!^_*(!]Q&E+^2A==*#XL^*8WC\^[72R6N/ N-]?25>)+#:
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M4"@4"@4"@4"@4"@4"@4"@4"@4"@KWG/_ %1Y=_S O_:&BXL*B% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H*]Y0_ZPX\_[V1?\AG47%A40H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H%!7O.?\ JCR[_F!?^T-%Q85$*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M05[RA_UAQY_WLB_Y#.HN+"HA0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"O><_P#5'EW_ # O
M_:&BXL*B% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H*]Y0_ZPX\_[V1?\AG47
M%A40H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H%!7O.?^J/+O\ F!?^T-%Q85$*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!05[RA_P!8<>?][(O^0SJ+BPJ(4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@KWG/_5'EW_,"_\ :&BXL*B% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M*]Y0_P"L.//^]D7_ "&=1<6%1"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%>\Y_ZH\N_Y@7_
M +0T7%A40H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H%!&,VPY,QB6UINZRK-.M
M$]JZP)\(6#<!]EMUI$4)#;H$*BZ2*BC0:;\"YS^TV[_T"S?H5%/P+G/[3;O_
M $"S?H5 _ N<_M-N_P#0+-^A4#\"YS^TV[_T"S?H5 _ N<_M-N_] LWZ%0/P
M+G/[3;O_ $"S?H5 _ N<_M-N_P#0+-^A4#\"YS^TV[_T"S?H5 _ N<_M-N_]
M LWZ%0/P+G/[3;O_ $"S?H5 _ N<_M-N_P#0+-^A4#\"YS^TV[_T"S?H5 _
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MGT0H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MKN^9-$^R77I1(N"B% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M\?C>HCEZAN;'5MI=XN*(;EZ?>*.GQTH5H;UQ=RK8<6X&O%JQ=;U>^.RD+?+
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M"I)IUHF(E(Q##,WY-=N!X\S<\-'CV"&/MR()A!;%V;,5 ;9< $;<1O9H.U'
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M<)21YO[P-A;M!*BM_P >Q,2>S/CA.+[!,M$^SPIC'(;I07[>34<H2B,6YN/
MVDB24W88^9PM0,]=JZJ1J<$PEBT8CPYDL*P.0LO>RQ\+U<QBFW</12$N@N!(
M-11Q&"06DVGY$\NE!TQ9<DM-_D7>+;7#.18YI6RY-NM.,J$D6FWM$[@CN%0=
M A,=177HM$<V9$6.V[F7DE[+<ERW$VYC]G.V%C;5Q2/,:;M+ ..&42'($B T
M4-55/#2BI5F#ERSVS<=8-Q[+DW&VS) WVY7[(XLIQLX...B;3<]MT8SI%(EH
MST\BJ@$OV:#5AB.<C&Y7XANI,.3\WMDO)L?N%N8DQ[7ZZ>)1IL53?-WMJ3XM
M/$'<75'C+3X4$JA\VQ7[';,<Q[&[A,Y*48L*1A\J',@MPW!5L'SDRCCDR##(
MZDC@J2'T0==>@C5-<=NY?S9R7,EW;(L>BLLX^$618YLBU,R]8;V_<8)M>5M4
MTZ+Y==/C02+V]V:58,=RRU2DEEZ?+[^+$FX[RE26$EKL?<<<1%=5Q/,KGY7C
M0U6,F$<JP9,<V')N.&1.6)TK-($0#D*Y9VVTU5UAO<;K#;ZL.O-B):@*^541
M:#%R"W1[CA_*DSCZSRV..;E,Q4[%$CQ'HT:3<6+BRMRD0HB@!BWM[ N&+:"1
MMF2:Z*M!O,YP:WY#>^?[M=<?^97&+88*XU*?BDZ026K0\XA0B45^]%T0\S7F
MW(B?50;RQP(\7GK%;[>[::3[Q@K$6%=GHIF3EVCND[($WD!=CR1U\RN**J/E
M^J@S>4V[)#Y/L%\Y,@_,>,&;+,CPT?AN7*!&OSDAM5<D,MM.HA.1MP,F8Z:[
MD3J5! ';9E^)<=XUR'8+3<EDX]=[]#QNQN ZL]C%\B-Z/;VGFCW.?<.^B=1L
M^H-CMZ:45N>*,$N]@SIK!94>4>,<2L3Y%BNKR$+<V5D[;;C9 JHB.+'!9K9*
MFNU7-*(P>,L&AX[;N KQ;; 5NO\ (68&2SPCN-RS;?M$MP@F.*FY05X6]HNK
MH*H*#ITH(O8[#>$R&#;;W*2/RD&5E/E%#QJ4]?5#YB9(^=X*6TP5O*(H@2[=
MB,_=H"FG4J[>,L0M7ZP.2,PN-F!,B3(SCVV[2&51Y(/RR$FU@S3H!&3FY0^T
MOCKI1$(]PEOL_P"+PNEQ 793EA.!'@7^R2+U89XF^X2QX;\$DD1)^J^8P34A
M5O;JH]!C9P,0@9IRAC9YMB/_ $>WQW'WVFZ =PCPYKLP1<CF\^)(X\V"J.XU
MW^)>*T$3L++,/%>&KIRO;I<[ ;;8YT>:S-B/S&(E[(F6X;D^-L-5%&!>:9)Q
MLD U_)546@]8L2?8L1Q?)7[=/B<?V;D9^\V6,45\G[?BKL64PPX49 [S;'>=
M4@!0W V8]-*#ZNRRLCQ[D&\VNVSUA77/L:FVWOPY##K\-E;0*R ;<!#5I>V1
M(6GV>JZ4&JY6M=E6!S!;LUL$N[<DWB24C")4:!)ER'+4W$CI#&'(:;)&PCN"
M\LD!(?RE)"W)J5T%RQ;V;KQ9D5MEMW1V/)@*T^&/@CESV*H[E8;(@WZ)U)O7
M4PU%-572B.>&&CG<;<O0,>L\*Y0I5@9%K)L<M,ZQ1ITIL70&*5L?4@]2V*H9
MN1DT42$3ZBB45*.2;?88^4<A2>2K!+O;%TL,9KC]YJ"_/1IJ/"=*7'CNM-DD
M60DA%>(R,%45$MV@KH1Z81AUJRZ]\4!E-F;O=CC<8LFGK6/4P?6&5O!-V\5;
M(U;)S:A?62)\:";<&7;\/\2X):;\W.9GSG)-KA,OQY+CC?9?DDT#JJ*JT LM
M(@DYH.FU->J4-8WN6C]_$\8<<.='@1LJM$FXS[2VZ[-AQ&B<5R0UV <-"!.J
M$(+_  4,8_'5^XX;>OC43+\JRAA+:])N43*(US>BMPF/YXFQDP61(E0MJ@.X
MB3H@K00CBZQ9':I-S"5:;G;[Q>,=FAPZY<GE?&T6G<Z;5M>51_P>4.Z.Z7=4
MU[6UO=JR0T&OX9LZMY=@;<5[L9)9XL@,JBP<9EVN6"NPU&0W?+A(E[7R.0B&
MV:-FKCJ;P0055HK=<:1<8A2<8M&08Q<)G.\2]RY.1W)B,]'E-&ZY([TZ5/46
MVW8)LD"-M]TQ-";$051\I&IM\HV,>PWC4K?<2R^Q<CMS[Q%&!+1F+".^2I;<
MDWU;1I67&W6U Q-47=]2Z%95RQ\HUMYML=HLDEN^RLFAW2YQ+9%=8G3\6?\
M0')"*^" CO= 9GW;;BEN4TTW&FH>[S-EN#_(EVX?M+T/ CP"XP[@D& ];X4O
M($$EB"Q&-EHG)#3'<%PFP_+ 5U+HA'OE.$8EC/&/'8,0"QZ,R<>XSI167YU9
MOF+EM1HG+Y"0A=<5W7M@^J*3;NU55*";\1Y7;<=X[L+5YLR8U%N=[?LMC9AL
MSEA2SEONN,28[$G>]$C2%0B:;>T$$5!31%&@V//\D8^#1Q?LH7J ]=8(3O5I
M+=MT-E'%<]7.CPE1V1':(!WL?9-53?Y=:&*2MEHOLO&.9(.-P9,FUW$\;N$=
MBQ6R1C\:X6T]B7-+9$<-5U=89=:(@/<ZO\(ZE;N.QB<W)^0KGQ=97(F,2>.Y
M$8#B6R1 B2+BVY(38PV;+>YP0V": /5=$TU1:(RL1XMQ9<KXUA3,38*TR\'<
M>OS4F(JL2+B'HD;*<)CM=>%'7]O?12'5=/#H'SQ; O2%[?#N$.<AP+3D[$LI
M+3R%''8PVR#RFGDU$4%M#TU1.E!@<<83'LN)\(Y'"L!P<MD7Y\;_ '/TSC=P
M6))B7+N!*-10^T1"UY7/*.@Z:4'W>+,S^#;F=^&;;(T?D?(+@U-?M!7NTMH<
MF2C3ER@DHFY%<0]K;H)Y'% ]43K0:Z="AW'B3%[K=\.CP\;L.?QYLE8,.8];
MW[*4@BD7"+!E"[(8BO*YIZ?:HHB>5-BC15D6O&(;6><Q9W(QIRZY-#<83'WA
M0FICK(X_'16(+ZI]T3I$;:FUUW+YOLT16G%K$=[D;C6=9[7"AP%AW>VWN-8[
M)<+>S#)R"+S<2YSYI$<U[<"_SJ(N]%-?,74KTLEEMENXQM%HF6%\,>Q_.9SG
M)MGBP'P(H*2ISD1Q]H 1945K?"<-&T<'M"G14!4H/3(K2%UP/EMS![3+8XRO
M4W&PQ^#&BO16GY2360NS\*+VP<!HT5L2,002(#(?BM!(>9L4PW&;ACD>'#BV
M.SP+=<(]OAW+'SO>(.++>!QV.3,,A=C3'%3>+P#J8;Q157I1%G<>97#@XMQ_
MCMZM$G&+]?;<86W'W_4RU8&VLB1M.2'4,A5&U$A%\]^G3J0E06-1"@4"@4"@
M4"@4&+.N5OM;0/W*4U$9==:CMN/F+8D^^:-M-BI*FI&1((BG5571*#*H% H,
M6%<K?<A?*W2V98QGG(D@F'!<1N0RNUQHE%5T,%Z$/BB]%H,J@4&JR3';/EMD
MF8[?H_JK3.! D,H9M%Y20Q(3;42$A(4(2%45%1%2@U.)<?6/#Y4VYQ7Y]SO=
MP!IB5=[Q,>N$PH\=25I@7'E78V"F1(((B*2JJZKUH)70*!0*# O-[M./0?F5
MZEMPH".LQU?=70>[*=%AH>GQ-PQ%/K6@_(5]M%RN-SM$&6#]RLSC3-TC#KO8
M<D-"^V)ZI^4V0DGU+0;"@4"@4"@4'X1((J1+H(IJJ_4E!%+G:<1Y6Q>!(&2<
MNSOFS=+-=K=(=BOM/MZ]J1'>:43$DU7^)5145%5*#*Q'"K+A<66S:UD2)=Q?
M]7=+G<)#DR=+D;!;0WGG54EV@ @ IH(BF@HE!L7L@L4=+D4BYQ6ALPBY=R-Y
ML4AB3?=17U5?N]0\_GT\O7PH,]MP'6Q=;)";-$("3JBBJ:HJ4'U0*!0*!0*!
M0:^R7RT9';F[O8Y;<ZVNF\TW)974".,Z;#J(O]RX!"OUI0;"@4$7R%G$,KN
M8->) O7:(D+(AMH.&V^+<.8AQW_+IY$?9T\>NFBT&YD7NTQ;O"L,B6VW>+BT
M_(@PR7[QUJ)L1XA3Z [@:_PT'Y<KY:;._;HUSE!&?NTE(%N ]=7I2MF\C8Z(
MO78V9=?HH-A0:^^7RT8U:9=]OTMN!:((=V7,>71ML-434E_A6@1[Y:9=WFV&
M/+!R\6YIB1.B)KO::EJXC)%TTT/M'I_!0;"@_"(0%3-4$!15(E71$1/%56@Q
MX%P@W6$Q<;9):F6^4".QI3!BXTXV75" Q54(5^"I09-!JIV38];6;N_-N<=I
MNPL>KO7W@D41A6R=0WA'4@10%235.J=4H-BP^S*8:DQS1R.\ N-.#X$!IJ*I
M_"BT'I0*!0*!0*!0:6U9?C%[AVF?:[M&D1;\)G921Q!*6+0J9JR):$6T14BT
M3HGC0;J@U]XOEIQ^*W.O,L(<1U]B(VZYKM5^6Z++(=$7J9F(I_#0;"@4"@P&
M;W:7[Q*Q]F6V=ZA,,RY4)%^\;8DD8M&J?02MFB?P4'XY?+2U>V,<<E -[DQG
M9[$)=>X45@P;<<3IIH). B_PT&8^^S%8=DR#1MAD"<=<+P$ 34E7^!$H/"U7
M2WWNV0[S:9 2[7<&6Y4*4WU!UAX4,#'7X$*HJ4'[.N5OM;0/W*4U$9==:CMN
M/F+8D^^:-M-BI*FI&1((BG5571*#PA7^S7&Z72RP9K;]ULI,A=8@+JY'*4TC
MS2&GPW@NY/JH-C0*!0*#7VB^6F_,/R;/*"6Q%DR($@V]= E0W%9>;75$Z@8J
M*T&PH% H-1"RC'KC?KGB\&Y,/Y#9@8<NEM T5^.$H=[2F/PW#U3^%/I2@]SO
MUD:*Y Y<HH%9@%V[H3S:>C;)M74*1JOW:*";]3T\O7PH,QA]F4PU)C."['>
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M^-![V^XP+M"9N5KE-3;?)'?'E1S%UEP%\" Q54)%^E%H,F@4&-$M\* 4DX;
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M)83S^]H@?LAGW.U_]#5.VV7Y(^6@E%A=R3!LL@VRWWVZY*W<\&G7P[;=7DE
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MY1XV@:115#5!V"2*5!KUR;(6\0SFWV+.+A<68&=6;'[1DG?:DRF(4MRVMO-
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9!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>px_26cumberlandproxy1pg02-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 px_26cumberlandproxy1pg02-bw.jpg
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M_\0 M  !  (# 0$! 0            8'! 4( P(!"0$! 0$!
M      $" Q   0,# P,# 04#! D-"@(; @$#!  %!A$2!R$3"#$B%$%183(C
M%7%"%H%2,Q=B<K,DM'56-QB1H8*R<],T=)0UM3@)L9+20U-C@Y,EE39VP=%5
MA2:BA,34I48G*!FCPT149$6DAI9'5W=($0$! 0$! 0               1%!
M,2'_V@ , P$  A$#$0 _ ._J!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!05WFO.G%7'=W6PY=D"0KN$=)CL1F+,FFU')=$-WXC+R-HNJ:;U3U1
M?K1<>N3\V\78=;[-=+]D334+(65E68XS,F<4F.((XKHA$:=- 0515(A1*&/N
MZ\S\8V7$[5G%PR)D<9OABU:)C+;\DY+AJJ;&V&&S>4A450Q[>HKT+1:)CS@\
MW\5W'#KCG\7)&5Q2T.K&N4UQJ0RXP^BBG;*.ZT+V]5)-H]O4M?;K1<;#!.4L
M#Y+&>N%W=+BY:S!JX,&Q(B/LDZBJ&]F4VTXB%HNA;=%T5->BT1,*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#FOG?),<@Y!<N.\&@
MVIKEG/[<L+(\@G&U%8@64F^R3LMX]-Q=I-&FTU+1$+1?8)%C18S9\?P;R)P*
MQI<8\G&;;QV4*S75UQOL27F9+RR'1+<H(1#W#)!+H/W4$>XIRK \!\?;1G&7
MVEF[S8&0W/\ JZA&(]\Y+SV@)&(T7MCO B<<]!V_4MJ*5H<YQ:]6/C:WY-,N
M]GD9GE7(MOON6'%=:EVFV.O!(^.Q)[9F),M&6YU2715734M-RA=G"=_R-CEO
M/\"RN5:\FO=MC0)SF;VZWQ[=*E \V*!'EI&3:2MB2(VBJJH@KU7IH2NA*(4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@KK(^!N(<NO<
MO(\DQ2+<;W.42ES7B>WN*V MCKM<1.@B*=$^E%UZWSA#BG(\=M6*7G%XLBPV
M/5+1&176BC":[B%MULQ<025-2'?H7UUH:];]POQ;D]ML]GOF+PY5JQ]IQBS0
M]#::C-O;-Z +9"GN[8ZZ_91-?EIX6XKL=BN^,VO%H3%AOR EW@J).-R.SKVU
M+N$2HH*NHJBHHKU3K0ULL%XVP;C2WOVS!K*Q9XDHT=D]I3<==,4T%7'72-PM
MNJ[4(M$U73UH)50*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0:NUY-CE[>./9;Q!N+[8[W&H<
MEJ08AKIN5&R)435=-:#:4"@4"@4"@4"@4"@_%5$ZJNB>G7[5H/V@4"@4"@_%
M5$ZJNB>G7[5H/V@U]TOMDL8-N7JY1;:V\JBR4Q]N.AD*:J@JX0ZJGW4&5%EQ
M9\9J9!?;DQ'A0V9#)BXV8KZ*)"JHJ?>E!@S<EQRVS6[;<;Q"AW%W:K421)::
M>+N+M':!DA+N7HG3K0;2@4"@_-4UVZ]5ZHGUT2@UA9+C@7-+(=XA#>5) 2W+
M):25O)-R#VMV_547733TH-I0*!0*!0>4F3&AQW9<QX(\5@5<>?=)&VP 4U4B
M(E1$1$]56@T7\?X)_E1:/^7QO]\H,RWY3C%W>^/:KU G2%]&HLIEX^G]B!*M
M!MJ!0*!0*!0*!0*!08=RN]JLL=)=XG1[?%(D;%^6Z##:F2*J"A.**:JB+TH/
M%S(; U; O;MUAA9G-.W<2D-)%+5=J:.J6Q=533UH,BWW*W7:*,VU2V)T(U5
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M[I%FS!4XEN8 Y$MP$73?VVT51#5%3>>@JJ*B+K0Q&H/E/PE<,8E96WD*MV^
MZU'G1W(S_P QDY"JC:JP($9"JI^,$(?HJZT,67B.66+.<=@97C4A9=CN0$Y#
MD$V;*D(&3:Z@X@DFA"J=4HBO_(;EF!Q3@$^4-R6VY5=(\AC&#^.4E"FM@BIJ
MFP@'3<BZN>W]OI18H3PWYJL9_JN-9K?I,SD+*[TK\/Y(2))R!^*"(I/[2 41
M0)$$B33Z46Q7GCOD5AQ'R,SG(LEGL6NR6]B^.29D@D !3Y[8H@IZD2JN@@"*
M2_1*%=88AY4\*YKD#.,VF^FQ<Y;B,0/G1G8K4ETBVB#;ACHA$OX1/:JKT3KT
MHF+2R7)\?P^S2<@RBXL6JS1$17YDDM@)JNB(GU(B7H(BBJJ^B413EL\Q>!;G
M=!MB7]Z(CA;&YTN'(9BJOTU-1U!%^TQ%$^NE%Q>L>1'EQVI45T'XKX"ZP^T2
M&V;9IN$A(=45%1=45*(K7R)1%X.SO7K_ .R9'_<2BQ0'@;/B6GC_ #V[3B[4
M.%,;DRG4%2466(I&2Z"BJNB(JZ)1:NZ+Y0<)2\:G98WDJ!9X#X1'"=C26GG)
M#@*X+;+)MH;BZ)JNP51/JJ43&5QQY%\4<IW0K%BUX)+YM)QJW363BO.@";B5
MK>FT]$1541+<B)KII0QRYYE<[2[A>@X\PC(I#-L@I(B99!CMN1E*:T[L[9ND
M(JX"(B^T"V+]=?H61UQQ]R[QYG.*2\CQN\"=@L2(Q<YTIMR"TP33(N$I+($-
M!0515+T^^B(([YD\!M71;;^O2#;0^V5P"#)**BZZ*NNS>J?>@4,7"UEN.2<7
M/-(5Q9F8P$1VX?J44N^TL9@2,R'MZJNU!+44ZZIIZT16#GE;P>&,O96WD!NV
MUF4, 6ABR!E.2"#N: RX DHB/4CTVIZ:ZJB47&7/\G.'+7C^/9//O3S%IR@9
M)6=Q8,LS<^$]V'T( :)14'/;UZ+]-4H8Q<O\JN%,*OKF.W.^E*N4<^W,_3X[
MDMI@T711-QM-JD/[P@I*GHO7I0Q:.,93CV:62+D>+7!JZ628BK'F,*JBNU5$
MD5%1"$A5-"$D147U2B*MS'RLX3PJ\/6&XWTIMRC&K<L+:PY+;9<%=%$G!38I
M(J:$(DJHOK1<3;%>6./\VQF;EV+WMJX66VM&]<2;$Q?C"V"N$CK!"C@KM%51
M%'W:=-:(XAN7DA&OGDM:LGN^327>(K'.-RV-BP\##;10S;1Q8P@CAGW"TWF"
ME]FB=*-8[\QK([1E]@M^36%]9-FNC(R83Y ;2FT?HJ@:"2?L5*,OO(;Y;\9L
M-SR.ZN=JV6F*].EG]4:CMJX6GVKHG1*#^0V0?Q=G3V3\N2&26+^JMG<I8%HC
M,JYDZZR >B[11I114_#[4^J4;?U#XBY,BYWQ#9\_E$1O# );R+0*XXDN"*A)
MVM@BDJD0*8"B:JA)]M&7OQQS9QORQ(GQ,&NZW"3; ;=EM.1WXI"V\I")(CX!
MN34=%VZZ=-?5*&/KD?FGCGB9RWLYU=EM[]T%TX33<=^49 PHH9*C 'M34T1-
MVFOT]%H8^LPYFXZP+'+;E&67=+= O+0/VMAQIU9CX& N>V.(JXFB&._<*;==
M"TH8@V/^8/!.07)FUC?7K<]()&VGKC%=CQU(ET1"=T( 3^R-13[Z&//RRM''
MU\X[M4?D7)'\9L@WAEV-/BQ#GFY)2+)06]C:$J(H*9;O['[Z$5CS% QRW>%M
MJA8E<W+SCK+L)+?<WF%BN/ LTU4E:)$45W*J=:+/5@^'\Z%:_'2UW*XR&XEO
MB/7-^7*?)&VFVFY3I$9D6B(@HFJJM$KWG>9W L.:<,+Q+E@!;5E1X+Y,*J+H
MJHI")*GWH/[*&+5QO.L2Y$Q1_(L-NC5VM#C;K2O-;A('1#56W&S03 T147:8
MHNBHOHM$<'>&.;XIQY<LXR?,;DU;+3'ML5ONN:DX9G(71MIL$(W"73T 5^U>
ME&J[ X_\E^(.2;P./X_>R:O;RZ18-P9<B&^J)KHT1IL(O['=N^ZB8J_R^QWB
M6]W3%7.2LREXM(9CS!MS<2WNW!'P(VE-25H5V[50>B^NM"(CYSM16N/N-0AN
M=^*V;P1WR'81M)%902T^FY$1=*+$CY/LO'=Y\9N*(W(^22,7L[<2S'%F1(;D
M\G)'Z22(VH-HJHFU2+=]U#KXSWEO&^'_ !PQ_'>.<I><O]RMS?\ "=S.";;L
MB(,L1D.JAMJ#)(!'MW^[7TZ]:#7^+WD%@..<:2;5F5\EO94S)N%YNY%&F37E
MCD8*3[CH-GNZ+J7N5?MH6.F^/.3L*Y4M$B^8/<?U&WQ9"PY!$T[','A 7-%!
MX0+11-%1=-%_D6C+2Y9SSQAA671L$O\ =G&\JE_'1BWL1),DE*86QD5)ELA0
MB73HJ_5/MHN+)HB+9WR/A/&EJ&\YM>&;5#<50CHYN-YXQ351::;0C-4U37:/
M3ZT%;8WY=<%Y+=&[2U?SMTAXD!AVYQW8L<R5=$17B10#]KBBE%QF>2O*%DX_
MXRNT9^Z';\@R.WS8F.., Z9'([0BJBXTBHVJ(XBH9$FGJBT(XL\9L5X)RJ>U
M;.2)TU,WFW1B/CUL8%U(SC8H)HIF#1A[SU D,DZ)]]&J_IS1A_,2[X%;^2_+
MB_X-<I3L"!=[]=1=E11 G05IM]]-J'[>I B+K]M&^)]S-X86WCW KIF^,9+)
MF.V4!DRH4]IL>XQO025MQO;H0Z[D1177T]:)*M7Q1YHD2^%;[=.0K@Z]#P=Y
M6W+JZCDAY;<K0N A[4(S)M=PI]=NU/I1+$\G^6/!\#'8V3+?G'X,R2[$BL-1
M7_E&; @3A=DP D =X^\M$5>B:JBT,3:5R[QW P>%R-<KXU!Q&XMB[!FR@<9-
MY#UT%MDA[I&NB^T05=.OI1%>6GS%X&NUR"V_KST'N%L;ES8;[,95^FKFU=B+
M]IH*?;1<6CF7(6*X'B_\9Y#+,<9U9W7&(RY-;0).B-.+\<3782J*(?IJ2?;1
M&+@'*N!\GV>7?<,NX3K= =5B:;@.1C9-!0]3!\0)!45U0M-J]>O1= BEF\FN
M'<BD76-8;R_<3LD.5=+D<>!-(&H,%-7GMRLHBBFJ::=5U32BXDO''+V <LL7
M"1@MT6XA:S;;G";#T8VU?0E;7:^ *J%L+14^Q:(U_(7._&'%MWB6'-+P4*[S
M6$EQXC463*-62,FQ)>PV:)N("1-?72BXL8#[@":(HH2(6TDT)->NBHOHM$?S
MF\U+;(N_/]MM,-$69/M=NBL(OHKKTAYL$7^54HU%P^!F3NNXIE6 SEVS;!<1
MEMM%T(6IHJV8HGV"XP2K]Y4*YG\CKI.Y!Y@S_(H?YMGQMUNWDXBZB#41QN F
MU?KO>W%_*M%CLOP_G0K7XZ6NY7&0W$M\1ZYORY3Y(VTVTW*=(C,BT1$%$U55
MHS7O.\SN!8<TX87B7+ "VK*CP7R85471512$25/O0?V4,6&US1QI(P"5R=$O
MK<G"X*B$V>PVZX;+AN T@.,('=$]S@>U0UT5%].M#'%G#'DC&8YLOV=<N9-)
M=L[MLF0+,XK#SK+2.S([K;;4=@"[2*VVJJNW^V75:+8[:S_EOC_C&UQ[MF=Y
M;M[,Q-8,=!-Z4_HB*O;9;0C5$U34M-J:]52C*+8'Y.<.<B7=JP6.^+'O4@D"
M)"N++D0GS7T%HS381+Z(&[<OT2BXDW)'+V!<3,6^1G5Q.WM70W6X2A'?DJ9,
M(*GT8 ]-$,?6B(X_Y+<0,YM;\ "]'(O]Q=BQ6/C1W7HXR9VU&6C= 51"53%"
M]4%5T)45%T+BH.!L7X=M7/60SL1S:7>LQ(;J,VRO6UV*RTA2A5[:^0H);#T%
M-%Z^M%JZ.1O(GB?BVY?HF4WI?UQ!%QRV0F7)3[8&FHJYVTV@JHJ*@F2*J==-
M*)CXX\\CN).3KJ-BQF]J-]<0B8MLYER*\Z@(I%VE--IJB(JJ(DI:)KII0QRK
MYP@"\V8;J*+NM,02U3U3]1D]%_U:+':'(7*."\6VQJZYQ=V[8Q()0B,[3>D/
MF*(I(TRTA&6FJ;BTVCJFJIK1E6UD\Q>![U<&[<M]>MQO$@-R+A$>8C[E]-SB
M(0@G]D>B??1<7NVXVZV+K1(;1HA 8JBB0JFJ*BIZHM$4YY+\G6;CSC2[PY5S
M<MN19# FPL>)EMTC.2C:"6TVQ5&U1'$T,E33Z46.*_&;%>"<JGM6SDB=-3-Y
MMT8CX];&!=2,XV*":*9@T8>\]0)#).B??1JN\>1^>.+N*GAA9A? 9NQBC@6N
M,!RI>PO0B;:1=B+IT5Q1U^E&<8/'OD?Q%R9<1LN-WU O;FO8ML]HXC[NB:_E
M=Q$$UT37:!*7W4,;SDCF' .)6[<[G5R.W!=E>&#LCOR=ZQD!7/Z #TT[@^OV
MT,1UWR7X@#.(G'S=Z.3?YKS$1HHT=U^,DJ4HHVRKK8DF[4A0M.@KT)45%T&+
M<HA0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#^?'@#_G'R?_ !)_]=LT:J.^(G'F
M+Y_RY>4RV U=+=983\YB!(%#8<DE);:%707H8B)DNTNFNGV46O#R#XZQB#Y,
M0<+L,)NT62^OV=IZ)"$666BGF#+JM *;0U_%HB::T(L_S2XJX\P?CS%[EB&/
M0[+,:N8VY78;2-F['.,\XJ/$GN<)":%4-Q5+UZ]:)&;R3(?E>"F,.R#5QQ&+
M2TA+Z[&G^V"?R"*)0ZV_B)PCQQ>^)&LNRBPP[]=[^_+;-RXLC)1B/&=*,+;2
M&BH"ZMD:F.A=?71$H6JPXN@_U0^9C^$8VZX./2)<FV'&(E+6%)BK+:;)555+
MM'V]"7JNW[Z'&'PCC4#R.\A,FR'D9#N%OBA(NJVUPR$30) ,1HY;51>TT!)[
M47KM1%U15H7XE_F;P?@F$XO9\]PFV,V&6EP;MDZ)#U:CN@\TZZVXC:+H)@K6
MGLTU0NOHE"5JN=<ON>=>)'&&2WITG[L_=4CS)!]3=<A,SHJN$J^I'VMQ+]JT
M)ZLWQQ\<.*KUQ+C.4Y58&[OD5S(KH]*DN.Z(@O&C32-H: K>P4W"0JA*JZ_3
M06J.C8/AY>9RX.5DBKB"7-R/^BJ']Z]M+>3B)MU_G^[]M%XOGR0PKQTM#6+?
MUBWBX66/98Z1K!BUE,2!R(+N]W2/VC4$/\!.[PUVHFNHT9CFWG[->+LSQRTO
M<:<9R,6@Q)2-IDQPVH+,EI6C3XZI'W X2JB&A&XI>U?M6C47#R Z^]X'XT<D
MB)Q MP"I>O;;ED )^Q!1$3[J)UN_$7A7C?(N(OXGRG'H=\NU\DRV7'[@TCZL
MQHY]@6V=VO;7V*6\-"U7UZ)H+57>(]LC0?(++L1%.]8CMUXMDB*[[@>C-2VF
MT$T7UZ)_W?MH5K(V#X>7F:N#%9(JX>ES<CI95!?B]M+>3B)MU_G^[]M%X_HK
M9K-:\>M<2R62(W!M,%M&8D1E-K;;8^@BGV48<B?]H+_\&<)_X]-_N+=&HJ7F
M7C&Y89B'&//.$H4(I%HL97AZ,FBQKNU$:-F7HG1$>VZ%TT[B==5<H1H^1N2[
M=RSS'QSF<+1N8_'L<>\1$%1&/<6)QH\V.JJJAU0P7^:2?76BK)\SKS=<OYDQ
M'BM))1K* 0MHZ^Q9EUD*R3Q#T0M@((CKZ>[3\2T2+US;Q6X<+C2YV6T8^S;[
MI!@/.V^^"I?.24PTI X\ZJZN(1#[Q+VZ*NU!Z:$U07A]*AYKB&=<99A#;O>+
MV]EJ^VR#,17&F)/Y@.;>O1"5 )$3T7<OJ2T6M7X/X3B699+E'\4V>-=EMD>%
M)MY2@WJP\CQ^X.O15VI_J4*S[]_U^&O\<P/^C&:''E=X#'-/FJ]C68J4K'K?
M-DP0@$1"'Q+/&<=1D=%14%QT%,]%Z[RH<=%<E^(G%?(!6P[9$;Q!V I#(.QQ
MF6/DLDB: 8:(&X535#VJOJBZ_0FN</,^XR;7DN"<62+E.FXYC]GC/O2)!"[+
MD.NNG&5YW1 %QU&F$T)43J1?SEHL>/).:^,-^XUD8KA>"76TY+"9']#N_P"F
MLM/]]M4_X3(%\G'1-$43[B%ZZIU1*#H#PBR2[7GB!VSW=72/';D] A$\A;DB
M.-MR '4NN@DX8HGT'1/2B5:7.O\ F8S_ /Q!<O\ !CH1_/KQ^Q#GG)K7D,CA
MJ_\ Z1'AN1TND9)BQ#?=,7%:V^PA71$+J1#1JL:VMY5RIR-'XXYUSVXV)Z%*
M6*VW=D<E@$W>C:LB/<%MHS3H+I>WT]45-0Z9\KV8G$/CO9..L)%R#9IDUFU.
MJA?F'% '93V\T1-2>=%"<TT0M2331=*)%/\ %^<>,%AXTCXWF>#7.]9'/:-;
MU>$MS#[O=<(M/BR"?$VQ =J"K>WTU7KK0^OCQ<SB]X5'Y:@6DI(VB+C%RR*U
M?)!1VR[6B RXH]1$B!U.YIZ[4]=$H5(?"?BS#L\7*<RS:W,Y!-A/LQ(D>XBD
MED3?$W7GC;<W"9E[40C1=.OU6A4-\MN,\7XYY6LJXC$"VVN^16IKMM9Z,LR
MD$T:M#^X!((KM3HBZZ=.B%CH_P J;'P1*GV&]\P9%=(<V&VH6RPVMQ'%D,=W
M>\JL=HU#N:(!.[PUVHB+J-&8Y?Y^S7B[,\<M+W&G&<C%H,24C:9,<-J"S):5
MHT^.J1]P.$JHAH1N*7M7[5HU%M\CNOO>"F(G)(B<1;< J7KVVWW0!/V(*(B?
M=1.MAXI^/?&>7\4QLPS"S)=KQ<YSSC#SKKP(PS ?[8 "-F*:*;9*>J+N1=J]
M.E"U7&'6*#SGY>9 SG"%-M$2=<GB@&2H+D>UFL>,PNBI[$1 W(GXM%^VAQ/_
M #3X:P'&L&M>;8E9(EBN4>XM6^6U;V@C,/QY#3A(I-MH@[P)L="1-=%777IH
M)6%EW_4'QW_=(W_2;M#KVQ?_ *@=Y_\ JK_I<:'7KX5</X#E6"7G+\ML<2^W
M%VY.VR,%P:&2TQ&889<78VXBBAD3Q:EIKHB::=:%J&<'6B)AWF?<,8L6Z/9H
MTV^P68Z$2HD5MA]QMI55554%0#U_FT+XQ\-L=OYR\O,@:SH5G6F)-N;WP'"5
M <CVLUCQF%T5/8*("DB?BT77U6AQ/?-/AO <:P:V9MB=EB6&YLW%JWRFK>T$
M5B1'D-.$FYIM$'>!-)H2)KHJZZ]-!*OCQ9_S X3_ ,5?_P +?HE?'D]C&/7S
MAW)[G>+:Q.GV2W2I5ID/#N.,^0HBFVO31>B4(H[P3PG$KQC%VRNYV:-*R6T7
MI1MMT=#=(8%8K2Z 6O1-2)?Y:+54<&X%CO(?DU?;5E,49]G@RKQ<G(#NO:?<
M9DJ "XB::BA.(2CZ+IHNJ:I1:VWFU@V*8+F>+SL-M<>Q%<83KDEFW-C&9[L5
MT4!P6VT$1+0NJBB:Z)]:)&U\XLNN-QR#!L0E/N#9PM3-ZE--)T.3-<-E3VZH
MA$ -$@:^FXOM6A&MY!S3Q=O7&DG$\0P2[6S)(D9$LEY*VL-2?E-Z*BR9 /DX
MX+FBB>]"]=41%1-!]7QX.Y)=KOQ/+L=W5TEQZY.18*O(2*,1]L'Q!%+^:9.:
M?8FB42K-\B?\QV>?XHD?]Q*$<S^'?^9/EG_<W_\ HYRBU%/"+C'#\\ON47C+
M[6Q>6K"S#"#!F@CT9'9I/*3A-%J)*B,:#N14ZKTUTT%8^=8S9N//,S&[;A\4
M+5;'+S8GVX4=%!EKYILB\ #K[0/4O:G1-VB:)TH<9'G7C&/8_G5AFV6VL09=
MZBRIUU>8':4F23_5QS[2^^A$P\P85DXVXPQG"\%MC%@L^5SG+A>8\$5:"04!
MEG8+G5=4W. 6B_4!7Z4(B&.YKXK1>+8V&W?!KO)R%^ *7#($ML<YB7)QKWO,
MR5D(X("XNK8_AVHB**]=1]9_B=D5Y'C;E["YR.I;&+')ND!MP206G7(K[+^W
M5/W]&UT_L5^^A6D\,N'L-Y.NN4W3-K<EUM]D9BLQ(3AN RKTY7MQEVR%54!9
MT%-=/=KZHF@K<><..6?#V^-,9QV/\.S6NWSX\*.A$>QL7&/4C52557JI*NJK
M0BV<YX#XOL'C+<3BX_$2^VVQ!=1OO;']0.<TR+Q&K_X]IEJBMZ[-JZ(E$U4'
M!^9WC$/%#E>YVN2;,J+.;8@N JH3+ES"-$-P%3J)(A;D5/14UHM]17Q_S+@'
M#L<N#G)>(3<FR:?(,!>_3V+A$9A" H(M(\Z*"XI*:D2#KZ=:+6QX(O5D@>2C
MEOPR!-8XQS IEK<M-P;)%6#*CFX+3@[G$T;=%!%5)5V>J]5HE?D;!\/+S-7!
MBLD5</2YN1TLJ@OQ>VEO)Q$VZ_S_ '?MHO']%;-9K7CUKB62R1&X-I@MHS$B
M,IM;;;'T$4^RC#FKSDY!_AOC2)A<-W;<<MD['T1?<EO@J+KOIU3<XK0_>.Y*
M+%,<>9SP#:_&R[<7Y#D"LY5DC<F=/T@3'18N6J+#3N RHJC?995="TUW?;16
M_P# ?D+X]QR#C&<[HU,%+U: )=$[[2"U)!/M4@[9HGV 2T*U5AC%X\>8R6<!
M5C%<H?\ C1A3V@L"^&BL"G]BQ*$0U^QM:''YFD<_(7S#;Q@A5_%\;D) F J:
M@D*S$KDQ"^YV0IM(7]D-#BT_):U>.\3.+1E/+%]N;^01&F.QB< AD-/0F#(T
M V>WJV#A;M55X-W73[A',7D)EF 9DW8KIQ]QP_A=K;5]I;JY$;@-7 51M1%&
MV$5I2;ZKN0R+0NOTHL7EY-O2)'B7Q:_+52E.%8C>(OQ*:V9]55=?JM$GKQSC
M_J&8W_\ 4/\ AQT.M]Q!:,(O?ARQ;^1KV_8,/*5,.XSXSR,.*C<\R!OJV[OW
M&@^Q 5271$2AU6,G+O&^%Q]=<#XZX[NF;W5(DK=E4N T,IMPQ,ADE( 5> 6>
MBHB- .T>OU6@EO@,](6S<E,*JK$ ;<8#^ZCAMS$)4^]4$=:%5UX7\8XIR%G-
MXFY=!;ND&P0VWXUMD)OCN2)#B@)N@O0Q 1+VETU5%7THM2#S0XUQKC/(\0S#
M 8;>/OW-9/>CVY/CM-R[<;+C3[0!H@$O=Z[-$]J+IKJJDC]\VKL]?K?Q/?)"
M(,BYV5Z:Z*)HB'("*X2(G[2H1)_-W_-IQA_L_P# V:$8WDM_U3^'_P"ULO\
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M.XN-LGNN9X-9<HO=K.R72YL*])M;B."3!;R%$5'1$NJ(A)JGUHRYQ\[L>O\
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MG0K9#?N-QD-1($4">DRGS%IIML$U(C,E1!1$]55:"BY_F3P)!N)6_P#79$H
M+8<V-"D.1D7T54+8A$B?:(KK]-:+BSV.3<%F83*Y%M]Y9G8?"9<DRKC%0GD;
M!A-SB$V JXABGJ"CN^ZB/YM73)^-^1_(6]9+R3>9B\<39LQQJ<P#_?*&T!#"
M;$$;-P!T1M%39JB?9ZT;?T:X@L&%XYQU8H/'JNGB$AE9]K>D;E><:GF4E#/>
M(EJO<Z(0HJ)HGTHQ4XH% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M5_DHUU(<[S%SGB[<&8 P_P#),+?"B7G82JH39,@8LDC^]&8PN_<A4$IPQ?\
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MD95)AEI@5%ED25$WJ.\R(M$34M$Z)JI+5YT0H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M""KR0Y#4A00]=N[MD6FNBZ:T&RH% H%!K;KD-@L2M)>[K#MJOH2LI,D-1U-
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MS>R71FX8N##LHI\?<8HW'%2<U'3>A"@KJ"CN3TTHB Q?*#A*7C4[+&\E0+/
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M'5(^X'"540T(W%+VK]JT:B?\LY=>K9X<\8V-A]QL+_LCSS1513AP>Z8,JO\
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M(J;D[D5F<Z.J?5-12A6Q\*^-<3Y$F9AFF>6]G([E&?89CMW,4E-=V7W7GWG
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MXQVWY R&G$[;JQ6&V5'\X55-PNF*(J[?HJ#$OP3Q7NP>-U^P>^*W"SO)G@O
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MXCIBB=H^H^U$]:(FU H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M$=S851=9A/$ZKRCM4575C<FW<F[\.NBT7B6\S<377Q0NV,Y]QEDTXFY;Q1I
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M&+!#Q3&[/C%O52@V:%'M\<BZ$3<5H6A5=/JJ#JM&6VH% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H%!5?*'$]UY2R+'F;M?OC\:VIQN?<\;991'I\^,
MXI-(X_KJC.U="'[OM5" JU*(4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&-/N-
MOM44YUTELP83>B.29+@,M"I*@IJ9JB)JJZ)UH--_'^"?Y46C_E\;_?*!_'^!
M_P"5%H_Y?&_WR@W[+S4AIM]AP76'10VG05" @)-4(53HJ*GHM!]T"@4"@4&K
M3)<<6Y_HJ7B$MYW;/T[Y+7RMZ)NV]K=OUTZZ:>E!M*!0*!0*!0*#\5431%73
M7HGWK0:VZ9'CUC-MN]7:%;7'D4F@F2&HZF(]%44<(=43[J#9"0F*&"H0$B*)
M(NJ*B^BHM!^T"@4"@UUTR"PV/M?K=TB6WO[NQ\R0U'W[--VWN$.NFJ:Z4&O'
M/L%)4$<GM*DJZ(B3XRJJ_P#K*#>1I,:8P$J&\$B,ZFYMYHD,"3[4(55%H/6@
M4"@4"@4"@4"@4&)<KI;+/$.?=YK$""W_ $DJ6Z##0Z_:;BHB?ZM!H[3R1QY?
MYB6^QY99KE/)4$8L.X17WB5>FB VXJK_ *E!)Z#\U1%1%7JOHE!^T"@4'XBH
MJJB+JJ=%^Z@_:!0*!0*!0*!0*!0*#\U35$UZKZ)^R@_:!0*!0:N!DN.728Y;
M[9>(4V>TA$[%C26GGA0%024@ E)-%71=4H-I0*!0*!0*!0*!0*!0*!0*!0*!
M0?FJ:[=>OKI]=*#]H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H%!#.5>.;?ROA%PP>Z3'H$*X&P9RHR 3HK&>!Y-$-%3JH:+
M0<(^2/C)C/"6'6S)+->YURE3[F%O-B6#(MBV4=YY216T1=45M$_EHW*EO$'A
MMB')'&U@S:?D=RAS;PRXZ[&8;85H"!YQK0=PJNF@:]5HFNI\CY)XTX&QBR6+
M+K\,;X,&/#M\;8KTZ0U$;%A'$98%51%V]2T0->FM$:K!_*'AC/[JU8K1?EB7
M>02-Q8MR9.'WC+T%LS3MJ2KT0=^Y5]$6ABXJ(BO('(V*<86,,CS*4Y"LYR B
M?):CO2=KKHD0H0L 9(B[53<J::]/K09>&9IC?(&.1,KQ.8D^QSNXD>1L-HMS
M+A-FA X@D*H0JFA)]_I011>>N,%Y!_JN:NSC^:_)^$L!F))<%'T#N$*O"VK?
ML'537=H.BZ^E%Q1D?&>'$\L5O(9M++D;]3<<_AG]-=2/WUAJBM_*V[-$#W;M
M?NHO'2.?<EX1QC:@O&;W=JUQ'24(P$A./OF*:J+33:$9JFJ:Z#HFO72C*"87
MY4<*YS>&;!:[Z4.ZR31N(S<F'(@O.$NB"#A)LW*JZ"*DBJOHBT7$EY$YNXYX
MJG0+?G-S=MK]S;)Z&21),ALP;) +WLMFB**JFJ+]M#&^S3/,5X^QI[+\JGI#
ML#"M"4H -]560: V@@T)$6JE^ZGIU]*(\\!Y$Q+DZPKDN%SUN%H1]R(3RM.L
M$+S2"I"H.B!)T(5]/1:#1X+SCQMR5?Y^-X9=3N5SMK9OS-(LAID6VW!:54=<
M;$"U(DVZ+U3JG2BXF.19!:L4L5PR2^/+'L]K8.7-?0"<4&6DW$2 "$2Z)]$3
M6B. L4\D8LSR2D9OG632'>/;<Y=F,=_(>[+,1Y#;C*,5H%)#,-N\B#<O[RT:
MQL//"Y0KU<^/+S;3[T"XVE^7$=VJ*FR^;3C:Z$B*FHEKHM".BKKY3\*X.]#Q
MBZWTI%RB,,LSOTYAR8Q'<$!11-UI%!5']Y&U+3T7KTHF+AQO);#F%DB9'C,]
MJYV2<*G%F,+J!HBJ))UT5"$D42$D145-%36B*VS[R:X=XYNSE@OU\5^]L%LE
MP;<R<LV"3]UT@38)?:&[<GU2BXE/'?+7'_*D)V9A%Y:N*QM/EQ%$V93&[5$5
MQEU!-$5470M-J_1:(FM!Q!_VA:)KQXOU_P#;'7_D5&H],5\&,0R?"[%D297<
MHL^\6R)<%'LL.LMNRXX.JB#[2444OYW\M#4)\9+_ )7Q/Y"2.'YD]9=DES)U
MHN$9LR*+\J&#AMRF17\)*K6U?1=I+NZHF@KLBZ\]\56+.)''=XOPP<HB"KDI
MJ0R\W':!(OS5(Y) C*)V?=U/[O7I1,>7&O/W&G+-WGV/"Y[\FXV]I93H/Q7H
MXG'$Q;5P",433<8]"T+KZ>M#&IS?RCX7P*[.V*[7Y9=WC$K<N-;67)G9,>BB
M;@)VT)%Z*._<B^J)0Q*^.N8>.^58[KN$WIN?(C"ARH)B;$MD573<;+J"6W7I
MN%%'[Z)C2Y=Y$\3X'E!X?E]W>M5[!6M0?A2U95M]$4'$>%HFU#KU)"T145%]
M%HN)!R%RM@?%MKAW?-KL-OAW!WL0MC;DEQXD'>J@VP)DHHGXBTT35.O5*(C=
MU\CN*+'B]DS*ZW.5&QS(BD!9YAV^;H\L54$UVHRI"BJOL4D3=HJIJB47%CV&
M^6O)K+;\ALDA)5HND=N9!D"BBALO"ABNTD1471>J$FJ>B]:(@V)<\\89UETG
M",5NSEQR&)\A7V@B21:$8A;'"[QMBVH[E1$5"ZZIIZT7%DT1_./FRY3>7_)M
MSCW,<B3&\0MTY;7"=DKI%C-ML[U<02(0[LD^@F7\X45=HI1J)?RGX01L?Q \
MCXMNMROM\AJTY^E/HRZ<ILS$2*.3(MZ$"+W-%W:BBZ+KI0U=O"V<Y;@W"4B[
M\^L3;.YB[Z12N,]LWI+\!TF@CN&C>\S(3=[*KIKH**NJZK1*YOX8\D8S'-E^
MSKES)I+MG=MDR!9G%8>=9:1V9'=;;:CL 7:16VU55V_VRZK1;';>?\M8!QA:
MHUWS2\-V]B=K\!E -Z3(T1%7MLMB1JB;DW%IH.J:JFM&5?8_Y@\$Y!<F;6-]
M>MST@D;:>N,5V/'4B71$)W0@!/[(U%/OHN/SRCYG8XOP&5!LUW*V9]>617'2
M".3^X&Y#(R20U FP5&C+:IKZ^G6A(K_PSY>QJ?CH8'>;R_,Y'NMRN%S<:D!(
M><>%6Q<)PY!"H*JB!+U/7I1:N;D?R%XIXLG):,JO7_MM1$RMD)HY<AL"35%<
M1M%%O5.J(9(JIU1-*)C/XVYMXUY81YO"[T$JX1A[DBVO@<:6 :Z;^TZB*0HJ
MHBD&X4UZK0PR;F[C;#\TM_'^0W8H>47/X_Q(RQWS;5)CBM-*3P@K8(I(NJD2
M:>J]*&(?+\O.!H=^6PGD9.J+B,G<F(S[L!#UT_IA%=PHO[XHH_772AC;Y[Y+
M\/<=3FK7?+\DFY.M@]\6V-E-(&G10P,R;U =PJA"BEN5%1=-%UH8F^#Y]B7(
M]B;R3#+FW<[29*T3@(0&VZ*(I-NMF@F!HBHNA)Z*B^BHM$17DCR!XKXKF#:\
MLO2#>B$36UPVSE20 TU0G!;14;U3JF\D54ZIK1<97&W.7&?+!.Q\-O0R+E''
MN/VR0!QI8MHJ(IHVXB;Q35-2#<B?6ACUSWFGCOC.[6RR9C<S@W*[CO@,A&D2
M-X[T;ZDRV:#[ET]RT,1/*O*_A#$;Z[CUPOQRIT8U:F.0([LMAAP5VD).-IM)
M1_>1O=IZ>O2AB;7/EGC^TX$G)S]Y;>P@D;4;K%!R2*]YU&!38T)'JCB[2';J
M*Z[M-%HCB?@'R.CQN5\@S/F/)I#J3[<5OM;I,O.M IRVW$::9C@0M!H*K^%$
M^U=:-6/Z&T907DCF' .)6[<[G5R.W!=E>&#LCOR=ZQD!7/Z #TT[@^OVT7$1
MRWRJX5PRZ-V>Z7QQ^>0-NOMP8SLE&!>%#%'2%-J%M+5015)/JB+0Q9^*Y;C>
M;V2/D>*7)FZV65KV9;"JJ:CT(2$D0A)/WA)$)/JE$<*>(2(GDOEZ(FB)"O&B
M?9_[1CT:KL7DGFKC?B=MG^-+R$2;)%3BVYD#D3' 1=-R--HJB.J*F\]HZ]-=
M:)C5\=>1/$W*-P_1L7O>E[5%)NV3FCB2'!%-55I'$07%1$U40)51.JII0Q-<
MPS3%\ L3V29?<VK59F%0"D/:JI.%KM!L 0C,UT700%5Z+]E$4Y$\T.!94P8A
MWB9&;,MB2WH$A&4U735=HD2)^T:+B\8U\LTRS-Y%&N$=VP.1_FA<Q=#XJQ=F
M_N]W7;LV^Y2UTTHBD;EYE\#6Z<<$;U*FHV6PI42$^;&J+HNTB$5)/O%%1?I1
M<6O@O(F&<E6?]=PJ[-76WB7;>5M"!UES378ZTX@F!:?0A37Z41'^2>=N,>*'
M&HF8WH6+J\*.-6N,V<J6K:ZZ&3;:+L%=%T(U%%^E%QY<;\_<6<JRBMN)7M#O
M(B1_I<MLXLH@!-5(!<1$<1$ZKVU+3ZZ4,691&'=KM;+#;95YO4MJ!:H39/2Y
MD@T;:;;'U(B+HE!35J\NN";O?V\?CY";+CSO88GRHK\>$9JNB?FN"FQ%7]YQ
M!'[5HN)=B7-_&V<9?<<%QJ[%,R6UI(*;&^-(; 4ANBPZHNF"-DB&2(FTEU]4
MZ4,9?(O+_'?%49I_-[TU;WI(J46"(F_+>%%T509:0BVZ]-RH@_?1$2PKRFX6
MSN[-6.UWY8=VDDC<6/<V'(:/&71!!PT[:DJ]$%30E7T1:+BY:(A7*O(MBXPP
MV9DE]F_ $D*);WNRY)19SC3A,BH-B2Z*H?7I]JT''7BKS]"8S7*)W+&22I62
M94=K@V=Q]IZ0CCB.OBK8]D%!D$)T-!T$.OW4:L=GYYR5@_&5K"[YO>6;5%=4
MAC >YQ]\A351:9;0C/35-=HZ)KUTHRKK&?+C@S*+HW:&+^=NE/D@,.7..Y$8
M,E71$[Q(H#_Z0AHN+HFSHUN@R+E+/9#B,G(?<1%+1IH5,ET355T1/I1$(XWY
MHX[Y:<N+6"W,[BY:A9.<AQI$;8DA31O3OMANU[9?AHN)_1"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4')_GY_FNQW_'[?\ @4JC
M46AXL_Y@<)_XJ_\ X6_1*Y(XAQV'Y'^262W?D+?.M<,9=T6VF9")M,2&XT6*
MNU4)&FQ<'5$7KMT7\2T6_$T\RN#,!P[#[9GF%VMFPSFI[5NFQ8:=J.\R^VX8
MGVT7:+@$WZBB:H2ZZZ)0E='>-V8W/.^%L5R"].D_=B8=ARY+BZFZ<%]R,CA*
MOJ1BVA$OU+6B5)N4L'B\D<?9!A<I!1;K$-N*X?HW+;T<CN+_ &CH@2T1R#X@
M<JI@.+<D8EDXFT6*1Y&2-0W.CB+&1(\MGKZ+W!8$4_G$M&J]O"'$IN69IEG-
M&0IWY0NNQ8D@DZ'<;B7?EN#]A"!"/['5H5HXO_7X+_'+O_1A4.(USKEUFR#R
MFDCR*U,N&#8[*9@':H*;WBB164<)L!WAT=>4E-4)%VDNB]$HL\8W/N6<#YO8
M+<7%N&S\<RF"^(N&%N9@Q7H2@2$+B1W3W.(2 HDHZZ:ZK0BSN9;=<^4?$/">
M1KB+C^1XTC93I#J+WG(ZNE;GS+=U53-METB^Y5]*)/46Y9Y#G<A^/W"V'0W>
MY>+_ "5B3!UU-7K,26UKN::K^:3R.??0??".=S^&\#YTPNYO(U>L;$R@;"]J
M7$W"M)F/VHCJQU33U2A5L>!V$_H_'EWS:0WME9+-[$4U^L*W;FT5%^FKQO(O
M]JE"NI+O:;;?K9+LUYBMS;5.:)B9$>3<VZT::$))]45*,OYU\28-A]Z\LLCP
MVZV6++Q://O[,>TNANCMMQ774:$1U] 040:-7Q)?/>%$MEYP"W6]D8T&';),
M>+';3:#;+3C0  I]$%$1$H1:G)7 G%V-^-=T6!CT,;W:K.W<&[ZC0_J!S&@
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MTGL1'7&79$B:V*!']D<B!IIC02%-47411!TU6BVNTJ,E H% H% H% H% H%
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M170?;W#ZIN;54U3[*#+H/Q5044B71$ZJJ^FE!^T'XBHNJ(NJIT7[E]:#]H%
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M 8. +C9(;9HA 8KJBHO5%14]46@^J!0*!0*!0*!0*!0*#32\NQ2!?(V,3;Y
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M3CI(JHVVV"$9FJ(J[0%5T15]$HRJ&#YG<"S9H0SO,N()EL25)@OBRFJZ(JJ
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M#OE^D/76?'?!6WFT-4:9 D)$)/RFP+:OHI+1*H/S8XNR1WD&TYOB5IG3TO<
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M =4U123\6U%$JDW_ "6YVD8 7%J8'.#,#A_HY7QMB:,WM*'84TC(TA"^H_\
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MU3:.M$\3'SOQC),@O&$E8+-.NC<>+/1\H,5Z2+:DXQM0E:$M-=%TUH1T)R?
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MVL+:EW_3O@;),>2I_&^5W->PX>W3N!Z^M%M=240H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H*'Y^\CK9PQ?,4L8M!,F7.4W)OS6BFY&LB$K9N B$/YIEJK6NJ+VR1?5%
MHLB\84R)<8<>X0'@DP9;0/QI#2H3;C3HH8&*IT5"145%HBB.?.2<[Q/../\
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M6F[-,,RV^T:@A$)O NA:;AZ>E%QU_;?F-6J&MVD-2)X1V_G2V1[3#CP@G<<
M55=H*6JHFO1*,H[A?*& <B.7%G";_&O+MJ-&YX1U+5M2U023>([@+:NTPU%?
MHM!#,PY$R:R\_<>\>07&1QK(X5QD7-LVD)Y7(C#S@;'-?:FH#]**A'!GD1?<
MPS_)./LY!IJ7\R>F(3FF58;E!;G"!^-ZJAN "(XFG73=K^[0L1T_([D1CQUQ
MOD$_A)DN07QRRRKV]')+?;HZ//"DAQIK<JZ"WI_\A5T12XLCAW*.5KED3D*_
M7RQY_@4B%\B/F5@.,R46=N_X*_';<W>X4545&^G35?5$)568ES+ROF/Z]*D<
MGX;B06N[S+6S;;VRRS)-F,HJ+R(;PJH+NVHOVBM%Q->5N1^3\4E<3XS9,FLC
M-TS );=WR)^,)VTS8;CFV^UJ>@MDCA::+UU2B/S"^4^36>60XGR.^6#*RNUG
MD7*#?+$T2);Y#*'L24 FH[%4?P^ON'KUTH--<<G\EK=RQ:.)SR['SN-WM;MX
M:N"6HT9!MDW05M1W:J2]I>M!TG;1O<'&HZ7Z2S,R&/#3Y\N.VK3#LH&_>8-J
MJJ(J2:HE$<FS/([E5KQVQCDB$4.3F-VR8K,XRD/>T\P@2%%L6@)%W$30IJ*Z
MT:Q9$_GF7?UX;O&$O,M67.[H<"^Q7VT>>95H0[K&[4=AMGN'=IUZ$G3U)BP^
M;<LO.#<5Y-EN/FVW>;5&%^(;X=UM"5T 74%5->A+0BH< SKE')WL9E2>7,'>
M_5OA2)./,ML_J2@^@.NQ1!'MR/(*D'X>A4'HWY%7JQ^2EYXQRH6AP,WXEKM5
MQ%G8L6XS(K3[ O.HJHHO$K@(BIZZ+^$2H8Q[[R[RR6,\RW;'I$)9W'=^[-O9
M.(AH=I94N^)^_J0@O<W_ -@OV] D?)W-UX:P'CZX<:JQ_%O)4R!'LS<D.^#+
M4@!-\B'5$7M$8-GKZ:JOTH8B60\M\E/\PYI@ENSS&<.LV-# ^([D3+0%)*3%
M:-S89N BJAJI*GT0DH8V_(7)W)&!<(Q\QC958LFR"3>V(;-ZM,<7;<4-Y2!0
M1!=(2,3 MQ(7W>O6@Z+GS8UM@R;C,/MQ(;3DB0YZ[6VA4R7^1$HCFC%LM\E>
M8+%)Y*P:X67&\7>=D)C6.3XOR7YK,4R;UD/KKL4S AU!435/1!T52L?)O)#*
M[CP)9^1,69C6;+G;\SCMZBR6EDL,2$1Q'4!"5%T7\MQ-=5%%V]5ZT,;FW<C<
MO8-S!B7'7(ESLF3VW,6Y*,/6=DXLV$[&!30W&]5_++TU5.ON5%38J*$-L',?
M*F5W?+&RY,P_$(]CODVTQ(%]9::DN,1G- =3>Z&X=%VZ_:BT7'4F&N79W%K4
M]?;I#O5T>CBZ_=K8*!"DHY[@<91")-BBHZ*BZ+ZT9<ZQ\^YZR[*^3HF+9-C]
MHM&"W)Z(PS=H>B.,IW2;WO[M!1$;T(R_;16ONWD=R!>.'N.<RL10+!D.57],
M>NDB6RKL -"<:5\.X6HMZBAEU7;U'5=-:+C?6?E;D_%^5\.P7*LBQS-[9F"R
M6B7'VU;F0"CAO1UP1,D[:_V7J@GZ;>I&2&><S\NYQE=HXGN=LQ;#<-F%:7[O
M<(OSI,^X-*J.B $BB+:**]4T7;HNJ[M!#7!S3RO-X\Y(MCC$&!S#Q>XV[<OC
MM+(@3K?U,GF@<745)H'#_D'HF[:(QO>0^=[NWQ!A&3<?BP>:\A2;= LL9T>\
M#<F3I\A%#7KVS165^Q21:&/AWEC.HN><Q8J<R,]$P3&&KI9G5BH)+/6VMR"<
M<1"]PJZI%L^SIK01"W<D>2<;BB%S>=RQ^^8Z,?\ 4KACJPW(DKX0.*#NQX%T
MWBB*7V:?0OPJ5MN2><\K=RGC>#@N16G%\<SFRN7@[KD+($Q'5&E> 7#(Q055
M$1O37\:T3$EL^8\@0<#Y RB;GV,YD_8K-)F6Q<>:;,8LQB.\\*R.VZ:*A;4T
M%=-=%H(-$Y)\D;9Q9;^;I%PQ_(,9^,W<;ECR1'8<M(1'L<V/"JIO#U^S3KH6
MFBE=/XW?H.4X]:<EMBJMNO$./<(N_H7:E-BZ*$B>BHA=:,JL\C>=H_".-6^5
M$9:G9/=I0-P+>ZJ[5C,&)RG3VJBHB O;%=?QF*Z*B*E%D6ABV2VC,L=MF4V%
M])%GNT<)41WT78XFNTD15T(5U$Q^A(J41MZ!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!08MSFE;K=+N 1GII167'QAQ1
M0Y#RMBI(VT*J**9::"BJG6@_F/R+Q/Y&\E9I=\TO>#W-)MT?5P&$$"!A@?:T
MR"[D]K8((HOUTU7JM&W77B6?)]CPY[ >2L=GVQ+(N^PW&6*=MR&Z6JQU)"5=
MS1*JA_8+HFFRC->O.?&T_/>6^)WI&/K?,-MSER'(E,4.,TV^#/;[J*2=%(=4
M_90B4YQP3BESXGRKCG![9#Q[]=;%]I& [;)3HQMNLDYMU712: 25$70?I0U5
M5SR[GJ^<9N<.?U6SXV8R[>F.S<B<>:2RI&)OXSLE'D]JJ3>J[1+HJZIK^%2O
MG...,OX^NW!;V+XY-S"'Q[$FM7;]-V 1O.M,CN3N+[4,]Y(B_3I02K/\BS[E
M?B;.L93C>\V&YN0&DMS<TV#66X4@-6VT O413<NOTHB&7R/S!R?Q58^#8O'<
M[&HY1K5;KWD]W?8&,S&MG9(W&VP+>:D;**@IUTZ?75"NHW;6,'&#LL 2<"-
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M[B7C;%+3?9%K1MR,$E76Y!M?%:D.$9E*9;Z*YHFFE&L8DGRAYBXWR"S1>=,
MBV/';P[VDN%O<(B; 5%#-%1^2!JWN0B;U$M/2ABZN<>;;!PEBK=[N+*W"[W
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M'Y\2R1<>NELE+%NMNM[:-1%=)L2!YH4ZH)CTT+4D45354T525I/-7_,+=/\
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MVZ>M&5%<L7;C^\>-^;R..)%K?L(VXATLW9%AL]P>T@91-A(G[I(BT5]^&_\
MU?,9_P!VN7^'OT*JOB+_ *[G)/\ Q*?_ ':%1>-YY^?YKL=_Q^W_ (%*H1X6
M'&?-L[%:SM>98XW;"AQRAMFTRIBPK0J DJVXNJ#HB]5H?&=Y3L95%\7XD?-Y
M3,W+6Y5M&[RHJ(+#DE#+<0((-II^P$_91)ZNC@K_ #,8!_B"V_X,%"N=/$!$
M#F7F1NUHB6!)CG;1O^B1$N$E(^FG3\&_;]U%JV/,)9R>/V4?"W;5. DK9Z]C
MYS&[T^FNW7[J)&Y\8?TS^H;"/TK9\?X)=WM^GR>^Y\C7[^[OUH51OD"K(^6_
M$BV;;^N;K8EP[?XNPMQ<3WZ?^;[FNO[OW:46>(;R-QO#Y7\M<^PV02MS)-G%
MZTO[U &K@Q:HAL$YHBZAN]IIIZ+]M#BK<ZY+N5WX7M?$>8H\QFN"7Y8S;+XK
MN6W-1WF>V9:K[X[GY6G\S;IKHM%?U"L?_,MM_P"*L?W,:,.*?*!K*7O*; &L
M)>8CY8=L@I:'Y:(L<)/S9NU311--/]BM&IXUW.V,>4[V%_J/*TZ!>L M4AB9
M>+?9'&(SI-BX@;B5(X$J)NT140D'7<HKIT$QNO)G(\:ROQ5X_O>'QEA8VY=(
M4>! )=2C##A38Q,*OU5LFU#=]=-:$]2'&<:\V',;LSEFS''&K0<&*4!IQIE7
M C*R*MB2K;RZH.B+[E_;0^-YY*Q\MB>*;\;.Y;$[+VSMHW>7$1!8<?\ FAJH
M((-IIIIZ G[*)/4(XJQ[S!D\<XP_A666"'B;D!HK1%E--$^U&5/8+BK <521
M/[-:+\>O@<,P+QRF-Q,7)XR;<DMP/P$\CD_>J:(G12U^E"H/9N6N,\G\G,EY
M)Y*NXQ<2ML>3;,:9)B1*!]O8L(506&W%02:-YY=W[QII0XEGA3G-KLV:9CQ+
M N?ZCCLE]ZZ8M-(2:1](Q=IQ4!Q!)"=9[3FU133ME0K8XI_U^,I_XD?_ $9%
MH<=F49?SUQ5KF!WR2Y8'AM^WL7M)UR6>5S0%;6+^H>@[Q+W;]M&G6?#;'/3+
M]X_KIDVR0PHQ_P!&_2T!%0T5SO;]@!]-FFM$K-\A%F)PCGBP-W?_ $>5NV^O
M9V?G?R=O=K]U"('X4_IO]0UL^#L^5\^X?J>S3=\GOKMWZ?7L]K^32A5<>;:Q
MQS?B<K7I_%:3'U:[?]-V_DQ.QKIU_I-^S[]U%C0>0@Y@?EUBPX"<=O,%ML3]
M).;M^.CO]]Z[]R*FFW=]/6A/%Y\9QO*IK,81\GS+(]AB _\ ." +:2%/M%VM
MNUL5_I-NO7TUHGQ?-$<G^?G^:['?\?M_X%*HU'2F%_\ P.Q[_%D+_!PHR_G]
MXZVKGJY7#.EX6O=LM#+<YG]9&Z !JX9'([/;WQI&FB(YK^'U^M&JV[D'E2W^
M6O';'+]S@W;*%&*;$FVB(LI"4Y2 "H#+";D-'%7V?5.M#C9\HQ,_F^:#T;C"
M=%MN9E!9^!,GH)1P!+5J[N0FGDZM[D3V+UH<7+B..^8T?*+._F&6V"5BK<MH
M[S&C--(\Y$0OS1!4@-KN4?30TZT3XZ.HC@#)H_),KS,RYKBB7#A9=V05M^XH
M),=A+=%[B:$VXFY>FGMHUQX<TVKF^QW3$LQ\C6X^5\?6JX"V=OLCS,9ONNBI
M[3066U531OU)-%1%#<&[6A$K\DKK:;[SCP=>9KB.X-<AMTUEUY-&39DSVW#4
MD+HB*VK6_P"ZA';=&7%OAX]&8Y6YB<M!@WB+<@G&G 5!CBT,V4L==?1$1K?I
M]U&JKS#N4.*LOYQS_D;EJ[?"L-QB2K1C\0XTF01Q)0+#$D1AIW8HQ15"U1/<
MYJGUH+$\&,\C,2LLXF6>,Z'$?<N^/RT0FT>80TCOJ(N(A"A?DNB"IK[BU^M"
MH8R?*C?EIR.?$#4![*$"7WF[HH(RL/N1=^S>0^_?V].OIK]-:''Y97<U\E>5
M8/'O.-^C8_(Q22XXN*-Q5COS#;T*0VT:*HJ2@VGN5POR]3 535:'B<^5B(GD
M#PNB=$29"T3_ .>C-".@_((89<(YZD]!5C]&EJ&_33O(VJL^OU[FW3[Z)$%\
M+%EKP):4D[NRDVX)#W>G9^02KI]W<W_RT*K3SB4/XNXH2\?_  7^7*6;O_HM
MO?A][?\ 3^C^WZ:T6.S1V[4VZ;=/;IZ:?=1EQAX]*S_I5\OC8MO\/JW<E=[7
M]%WTN+.FW3I^+N[=/IZ4:OBKO&%CR!>M62KPQ)M3$!)C/ZJET1M35[8>S9O
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M6^-,^D%"Q#)X%UG".]8;3J#)V)U4D:<VFJ)]50>E$2>[7:W6*US+U=Y(0[5
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MD[39IZ].M#$G=O=J8LAY([*$;&W$6X',5%V)$%OO*YIIKIL]WIK05?\ Z4_
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M^<'%V 6+D[R'D89DBOC9YT^\&^L0T:>UCC(>'0B$T3W FO2C;KK_ $%N$_\
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MS1X915\R6M.O_P!$-^]/]RFT;X_I=1A_-GSI_P ]C/\ B2%_=9%&X_H[;O\
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MX)_Q6X_W2/0C8^5F+?J7CMQAEC((3UCC6Z,Z:>HQKC ;15U^SN,M)_+0B/\
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M=/\ _P",!P3_ "3N_P#ZR-_X=$Q97"OD[C?-F2SL:LUDG6R1!@E<3?EFR0$
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MA;I'TBR235&9;)(ZPXJ)U5!< =R)ZCJGUHP_G[Q/REFGBAG%ZQ3,K&Z];)9
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M22."VU7$77:0N$WT_L"-1_UJ+JR;9:[998+-KL\-BWVV,.R/#B- PPV/KH(
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M@VWR1EQ\%M:O"6X4>:60WJG_ )MXC#_Z6BZLN/&CPV&XL1H&(K(H#++0H#8
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MMLIJ9!>159DQW!>:-$5151,%5%T5%3HM!D4&/(N$"(]'CRY3+$B8:MQ&G7!
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M$**>[V[D0=26C3HC)+IC'CW@=FL.%6)HY5PFQ['C=G%P8XR;C*1=')4@_1-
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M\KQ8V8+Q0]$^,S-D');>9=95-"=+<"_NAHG4-C8>.^3+;>^ 'LF4[U.Q%C(
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M^S(>1J)WA47E9(D%WKO,/0=R#JNFM!M\YQ>_W3FWB?)K?!-^PV!O(AO$T2!
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MKP"V<5WO'L?17$D7RXRK>^2ND!&<F4K+Q&;KI)[E1/5=$T%$1"()A'&6>VO
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M*M"B% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M+4RZK[C6@WU H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M7Z;=2W$C9Q'HY+&&,Z))W%73;[O:6G4JVK)B<W'^5^(XD:PO6FV6O%+G'DQ
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M[CT"8].8=G3+BKTA!$T.<\3Q#H"(F@J6B4$NH% H% H% H% H% H% H% H%
MH% H% H%!^*FJ*GIK]4H-;CV/VG%K1'L=C86/;8V]6VR,W34WC)UPS<<(C,S
M,R,S(E4B556@V= H% H% H% H% H% H*^QKB\[3G-QY R#(9N27MYEV!9@F
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M=NN^-Y.#'S6K+D<$[;*?B(NU7F4)2%P45="VEN3ZIZT&?8^3,9R'!)G(MO\
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MW6FCU7<K>Y$/HFBT$CH% H% H% H% H% H% H% H% H% H% H% H% H/EPB
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M)^Q]MM#)$73>71-?O^B+0:_.;%=\B@^2=MLL1R?-"[8]-.WM(I.2(T1J/)=
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M+U$@ ]BI].J459=D04\H<KT30BQ&UJ7WJDQ]/^YI1.//RW5$\><S5?YD!/\
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M*@+JBF] )=5%"]=%T]*#X^%"^+\+X[7PU318^P>UHJZZ;=-/6@^SCL.]ON-
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M1DN[D5A8UN9BP6E9CQ8[)D:[ $BU(EU/7KU]0L(XL9QA(KC+9QD041DA101
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M4*OMLPH[#C>K;?177-Z#NZ$FJ#J%7V&6LSC7R7>.\0[\Z3CRO76V,#%A/N_
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MDRYKJQF$B1A=G2#D$#+"$?;:#?L;'<N@HG76@\<@XCXQRNZNWS)<3MEUN[Z
M+TV7&!UXA;% %%(D5>@HB)09N*\>8-@YRCQ#'H-D.<@#,*"P#*NBUNV(>U$U
MTW%I^V@P[#Q-QIBU^>RC'<5MMMO[^[=.C1P!P>XBH?;T31O<BZ%VT37ZT&-=
M>%>);Y<I5XO&&6F==)KA/2YDB*VXZZX7J1$J:JJT76YQ[ L+Q.VS+/C=A@VN
MU7!2*="C, #+ZF';+N B:%J/M77Z41@XKQ3QO@]QD7;$L8M]HN<I%%V7%8$7
M=A+JH 750!5]1#0?NZ4$JE18LZ,]"FL-R8<D"9D1W@%QIQLTVD!B2*A"J+HJ
M+ZT$#@\$\.6Z-/B0\(M 1[HB!.!8H'O 3%Q 1315$4,1+:.B:HBZ=$HNI%=<
M&P^^7JUY'=[+$F7^RJA6JY.M"4F.HKN38YZZ(O5$7T7K1&TNMIME]MLFSWF&
MS/M4UM69<.2 NLNMEZB0DBHJ4&FLO'V$XZMJ6QV*'!*QLR(UH)EI!*,S,<5U
M\&U]41PU4B^U:#:,V&S1[S*R)B"RW?9K+<67<!!$?=8855; B]5$5)=$H(Q"
MX;XJMV1IEL'$+7'R)'.^$YN, D#RKN[@#IM$]>N\10M?K0U.*"$91P[Q;FEQ
M_5\HQ.VW*ZKHAS76!1\T%-$1PPVJ>B=$W*M#6EY>XV=R'A>^\;X# A6]R4PR
MQ;(((,.&VC<IIXD1&QT'H)+^'JM%;[&N*N/<6NQY-9<8MMNR62&DFX18X-N;
MC'1SMZ(B!NZ[MB#N^M$>N7\7<>9\_'EYCC<&\2XJ;6),EE%>$$55V=Q-"4-5
M5=BKM^Z@W0XWCP6),7&TPTQI&?B?H_QV_A?'TT[?9V[-G]CMTH-+BG%W'>#_
M #/X2QJ!:2N JW-<CLHCCK9>K9&NI;/[#7;]U!^7/BSCJ\8U#P^YXS;Y.,VY
M=UOMIL#VHY*JJJLZ:*"KN7515-=:#WLG'&!8TY;W<?QRWVUZU-/,0'8L<&G&
MFY6BNBA"B*N]412W*NM!N+'8K-C-JC6/'X+-ML\1"&+"B@C;+:&2F2"*=$U(
ME5?O6@^8V/V2'>9V0Q8#+-\N3;3,^X "(^^W'14:$R]50$5=*# 8P7#8N/3,
M3C6.$SC5P5TIMJ;9 (SI2%W.*8(B(NY?6@9#@N'979&L<R2QP[G9(Z ,:%)9
M$P9[8[!5KIJ"H/M105%TZ4'KBN&XKA%M2SXC9XMFMN[N$Q#:%I#-4TWFJ=3+
M1--Q*JT&CA<-\56[(TRV#B%KCY$CG?"<W& 2!Y5W=P!TVB>O7>(H6OUH:W-[
MP?$,DNUJOM^LL2X7FQNB_:9[[0D_&< T<%6S]4T(4)$^WK0>88!A3<*);@L,
M)(,"XI>X4?LCL9N:&3B2@33HZA&2[O7K0;*98++<+K;+[.@,2+Q9N_\ I,YP
M$)Z-\L$;>[1+U'N B"6GJE!0%_P'E.5>;@LK \2RG)73?;L?)DPV(DB+&<U2
M.4J&D4S<>CBN@JV6G1-/KJ5=/'6'M<?X-8,,9D+*&RPFHARE'9W7!35PT'5=
MJ$:JJ#JNB=*(\<OXOX\SU^/*S'&X-XEQ$VQY,EE">$$55V;TT)0U778J[?NH
M-E*P_%9M@:Q639H9XTQVNQ:48 8@?'-'&D%H4040"%"'1/6@W=!#<MXEXTSJ
M6-PR[%K?=;B H"37V!^0H#Z"3H[344^B*NB4&S9PC#XV-.8;&L<%C%'FR9>L
M[+#;<4P/\2$V*(B[OJOJM!DW#&,>NULC6:Y6V/*M4,V'8L-UM":;.(J$RHBO
M1%!13;]E!HLGXEXTS2[,WW*L6MUVN["" RY3 FX0!^$7/_*"GT$]4H,UWCK!
M'X5RMKN.P"MUW?:EW.)V 1F1(C[.VX8(FU2'8.BZ?2@W%YLMHR*VR+-?H#%S
MM,H=DF%+:%]EP475-P&BHNBIJGV+0:/#N-<"X_21_!F/0K,<O1)+T5I!=<$5
MU02<74U%%]!W:)0;*W8IC=ILKV.6RUQHMAD=]'[<TV(L&DM25[<"=%WJ1;OM
MUH,2YX!A-ZQJ/AUVL$*9B\0&VHEK>9 F&19'8WVD5/8HCT%1T5*!CN 85B-F
MD8_C-AA6NSRT(9D2,R("^ABH%W5TU<517;J:KTZ4"X8#A5UQ=G"[E884K%(X
M U'M+K(E':%I- [8JGL44_"0Z*E!Y8SQQ@>&O-2<5QV!:)3$4H#<B(P#;OQ3
M=1XFR-$W$BFB&NY5U6@U\GAOBJ9D?\72L/M3V1*YWRG'&!2)]%W=TATV$YKU
MWJ.[7KK0U)BQ^R'?6\G. PN0M12M[=S4$^0,0C[JLH?KL4_=I]M!H<NXJXXS
MR6Q/S#&8%WGQD0694AE%>0$75 4QT(A15_"2JGW4$GM]NM]H@Q[9:HK,&VQ
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M]@D1XM^O<"URI:Z1&)TIF,XZNNGY8NF*EU^R@V;\AB*PY*DN@S&:%7'7G"0
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MC^3Q64?AOQI#UMO%M=?!$>91Y@A+3745UU%?5*#UA8E9N(,2O]QPNS3+U?Y
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M@N$9'4CDXAHKHQ]Y"*.J71>OHFA74O&N-67%,)L]JL$98L!8S4GM$ZZ^O=?
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MH$G:;+<J(B:IU1%HC-\:[0M@OO+5E^=(N00,G6.S,F.E(DDT$5M&T==)54R
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M7O%%3H77Z)0:D> +*_C&7VB]7VY7?(\Y:;8R'*)9-?+-MC^B;9:$$9:;#KM
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MWZ+KI09=@XZY4*RV#.K?R1<IF<3$AW"[VJ[. 6-/,24%R1&;B,L:LH(DJ-N
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MO.\BGW#(>1LHBRKR=FFV*R6VRQGHEIA_J#:MNRG =><<>=)-$T)4$4]$UT5
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M$<Z-C_2(7I1K&]\9/(6Z\GXC?+)ELL"Y#L,=V:$CMMLK+@FBJ#R-@(AN:)4
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MX\ZVA$6UM!%-5^@HB414N)\MYHYS5R_8+K**YXQAMM.?:+,VRR#B&R#;FP7
M;1PE+513>1>M%5A@^:^1?,-DGYWBO)MF@7E@Y!P>/F&(RO*+&I"T0O-D2=Q$
MT;(U+7ZFG70KJWBR^YAD6#6NYY]92L.7$)M7.WJB(/<:-11T$W%H+@HA[57V
MZZ==-:,IC0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#E?RF5$Y?\?\
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M+QG%D5KYR\KL1O& .E<L5P2W./7B]@V81^\??VM@1HF[4C;%/YWO5-1'6AQ
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M[,GGY3[<N3'M4V6I$\_;VMB-D1EU/:?<;$E^@I1*O>B% H% H% H% H% H%
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MF@+:\CMD6[VPB%PH<]AN2PIAU$E!T2'5/HNE!G,LLQF6X\=L6H[(BVTTVB"
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MCBZJO4T6@VMMMEMLT!BUVB&S MD4>W&AQ6Q98:!.NT !$$4^Y$H- WQGQRS
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M?P0;U9HK4_*;E,8MMC@/BXZ#K[JJ1J0-$!DB-B6FTD]RBGUHD>GC]RQ(Y?P
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MC<G\DR?(3*IW$&&WV%CW&5K> ,QRV9(:966K9K^1%%PQWAN!=-OXU'551O\
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MSS&V0 $"%JP;:K[3)-%72@V658M8LVQ^;B^31/G6*XB+<R+O<:WB!BXB;VB
MDT(47H5!\6_$L?M>*M83!A]K&682VQN#W'"TB*VK2M[R)37VKIKNU^^@B3O
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M1$)S'B+CO/[W:<CRZR!<KQ9%%;;))U]O8@.(Z@D+3@"X*&FNUQ"3U^U:":&
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MB)'AN[ET1>Z#CB"*K^\>T4^JI0Q?R+KU3THB"\F<OX'Q';6+AFEQ^,<M2&!
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M\F^2\_';5)=BWYC%1N5D)E4'N3X2&XTT1*J;$-=1WHOM71:+&OB<K_UK<D<
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MVZWJA@)PP S%4ZHH@I%K]/6AUN/$^P8_:N"L8D6>.TCEW9=EW20(BIORE><
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M/.NMB2O(?4$=)/;IK0U8%KX?RS)<$R/!N;\J',H]Y-M84N-%;@NP^TB$)@H
MB;Q<1#35%3IHNJ*J4-5TSXZ\_0+)_ %LYA[7'J"L5L"A_P!_A#5-O:$]5-!0
M?:@C(0=.B:)TH:L-WQHP$N&CX;9[K=O4OF#=U02E_JB=?EJFB"I=-BCT_+]F
MJ>M#5;S/&SG;(K''P#+.6AE<=L=IIR,S#_OQZ,P2$ &:H)%IM33N/&B+HNBZ
M474JY0\<;QDDKCU_CG(6<6_J\C+&M)R(ZRW$4.SVCZKM)4[7NW"NJT37M9.,
M_)>'>K=,O'+\>?:(\IAV?!2TQFU?C X).M(0MHH[Q11U3TUH?&FO/CURO'Y0
MRKD;CWD*+C3N3&/>96 ,HT9 0T E=0Q_$&NHHE#4KXOX#F8KF4GDWD'*7\UY
M#?86)'GO,C'CPV"3:0LMHI:*HZCJFU$0B]ON5:&KMHBHI_#MPF>05KYG&ZLA
M;K?:RMAVI6B5XR)M\-R.;MJ)JZB^GTHNLGFWA"T<R6NW[I[UBRNQNK)L-_BH
MJNQW"455"%"!2%5 2]I"0D**B^J*)57S/'#F//UA67F'E);QA$)T'7;7;HPQ
MWI7:_"CKB VFO]D?<5/5.O6AKIJV6V!9K;#M%K8"+;(#+<6'&;30&F&10  4
M^P11$2B*CYBX(/D&^6G/</O[N(\E6,%9A7I@.XV\QJ2HT\"*BZ)O-$)-?:1"
M0DFFA=1?&?'3-+SGEIY YQS4<PFXZ2.6.U18XQH3;PJA"X0B+8]"$3VBVFXA
M'<2HFVAK9\F^/-UOF=!RKQ9E+F%\@$VC-P=[?>B30$1!%<#Z+M$4)"$P+:*[
M4)-RC6%AOCIE$K/+?R3S9F*YI?[+H5C@,LI'@1GA7<+NU$ 542]PB#8>Y$)5
M+32AJ88YQ%<+'SQEO+[ET9>M^26UFWM6L6B%YDV0B#N)Q2VJB_&7HB?O?=U"
M'VCQ>C8WY L\Q8]<V8EA5R5+?Q_LEO&3-BNL.]HT+:@*;G<1-O3J*=-*&I7S
M=P[<>5YF%RH%U9MHXM=$N;XOM$ZKPH39;1VDFB_E_7[:$K9\[<8S>7>/)>%0
M+@U;)$F1&D)*?;)T$2.XAJFT51>M"(Y=>#+I<<]XNS ;PP$?C^ $&7&5D]\H
M@:[:DVN[047[%H:T?,_B]'Y*Y"LG(MAN;-FNT1QA;TVZR3HS$AN 3)HH$*HX
M@#VU5==10?3;U$K[Y*X%Y"R/EL>5L"S2/C%R;M[=N:[D-);@BB&+G])N!4)"
M_FT-;O!./^?[)E=ON>:\H,9#C+'=^=9PMC$8G][)@WHX "H[7%$_7Z:4&1P]
MP@7'EIS6RY',C7VW9A<9$Q^.+) W\:4"MFRXAJN[<*Z+0M:+@7QO>X1R_)[R
MQ>F[C9+PVD>VQ5:()#+(/*X".FJJ)*@Z"JBB:KUZ>E"U([MP[<+EY!6'F<+J
MRW;[1:W+8[:B:)7G"-N4"&+B%M1-9"+Z?3[Z&M47CXSD/-5ZY2Y#>@9)9WX:
M0+%CLB)WF8H!L$2-'E(25$1Q?P_B<5>FB4-8W)OC39;].Q?(N+FK5@^58Q/&
M<U)BP :8D"*B:"\$;MJ6TVQTU_=4D^M#6ER'Q[Y3#E7)^3./.0(V,OY(C3;S
M10!E.(RVVT*@JN[A_$UNU046AJQN+,0Y>QJ=<7N2L[:R^'(:;" PW":AJPZ)
M*IDJMB.NY%1-%H/WF_AFU\S8W%MKTYRSW^TOI-L5[8'>Y&?T1"140A50+1-4
M$A7<(EKTT42JGF^-G+W(,BUVOF7DP;[A5K?;D%:H,5&'9*M(HIW'!!KW*BJG
M<+>2:KIU76AJZN7N/W^2.,KU@%MEM6QVYMQVF)+C:N--#'D-/:;!5%T5&]J:
M>E!L,.PIBP<;V;CZ\JU=(T"T,V:>J@HLR6P81AS4%55VFFO36B*(A^-W+O'S
MLZU\,\GK9<,GNF\-IN489)Q5=Z+VC('4UT1/>*-JOUZ]:+JR.'>!K'Q;:+RW
M<)KF3Y-E!$>37J>.I2D/?JV@$1J@*KAJ6XB(U55)?1$%JN&O&SE? W+A:>%N
M33L.%7-TWEL]PCI(<B$[T)&'5%Q==$1-X]LOM553=0U(K3XQV_'>&,GXWM%V
M[^3Y:(G><GF-*JO2!<$QU!"4D;%-VT5,EU(B5>M#4M9X8@3^#8O#6320FMLV
MP+>MQ:!4V2&/<S(;$EU16S021%7KIHO1:&O3@KCW,.+L,'#,HOL>_P . XOZ
M+(9:<:=9C'J1,GO(MPB2_E_8B[?1$H59]$*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0>4F2Q#C/2Y1HU&C@3KSI>@M@BD1+]R(E!57^D[P+_EQ!_[U_\
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MSB FI; =0%/1.J[=>G6AB>41'<SSO$./;3^N9G=V+/;%-&0>?4E5QU454!L
M0C,M$5= %5T2@\<'Y%PGDBVN7;"+TQ>(3!HW(5G>#C1DFJ(XTZ(.!JGIN%-?
MI02B@KC(>?.'\4O,O'LARR' O, D;EPW$>4VR(4-$7:VJ>A(OK1<?6/\\<0Y
M5.<MN/Y9#G3FF'ICC+:.HJ,1@5QT_<")H(HJK0QJD\G.!ET_^CB#U_L7T_\
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M[MKQE6;?C=J1&7":VW)E 9$0)!%H%WZ(.FT:$\1[F+D?*L]Y&X<#), N>$C
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M?^KUE_\ \[O^DHU"-9C_  UQCEWC[8!N>+VMN?+Q6&^MV9B,LS0E%;P+OH^
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MF')JNW/'L3N"V7',>5UQJ,VT+CH[C1LA+71H2)$+W&2Z]$1*'CWX^M/ F/\
M-EJR#A[DEBTQ+D/Z?,PIIN3*:N#SNX4 'GC38*JHF**A:$/M71=*"J,DOF7\
M?^2'(7+.,,?)M.)79@<FB": 3MNN9(R0J/U%2%/=UV'L+3I07/:+Q;<E\R;'
MDMG<21:+QAK<^WR---[+S9J):+U1?W51>J+JBT.*#XZG<#0;OFX<MXG<<@N*
MWR1^FNVYJ0X#3'</<)=B0RB*I=>J+15VW,>(97C-RA<^(\<EX];G1:CW)JX
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MF/7M95ZDM*"!%865 />>XD73:T:]-?PT6-EY;8;E&=<2E8L1MCMVNRW.(_\
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M9E<KIA5VX^R5\W<MP"Y/VF=WB4W2CJX:LD2EU7:0NM)]P)0K2^)MQN,_*N9
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MF"2+@[<,<R*S,))W"X(AM-"4 U(0!2!3$@+=T(51:+ZD7'MNS3F_GF#S=?\
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M$$/J'HM!UIQ?:IMGPV%$G9<6<NJ3SHY(>Q?D ;A**(K;CHJ@?@U0U]*,JO\
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MT3%;>1%AL4WR8X:6; 8>6XO"W<.X**CX1Y(DR+B>A(*DOKZ^B]*+'7-&7/\
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MFNTT)A^Z1"UW%'U3=HNBHJ47KIO"?&WA"P1[!FL#&>U>[>U%NK$OYDYW;(;
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M<9@W&X6>#+N Z;9;\9EUY-O1-#(5+I^V@VE H% H% H% H% H% H% H% H%
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MKHNFE$97*/(G-#G/T#B/C.[VVUM3K0-Q [I&1UM' 1\W-30'#ZHVB(B#03?
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MJHM$8&-8OCV'6EJPXO;F;59V",VH<8=C8DX2D2HGWJNJT&B#B/C1M+Z+>,0
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MLQB!=[JC0L)+EM(XYVFU51'7[$4EHFL:P\*\48O=XU^Q[$;;;KS#4BBS8[*
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M(%(=0!212VZKI]%H)%$EQI\5B=">"1#DM@]'?;5"!QIP4(2%4Z*BHNJ+0>U
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MH8OR7<_ZS)]FA8=<+@=L:CM-K(?>8;)P6W7QV&+ "V*" >JF2KZ(BAF3>?\
MDN7XZ8'+M\X&N0<RN[F.K?B $4&V7S:[VW:HBZ2=L5+;_.)-"TT&-7S'A.>8
M-G'#$#)LUD9I:9&217&'[BR 2X\T941'D%Q"(B9<1141(EVJ/WT([-RJUW"]
MX[<K5:KL]8KC+8)N-=XP"X]&-?1P1)4153]M&7#/C_D.0<5< YGRW$O3TN%
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M10'[5,56CO.5_P"0)>591,Y3N6$38,I]C#,5M=KERXCK; [F?E.,,N 2NJJ
M6]55"U+39M&AB<9%SER?F''G$E@L<G^&<YY%N$FU7B[HUVSC_ILAJ,;C8$B*
M/=[PNKMT5-%$=*&-=E6)YEAGD?PY:,GRQ_,+?WW7;3<+@T#<]K<NC[3I@JJZ
M.Y!,")=4W*/TZAVQ1E0?E#R%F&*6W$<0P28-JR/.;NW:6[N0H2QFE)L"4-47
M:1$\'NT54'=IUT5"Q3_).&YOA',?!EKR?,I.9VIV^B[;9=Q: )K$A),-)(*X
M*D1MDG:(-Q*H]4_:5M.:<RO,7,LH:F<SO6>; ;+^%\.Q"+)EO 3($:I<2:#:
M)?A4][B^J_A04&A$+Y2R3+^3/$7&,YR&^._,A7!V%=8C;;8M7(DE*TP\]M1-
MIM"W^ZFA*2JM#J6\CY[F?&5IX]XN>Y FL?Q*VMTON;N0BD3XEM) 1N/'9CHX
M:Z;3]P^[TZH.M!D<9<Y7S&\FRNQ)DL_D;!(&/3L@L]\ND&3"F-R[:PK[D5PW
MVP(A(0+W+JFNW;IJ24,:%;;S1G'CYDG,MXY$?=2\P;BZ]B11VRM:VIMQR.ZV
MB+_1.: 9MDVFJ:"BKJJJ@=%^,?\ F%P?_B)?W=VB55?..47&-R+,MMWYD<Q*
MTMQ6QL>+8I%D3KT4H@0U*8# _O>XA0G!10VZ(G4B+$5MG,_)-T\/L@S61?'@
MS"S7AJV1[TV@-R28^3$7WZ#HI;7R!5TU5/7KJM#/K[S3(>:^.[;QCRM/Y D7
M1[*Y,!BZXSV :M8M3&1>%L&TU1?RT(#<5-ZE[A5*"9Y3>^1N6/(6\<48SELK
M"\4PZWLS)\FV(GRY<AX&33W+HNB*^(Z*NW05Z*I41J/&Z'D-O\B>6H&5W$+O
M?XT>,S+NC;(1DE;#$6WE:#V@1@@D8CT0M:+5A^4F4\AXIB-HEX4,]BSNW  R
MR[69D9-RB6T4125D3]H[NOYBZ(BH**2;J)$'\>>18=_SO]-L7+$[)+%+BF18
MKE\8AO8R&Q4M\>2/Y9H/J0@:^W=J/1"H5'[/SQGN.X'SCD\VYN76Y8[?AM.-
M!+$#:B))E.1Q5$04U0$7?H6J*HHGU6BXUG))<]<7<,6OD1OE"=<I>1+"*\PG
MVFU^*4P/D-K"=7<H(.G;<$4031==$TTH)SREEG)SW-O&V!8?E;MBC918MT]Q
M6FY#8GMD$[(1LTT5U #V:KIN0?OHCPX\S?/>-^6N3N/<NR:7F>.XKCKN3Q95
MPT26BL-QW]B%[E349"@J:JFHHJ(G5*"GXW-V;7C&9'(J<KW&-R23YR+?@,6S
MRW;,4=M[8D=31DF%4@130E)>GM(MVI(7%N93R1R+RSF_&O&V)WE[!H^28ZQE
M&1SH8JDP"=!U3CMJ>A(@*RHCHJ:[]2U0=*#6<?6?*<?\R'[/EE\7(YL3&S"'
M>7&0CR'H>UM6N^+?170U4"/]_3=]:'%V^1W*%RXDXNGY/9&P.^R'V;=;#='>
MVT_)W+W2%>A;  E%%Z*6FO2B12>?M\Y<"8M9.6)7(LK*W/DQF\GQNX@*0#26
MFJC'5-=B"J;-PB*_O)HFHT5N,PS'DK*_(FRX%A.6OXYC.1XRS<'U[+<@F&G1
M=>-QD#307R$! 3U]FJK]*(W/CSE&>1.4.1N)LNR)_*8.+DR];;I.1/E(+I:*
M)%U5442'5%5="1=O1:%8?G1:KA)XGBW5BZO1;? G-MS+2 BK,PI)"C9N$O5%
M94"4=/7<NOTH17W-N/998+3P/;2R=R_9,_?4>MEYN;(:,NR"@K'$FQ54(&B5
M/5?=18G=@N/)?&WDQCO&U[S>9F6/9=:I-PDI<FVVU8?::E'JR(:H"(4;H@*@
M[35--41:(J9WG*_\@2\JRB9RG<L(FP93[&&8K:[7+EQ'6V!W,_*<89< E=54
M MZJJ%J6FS:-%QUOP/GMWY)XOLN3Y#&6)D!H[%NC:MJRA2(KA-JX(*B:(XB"
M>B=$551/2B55%^O_ "+S'SGD7%^+99)PG#<*BMG<9EM$?GS);P@NB&NBB*$:
MHFBZ:#JJ*I)M"+1<GY(N,+F+@'+<J=EWG$[4[=;;EK+())?MS8-O.1WQUT7N
MMN@"KJI#N--Q:)14!L=CO$/P@R2^R[_(GVBY?&:MU@< 1CVXH]_1'":/55)7
ME7<71-%H=2+(KCR_Q)@O%')3>>R)K%V*U6]W$D8;:M;4%Z(CK3(BFNY1:;[;
MCA>]27<*II02#F/F&?/YLN7'$S.Y_'F$XU#:<DS[-"D3)TZX2&VGD#=&;,VP
M$7OK[?8OJI)H)&!9.:N09?!W*S#M^E3;UA;D0L<S7XAP)$ZWRY:-MN*V\VBH
M6ULM=R;MIHBZJFY1BV_'BQ\G7"VVSD[/,ZD7R-DEE8-C&U91J+%)Q6R:>0A+
M0G%:'WJ@#[C+7=T6B5H_*?-<[Q*9BJ0)%YM'&;ZOEE5]QEIMVY-F*(C3:&[H
M+0]==5(=W7UVZ4(QN <^2^EE,2T<I.YG:&;>Y+MMJO44V,B@N B"KANDB"ZW
MJNBJ&]$50_"JJBBJYMO/G)5M\7HV2_J[D_.L@R1S'X-WE(V1QFC:[FX4V[=4
M0%$=R+HI:_2BY]8O/6!<BX.SQLQE6=2<SMDS((A/!<&11Z-<AV[E8>U(U9,5
M)-A+[=J+]>@C=\C\RSLCYAR?#[IR)<..,.Q/;$@E98$F;*FSNB.&\45LR0!+
M=[25!4431-5):&)OQ)FE_P"8.%.0,7SHRN,^UL3K6W>G(QP_GPGXQK'D*V8
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M]QR'%47P=[49C?[&_:OX=$U7\*(B#0U:7'^,O89@V.8E(D#+?L=NBV]R2 J
M.%&:%M205551%TUTHB+<HX#G^2W&SY#QYFS^,W:TJ0NVN0)2+/.;+7I(8%41
M2354W*A=/1$5$)"HAQ[X_P!ZLV:7SDO-KQ F9?=;>Y:HT6R0D@6V.VZ B3BC
MT)PUVZ:KI]==>FT:U-I\4V_ZB'^'[_? =N W-R\VN]Q&208TK1!;56S/4DVJ
M8DFY.A=-%ZT-:S(/&[E[/&\:DY_R/'N<[%YL=V!&:@]N,4=I4)UUTQ4#<D.;
M 3<2:"B+]26AJ5Y7P?G=OY$NW)7#>71\;N>2,@SD-MN,5)<1UQM$07V^A:'T
MW:*'XMWNT)1H:]KS"N?"' &6RLMRV=E=_6%+<.ZW1TSUG3FTC,,1Q<(U!I'"
M'0=R]5(NFNB!(_';!I7'G#N,8[<6E9NRL%.N31IH82)QE()LD_G-H:-K_:T*
MM&B% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!B
MNVRVOSV+H]#8<N<4#;BS3: GV@=_&(.*FX4+3W(B]:#*H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M'KT7TH-+!P_$K7.6Z6RPVZ%<UUUFQH;#+Z[NB_F "%U_;0;J@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4&)<+7;;LP,:ZPV)T8' >!F4T#P(ZTNX#03
M140A7J*^J4&70*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
+0*!0*!0*!0*#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
